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ABSTRACT 
Alzheimer's disease (AD) is the leading cause of dementia in the elderly, presenting 
itself clinically by progressive loss of memory and learning and its prevention is a 
major public health challenge. The key event in the progression of AD are the 
sequential cleavages of ȕ-amyloid precursor protein (ȕ-APP) by two proteolytic 
enzymes, beta-site APP-cleaving enzyme 1 (BACE-1 or memapsin 2) and Ȗ-secretase 
to produce Aȕ40 and Aȕ42 in the human brain. From the therapeutic point of view, 
BACE-1 appears to be a promising drug target, which stimulated the design and 
synthesis of BACE-1 inhibitors. 
The present work describes the design, synthesis and biological evaluation of non-
peptidic, semi-peptidic and peptidic BACE-1 inhibitors. The norstatine based BACE-
1 inhibitors were synthesized to study the structure-activity relationship (SAR) at the 
P2´ position. The synthetic approach utilized L-phenylalaninol and isophthalamide 
derivatives, provided both hydroxyl diastereomers in a 1:1 ratio, which were isolated 
and investigated separately. To enable lead optimization and facile variation at the P1
position, a new synthetic route was developed by employing an organocatalytic 
approach. As a consequence, a variety of norstatine derivatives was synthesized by a 
proline catalyzed D-amination reaction followed by a Passerini reaction. For an easy 
removal of catalyst, clean and straightforward separation of the product, an 
immobilized proline derived catalyst was synthesized and successfully employed. A 
series of compounds was designed and synthesized as potential BACE-1 inhibitors, 
as analogues of MG132, which is known to have a broad specificity to inhibit 
cysteine, serine and aspartyl proteases. Biological evaluation of these compounds for 
BACE-1 and 20S proteasome displayed moderate BACE-1 inhibition. However, they 
turned out to be potent 20S proteasome inhibitors and promising drug candidates. 
The most potent 20S proteasome inhibitor BSc2118 that has low toxicity and 
effective inhibition encouraged further evaluation and optimization of the lead 
compound. The combined treatment of BSc2118 and calpain-specific inhibitor was 
evaluated on human melanoma cisplatin-resistant (MeWocis1) cells and found to 
affect two different proteolytic pathways, which can enhance the proteasome 
inhibitor–mediated death of the tumor cells, especially of the cisplatin-resistant cells. 
An agonist of the nuclear receptor peroxisome proliferator-activated receptor gamma 
(PPAR-Ȗ) acts to improve behavioural performance in an animal model of AD. 
Atherosclerosis, coronary heart disease and hypertension are identified as other risk 
factors for AD. A subgroup of angiotensin receptor type 1 (AT1) receptor blockers 
has been identified as ligands for the PPAR-Ȗ. Therefore, two active losartan 
metabolites i.e. EXP3174 and EXP3179 were synthesized and characterized for the 
PPAR-Ȗ–activating properties in the present work. Moreover, it was investigated that 
EXP3179 inhibits collagen-dependent platelet activation via glycoprotein receptor-
VI independent of AT1-receptor antagonism, which has a potential impact on 
atherothrombosis. Beside this, it was explored that AT1 blockade in astrocytes 
decreases hypoxia-induced cell damage and inflammation. AT1-R blockade could be 
of therapeutic benefit during neurodegenerative disorders accompanied by 
inflammation, such as Alzheimer’s disease, Parkinson’s disease, stroke and multiple 
sclerosis due to its anti-inflammatory and vulnerability-reducing effect on astrocytes. 
ZUSAMMENFASSUNG 
Morbus Alzheimer ist die Hauptursache für die Demenz älterer Menschen und äußert 
sich durch einen fortschreitenden Gedächtnis- und Lernverlust. Das Schlüsselereignis 
im Fortschreiten der AD ist die sequentielle Spaltung des ȕ-Amyloid-
Vorläuferproteins (ȕ-APP) durch die beiden proteolytischen Enzyme BACE-1 (oder 
Memapsin 2) und J-Sekretase, die so im menschlichen Gehirn Aȕ40 und Aȕ42
erzeugen. Aus therapeutischer Sicht ist BACE-1 ein vielversprechendes Target für 
das Design und die Synthese von spezifischen Inhibitoren. 
Die vorliegende Arbeit beschreibt die Synthese sowie die biologische 
Aktivitätsuntersuchung von peptidischen, halbpeptischen und nichtpeptidischen
BACE-Inhibitoren. Die auf Norstatin basierenden BACE-1-Inhibitoren dienten zu 
Struktur-Aktivität-Untersuchungen der P2´-Position. Ausgehend von L-
Phenylalaninol und Isophthalamidderivaten lieferte die Synthese beide 
Hydroxyldiastereomere im Verhältnis 1:1, die isoliert und getrennt untersucht 
wurden. Um eine Leitstrukturoptimierung und eine einfache Variation an der P1-
Position zu ermöglichen, wurde eine neue Syntheseroute unter Verwendung 
organokatalytischer Methoden entwickelt. Folglich wurde eine Vielzahl an 
Norstatinderivaten über sequentielle Prolin-katalysierte Į-Aminierung und 
anschließende Passerini-Reaktion dargestellt. Um die Aufarbeitung zu vereinfachen, 
wurde ein immobilisierter, von Prolin abgeleiteter Katalysator hergestellt und 
erfolgreich eingesetzt. Es wurde eine Verbindungsserie an potentiellen BACE-1-
Inhibitoren synthetisiert, die strukturell auf dem potenten, jedoch nicht-spezifischen 
20S-Proteasom-Inhibitor MG132 basieren. Die biologische Aktivitätsuntersuchung 
dieser Verbindungen zeigte eine moderate BACE-1-Hemmung; jedoch erwiesen sie 
sich als hochpotente und vielversprechende 20S-Proteasom-Inhibitoren. Der 
hochpotente Inhibitor BSc2118 mit geringer Toxizität und effektiver 
Proteasomhemmung initierte die weitere Evaluierung und Optimierung der 
Leitverbindung. Die kombinierte Behandlung mit BSc2118 und Calpain-spezifischen
Inhibitoren wurde an MeWocis1-Zellen untersucht und es zeigte sich, dass zwei 
verschiedene proteolytische Kaskaden beeinflusst werden, die den durch Proteasom-
Inhibitoren vermittelten Tumorzelltod, insbesondere den von Cisplatin-resistenten 
Zellen, erhöhen.
Vor kurzem wurde gezeigt, dass ein Agonist des nuclear receptor peroxisome 
proliferator-activated receptor gamma (PPAR-Ȗ) das Verhalten in einem AD-
Tiermodel verbessert. Arteriosklerose, Koronare Herzkrankheit und Bluthochdruck 
wurden als weitere Risikofaktoren bei AD identifiziert. Kürzlich wurde eine 
Untergruppe an  Angiotensin-Rezeptor-Blockern vom Typ 1 (AT1) als Liganden für 
PPAR-Ȗ identifiziert. Daher wurden zwei aktive Losartan-Metaboliten EXP3174 und 
EXP3179 synthetisiert und auf ihre PPAR-Ȗ-aktivierenden Eigenschaften untersucht. 
Ferner wurde untersucht, ob EXP3179 eine kollagenabhängige, 
thrombozytenaktivierende Wirkung besitzt, welche über den Glycoprotein-Receptor-
VI verläuft und somit unabhängig vom AT1-Rezeptor-Antagonismus ist. Diese 
Wirkung könnte sich positiv auf Athereothrombose auswirken. Weiterhin zeigte sich, 
dass die AT1-Blockierung in Astrozyten die Zellschäden durch Sauerstoffmangel und 
Entzündungen vermindert. Eine AT1-R-Blockierung könnte ein therapeutischer 
Nutzen bei neurodegenerativen Fehlfunktionen sein, die begleitend mit 
Entzündungen wie Alzheimer, Parkinson, Herzinfarkt sowie Multipler Sklerose 
auftreten. Dies kann durch die entzündungshemmende Wirkung der Astrozyten 
erklärt werden. 
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1. INTRODUCTION
1.1. Alzheimer's Disease (AD) 
The most common form of dementia among mid-to-late-aged people is Alzheimer’s 
disease (AD). According to World Health Organization it accounts for 50% of all 
dementia cases worldwide.[1] The symptoms of the disease include memory loss, 
confusion, impaired judgment, personality changes, disorientation, and loss of 
language skills. The ultimate cause of the disease is unknown. Probably there is no 
single cause, but several factors that affect each person differently. Age is the most 
common known risk factor for AD. Macroscopic changes found in late AD brains 
includes shrinkage of the gyri, widening of the sulci and enlargement of the 
ventricles along with the two major microscopical lesions: which are extracellular 
amyloid plaques[2] and intracellular neurofibrillary tangles.[3]  
1.1.1. Amyloid Plaques 
The main constituent of the accumulated amyloidic plaques in the brain is E-amyloid 
peptide (AE). The activity of two aspartic proteases (E-secretase and Ȗ-secretase) on 
E-amyloid precursor protein (APP) results in AE of length from 38 to 42 amino acids 
(Figure 1.1). D-Secretase pathway degrades 90% of the APP, rest is degraded by the 
consecutive cleavages of E- and Ȗ-secretase to build up extracellular AE deposits. 
The recognized amyloid plaques in the brains of AD patiens are neuritic and diffused 
plaques. The neuritic plaque of 50 to 200 μm spherical diameter, has a dense amyloid 
core and is surrounded by dystrophic neuritis.[4] In contrast, diffuse plaques do not 
contain an amyloid core and are not surrounded by dystrophic neuritis.[4] Unlike 
neuritic plaques, the amyloid deposits in the diffuse plaques are non-fibrillar[2] and 
are comprised almost exclusively of AE42, with little or no AE40.
1.1.2. Neurofibrillary Tangles
In AD victims, neurofibrillary tangles (e.g. entorhinal cortex, hippocampus, 
parahippocampal gyrus, and amygdale) are found in various brain regions consisting 
of ~10 nm of paired helical twisted filaments composed of phosphorylated tau 
proteins. Hyperphosphorylated tau protein poorly binds to microtubules and alters 
their stability.[3] This leads to disintegration of intracellular transport, cellular 
geometry, and neuronal viability, eventually causing cell death. Large pyramidal 
neurons mostly develop neurofibrillary tangles, particularly those with long cortico-
cortical connections.[4]
1.1.3. E-Amyloid Precursor Protein (APP) Processing 
APP is a single transmembrane domain protein with luminal N-terminal domain and 
a short intracellular C-terminal domain (Figure 1.2). It is overall expressed in a 
variety of tissues including brain.[3] There are three major isoforms in human, that 
have 695, 751, and 770 residues respectively (Figure 1.2A). APP751 and APP770 
are two longer forms, consisting of 56 amino acid domain are homologous to a 
Kunitz-type of serine protease inhibitor (KPI) (Figure 1.2A) and are extensively 
expressed throughout the body.[3] The most abundant isoform in the brain is APP695 
which is expressed predominantly by neuronal cells with a very low level of 
expression in non-neuronal cells. 
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Figure 1.1: Processing of APP by secretases. (A) E-Secretase cleavage of APP generates 
sAPP-E and the C-terminal fragment C99. (B) D-Secretase cleavage generates sAPP-D and 
the C-terminal fragment C83. Ȗ-Secretase process the C-terminal fragments from the both 
pathways and generates AE (Amyloidogenic pathway) and p3 (Non-amyloidogenic 
pathway). AICD is generated by processing at the İ-site from both pathways (modified from 
reference [5]).   
AE is derived from its large precursor protein (i.e. APP) by proteolysis.[7] Proteolysis 
of the molecule is a vital feature of APP biology. The half-life of APP is very short 
(about 2030 minutes). It is metabolized down into the non-amyloidogenic D-
secretase pathway or the amyloidogenic E-secretase pathway.[3] Tumor necrosis 
factor-D converting enzyme (TACE) are responsible for the D-cleavage; a member of 
the a disintegrin and metalloprotease (ADAM) family of metalloproteases.[8] D-
secretase pathway is predominant under normal conditions; it cleaves APP between 
amino acids 16 and 17 of the AE region. Thus it prevents the production of AE[8]
(Figure 1.2A and B). E-secretase process a smaller amount of APP and it cleaves 
APP between residues 671 and 672 (Figure 1.2C). A slightly truncated form of 
sAPP (sAPP-E) is released from the cell and a 99-residue C-terminal fragment (CTF) 
i.e. C99 is left behind at the membrane. E-site APP cleaving enzyme (BACE) carried 
out a cleavage at the AE N-terminus (Figure 1.1).[3]
Two homologs of BACE have been identified. An aspartyl protease of pepsin 
protease family BACE-1 is mainly expressed in brain and pancreas. The BACE-2 
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which probably has little effect on processing of APP, has a low expression in 
brain.[9] BACE-1 is expressed as a pro-enzyme, and moved through the Golgi where 
it is glycosylated and the pro-peptide is cleaved off. To cleave APP the release of the 
pro-peptide is not obligatory for BACE-1. Moreover, APP is not the only protein 
hydrolyzed by BACE-1, other substrates identified are sialyl-transferase ST6Gal, P-
selectin glycoprotein ligand-1, APLP1 and APLP2.[8] Finally Ȗ-secretase cleaves the 
CTFs generated from D- and E-secretase cleavage i.e C83 and C99, respectively 
either at residue 711 or at residue 713 to produce the p3 peptide or AE.[2] Low 
sequence specificity is shown by Ȗ-secretase processing (Figure 1.1) which generates 
AE peptides of different length. AE40 is the most abundant product while the longer 
AE42 variant is generated to a lesser extent.[9] Another cleavage occurrs 
simultaneously with Ȗ-secretase processing called İ-cleavage. It has been shown to 
occur at position 49 in AE.[10] The presence of presenilin proteins is required for both 
Ȗ- and İ-processing. The APP intracellular domain (AICD) resulting from İ-cleavage 
(Figure 1.1) is rapidly turned over but can be stabilized by interaction with Fe65.[11]
Despite intensive study, the functions of APP and its fragments are not yet fully 
exposed. Soluble sAPP-D was found to be capable of acting as an autocrine factor 
and as a neuroprotective and neurotrophic factor.[12] However, most of these 
functions have not yet been assured in vivo.
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Figure 1.2: Schematic illustration of the structure of the APP protein with the two pathways 
that are processed by secretases (A). APP has a single membrane-spanning domain (TM) and 
at the N-terminus a 17-residue signal peptide. Two APP alternate splice forms are presented 
here which comprise 695 and 770 amino acids, respectively. (B) D-Secretase cleaves APP 
after residue 687 resulting in sAPP-D and the carboxy-terminal fragment C83 in the 
membrane. Ȗ-Secretase cleaves the C83 fragment at residue 711 or residue 713 to release the 
p3 peptides. (C) On the other hand, E-secretase cleaves APP after residue 671 resulting in 
the secretion of the slightly truncated sAPP-E and the retention of C99. It can be further 
cleaved by Ȗ-secretase at residue 711 or residue 713 to release the AE40 or AE42 peptides 
(modified from a figure by Selkoe[6]).
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However, the APP derivative AE42 is thought to be a key factor in the pathogenesis 
of AD, as AE42 is more responsible for fibril formation due to its self-assembly and 
turned out to be a major AE constituent of amyloid plaques. APP mutations such as 
K670N/M671L (Swedish mutation) at the E-secretase cleavage site or 1716V, 
V7171,F,G, at the J-secretase cleavage site cause an increased production of AE42
and are responsible for early-onset forms of AD (familial AD or FAD).[13] Another 
early-onset of AD and an increased AE40,42 production is observed in Down´s 
syndrome patients who have an extra copy of chromosome 21 and overexpress 
APP.[14] Based on genetic findings in FAD and observations in Down’s syndrome, 
the role of AE in the pathogenesis of AD has been formulated as the “amyloid 
cascade hypothesis”.[15] The aggregated AE is then supposed to induce all subsequent 
pathology, including tau hyperphosphorylation, tangle formation, and neuronal 
death. Hence, AE42 clearance or decrease in production can prevent the succession of 
AD.
This target can be achieved either by E-secretase or J-secretase inhibition while E-
secretase is the first and most intresting step towards the inhibition of AE42 
production.
1.1.4. Therapeutics for AD
No causal therapy for AD is clinically accessible at present regardless of intense 
research endeavours. Anti-oxidant therapy, AChE inhibitors, nicotinic and 
muscarinic agonists, nerve growth factor (NGF), low molecular lipophilic 
compounds, anti-inflammatory drugs, drugs which interfere with AE formation and 
deposition, drugs those attenuate AE toxicity are the existing pharmacological 
advances related to AD treatment.[16] Several identified receptors and enzymes like 
GSK-3, PDE 4, and muscarinic M1 amidst others are targeted by more than 50 
compounds which are in development to treat AD. nACh modulators, AChE 
inhibitors, NMDA modulators, 5-HT agonists and vaccination are the other 
associated projects which are in progressed phases of research or clinical 
progression. nAChE inhibitors and vitamin E are established and authorized 
therapies for AD.[5, 16] The risk for the AD development is thought to be diminished 
by non-steroidal anti-inflammatory and cholesterol lowering drugs uptake.[3] Besides 
few non-peptidic confirmed E-secretase inhibitors, a number of compounds and 
vaccinations are piercing phase II clinical trials and stipulate progressed AD 
diagnostics.
1.1.4.1. E-Secretase: an ideal target for the treatment of AD? 
E-Secretase is an aspartic protease with the flexible flap region, which is crucial for 
substrate docking. The open and closed state of the flexible flap region is responsible 
for selectivity and activity of the enzyme.[17] Diverse novel features of BACE were 
explored after the investigation of flexibility of free and inhibitor bound BACE in
silico and found to be valuable for structure-based computer-aided inhibitor design. 
The only identified substrate was APP which made BACE-1 an attractive target for 
drug development before the exploration of APLP1, APLP2 and other substrates 
since the last two years. These findings can progress the drug development and can 
be exploited to identify BACE inhibitors.[8]
A standard nomenclature is mentioned in Scheme 1.1 to assign amino acid residues 
of peptide substrates as P1 Pn, P1 Pn  while the subsequent binding sites on the 
enzyme are designated as S1 Sn (upwards towards the N terminus of the substrate), 
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S1 Sn  (towards the C terminus) subsites beginning from the sites on each side of 
the scissile bond.[18] Subsites are defined by the surface of the protease that is able to 
accommodate a single side chain of a substrate residue. 
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Scheme 1.1: Schematic representation of a protein substrate binding to a protease.
(Reproduced by permission of The Royal Society of Chemistry [18])
The proposed mechanism of hydrolysis by aspartic proteases is depicted in Scheme
1.2. An activated water molecule is used by the enzyme to attack the carbonyl of the 
substrate's scissile amide. The two aspartyl E-carboxy groups at the active site (the 
aspartate proteases) are responsible for the activation of the water molecule. In the 
proposed mechanism, the Asp group that is closer to the nucleophilic water molecule 
was assigned the negative charge. The nucleophilic water molecule, which is held 
between the catalytic aspartates, attacks the carbonyl group near to the substrate 
scissile bond to generate an oxyanion tetrahedral intermediate, after its activation by 
the negative aspartate side chain. Protonation of the scissile amide N- atom and 
rearrangement results in the hydrolyzed products. 
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Scheme 1.2: Proposed mechanism of hydrolysis by aspartic proteases.[17]
BACE-1 is also called ASP-2 or memapsin-2 and BACE-2 as ASP-1 or memapsin-1. 
ASP-2 that belongs to the pepsin family is a novel membrane-bound, 501 amino acid 
aspartyl protease. BACE-2 causes additional cleavages close to Phe19 and Phe20.[16]
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BACE-1 is attached to the membrane through its transmembrane domain (455-480) 
and possibly active as a dimer. Cysteine bridge formation (Cys216/Cys420,
Cys278/Cys443, Cys330/Cys380), N-glycosylation and propeptide elimination is required 
for BACE-1 maturation. A markedly dissimilar localization and a less pathogenic 
APP cleavage pattern are exhibited by the homologous BACE-2. The catalytic 
domain of BACE has a ligand-binding pocket that is different from the enzymatic 
active site. The proteolysis of APP can be inhibited by the peptide binding to this 
exosite (e.g. Ac-ALYPYFLPISAK-NH2, IC50 = 1.3 μM).[16] BACE-1 deficiency 
results in the accumulation of unprocessed neuregulin 1 (NRG1), an axonally 
expressed factor required for glial cell development and myelination. Willem et al. 
reported recently that BACE-1 is required for myelination and correct bundling of 
axons by Schwann cells.[19]
1.1.5. BACE-1 Inhibitors 
So far, BACE-1 inhibitors are interesting therapeutic agents for AD. Similarity 
between BACE-1 and other aspartyl proteases made the design of BACE-1 inhibitors 
easy. However, the selectivity against other aspartyl proteases, especially cathepsin 
D (CatD) and renin, is a big challenge. The peptidomimetic approach has been 
effectively applied to the design of the first generation of potent BACE-1 inhibitors 
and the peptide-based transition state analogues are still the benchmark of BACE-1 
inhibition.[5, 16] Out of norstatines, statines, bis-statines, hydroxyethylenes, 
hydroxyethylamines and hydroxyethylureas based inhibitors, the hydroxyethylenes 
were found to be the first highly potent inhibitors. The determination of X-ray crystal 
structures of BACE in complex with potent inhibitors i.e OM99-2 (1) and OM00-3 
(2) respectively (PDB: OM99-2, 1FKN; OM00-3, 1M4H) at 1.9 Å and 2.1 Å, is 
likely to accelerate the discovery of a new inhibitor drug through the various 
structure-based approaches including virtual screening and de novo design methods 
(Scheme 1.3).[16] 
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Scheme 1.3: Hydroxyethylene-based BACE-1 inhibitors.[16]
Hydroxyethylenes were coordinated by two catalytic aspartates with four hydrogen 
bonds. The backbone conformations from P3 to P2 and the structure of the enzyme 
only differ in side chain configurations of various subsites. In OM00-3 (2) the P3, P2,
and P2´ residues have been replaced. P4 Glu is responsible for a more linear 
conformation at both ends of OM00-3 (2) relative to OM99-2 (1) that resides in a 
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new S4 pocket and an extra extended P3´ and P4´ residues. Comparative to the P2 Asp 
in OM00-3 (2), a hydrogen bond from the P4 Glu to the P2 Asn is more favourable in 
the OM99-2 (1) complex. However, the identification of small drug-like molecules is 
the major challenge. Peptide-based inhibitors with high molecular weight and various 
chiral centres are expensive to produce. Furthermore, the peptidic character results in 
low stability and poor oral bioavailability and low penetration of the blood–brain 
barrier of the inhibitor. The introduction of the isophthalamide was suggested to be a 
significant move towards less peptidic compounds 3–5 (Scheme 1.4) which may be 
essential for sufficient oral absorption and blood brain barrier penetration.[20-23]
Moreover, the C-terminus reduction and utilization of different transition state
isosteres were also employed by this modification.  
N N
H
N
H
O O
F
F
OH
O
5 Elan (IC50 = 30 nM, 
HEK-293 EC50 = 3000 nM)
N
O
N
H
O
O
N
H
3 Elan WO2003072535 
(IC50 = 200 nM)
4 Takeda WO2004014843 
       (IC50= 99 nM)
N N
H
N
H
O O
OH
OMe OMe
Scheme 1.4: Structures of BACE-1 inhibitors.[16]
The hydroxyethyleneamine (HEA) isostere has one less amide bond than the 
norstatine isosteres and lower molecular weight. One example of such inhibitors is 3
from Elan/Pharmacia which was known to be moderate inhibitors in FRET or 
cellular assays. Co-crystal structure of this compound with BACE-1 (PDB: 1W50) 
revealed key binding interactions between compound 3 and BACE-1 (Figure 1.3).[23]
The active site aspartates were identified by the secondary amine and secondary 
alcohol in a remarkable fashion. A proton from the catalytic Asp228 is accepted by the 
neighbouring amine and its 3-methoxy benzyl substituent is placed in the S2´ pocket. 
One of the N-propyl groups of the isophthalamide occupies the S3 pocket and packs 
against the phenyl group in the S1 pocket. Interaction of the phenyl rings in both the 
S1 and the S2´ pocket is in a T-shaped stacking with Tyr71 of the flap. Takeda (4), 
Glaxo, Upjohn Pharmacia and Elan accounted some 750 close analogues of 3.[13] A
series of benzylic hydroxyethylamines containing inhibitors are developed by 
Bristol-Myers Squibb, some of these compounds displayed good inhibitory 
activity.[16]
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Figure 1.3: A: a representation of binding mode of Elan 3 Hydrogen bonds to residues are 
shown as broken lines and the associated numbers (Reprinted from Journal of Molecular 
Biology[23] Copyright (2004), with permission from Elsevier). B: BACE-1 complexed to Elan 
3 (PDB: 1W51).
In early 2004 researchers of Kyoto University reported the norstatine compounds 
KMI-358 (6) and KMI-370 (7) as potent and cell permeable BACE-1 inhibitors.[24]
However, these compounds were found to be unstable due to the migration of oxalyl 
group from side chain nitrogen to the terminal nitrogen at neutral PH which was 
surmounted by replacing this group with a tetrazole moiety and improved the 
chemical stability with retention of BACE-1 activity (6, KMI-420: IC50 = 8.2 nM) 
and (7, KMI-429: IC50 = 3.9 nM) Scheme 1.5.[25] 
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Scheme 1.5: Norstatine based BACE-1 inhibitors.[24-25]
Another HEA inhibitor was discovered as reversible and selective BACE-1 inhibitor 
(IC50 = 25 μM, 8)[26] by Merck and NeoGenesis researchers with the aid of the 
NeoGenesis Automated Ligand Identification System[27] (ALIS) technology (Scheme
1.6). 18-fold enhanced potency (IC50 = 1.4 μM, 9) and a good selectivity for 
cathepsin D (IC50 > 500 μM, 9) was obtained by replacement of the side chain diallyl 
amide with a benzyl sulphate and an addition of fluorine atom at the 4-position of the 
D-methylbenzamide (Scheme 1.6).
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Scheme 1.6: Non-peptidic BACE-1 inhibitors.[26, 28]
It can be seen by a co-crystallized structure of modified BACE-1 (K75A, E77A) with 
9 (PDB: 1TQF, Figure 1.41.5) that the compound occupies the S4 to S1 subsites and 
does not have any interaction with the prime side of the enzyme. In fact the active 
site has no direct contact with the inhibitor. Moreover, the terminal aminopentyl 
residue coils back into the S1 pocket. The oxyacetamide NH forms an indirect 
hydrogen bonding with the catalytic aspartic acids through a water molecule.  
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Figure 1.4: BACE-1 complexed to 9 (PDB: 1TQF). 
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Figure 1.5: A: Hydrogen bonding network for BACE-1/inhibitor 9 complex (Reprinted from 
Journal Medicinal Chemistry[26] Copyright (2004), with permission from American 
Chemical Society). B, C, D: BACE-1 complexed to 9 (PDB: 1TQF). 
A further modification was attained by attaching a hydroxylamine moiety to an 
isophthalamide backbone which enhanced the inhibition to 11 nM (10) and it 
maintained 500 fold selectivity towards cathepsin D (Scheme 1.6).[28] The hydroxyl 
group of the inhibitor connects to Asp32, while the protonated D-amino group 
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interacts with Asp228 concurrently and causes an enhancement of activity. Further 
improvement in the inhibition may have occurred by the S1 subsite engagement and 
cyclopropyl orientation toward the S1´ site of the enzyme. Cell permeability can be 
controlled by the P1´ substituent disparity. The co-crystallized structure of inhibitor 
10 with BACE-1 was deposited in the PDB (2B8L). The inhibitor 10 showed good in
vitro (IC50 = 15 nM) and cell-based (IC50 = 29 nM) potencies against BACE-1 and 
was found to be 10-fold selective versus the homologous enzyme BACE-2. 
However, problems regarding its pharmacodynamic properties prohibited its 
advancement. Numerous current patents target a diversification of the side chains in 
order to improve the activity but still were not successful.[29-32] However, based on 
the this isophthalamide lead structure 10, MSD researchers have recently synthesized 
and evaluated reduced amide isostere that displayed impressive cellular IC50
values.[33-34]
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1.1.6. Organocatalytic Approach towards the Synthesis of Key 
Chiral Elements 
Norstatine derivatives are important building blocks for the synthesis of BACE-1 
inhibitors. Proline catalyzed reactions are widely used for the synthesis of D-amino 
aldehydes, D-amino alcohols, and D-amino acids, which are key chiral elements in 
many natural products as well as in medicinal chemistry. This approach can also be 
applied for the synthesis of norstatine-based peptidomimetics as evaluated in this 
thesis.
1.1.6.1. Organocatalysis 
Organocatalysis is an acceleration of chemical reactions with a substoichiometric 
amount of a non-metallic organic compound.[35] Organocatalytic reactions are 
becoming powerful tools in the construction of complex molecular skeletons. It is 
evident that they played a major role in the formation of prebiotic key building 
blocks, such as sugars, and thus allowed the introduction and spread of homochirality 
in living organisms.[36] In recent years the scope of organocatalytic reactions has 
been expanded significantly. Distinctive transition-metal-mediated coupling; Suzuki, 
Sonogashira, Ullmann, and Heck-type reactions, as well as the Tsuji–Trost reaction, 
can now be carried out under metal-free conditions.[37] Enantioselective 
organocatalytic processes have arrived at an unprecedented peek in recent years with 
a remarkable number of applications now accessible. Important chiral building 
blocks, such as D-amino acids, D-amino alcohols, aziridines, epoxides, 1,2-diols and 
D-sulfenylated, selenenylated and halogenated carbonyl derivatives can be 
constructed by chiral D-heterofunctionalised carbonyl compounds. Amine based 
reactions are the most popular organocatalytic reactions.[38] Asymmetric amino 
catalysis, amino acids, peptides, proline, imidazolidinone derivatives, cinchona 
alkaloids and their ammonium salts, as well as Brønsted acid derivatives have been 
used as chiral catalysts in these types of reactions.[39]
1.1.6.2. Proposed mechanism of L-proline catalyzed reactions
Ketones or aldehydes can form iminium ions with chiral secondary amine catalysts. 
These intermediates form a nucleophilic enamine species by reacting through an 
imine–enamine tautomerism or any related mechanism, which can be caught easily 
by an activated ʌ electrophile, for example, an aldehyde, ketone, or azodicarboxylate. 
The generation of reversible and catalytic enamines (III) from amines (VII) and 
carbonyl compounds (I) is the basis of enamine catalysis (Scheme 1.7).[37, 39] The 
spectacular amplification in C-H-acidity upon initial conversion of the carbonyl 
compound into an iminium ion (II) facilitate enamine formation. Addition reactions 
with various electrophiles (X=Y) is possible by this catalytically generated enamine 
(III) in the same way as a pre-formed enamine will show the reactivity.[40] The D-
substituted carbonyl product (VI) is produced by the resulting new iminium ion (V)
after hydrolysis with in situ produced water. 
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Scheme 1.7: Proposed mechanism of L-proline catalyzed reactions of ketones and aldehydes 
with electrophiles.[37, 39]
L-Proline (11, Scheme 1.8) is undoubtedly the catalyst of choice untill now for 
enamine-type reactions and beneficial over enzymatic methods. Although both 
enantiomers of proline are accessible yet the natural L form is used very often. 
Similar transformations comparable to complex enzymes like (class I aldolases) can 
be obtained by this simple amino acid (Scheme 1.7).[37, 39] The natural amino acid 
proline with secondary amine functionality has a relatively higher pKa value and 
enhanced nucleophilicity. It forms iminium ions or enamines by reacting with 
carbonyl groups or Michael acceptors as a nucleophile. This molecule promotes the 
formation of highly organized transition states with extensive hydrogen-bonding 
networks resulted in an exceptional enantioselectivity. The proton transfer from 
carboxylic acid group to the forming alkoxide or imide is crucial for charge 
stabilization and C_C bond formation in the transition state.[37, 39]
1.1.6.3. Important features of proline as an organocatalyst
It is a non toxic, inexpensive, water soluble and readily available catalyst in both 
enantiomeric forms. No inert conditions are required for its reactions. Observed 
reaction yields and enantioselectivities are moderate to good. No prior modification 
of the carbonyl substrates such as deprotonation or silylation is required. It is a 
nonmetallic small-molecule catalyst for direct intermolecular asymmetric aldol 
reactions or D-amination comparable to the best organometallic catalysts.  
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1.1.6.4. Immobilized proline catalyst 
Efficient re-cyclization and reuse of catalysts is always desired. Font et al. 
established an example during the synthesis of polystyrene-supported 4-
hydroxyproline, which was anchored to the resin through click chemistry (Scheme
1.9).[41] It is an insoluble, recyclable organocatalyst for the asymmetric aldol reaction 
in water. The high hydrophobicity of the resin and the presence of water are key to 
ensuring high stereoselectivity, whereas yield was increased by using catalytic 
amounts of DiMePEG.  
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Scheme 1.9: Polystyrene-Supported Hydroxyproline catalyzed aldol reaction.[41]
1.1.6.5. Proline catalyzed reactions 
In proline catalyzed reactions the electrophile X=Y should have an electron lone pair 
at Y that may be critical for efficient asymmetric induction in proline-catalyzed 
reactions. In addition to ketones, D-unbranched aldehydes can be used as donors in 
enamine catalysis both with aldolase enzymes as well as with proline and other 
aminocatalysts.[42] Proline-catalyzed direct asymmetric intermolecular aldol reaction,
direct D-amination of carbonyl derivative, proline-catalyzed Mannich reaction and 
proline catalyzed D-aminooxylation of aldehydes and ketones etc. are recognized as 
asymmetric organic reactions.[42]
1.1.6.6. Direct D-amination of carbonyl derivatives 
One of the many challenges for organic chemists is the enantioselective construction 
of molecules bearing a carbon–nitrogen bond via direct D-amination by using readily 
available starting materials. Jørgensen et al. and List et al. reported simultaneously 
the direct organocatalyzed D-amination of aldehydes using L-proline (11) and 
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different azodicarboxylate derivatives as the electrophilic nitrogen source[43-45]
(Scheme 1.10).
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Scheme 1.10: L-Proline (11) catalyzed D-amination of aldehydes.[43-45]
According to List et al., when a mixture of proline (10 mol%), the D-unbranched
aldehyde (1.5 equiv), and dibenzyl azodicarboxylate (1.0 equiv) reacted at 0 °C, the 
corresponding D-hydrazino aldehydes are obtained in high yields and ee’s (Scheme
1.10).[43] Since D-hydrazino aldehydes were transformed into their corresponding 
stable and crystalline D-hydrazino alcohols to avoid the recemization and isolated in 
excellent yields and ee’s.[39] The crystalline character of these amino alcohols further 
helped to improve the enantiomeric excesses by simple recrystallization. Jørgensen et 
al. also reported similar results.[44-45] The product obtained in his work was easily 
isolated just by the addition of water and simple extraction with diethyl ether. 
Moreover, the yield and enantioselectivity did not change when the reaction was 
carried out on a gram scale. The production of molecules containing quaternary 
stereocentres is a tricky and demanding goal in organic chemistry. The reaction of D-
alkyl-D-aryl disubstituted aldehydes with either DEAD (R2 = Et) or DBAD (R2 = Bn) 
catalyzed by either L-proline (11) or L-azetidine carboxylic acid (12) yielded the 
expected aldehydes in good enantioselectivity. The acquired yield was good in the 
case of L-proline (11) while it was moderate when L-azetidine carboxylic acid (12)
was used as a catalyst (Scheme 1.11).[45]
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Scheme 1.11: L-Proline (11) and L-azetidine-2-carboxylic acid (12) catalyzed D-amination
of disubstituted aldehydes.[43-45]
Some additional catalysts have also been used in the direct D-amination of 
aldehydes, which were designed to amplify the solubility and hence, the turnover 
number of the catalyst. 2-(Arylsulfonylaminomethyl)pyrrolidines 14 (Scheme 1.8)
accomplish all the requirements to perform as organocatalysts.[46]
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Tetrazole proline derivative (13) showed superiority to proline as a catalyst in the 
reaction of substituted aldehyde with DBAD to give good enantioselectivity and 
yield (Scheme 1.12). When L-proline (11) was used the enantioselectivity obtained 
in only 44 % and reaction completed in 3 h to 5 days. The lower pKa (8 in DMSO, 
12 for proline) and higher steric hindrance of tetrazole proline derivative is the 
probable cause of the higher reactivity and selectivity in comparison to proline.[47]
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Scheme 1.12: Tetrazole proline derivative (13) catalyzed D-amination of disubstituted 
aldehydes.[47]
Jørgensen et al. also pioneered in elaborating this reaction to ketones (Scheme
1.13).[48] The best results were obtained using DEAD as the electrophilic source of 
nitrogen. All reactions were regioselective, the main isomer in the amination 
occurring on the most substituted D-carbon atom to the carbonyl of ketone, with the 
larger substituent giving the higher enantioselectivity.
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Scheme: 1.13: D-amination of ketones using L-proline (11).[48]
Keeping in sight the significance of D-aminated proline catalyzed reaction; many 
organocatalytic reactions were performed in this study and their significance is 
elaborated towards the synthesis of BACE-1 inhibitors in the present study.
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1.2. 20S ProteasomeTarget for Oncology and Neurodegeneration 
O what avails the classic bent,
and what the cultured word, 
against the undoctored incident 
 that actually occurred? 
(Kipling) 
History proved that serendipity played a big role in science and technology. The sum 
of input of serendipitous discoveries varies widely among the several scientific 
disciplines. Pharmacology and chemistry are more common disciplines of science 
where this occurs most often.  
A set of peptide analogue aldehydes was synthesized as potential E-secretase 
inhibitors. In parallel to the targeted biological studies, the synthesized compounds 
were tested for 20S proteasome inhibition due to their resemblance with ȕ5 subunit 
signature/preferences for proteolytic activity and were found to be the most potent 
and promising inhibitors. This serendipity encouraged the design of more selective 
proteasome inhibitors. Therefore, some introduction of proteasome and its inhibition 
is provided in following sections. 
1.2.1. Proteasome 
Protein degradation is a key pathway in cells for the devastation of abnormal or 
damaged proteins and the elimination of proteins whose presence is no longer 
needed. The proteasome which is an extremely conserved intracellular nonlysosomal 
multicatalytic protease complex degrades those proteins typically tagged with a 
polyubiquitin chain. The ubiquitin-proteasome pathway plays a significant role in the 
degradation in many short-lived regulatory proteins. Such proteins administrate cell 
division, growth activation, signalling and transcription. Proteasome play a key role 
in controlling cell proliferation and maintaining cell survival. A disordered cell 
proliferation and a tumor development can occur by a deregulation of the system. 
Abnormality in the ubiquitin-proteasome pathway can also lead to inflammation, 
autoimmune and other diseases. This understanding has provoked research into the 
design and synthesis of diverse proteasome inhibitors and the estimation of their 
therapeutic potential. In recent years proteasome inhibitors are the most promising 
and novel class of anti-cancer drugs.[49]
1.2.1.1. Proteasome structure
The structure of the proteasome was resolved from the electron micrograph of the 
complex purified from different organisms. The 26S proteasome is composed of two 
distinct units: a 20S proteolytic cylinder of about 700 kD flanked by two 19S 
regulatory caps (also known as PA 700). One more form of proteasome comprised of 
a 20S unit flanked by two 11S subunits is known as the immunoproteasome which 
plays a role in Class I antigen processing. The 20S proteasome is a large cylindrical 
structure consisting of four stacked rings, each of them composed of 7 subunits. The 
eukaryotic proteasome is composed of a stack pile of two outer rings of 7 unique but 
related D subunits and two inner rings of 7 unique but related E subunits (Figure 
1.61.8).
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Figure 1.6: (A) Schematic representation of the DEED sandwich fold of proteasomes. Two 
E-sheets are stacked between two layers of D-helices. The core structure is shared by the D-
and E-subunits of 20S proteasomes and by HslV. Differences occur at the N and the C 
termini. In 20S proteasome E-subunits, helix H0 is missing. In HslV, this helix and in 
addition strand S10 and helix H5 are absent. (B) Superposition of HslV (yellow) with the E-
subunits of the T. acidophilum proteasome (red) in complex with calpain inhibitor I. (C)
Ribbon diagram of the D-subunit of the T. acidophilum proteasome. (D) Ribbon diagram of 
the E-subunit of the T. acidophilum proteasome. “Reprinted, with permission, from the 
Annual Review of Biochemistry and Biomolecular Structure, Volume 28 © 1999 by Annual 
Reviews www.annualreviews.org” [50]
Figure 1.7: (A) Sphere model of E. coli HslV. (B) Ribbon diagram of E. coli HslV. (C)
GRASP representation of E. coli HslV. (D) Sphere model of the T. acidophilum 20S 
proteasome. (E) Ribbon diagram of the T. acidophilum proteasome. (F) GRASP 
representation of the T. acidophilum 20S proteasome. (G) Sphere model of the S. cerevisiae
20S proteasome. (H) Ribbon diagram of the S. cerevisiae 20S proteasome. (I) GRASP 
representation of the S. cerevisiae 20S proteasome. “Reprinted, with permission, from the 
Annual Review of Biochemistry and Biomolecular Structure, Volume 28 © 1999 by Annual 
Reviews www.annualreviews.org”[50]
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Figure 1.8: Ribbon diagram of the S. cerevisiae 20S proteasome. E1 is drawn in blue, E2 in 
red, E3 in green, E4 in light purple, E5 in yellow, E6 in green-blue, E7 in dark purple. D1 is 
in green, D2 in pink, D3 in light blue, D4 in dark blue, D5 in grey, D6 in dark yellow, D7 in 
rose. The colors are the same as in Figures 1.7 (G) and 1.7 (H). “Reprinted, with 
permission, from the Annual Review of Biochemistry and Biomolecular Structure,
Volume 28 © 1999 by Annual Reviews www.annualreviews.org ”[50] 
The 19S particle consists of 18 subunits. It is responsible for the recognition, the 
deubiquitinylation and the unfolding of the protein substrate before its translocation 
to the catalytic core of the 20S proteasome. This regulatory complex comprises 
polyubiquitin receptors, an isopeptidase activity that catalyses the discharge of free 
ubiquitin and six ATPases required in particular for the denaturation of the protein 
substrates. The whole complex connects with the ends of the 20S core to permit the 
proteolysis in an ATP-dependant way.[49]
1.2.2. Peptidase Activities of the Proteasome 
20S proteasome contains three main activity domains that differ from each other on 
the basis of their active sites, kinetics, pH optima and sensitivities to inhibitors. 
These peptidase activities of the proteasome are designated as “chymotrypsin-like” 
(CT-L), “trypsin-like” (T-L) and “peptidyl-glutamyl peptide hydrolyzing” (PGPH) or 
caspase-like activity. The cleavage after hydrophobic, basic, and acidic amino acid 
residues are made by these three activities respectively. Each E subunit can be 
allocated to a specific activity. The subunit E1 is responsible for PGPH activity while 
E5 and E2 provide the CT-L and T-L activities respectively.[49] Besides these the 20S 
proteasome possesses two other activities: a branched chain amino acid preferring 
(BrAAP) activity, and a small neutral amino acid preferring (SNAAP) activity.[50]
The implication of the amino terminal “Thr-1” is depicted after the analysis of the 
proteasome catalytic mechanism. It was proposed to be a catalytic nucleophile for the 
proteolysis. Ser, Cys, and Asp act as nucleophilic catalysts in numerous non-
proteosomal proteases and not engaged in the proteolysis. The inhibitor was found to 
be in a close proximity to the hydroxyl group of the amino acid terminal Thr-1. It 
was disclosed by the X-rays analysis of the 20S proteasome complexed with the 
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inhibitor 30 N-acetyl-Leu-Leu-norleucinal (ALLN). It forms a hemi-acetal 
intermediate group which blocks the proteasome activity.[51]
1.2.3. Role of Ubiquitin-Proteasome Pathway in Diseases 
The proteasome regulates the levels of proteins engaged in cell cycle control such as 
G1 and mitotic phase cyclins,[52] cdk inhibitors,[53] various oncogene tumor 
suppressor proteins,[54] and other regulatory proteins.[55] It is proved that 
ubiquitin/proteasome-dependent proteolysis plays an indispensable role in 
controlling cell proliferation and cell death. It also plays a role in immune 
surveillance,[56] the possession of long term memory,[57] and in regulation of 
circadian rhythms.[58] The progression of diseases are interrupted by  ubiquitin 
proteasome pathway in two different manners. One is stabilization and accumulation 
of normal and abnormal proteins[59] and other is abnormal degradation of proteins.[60]
1.2.3.1. Role of proteasome in cancer 
The reduction in growth inhibitory activity can be the main cause of unregulated 
proliferation of cancer cells, particularly the low levels of tumor suppressors. 
Tumorigenesis can be promoted by the degradation of the tumor suppressor p53 and 
the p27kip1 inhibitor of cyclin dependent kinase. Extreme degradation of significant 
cellular proteins by the proteasome ubiquitin pathway such as p53, Bax, NF-țB
precursor p105 also plays a critical role in the development of drug resistance in 
human cancer. The expression of these proteins can be restored by inhibition of 
proteolytic degradation by means of proteasome inhibitors. The product of the tumor 
suppressor gene p53 is an unstable nuclear protein. It has a short half-life in normal 
cells. p53 plays a key role in cellular responses including cell cycle arrest and cell 
death in response to DNA damage. In this scenario, the level of p53 increases due to 
its stabilization, leading to cell growth arrest or apoptosis. p53 dysfunction can 
provoke abnormal cell growth, increased cell survival, genetic instability and also the 
drug resistance.
A number of proteasome inhibitors effectively persuade apoptosis in tumor cells in 
vitro, exert anti-tumor activity and may prevent metastasis in vivo. Moreover, tumor 
cells resistant to conventional therapy are sensitive to proteasome inhibitors, 
representing the importance of proteasomal targets. Inhibition of the 26S proteasome 
results in the quick accumulation of p53, p53-inducible p27, MDM2 or Bax[61] in the 
cells which immediately enter apoptosis. Proteasome inhibitors may also prevent 
angiogenesis and metastasis in vivo by inhibiting NF-țB transcriptional activity. It 
causes an additional increase in the sensitivity of cancer cells to apoptosis. Tumor 
growth needs the induction of new blood vessels to provide nutrients and oxygen. 
The process of angiogenesis depends largely on the transcriptional activation of 
pathways leading to the production of growth factors that initiate angiogenesis. This 
step is critically dependent on proteasome function. For example, lactacystin has 
been shown to prevent angiogenesis in vivo and in vitro offering a possibility of anti-
cancer therapy.[62]
1.2.3.2. Role of proteasome in neurodegenerative diseases e.g. Alzheimer´s and 
Parkinson´s Diseases 
The contribution of proteasome to the neurodegenerative diseases e.g amyotrophic 
lateral sclerosis, Alzheimer, Parkinson, Huntington and Creutzfeld-Jacob diseases 
cannot be ruled out. The ubiquitin conjugates accumulation has been observed in the 
inclusion bodies of neurodegenerative diseases.[63] The intracellular concentration of 
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the holoproteins, presenilins 1 and presenilins 2 (PS1 and PS2) can be regulated by 
proteasome. It seems to play a critical role in the maturation of the APP into AE40.[64]
Senile plaques are thought to derive from the abnormal levels of AE40. AE40 could 
prevent ubiquitin-dependent protein degradation in vitro.[65]
Proteins encoded by the Huntington genes aggregate in ubiquitin and proteasome 
positive intranuclear inclusions bodies in Huntington disease. It suggests that the 
accumulation of the protein could be due to its stabilization.[66]
The Parkinson disease and the Angelman syndrome exemplify other abnormal 
functions of the ubiquitin-proteasome pathway. Mutations in the UCH 
(ubiquitincarboxyl terminal hydrolase L1), parkin and D-synuclein genes cause an 
autosomal dominant familial form of Parkinson disease.[67] UCH is considered to 
regenerate ubiquitin by cleaving ubiquitin chains. Mutations in D-synuclein and 
parkin destruct their degradation by the proteasome 26S and their aggregation directs 
to the production of proteinaceous Lewy bodies.[68-70] In patients with Angelman 
syndrome, the UBE3A gene encoding an E3 ligase (called E6-AP) is modified, 
directing to the accumulation of an anonymous substrate and thus create a 
neuropathological disorder.[71]
1.2.4. Proteasome Inhibitors 
The key objective for pharmacological development is the proteolytic machinery of 
the proteasome. On the other hand, the upstream ubiquitination pathway is targeted 
by very few pharmacological approaches. The hydroxyl group of the N-terminal Thr 
of every catalytic E-subunit is the nucleophile catalyst in the 20S proteasome-
mediated proteolysis. Peptide aldehydes have extensively been used as inhibitors for 
both serine and cysteine proteases. The aldehyde functional group is readily 
subjected to a nucleophilic attack by hydroxyl or thiol groups. Moreover, proteasome 
employs the hydroxyl group of the amino terminal threonine as a nucleophile. The 
commercially available peptide aldehydes were the pioneer proteasome inhibitor 
family known (Scheme 1.14).
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Scheme 1.14: Synthetic peptide aldehydes as proteasome inhibitor. 
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Non-peptidic inhibitors constitute another class of inhibitors. They display a wide 
variety of scaffolds of core structures and pharmacophores. Leupeptin (29),
renowned as T-L activity blocking agent of the 20S proteasome as well as a standard 
serine (trypsin, plasmin) and cysteine (papain, cathepsin B) protease inhibitor in 
early 1980s.[72] Calpain inhibitors I (30) and II (31) were also exposed to inhibit the 
CT-L activity of the 20S proteasome later.[73] The proposed mechanism of hydrolysis 
by threonine proteases is shown in Scheme 1.15.
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Scheme 1.15: The hydrolysis by threonine proteases.[74]
MG115 (32), MG132 (33)[56] and PSI (34),[75] are some further developed aldehyde 
inhibitors with increased potency and increased selectivity towards the CT-L activity 
of the 20S proteasome (Scheme 1.14). An improved potency of peptide aldehyde 
with an additional ketone moiety at a position yielding a glyoxal was also attempted 
by researchers (35).[76] Lactacystin (36) is a Streptomyces lactacystinaeus metabolite 
and epoxomicin (37) are discovered afterwards as 20S proteasome inhibitors 
(Scheme 1.16).
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Scheme 1.16: Proteasome inhibitors. 
1.2.4.1. Peptidomimetics 
The low oral availability of peptide based therapeutics is due to proteolytic 
degradation, rapid clearance and in some cases, poor solubility and an aggregation 
tendency.[77] The therapeutic potential of peptides can be improved by the use of 
peptidomimetics without changing its main biological effect. The term 
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peptidomimetic referring to any compound designed to carry out the function of a 
peptide like performing a specific biological effect through inhibition or 
agonist/antagonist activity. Usually, peptidomimetics are originated from a lead 
peptide sequence by the structural modifications to improve binding affinity and/or 
metabolic pliability. Side-chain manipulation, turn-mimics, amino acid extension and 
backbone modifications are the common alteration involved in peptidomimetics. The 
pseudopeptide approach seems to be promising since the structure and conformation 
of the original peptide should largely be preserved in the resulting biomimetic 
polymer.[62]
1.2.4.2. Pseudopeptides 
The D-carbon atoms of peptides comprise the inversion of configuration to yield D-
amino acids is generally a widespread manipulation.[78] The significance of this 
substitution in getting compounds with enhanced biological potencies, distorted 
conformational properties; improved resistance to enzymatic degradation has been 
extensively known and exploited. A methyl group replacements by D-hydrogen of 
the common amino acids or any other substituent are further examples of D-alkyl
modification.[62] Replacements of the D-carbon atom isoelectronically by a trivalent 
nitrogen yield azapeptides or azatides.[79] Peptoids,[80] azapeptoids,[81]
ureapeptoids,[82] amino oxypeptoids,[83] retropeptoids,[84] and E-peptoids[85] belong to 
a new class of pseudopeptides in which the side chains are shifted on nitrogen atoms 
of the backbone (Scheme 1.17).
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Scheme 1.17: Different fragments of peptide and pseudopeptide chains. 
Azapeptides,[86] hydrazino azapeptoids and N-azapeptoids[87] have been also 
designed for proteasome inhibition. The most prominent proteasomal inhibitor 38
(Scheme 1.16) (Bortezomib®, VELCADETM) is approved by the FDA as a 
prescription drug for the treatment of multiple myeloma.[88]
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1.3. Hypertension and Alzheimer's Disease 
Dementia is a common neurological disorder in the elderly population and its 
prevention has become a major public health challenge. Several recent studies 
demonstrate associations between cardiovascular disease and its risk factors and the 
incidence of AD.[89] Heart disease and stroke are major leading causes of death and 
disability in the world.
Several reviews focus on the cardiovascular risk factors hypertension, 
hyperlipidemia and diabetes mellitus as targets for prevention of cognitive decline, 
overall dementia and AD. Observational studies and clinical trials regarding the 
association between anti-hypertensive, lipid lowering and anti-diabetic medications 
and the risk of impaired cognition, dementia or AD are reviewed.[90] Based on these 
data, it was proposed that early interventions at reducing these cardiovascular risk 
factors may have an impact on future incidence and prevalence of cognitive deficits 
of many etiologies including AD.[90-91]
Moreover, several studies reported that blood pressure is increased in victims of AD 
decades before the onset of the disease. High blood pressure has also been related to 
pathological manifestations of AD (senile plaques, neurofibrillary tangles, 
hippocampalatrophy). The exact mechanism behind these associations is not clear. 
Hypertension is also a risk factor for stroke, ischemic white matter lesions, silent 
infarcts, general atherosclerosis, myocardial infarction and cardiovascular diseases, 
and often clusters with other vascular risk factors, including diabetes mellitus, 
obesity and hypercholesterolemia. Arteriosclerosis is hardening of the arteries. The 
walls of arteries have a layer of muscle and elastic tissue that makes them flexible 
and able to dilate and constrict as blood flows through them. High blood pressure can 
make the artery walls thicken and harden which leads to narrow blood vessel. 
Cholesterol and fats are more likely to build up on the walls of damaged arteries, 
making them even narrower. Blood clots also can get trapped in narrowed arteries, 
blocking the flow of blood. Narrowed arteries may not deliver enough blood to 
organs and other tissues and can cause a heart attack. A blocked artery to the brain 
can result a stroke. Untreated hypertension can cause the heart and kidney failure. 
Also these risk factors have been related to AD. Hypertension may thus cause 
cerebrovascular disease that may increase the possibility for individuals with AD 
encephalopathy to express a dementia syndrome. Hypertension may also lead to 
vessel wall changes in the brain, leading to hypoperfusion, ischemia and hypoxia 
which may initiate the pathological process of AD. Finally, subclinical AD may lead 
to increased blood pressure, and similar biological mechanisms may be involved in 
the pathogenesis of both disorders. Several observational studies have reported that 
use of anti-hypertensives decreases risk of AD. Even though hypertension only 
results in a moderately increased risk of AD, or overall dementia, better treatment of 
hypertension may have an immense effect on the total number of demented 
individuals.[92] Recently it is suggested that a neuronal energy crisis brought on by a 
relentless chronic brain hypoperfusion (CBH) is responsible for protein synthesis 
defects that later result in the classic AD neurodegenerative lesions such as the 
formation of excess E-amyloid plaques and neurofibrillary tangles. Knowledge of 
how heart disease and stroke can progress to AD should provide a better 
understanding of the physiopathology characteristic of AD and also target more 
precise therapy in preventing, controlling or reversing this dementia.[93]
Anti-hypertensive medicines fall into several classes of drugs like diuretics, beta-
blockers, calcium channel blockers, angiotensin converting enzyme inhibitors (ACE 
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inhibitors), alpha-blockers, alpha-beta blockers, vasodilators, peripheral acting 
adrenergic antagonists and centrally acting agonists.
1.3.1. The Renin–Angiotensin System (RAS)   
Renin was isolated 100 years ago as a first component of the RAS  from kidney 
extracts. When it was injected to rabbits a vasopressor response was induced.[94]
Various active peptides which control fluid homeostasis, blood pressure, hormone 
secretion, behavioral and cognitive responses are generated by a complex enzymatic 
pathway RAS.[95-98] The juxtaglomerular apparatus of the kidney release a proteolytic 
enzyme renin when arterial blood pressure lowers. It converts the inactive precursor 
angiotensinogen to the decapeptide angiotensin (Ang) I (Table 1.1). While 
angiotensin converting enzyme (ACE) which is a zinc metalloproteinase also known 
as dipeptidyl carboxypeptidase 1 (DCP 1), hydrolyze Ang I at the carboxy terminal 
dipeptide His-Leu to form the active octapeptide Ang II.[99] The degradation of 
bradykinin, an active vasodilator is also influenced by ACE which is present in the 
endothelial cells of the blood vessels. In 1940 two independent research groups 
isolated Ang II, a potent vasoconstrictor peptide.[100-101]
A number of central activities modulating autonomic nervous system action were 
employed by Ang II[102] like hypothalamic-pituitary-adrenal axis and vasopressin 
secretion,[103] stimulation of thirst[104] and baroreflex control.[105] The enzymatic 
action of aminopeptidase A, a zinc metallopeptidase which is responsibe for a 
cleavage of the N-terminal aspartyl residue, Ang II is metabolized to the heptapeptide 
Ang III (Table 1.1)[106-107] whereas Ang III is cleaved by aminopeptidase B to Ang 
IV, a 3-8 hexapeptide fragment of Ang II.[108] Lastly, Ang IV is degraded by 
aminopeptodase N and dipeptidylaminopeptidase into NH2-terminal deleted peptides 
(Table 1.1). Besides affecting blood flow regulation, Ang IV has been concerned in 
modulation of exploratory behavior and processes documented to learning and 
memory.[108] 
Table 1.1: The Renin-Angiotensin System (RAS) 
The physiological and pathophysiological actions on the cardiovascular system by 
Ang II are exerted through the AT1-receptor subtype.[109] The AT1-receptor is 
engaged in the physiological regulation of blood pressure besides volume and 
Amino acid sequences Transforming enzymes RAS components 
Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-Leu-
Val-Tyr-Ser Renin
Angiotensinogen 
p
Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu
Angiotensin converting 
enzyme 
(ACE)
Angiotensin I 
p
Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu Aminopeptidase A
Angiotensin II 
p
Angiotensin III 
pVal-Tyr-Ile-His-Pro-Phe-His-Leu Aminopeptidase B
Angiotensin IV 
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electrolyte homeostasis. It has a contribution to hypertension, cell proliferation, 
fibrosis, left ventricular hypertrophy, nephrosclerosis, vascular media hypertrophy, 
inflammation, generation of free radicals, endothelial dysfunction, neointima 
formation and other processes leading to atherothrombosis. These disadvantageous 
actions of Ang II via the AT1-receptors are in some cases neutralized by stimulation 
of AT2-receptor.[110]
Nevertheless, the AT1-receptor is expressed in much greater density than the AT2-
receptor in many tissues of the adult organism yet the actions of the AT1-receptors 
dominate by far.[109] The condition alters in tissues undergoing repair, such as in 
cardiac infarction, chronic renal disease, cutaneous wound healing, or cerebral 
ischaemia where AT2-receptor expression is increased, strengthening the actions of 
the AT2-receptors such as anti-proliferation, anti-inflammation, anti-fibrosis, or 
neuronal regeneration.[110] This enhancement in AT2-receptors can be one of the 
body’s own mechanisms of protection. Angiotensin II type 1 receptor blocking 
agents or called anti-hypertensive drugs act by blockade of the potentially harmful 
AT1-receptor mediated actions of Ang II. Though, there is an evidence that ARBs 
also mimic the ‘natural’ mechanism of tissue protection. Moreover, they cause an 
increase in Ang II production whereas; they leave the AT2-receptor unimpeded and 
in this way shifting the balance between AT1 and AT2-receptor actions towards those 
of the AT2-receptor (Figure 1.9). This mechanism may account for the valuable 
effects of ARBs in diabetic nephropathy and may also play a role in stroke.[111]
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ACE
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• Reactive oxygen species (ROS)
• Apoptosis
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AT1 AT2
Figure 1.9: Schematic representation of the proposed effects of angiotensin II acting on the 
angiotensin II type 2 (AT2) receptor after blockade of the angiotensin II type 1 (AT1)
receptor in brain tissue. (ACE) angiotensin-converting enzyme (modified from reference 
[111]). 
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1.3.2. Active Metabolites of Losartan and their Therapeutic 
Implications
The angiotensin converting enzyme 1 inhibitors like captopril, quinapril, enalapril or 
ramipril showed the beneficial effect of a chronic RAS blockade in patients with 
ischemic heart disease, congestive heart failure, post myocardial infarct (MI) in a 
variety of large-scale clinical trials.[112] It was documented that other enzymes such 
as chymase CAGE, cathepsin G, tPA, elastase tonin and others also generate ANG II. 
Additionally, ACE is identical to kininase II, an enzyme degrading bradykinin and 
other kinins to inactive metabolites. In approximately 90% of all patients using ACE-
inhibitors catch dry cough as side effect. Takeda[113-114] developed some potent drugs 
to interfere with the RAS in the mid-1980th, angiotensin receptor type 1 antagonists. 
The first non-peptide AT1-receptor antagonist was Losartan, the group name: 
sartans. Today irbesartan, candesartan and valsartan are all recognized in the market 
and others which were designed by compouter-aided programmes,[115] e.g. tasosartan 
and telmisartan are following close (Scheme 1.18).
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Scheme 1.18: Sartane drug family.[112]
They provoke anti-inflammatory, anti-mitogenic, pleiotropic and anti-aggregatory 
effects, independent from their AT1-receptor antagonism. A number of active 
metabolites of losartan are known. There is recent evidence for interactions of these 
derivatives[116] with other receptors and cellular signalling systems. The clinical 
observations that AT1-receptor blockers elicit potencies in patients with 
cardiovascular diseases via the regulation of inflammatory, growth and homeostatic 
factors leads to focus on specific, reactive sartan metabolites, which hold potential 
for future indications and possible drug interactions in cardiovascular diseases. 
Characteristic of most of these compounds is a biphenyl tetrazole unit or any other 
related replacements with the original, advanced lead losartan.[117] Carboxylic acid 
moiety is another common character of the sartans which showed another important 
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interaction with the receptor, but cause lower oral absorption. Therefore, a prodrug is 
required in which carboxylic acid is masked as either a labile ester or an oxidatively 
labile precursor which can deliver acid after absorption. AT2 and AT4 receptors, 
which are the other known ANG II receptors can be blocked by the sartans.[118]
Losartan was shown to be 10000 fold more selective for the AT1 receptor than for the 
AT2 receptor. The sartans are metabolized by enzymatic oxidation by the 
cyctochrome P450 family.  
Losartan is hepatically metabolized by the cytochrome-P450 pathway (Scheme
1.19)[112, 119] and exerts its anti-hypertensive actions in vivo predominantly by its 
main metabolite, EXP3174.[120-122] During hepatic metabolization of losartan, 
additional active metabolites are produced, including EXP3179 (Scheme 1.19). The 
metabolite (EXP3174) is 10 to 40 fold higher potent compared to losartan and is 
bound to the AT1-receptor as insurmountable antagonism by interaction of the 
tetrazole with Lys199 in the trans-membrane helix 5 of the AT1 receptor.[123-126] The 
involvement of His256 in biphenyl pocket construction was established by site 
directed mutagenesis and found to co-operate with Lys199 binding to the tetrazole 
moeity.[127-128] Losartan was found to be a prodrug of EXP3174 but the 
pharmacological effects are in fact a collection of activities of both. 
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Scheme 1.19: Losartan metabolites. Losartan is actively metabolized in the liver 
predominantly by the cytochrome P450 isoenzyme CYP2C9. The first oxidation results in 
the aldehyde EXP3179, which is additionally oxidized to EXP3174. [112, 119]
A radioreceptor assay in combination with HPLC analysis concluded that losartan 
and EXP3174 are the only compounds accountable for the Ang II antagonism.[129]
The Losartan Intervention For End point reduction in hypertension (LIFE) study has 
shown that hypertensive patients receiving the angiotensin type 1 receptor blocker 
(ARB) losartan, have a 25% lower rate of new-onset diabetes than patients treated 
with the E-blocker atenolol.[130] Although this data suggest a possible anti-diabetic 
action of losartan, but still the molecular mechanisms are widely unknown. It was 
recently demonstrated that a subset of ARBs, including losartan, induces the activity 
of a nuclear hormone receptor named peroxisome proliferator–activated receptor Ȗ
(PPAR-Ȗ) by partial agonism.[131-32]
The direct activation of the ligand-binding domain of PPAR-Ȗ by ARBs is 
independent of their angiotensin type 1 receptor (AT1R) blocking actions.[131] PPAR-
Ȗ functions as a transcriptional regulator in adipose tissue where it regulates multiple 
genes involved in lipid and glucose metabolism.[133] Activated by synthetic full 
agonists like thiazolidinediones/glitazones, PPAR-Ȗ markedly improves whole-body 
insulin sensitivity resulting in decreased levels of fasting plasma glucose, fasting 
plasma insulin, and plasma triglycerides.[134] Thus, PPAR-Ȗ activation by ARBs 
presents a promising molecular mechanism for metabolic actions of these 
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compounds. Losartan induced PPAR-Ȗ activity only at high concentrations in
vitro.[131] Recently it is described that PPAR-Ȗ played an effective role in the 
amyloidogenic process causing AD.[135] Further reports indicated that PPAR-Ȗ
agonists down-regulate AE generation, although the mechanism of this phenomenon 
still remained controversial. Sastre and colleagues[136] reported that PPAR-Ȗ agonists
modulate processing of APP through regulation of E-secretase, whereas Camacho 
and co-workers[137] showed that activation of PPAR-Ȗ directly affects the stability of 
AE externally added to the cells, suggesting the activation of a rapid clearance 
mechanism. It is reported that, in cultured cells, overexpression of PPAR-Ȗ
dramatically decreased AE production, concomitantly increasing APP ubiquitination. 
Moreover, it was demonstrated that the reduction of AE secretion protected the cells 
from H2O2-induced necrosis, suggested a novel mechanism at the basis of the anti-
inflammatory properties of PPAR-Ȗ and an additional pathogenic significance for AE
accumulation.[135] The evidence provided that PPAR-Ȗ decreases AE secretion by 
increasing the rate of APP degradation. Previous reports indicated that proteasome 
inhibitors increase AE secretion.[138] This observation, together with the finding that 
PPAR-Ȗ induces proteasome-dependent degradation of proteins such as cyclin D and 
oestrogen receptor-D[139] supported the hypothesis of an alternative, PPAR-Ȗ-
mediated, APP processing mechanism involving the proteasome system. It is 
established that PPAR-Ȗ overexpression did not directly stimulate the proteasome
activity, but appreciably (P=0.001) enhances the ubiquitination level of APP.
NSAIDs were suggested to decrease the risk for AD[140] as some NSAIDs can 
activate the PPAR-Ȗ.[141] In addition, it has also been argued that NSAIDs may 
interact directly with the Ȗ-secretase to affect amyloid production.[142] PPAR-Ȗ
depletion potentiates E-secretase (BACE-1) mRNA levels by enhancing BACE-1 
gene promoter activity. On the other hand, overexpression of PPAR-Ȗ, in addition to 
NSAIDs and PPAR-Ȗ activators, decreased BACE-1 gene promoter activity. These 
results proposed that PPAR-Ȗ could be a repressor of BACE-1. It was also 
established that in vivo treatment with PPAR-Ȗ agonists amplified PPAR-Ȗ and 
reduced BACE-1 mRNA and intracellular E-amyloid levels. Fascinatingly, brain 
extracts from AD patients illustrated diminished PPAR-Ȗ expression and binding to 
PPRE in the BACE-1 gene promoter. This data strongly support a major role of 
PPAR-Ȗ in the modulation of AE generation by inflammation and suggest that the 
protective mechanism of NSAIDs in AD involves activation of PPAR-Ȗ and 
decreased BACE-1 gene transcription. 
However, in the light of the present evidence, it can be assumed that the 
neuroprotective effects shown by certain NSAIDs, agonists of PPAR-Ȗ,[143] are not 
related to the inhibition of the AE-induced inflammatory process, but more likely to 
the capability of decreasing AE levels.[135] The losartan metabolite EXP3179 has a 
significant molecular homology with indomethacin, an anti-inflammatory 
cyclooxygenase (COX) inhibitor, and mediates a variety of AT1R-independent,
pleiotropic functions (eg, inhibition of platelet aggregation, endothelial adhesion 
molecule expression, etc).[119] Indomethacin has been also identified as an activator 
of PPAR-Ȗ.[140] Given the structural homology of indomethacin and EXP3179, it is 
likely that EXP3179 has also PPAR-Ȗ–binding properties. PPAR-Ȗ–activating 
properties of losartan in vivo might be enhanced by its active metabolites and that 
PPAR-Ȗ activation by losartan metabolites may provide a potential mechanism of the 
anti-diabetic actions of losartan observed in clinical trials. 
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Moreover, the fact that PPAR-Ȗ agonists have been used for years in the treatment of 
Type II diabetes[144] raises the possibility that PPAR-Ȗ could also soon become a drug 
target for the treatment of AD and PPAR-J agonists may also be effective in the 
treatment of other chronic inflammatory disorders of the CNS including AD, AIDS 
dementia, and possibly stroke. Collectively, these studies suggest that PPAR-J
agonists may have differential effects on autoimmune and infections diseases of the 
CNS.
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2. AIMS OF THIS STUDY 
This thesis encompasses the following aims. 
x The main objective was to design, synthesize and evaluate new chemical entities 
for the treatment of Alzheimer´s disease. This task includes the following 
workplan.
1. Synthesis of non-peptidic and semi-peptidic BACE-1 inhibitors as candidates 
with improved cellular activity.  
2. Synthesis of norstatine derivatives via D-amination and Passerini reaction and 
the application of this approach towards the synthesis of potential BACE-1 
inhibitors.
3. Synthesis and evaluation of solid phase supported organocatalysts for 
simplified separation of D-aminated products. 
4. In situ generation of hydroxyethyleneamine moiety by modified Passerini 
reaction.
5. Synthesis of tri-peptidic aldehydes as BACE-1 inhibitors with improved 
pharmacological profiles. 
x Based on the serendipitous results of tri-peptidic aldehydes (target BACE-1 
inhibitors) on 20S proteasome inhibition, studies were extended for the design of 
more selective proteasome inhibitors (diazenecarboxylate derivatives) with 
improved activity, bioavailability and binding specificity. 
x Investigation of losartan active metabolites i.e. EXP3179 and EXP3174 for their 
proposed
1. PPAR-Ȗ regulatory activity. 
2. Inhibition of collagen-dependent platelet activation via glycoprotein 
Receptor-VI independent of AT1-receptor antagonism 
3. Angiotensin receptor II type 1 blockade in astrocytes. 
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3. RESULTS AND DISCUSSION 
The main objective of the present study was to prepare and evaluate novel chemical 
entities for the treatment of AD. AE peptide is the major constituent of amyloid 
plaques in the brain of AD patients and believed to play a central role in the 
neuropathology of AD. AE is generated from the APP by two proteases, E- secretase 
generally referred to as (BACE-1 or ASP-2) and Ȗ-secretase. BACE-1 has been 
identified and validated as an aspartic protease[145-148] and BACE-1 inhibition is 
currently perceived as a promising target for the treatment of AD.[5, 16, 17] Therefore,
in this study novel BACE-1 inhibitors were designed and synthesized. 
3.1. Design and Synthesis of BACE-1 Inhibitors 
A large number of peptidomemetic BACE-1 inhibitors are known since the discovery 
of this enzyme. However, their high molecular weight, poor blood brain barrier 
(BBB) penetration and low oral bioavailabiliy necessitated further drug development 
to obtain inhibitors having small molecular size, high selectivity and good potency. 
Several statine, homostatine (hydroxyethylene, HE) and norstatine 
(hydroxymethylcarbonyl) based classic transition state isosters are recognized as 
aspartyl protease inhibitors.[5, 16, 17] The co-crystallized structure of homostatine 
isostere based inhibitor OM99-2 (1) with BACE-1 provided the possibility of 
structure based drug design.[16] Moreover the X-ray structure of BACE-1 and the 
structure-activity relationship (SAR) of transition-state-like inhibitors[5] facilitate the 
design of hydroxyethylene- and norstatine-based scaffolds. Unfortunately, 80% of all 
aspartic proteases accept phenylalanine at the S1 pocket of the enzyme, thus, 
selectivity has to derive from either the flanking amino acids or non-natural 
phenylalanine derivatives. Such non-natural phenylalanines may be presented as 
norstatine or as hydroxyethylene isosteres. S-D-Amino aldehydes are common 
intermediates for the synthesis of such transition state mimetics and are thus 
extremely versatile building blocks. The introduction of the isophthalamide moiety 
was an important step towards less peptidic compounds, which is mandatory to 
obtain sufficient oral absorption and BBB penetration as shown by Elan 3.[20-23, 149]
The modification also enabled further reduction of the C-terminus and utilization of 
different transition state isosteres. 
Furthermore, the structure of BACE complexed to Elan 3 (PDB: 1W51, Figure
1.3)[20] revealed that the hydroxyl group hydrogen bonds to Asp32, while the 
protonated secondary amine hydrogen bonds to Asp228. The preferred 
strereochemistry of the hydroxyl group is R in HEA derivatives in contrast to 
norstatine derivatives, which are prefered in S-stereochemistry. The benzyl group 
occupies the hydrophobic S1 pocket on the non-prime side, where it interacts with 
Tyr71 in a T-shaped stacking while S2-S3 pockets are occupied by isophthalamide. 
However, the 3-methoxybenzyl group interacts with S2´ on the prime side. Moreover, 
researchers from Kyoto University introduced an unnatural amino acid, 
phenylnorstatine with a hyrdoxymethylcarbonyl (HMC) isostere as a transition-state 
mimic in their potent inhibitors (Scheme 3.1).[24-25]  
It was anticipated that the BACE-1 inhibitory activity can be further improved by 
combination of isophthalamide and norstatine moieties. Moreover, the replacement 
of hydroxyethylene moiety with hydroxymethylcarbonyl (norstatine) reduces 
rotational freedom, which was expected to have a positive impact on potency. Based 
on this hypothesis, analogues of Elan 3 containing norstatine entity (i.e. compounds 
9699) were designed and synthesized as new BACE-1 inhibitors (Scheme 3.1). 3-
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Methoxybenzyl group was replaced by benzyl, cyclohexyl, 2-morpholino ethyl-, and 
picolyl groups to study the SAR of this position. Therefore, several isophthalamide 
building blocks were synthesized and transformed into norstatine derivatives in order 
to investigate their impact on BACE-1 inhibitory activity. 
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3.1.1. Synthesis of Norstatine Derivatives 
The first step towards the synthesis of proposed BACE-1 inhibitors 9699 was the
production of isophthalamide building blocks 66–67, 76–77 and 84–85 as depicted in 
Scheme 3.2–3.4 respectively. Isophthalamide building blocks 66–67, 76–77 and 84–
85 were synthesized from commercially available isophthalic acid 58, dipicolinic 
acid 59, chelidamic acid 68 and 5-hydroxy-isophthalic acid 69 as illustrated in 
Scheme 3.2–3.4. Isophthalic acid 58 was converted to its methyl ester 60 using 
catalytic thionyl chloride in methanol, while dipicolinic acid 59 was converted to its 
corresponding methyl ester 61 by refluxing it with methanol in the presence of 
catalytic H2SO4 for 8 h. The monohydrolysis of methyl ester group in 60 and 61 was 
accomplished by base hydrolysis using KOH in methanol-water (1:1) to furnish 
mono acid 62–63. The amide coupling of compound 62 with dipropylamine using 
thionyl chloride in toluene and DMF afforded compound 64. However, an 
improvement in yield was observed when EDAC (N-(3-dimethylaminopropyl)-Nƍ-
ethylcarbodiimidhyrochloride) and HOBt (N-hydroxybenzotriazole hydrate) were 
employed as coupling reagents. Amidation of compound 63 to its corresponding 
amide derivative 65 was carried out by treating it with dipropylamine in the presence 
of EDAC and HOBt  as coupling reagents. The methyl esters 64–65 were hydrolyzed 
to their corresponding acids 66–67 by base hydrolysis using sodium carbonate in 
methanol-water (1:1). X is either CH or nitrogen providing an opportunity for 
modification at position 2 of new isophthalamide building blocks 66–67 (Scheme
3.2).
Results and discussion 34
X
HO
O
OH
O
X
MeO
O
OMe
O
 KOH (1.2 eq), 
MeOH, RT, 6 h
X
MeO
O
OH
O
X
MeO
O
N
O
Na2CO3 , 
MeOH:H2O (1:1),
X
HO
O
N
O
62: Dipropylamine, Toluene, 
      DMF, SOCl2, reflux, 3 h
63: Dipropylamine, EDAC, HOBt, 
      TEA, DCM, RT, 6 h
RT, 15 h
58: CH3OH, SOCl2, RT, 72 h
59: CH3OH, Cat. H2SO4,
      reflux, 16h
58 X = CH
59 X = N
60 X = CH 95%
61 X = N 60%
62 X = CH 99%
63 X = N 92%
64 X = CH 84%
65 X = N 88%
66 X = CH 97%
67 X = N 82%
Scheme 3.2: Synthesis of isophthalamide derivative 66–67.
5-Hydroxy-isophthalic acid 68 and chelidamic acid 69 were employed to introduce a 
5-substituted isophthalamide derivatives, as depicted in Scheme 3.3.
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Scheme 3.3: Synthesis of isophthalamide derivative 76–77.
The diester protection of 5-hydroxy-isophthalic acid 68 and chelidamic acid 69 was
carried out by refluxing them with methanol and catalytic H2SO4, followed by base 
hydrolysis to their corresponding mono esters 72–73 using NaOH in THF:H2O (1:1) 
(Scheme 3.3). The resulting monoesters 72–73 were converted to their 
corresponding amides 74–75 by treating with dipropylamine by employing EDAC 
and HOBt as coupling reagents which were further hydrolyzed by base hydrolysis 
using NaOH in THF:H2O (1:1) to their corresponding acids 76–77. Acid base work 
up was employed for purification in the synthetic sequence illustrated in Scheme 
3.2–3.3, which avoided flash coulmn chromatography. Surprisingly, an overall 
reduction in yield (5060%) was observed in Scheme 3.3, which was probably due 
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to phenolic hydroxyl functionality. Furthermore, the resultant isophthalamides 76–77
were only soluble in highly polar solvents like DMSO and DMF.  
As a consequence, an additional methodology is required to ameliorate the yield and 
solublity of isophthalamide derivatives 76–77. The new synthetic pathway proposed 
the benzyl protection of phenolic –OH functionality in compounds 70–71 using
benzyl bromide and K2CO3 in acetone at 60–70 °C (Scheme 3.4), to avoid the loss of 
product during acid/base work up and its oxidation to quinones in forthcoming step. 
Resulted benzyl protected diesters 78–79 were hydrolyzed by the base hydrolysis 
using NaOH in THF:H2O (1:1) at room temperature to their corresponding 
monoesters 80–81. Amidation of compounds 80–81 was carried out using 
dipropylamine, EDAC and HOBt in CH2Cl2 to attain compounds 82–83.
Substantially, better yield was obtained for compound 83, when PyBop was 
employed as coupling reagent. The methyl ester groups in compounds 82–83 were
hydrolyzed in similar manner as described for compound 80–81 to yield the 
isophthalamides 84–85 (Scheme 3.4).
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Scheme 3.4: Synthesis of isophthalamide derivative 84–85.
The isophthalamide derivatives 66 and 84 were readily transformed into their 
corresponding amides 86–87 and 90–91 by treating with L-phenyl alaninol and L-
tyrosinol (Scheme 3.5–3.6). The reaction of 66 and 84 with L-phenyl alaninol was 
promoted by EDAC and HOBt to yield 86–87 (Scheme 3.5), while PyBrop was 
employed as coupling reagent for the reaction of 66 and 84 with L-tyrosinol to afford 
90–91 (Scheme 3.6). Remarkably, better yield and cleaner product was obtained 
when reaction of compound 84 was performed using ethylchloroformate as coupling 
reagent (Scheme 3.5). The phenolic –OH group in compounds 90–91 was benzyl 
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protected using benzyl bromide and potassium carbonate in DMF to afford 92–93
(Scheme 3.6).
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Scheme 3.5: Synthesis of the intermediate 88–89 of BACE-1 inhibitors.
The primary alcohol functionality in compounds 86–87 and 92–93 was converted to 
corresponding aldehydes 88–89 and 94–95 by treating with IBX in DMSO. 
Surprisingly, the reaction was rather slow and a poor turnover led to a mixture of 
unreacted alcohol and aldehyde. Furthermore, 4050% yield was obtained after a 
laborious purification (Rf = alcohol/aldehyde; 0.70/0.75) by column chromatography 
using ethylacetate:hexane (4:6) as eluent. Other eluent systems like ethylacetate–
hexane, CH2Cl2–methanol and CH2Cl2–hexane helped a little. As a consequence, 
oxidation of these alcohols was considered to be executed by any other method 
which can afford a complete transformation of alcohol to aldehyde. Fortunately, 
Swern oxidation provided significantly higher yields (78–96%) than other 
investigated oxidizing agents (Scheme 3.5–3.6). Thus the aldehydes 88–89 and 94–
95 were synthesized by successive addition of oxalyl chloride (COCl)2 and Et3N to a 
mixture of their corresponding alcohol and DMSO in CH2Cl2 at –78 °C followed by 
stirring at ambient temperature for 1 h (Scheme 3.5–3.6).
HO
O
N
O
L-Tyrosinol
PyBrop, DIEA,
DCM, RT, 6 h
N
O
N
H
O
OH
OH
BnBr, K2CO3
DMF, RT, 3h
N
O
N
H
O
OH
OBn
N
O
N
H
O
O
OBn
R
R
R R
66 R = H
84 R = OBn
90 R = H 86%
91 R = OBn 89%
92 R = H 92%
93 R = OBn 95%
94 R = H 80%
95 R = OBn 78%
DMSO, 
oxalyl chloride
Et3N, DCM,
_78°C, 1 h
Scheme 3.6: Synthesis of the intermediate 94–95 of BACE-1 inhibitors.
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The norstatine derivatives 96–99 were synthesized as outlined in Scheme 3.7. The 
Passerini reaction of aldehyde 88 was carried out using various isonitriles to yield the 
potential BACE-1 inhibitors 96–99. A diastereomeric mixture was obtained in all 
reactions and the ratio (dr) was determined by 1H NMR spectroscopic analysis of the 
crude reaction mixture (Table 3.1). The diastereoisomeric mixture was separated by 
column chromatography (Table 3.1). It was a tiresome task to separate both 
diastereoisomers having almost the same polarity. The compounds were eluted from 
column using hexane as an eluent whose polarity had been slightly increased by the 
addition of dichloromethane (1–10%). The separation of these isomers still took 
many hours. The separated compounds were assigned as “a” for less polar compound 
and “b” for comparatively more polar compound. 
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Scheme 3.7: Synthesis of BACE-1 inhibitors 96–99.
Table 3.1: Synthesis of compounds 96–99. 
Entry R Product  dr[a] [%] Yield [%][b]
1 Benzyl 96a, 96b 50:50 90 
2 Cyclohexyl 97 80:20 90 
3 3-Picolyl 98a, 98b 60:40 80 
4 2-Morpholino ethyl- 99a, 99b 50:50 80 
[a] The diastereomeric ratio (dr) was determined by 1H NMR spectroscopic analysis  
of the crude product. [b] Isolated yield of diastereomeric mixture of 96–99.
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Scheme 3.8: Synthesis of compounds 101–102. 
A new series of intermediates (102, 104) for BACE-1 inhibitors was designed and 
synthesized by substituting dipropylamide moiety with nitrile group to evaluate its 
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impact on enzyme inhibitory activity (Scheme 3.83.9). This nitrile functionality can 
be further transformed into tetrazole moiety. The first step toward the synthesis of 
intermediates 102 and 104 was the coupling of commercially available 3-cyano 
benzoic acid 100 with L-phenyl alaninol and L-phenyl tyrosinol to afford compounds 
101 and 103, respectively. The primary alcohol functionality in 101 was oxidized 
using IBX in DMSO to obtain aldehyde 102 (Scheme 3.8).
However, an unexpected coupled product 103 was obtained by reaction of 3-cyano 
benzoic acid 100 with L-phenyl tyrosinol as mentioned in Scheme 3.9, which was 
characterized by spectroscopic analysis of purified product. Additionally, single-
crystal X-ray analysis offered final confirmation of the structure (Figure 3.1).
Fortunately, this unexpected product avoided the benzyl protection of phenolic 
hydroxyl group in 100a and can reduce one step toward the synthesis of aldehyde 
104a (Scheme 3.9). This spontaneous protection can easily be removed in final step 
by base hydrolysis using 1N NaOH. These intermediates 101104 can provide a new 
scaffold for synthesizing potent BACE-1 inhibitors.
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Scheme 3.9: Synthesis of intermediate 104 for BACE-1 inhibitor.
Figure 3.1: X-ray crystal structure of compound 103 showing the atom labelling and 
displacement ellipsoids drawn at the 50% probability level.[150]
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3.1.1.1.Biological Evaluation 
To examine the specificity and selectivity of the synthesized inhibitors 90, 93, 96–99,
101, 102, and 103 were profiled in the fluorescence resonance energy transfer 
(FRET) based assay with full length BACE-1[151] and results are shown in Table 3.2.
Table 3.2: SAR of compounds 90, 93, 96–99 and 101–103 for BACE-1 inhibition.
FRET (BACE-1) FRET (Cat D) 
Entry Compound Structure IC50 PM IC50 PM
1 90 N
O
N
H
O
OH
OH
200 nd
2 93 N
O
N
H
O
OH
OBn
OBn
>>200 nd
3 96a N
O
N
H
O
OH
N
H
O 20 1.0
4 96b N
O
N
H
O
OH
N
H
O Activating 17.5
5 97 N
O
N
H
O
OH
N
H
O no inh. no inh. 
6 98a N
O
N
H
O
OH
N
H
O
N
Activating 30.2
7 98b N
O
N
H
O
OH
N
H
O
N
Activating 26.7
8 99a N
O
N
H
O
OH
N
H
O
N
O Activating 27.8
9 99b N
O
N
H
O
OH
N
H
O
N
O no inh. 1.6
10 101 NH
O
OH
N no inh. nd
11 102 NH
O
O
N no inh. nd
12 103
N
H
O
OH
O
O
N
N >>200 nd 
nd = not determined 
no inh.= no inhibition
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This assay was carried out at Hoffmann-La Roche, Basel. FRET is a convenient 
method in which the fluorescence signal enhancement is observed after the substrate 
is cleaved by BACE-1 thus separating the quenching moiety (Dabsyl) from the 
fluorochrome (Lucifer yellow). All enzyme assays were carried out at 20 °C on a 
FLUOstar (BMG Lab Technologies, D-77656 Offenburg) using 96-well microtiter 
plates (DYNEX Microfluor 2, Chantilly, VA). The volume of assay was 100 PL.
Usually inhibitors dissolved in DMSO were added into a well followed by buffer and 
enzyme. The concentration of DMSO was kept below 4%. The enzymatic reaction 
was started by adding the substrate. The fluorescence enhancement was measured at 
Oemission = 520 nm with fluorescence excitation at Oexcitation = 430 nm. At various 
inhibitor concentrations reaction kinetics was followed for 30 min. Assays were 
performed at enzyme concentrations that warranted a linear progression of product 
formation.[151] A known peptidic inhibitor of the hydroxyl ethylamine class was 
always included in the experiment as a positive control for inhibition. The results are 
given as IC50 (PM). This assay was found to be very good with known BACE-1 
inhibitors, however only if the compound is water soluble at the assay pH of 4.5. 
Depending on charge and poor solubility of the compound this assay may give 
apparent inhibition which is not specific.
A E-secretase inhibitor has to be very selective because aspartic proteases are widely 
distributed in the body and the treatment of Alzheimer’s disease will be a long term 
therapy. Moreover, BACE-1 selectivity is important because the target enzyme 
resides in the brain, where closely related ubiquitous enzymes cathepsin D (Cat D) 
and renin can be found. BACE-1 inhibitors with poor selectivity against these 
enzymes are possible to cause undesired side effects. Therefore, the selectivity of the 
synthesized inhibitors were also profiled for FRET based assay for other distinct 
aspartic proteases like cathepsin D and the SAR data is shown in Table 3.2.
FRET cathepsin D (Cat D) assay is like the FRET for BACE-1, but using a peptide 
substrate with a different amino acid sequence that is optimal for cathepsin D (Cat 
D). Cat D was used from human liver as obtained commercially (Calbiochem). 
Cathepsin D is a lysosomal aspartyl protease that is homologous to BACE-1. Many 
BACE-1 inhibitors of the statin and hydroxy-ethylamine series also inhibit Cat D.[151]
The Cat D assay provides an assessment of relative specificity of inhibitor for 
BACE-1.
As these BACE-1 inhibitors were synthesized by inducing a hydroxymethylcarbonyl 
(norstatine) instead to hydroxyethylene group in Elan 3 and replacement of 3-
methoxyphenyl group with benzyl, cyclohexyl, 2-morpholino ethyl- and picolyl 
toward S2´ pocket of enzyme, to surmise their effect on enzyme inhibitory activity. 
SAR analysis showed that compound 96a which have benzyl group towards S2´
pocket showed inhibitory potential in FRET BACE-1 as well as FRET cathepsin D 
assay with IC50 values of 20 μM, and 1.0 μM respectively which depicted its non-
selective nature. The second separated diastereomer 96b with same structure but 
different stereochemistry showed insignificant activity for BACE-1 while displayed
an IC50 value of 17.5 μM in FRET (cathepsin D) assay. Compounds 98a, 98b and
99a which contain a picolyl and 2-morpholino ethyl- group showed little activity in 
FRET (BACE-1) assay while they inhibited the activity of the cathepsin D with IC50
values of 30.2 μM, 26.7 μM and 27.8 μM. Similarly, compound 99b with a 2-
morpholino ethyl- moiety displayed no inhibition of BACE-1, while it displayed 
significant (IC50 = 1.6 μM) inhibitory activity for cathepsin D. It is evident from the 
results (Table 3.2) that compound 96a and 99b displayed higher inhibitory potential 
for cathepsin D with IC50 values of 1.0 μM and 1.6 μM, respectively, with moderate 
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selectivity. Whereas, compound 96b (IC50 =17.5 μM) displayed gradually decreased 
inhibition of cathepsin D but more specificity. Further decrease in BACE-1 
inhibitory activity observed in case of compounds 98a, 98b and 99b. Surprisingly,
compound 97 which has a cyclohexyl group displayed no activity in both assays. 
Compound 90 and 93 were investigated on FRET (BACE-1) for SAR analysis and 
displayed marginal activity.
The above results demonstrated that, compounds 96b and 98a, 98b and 99b were
found to be more selective for cathepsin D than BACE-1 inhibitory activity.
However, 96a with a benzyl moiety toward S2´ pocket displayed considerable 
activity (IC50 = 20 μM) for BACE-1 inhibition and found to be the best among the 
investigated compound. It is apparent from above results, that out of four different 
substituents cyclohexyl, picolyl, benzyl and 2-morpholino ethyl-, only benzyl moiety 
is crucial for BACE-1 inhibitory activity while none of the other substituent is 
responsible for activity enhancement.  
3.1.2. Application of an Organocatalytic Approach towards the 
Synthesis of BACE-1 Inhibitors
The norstatine derivative 96a was identified as a lead structure for E-secretase 
(BACE-1) inhibition in a fluorescence resonance energy transfer (FRET) assay (IC50 
= 20 PM, Scheme 3.7 and 3.10) with isolated BACE-1.[151] The first synthetic 
approach utilized L-phenylalaninol and provided both hydroxyl diastereomers 96a
and 96b in a 1:1 ratio. These diastereomers were isolated and investigated separately, 
but the relative stereochemistry of the hydroxyl group was not established. The 
compound assigned as 96b displayed much weaker inhibition (IC50 > 200 PM). This 
result stimulated the two-step synthesis of further norstatine intermediates (Scheme 
3.11).
The enantioselective synthesis of nonnatural amino acid derivatives is described 
here. Moreover, their elaboration to the target norstatine derivatives and their activity 
as BACE-1 inhibitors is depicted in this study. Preferentially, the high 
enantioselectivity in the D-amination should be accompanied by low 
diastereoselectivity of the Passerini reaction to allow simultaneous profiling of 
diastereomeric mixtures; thereby minimizing the efforts towards the synthesis of 
inactive compounds. An edge on face stacking of the S1-phenylalanine on the tyrosyl 
residue in the active site was observed for the similar ASTEX inhibitor 105[23]
(Scheme 3.10 and Figure 3.2), which was identified in a high throughput 
crystallization screen. This compound displays similar activity on BACE-1 as the 
Elan compound 106[152], but adopts an unpredicted orientation for the benzylamine. 
The phenylalanine binding to S1 pocket suggested electron deficient peptidomimetics 
for this position. Therefore, electron deficient peptidomimetics were employed by D-
amination of selected aldehyde. 
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Scheme 3.10: 96a/96b, ASTEX (105) and Elan (106). 
Figure 3.2: An edge on face stacking of the S1-phenylalanine on the tyrosyl residue in the 
active site was observed for the ASTEX inhibitor (PDB: 1W51, 1TQF). MOE (Molecular 
Operating Environment) 2004.10
3.1.2.1. Norstatines from Aldehydes by Sequential Organocatalytic D-Amination 
and Passerini Reaction 
The results for the direct D-amination of selected aldehydes with different 
azodicarboxylates catalyzed by L-proline or D-proline (Scheme 3.11) are presented 
in Table 3.3. The aldehydes were reacted with the azodicarboxylates and 10 mol% of 
D- or L-proline at room temperature under ambient conditions in CH2Cl2. The D-
aminated products 109–138 were formed in 7093% yield (Table 3.3). Even the 
notorious phenyl acetaldehyde reacted in moderate yields if freshly distilled.  
The disappearance of the typical yellow color of azodicarboxylate indicated the 
endpoint of the D-amination reaction. The isolation of the D-aminated product is 
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remarkably easy: the reaction mixture was filtered through a Solid Phase Extraction 
(SPE) C18 column with dichloromethane and acetonitrile. The solvent and the excess 
aldehyde were removed in vacuo to provide the pure D-aminated products 109–138.
When complete removal of the aldehyde was not possible in vacuo, the 
azodicarboxylates were reacted at a stoichiometry of 1.5 to 1 versus the aldehydes. 
Excess azodicarboxylate was scavenged by PS-Trisamine after complete conversion 
of the aldehyde. The L-proline displays poor solubility in CH2Cl2 and is easily 
separated or recovered. This poor solubility of amino acids in polar solvents may 
lead to chiral amplification.[153] Reactions run in acetonitrile, where proline is readily 
soluble, were much faster, but catalyst removal required elaborate work up. The 
catalyst removal is important, as it will undergo an Ugi reaction in the following 
sequence and will eventually contaminate the desired product.  
The short reaction time, simple work-up, moderate to good yield and mild reaction 
conditions demonstrated the usefulness and versatility of this method. 
H
O
N
N
O
R2 O
R2
L-proline 10 mol %
DCM, RT, 3 h
N
N
O
R2
O
R2
H
R1
OH
O
N
H
R3
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O
R2
O
R2
H
R1
H
O
(1.5 equiv.) (1.0 equiv.)
(1 equiv.)
R1+
109-131
139-161
D-proline 10 mol %
DCM, RT, 3 h
N
N
O
R2
O
R2
H
R1
OH
O
N
H
R3
N
N
O
R2
O
R2
H
R1
H
O
(1 equiv.)
132-138
162-168
R3NC 1.5 equiv. TFA, 
pyridine, 1 M in DCM, 
0 °C to RT, 6-24 h
107a: R2= tBuO
107b: R2= iPrO
107c: R2= morpholino
107d: R2= BnO
108107
Scheme 3.11: Two step synthesis of norstatine intermediates. 
The 3-(3,5-difluorophenyl)propanal 108f was obtained by the Heck-reaction of 1-
bromo-3,5-difluorobenzene  and allyl alcohol using palladium acetate (Scheme
3.12). It was reacted further with di-tert-butylazodicarboxylate and dibenzyl 
azodicarboxylate in the presence of L-proline and D-proline (10 mol%) to provide 
the bis-N-Boc and bis-N-Cbz protected difluorophenylalaninal analogue 131 and 138
in 90% and 86% yield, respectively (Table 3.3).
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BrF
F
OH
Pd(OAc)2
2.0 equiv. K2CO3
 4 Å powdered sieves
1.0 equiv. TEBACl,
DMF, 60 °C , 6 h 
   95 %
1.5 equiv.
F
F
O
3-(3,5-difluorophenyl)
propanal
1-bromo-3,5-difluoro
benzene
108f
Scheme 3.12: Synthesis of 3-(3,5-difluorophenyl)propanal (108f).
Table 3.3: Two step enantioselective amination and Passerini reaction of aldehydes. 
Entry R1 Aldehyde R2 R3 Product  Yield[a]
[%] 
dr[b] [%] Catalyst
1 Me 108a tBuO chexyl 139a,b 88 80:20  L-proline
2 Me 108a tBuO 2-morpholinoethyl 140a,b 90 80:20  L-proline
3 Me 108a iPrO chexyl 141a,b 70 40:60  L-proline
4 Me 108a iPrO 2-morpholinoethyl 142a,b 50 80:20  L-proline
5 Me 108a morpholino 2- morpholinoethyl 143a,b 36 80:20  L-proline
6 Et 108b tBuO chexyl 144a,b 80 80:20  L-proline
7 Et 108b tBuO 2-morpholinoethyl 145a,b 97 80:20  L-proline
8 Et 108b iPrO 2-morpholinoethyl 146a,b 73 60:40  L-proline
9 Et 108b iPrO chexyl 147a,b 97 80:20  L-proline
10 Et 108b morpholino 2-morpholinoethyl 148a,b 60 60:40  L-proline
11 iPr 108c tBuO chexyl 149a,b 81 80:20  L-proline
12 iPr 108c tBuO 2-morpholinoethyl 150a,b 78 70:30  L-proline
13 iPr 108c iPrO chexyl 151a,b 70 40:60  L-proline
14 iPr 108c iPrO 2-morpholinoethyl 152a,b 72 60:40  L-proline
15 iPr 108c morpholino 2-morpholinoethyl 153 20 -  L-proline
16 Ph 108d tBuO chexyl 154a,b 98 80:20  L-proline
17 Ph 108d tBuO 2-morpholinoethyl 155a,b 72 80:20  L-proline
18 Ph 108d iPrO chexyl 156a,b 78 90:10  L-proline
19 Ph 108d iPrO 2-morpholinoethyl 157a,b 80 90:10  L-proline
20 Ph 108d morpholino 2-morpholinoethyl 158 30 -  L-proline
21 Bn 108e tBuO chexyl 159a,b 61 80:20  L-proline
22 Bn 108e tBuO Bn 160a,b 86 50:50  L-proline
23 3,5-difluo- 
robenzyl 
108f tBuO Bn 161a,b 86 80:20  L-proline
24 Methyl 108a tBuO Bn 162a,b 86 50:50  D-proline
25 Ethyl 108b tBuO Bn 163a,b 91 60:40  D-proline
26 iPr 108c tBuO Bn 164a,b 97 50:50  D-proline
27 Ph 108d tBuO chexyl 165a,b 93 80:20  D-proline
28 Ph 108d tBuO Bn 166a,b 93 50:50  D-proline
29 Bn 108e tBuO Bn 167a,b 86 80:20  D-proline
30 3,5-difluo- 
robenzyl 
108f BnO Bn 168a,b 86 80:20  D-proline
[a] Isolated yield of diastereomeric mixture of 139ņ168. [b] The diastereomeric ratio (dr) was 
determined by 1H NMR spectroscopic analysis of the crude product.  
The enantiomeric purity of the D-aminated aldehydes is known to decrease upon 
storage, extended reaction times or isolation on acidic media. This problem was 
avoided by the rapid conversion of the D-aminated aldehydes in Passerini reactions, 
which are powerful, economical, multiple-component reactions[154-158] (MCR). The 
reaction of the protected D-amino aldehydes 109ņ138, isonitriles, trifluoroacetic acid 
and pyridine[159] lead directly to the diverse D-hydroxy-E-amino amides 139ņ168 in
moderate to excellent yields, usually with no or very little diastereoselectivity 
(Scheme 3.11, Table 3.3, the descriptors a and b relate to the polarity in 
chromatography, they do not assign stereochemistry. Compound a is less polar than 
compound b. The reactions proceeded under mild, nearly neutral conditions, 
typically between 0 °C and ambient temperature, through a trifluoroacetoxy 
intermediate.[160] Which underwent hydrolysis upon extractive workup with saturated 
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aqueous sodium bicarbonate solution. Dichloromethane was the solvent of choice as 
it was superior to acetonitrile and tetrahydrofuran in reaction rate and yield. The 
diastereomeric ratios of the hydroxyamides were observed in the range of 1:1 to 1:4 
by NMR and HPLC analysis. Very similar diastereoselectivities were observed for 
the Passerini reaction by Zhu et al. They observed no racemisation of the aldehyde 
during the Passerini reaction as monitored through chiral HPLC analysis.[161]
The diastereoisomeric mixture 139168 was separated by column chromatography. 
Due to almost the same polarity of both diastereoisomers, it was a tedious job to 
elute the compounds from column using hexane as an eluent whose polarity had been 
slightly increased by the addition of dichloromethane (1–10%). These isomers were 
separated in many hours. 1H-NMR investigation of (e.g. 141a, 141b, 152a, 152b) by 
the chiral shift reagent Eu(tfc)3 did not reveal any significant racemisation. 
3.1.2.2. Assignment of the absolute configuration of selected intermediates
In order to assign the absolute stereochemistry of the D-carbon (* in Scheme 3.13), 
L-phenylglycinol 171 and L-phenylalaninol 172 was synthesized by the same route 
and compared for their specific optical rotation [D]
20
D  to the commercial references. 
Synthesis of 171 and 172 involved different steps (Scheme 3.13) including D-
amination of the respective aldehydes with di-tert-butylazodicarboxylate, followed 
by reduction with NaBH4, Boc-deprotection and NN bond cleavage. The specific 
optical rotation [D]
20
D  of the products was measured on a Perkin-Elmer 241 
instrument. The enantiomeric excess (ee) was determined to be between 9699%
(Table 3.4). This confirms List’s[43] finding that D-proline catalyzed reactions 
provide to S-(or L) configured amino acid analogues. 
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N
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(10 mol %), N
N
O
O
O
O
H
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H
O
(1.5 equiv.)(1.0 equiv.)
(1 equiv.)
DCM, RT, 2-4 h
NaBH4 (1.2 equiv.)
MeOH, 1-3 h
O
N
N
O
O
O
O
H
R1
OH
i) TFA/DCM, 3 h
H2N
R1
OHii) Ra-Ni/H2, 500 Psi,
   MeOH, 25 °C, 28 h
136 R1 = Ph
137 R1 = Bn
*
*
*
171 R1 = Ph
172 R1 = Bn
169 R1 = Ph
170 R1 = Bn
Scheme 3.13: Synthesis of L-phenylalaninol and L-phenylglycinol to measure specific 
optical rotation against optically pure references.* = D-carbon 1. 
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Table 3.4: Enantioselective synthesis of L-phenylglycinol and L-phenylalaninol. 
Entry Substrate  Product  R1 Yield[a] [%] ee [%][b] Config.[c]
1 169 171 Ph 99 96 S
2 170 172 Bn 98 99 S
[a] Isolated yield. [b] Determined by comparison of the specific optical rotation [D]
20
D  of 171 and 172 
against optically pure samples of L-phenylglycinol and L-phenylalaninol obtained from Aldrich. [c] 
The absolute configurations were based on the specific rotations of 171 and 172.
3.1.2.3. Relative configuration of 151a and 151b 
The compound 151b derived from the enantioselective L-proline catalyzed amination 
and the subsequent unselective Passerini reaction at the same yield as the less polar 
151a. 151b turned out to crystallize readily from MeOH/DMF/H2O:10/20/1. Single-
crystal X-ray analysis was performed to assign the relative configurations of the two 
chiral centres labelled in Figure 3.3 as C10 and C12. The relative configuration of 
C10/C12 was found to be syn. The absolute stereochemistry of C12 should thus be R
(or D) and S for C10. Keeping this finding in mind, it was believed that the absolute 
stereochemistry of the other separated diastereoisomer 151a will thus be R at C12 
and R at C10. 
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Figure 3.3: X-ray crystal structure of compound 151b showing the atomic labelling and 
displacement ellipsoids drawn at the 50% probability level. 
The application of these methods to a concise synthesis of a BACE-1 inhibitor is 
illustrated in the Schemes 3.113.12 and 3.143.15. The N-protecting groups and the 
NN bonds in compounds 162168 were removed and cleaved, respectively and 
converted to norstatine derivatives 183193. Compounds 162167 were first treated 
with 1 mL of 18% HCl in dioxane and stirred at room temperature for 30 min, and 
then with H2/(Raney-Ni) at 34 bar, to afford the compounds 183193 in 70% overall 
yield. Simultaneous Cbz deprotection and NN bond cleavage of 168 was achieved 
in a single step by treatment with hydrogen over palladium on charcoal at 34 bar.  
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Scheme 3.14: Synthesis of norstatine derivatives. 
Table 3.5: Synthesis of norstatine derivatives 183193 by deprotection and NN bond 
cleavage.
[a] Isolated yield of 183193 after silica-gel column chromatography. 
The compounds 183193 were treated with 3-(dipropylcarbamoyl)benzoic acid 66
(synthesis of 66 mentioned in Scheme 3.2) by using EDAC and HOBt as coupling 
reagents, to result in the potential BACE-1 inhibitors 194204. All of the derivatives 
were characterized by their usual spectroscopic and analytical data mentioned in the 
experimental part. The next step in the variation of the lead structure 96a (IC50 = 20 
PM) are depicted in Scheme 3.15 (Table 3.6, entry 11). This compound 
acknowledges the SAR of the Elan inhibitors[152], which feature a 
difluorophenylalanine moiety at P1. The trifluoromethyl group at P2´ was introduced 
to interact with the polar pocket. These pockets can be occupied by carboxylic acids, 
but the resulting diacids display low membrane penetration and thus only moderate 
inhibition in cellular assays.[24, 25, 162-164]
Entry Substrate Intermediate Product R1 R3 Yield[a] [%] 
1 162a 173 183 Me Bn 86 
2 162b 174 184 Me Bn 86 
3 163a 175 185 Et Bn 40 
4 163b 176 186 Et Bn 60 
5 164a 177 187 iPr Bn 55 
6 164b 178 188 iPr Bn 81 
7 165 179 189 Ph chexyl 73 
8 166a 180 190 Ph Bn 90 
9 166b 181 191 Ph Bn 93 
10 167 182 192 Bn Bn 86 
11 168 – 193 3,5-difluorobenzyl Bn 98 
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Scheme 3.15: Synthesis of BACE-1 inhibitors 94204.
Table 3.6: Synthesis of potential BACE-1 inhibitors 
Entry Substrate Product R1 R2 Yield[a] [%] 
1 183 194 Me Bn 86 
2 184 195 Me Bn 86 
3 185 196 Et Bn 91 
4 186 197 Et Bn 91 
5 187 198 iPr Bn 97 
6 188 199 iPr Bn 81 
7 189 200 Ph chexyl 93 
8 190 201 Ph Bn 86 
9 191 202 Ph Bn 86 
10 192 203 Bn Bn 86 
11 193 204 3,5-difluorobenzyl Bn 77 
[a] Isolated yield after silica-gel column chromatography. 
3.1.2.4. Biological Evaluation 
The compounds 194204 were profiled in the FRET based assay with soluble 
truncated BACE-1.[151] This assay was performed at Hoffmann-La Roche, Basel and 
the results are shown in Table 3.7. Compound 203 displayed poor inhibition (IC50 > 
200 PM) in all the three assays: FRET BACE-1, RLBA (radioactive ligand binding 
assay/Tween) and RLBA in the presence of bovine serum albumine (BSA). The 
difluorophenylalanine 204 displayed weak inhibition in the FRET and RLBA (BSA) 
assays with IC50 values of 220 PM and >200 PM, respectively. This weak activity 
does not confirm the hypothesis of an edge on face interaction of two aromatic 
residues. This may be due to the rigid structure of all inhibitors due to norstatine 
moiety, which compelled the molecule to obtain an orientation other than which was 
mandatory for the activity. The compounds 194201 have no activity in either of the 
FRET, RLBA (Tween) and RLBA (BSA) assays. 
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Table 3.7: SAR of compounds 96a, 96b and 194204 for BACE-1 inhibition. 
N
O
N
H
O R1
OH
N
H
O
R2
FRET
(BACE1)
RLBA
(Tween)
RLBA
(BSA)
Entry Compound R1 R2
IC50 PM IC50 PM IC50 PM
1 194 Me Bn no. inh. no. inh. no. inh. 
2 195 Me Bn no. inh. no. inh. no. inh. 
3 196 Et Bn no. inh. no. inh. no. inh. 
4 197 Et Bn no. inh. no. inh. no. inh. 
5 198 iPr Bn no. inh. no. inh. no. inh. 
6 199 iPr Bn no. inh. no. inh. no. inh. 
7 200 Ph chexyl no. inh. no. inh. no. inh. 
8 201 Ph Bn no. inh. no. inh. no. inh. 
9 203 Bn Bn 20 >200 >200 
10 204 3,5-difluorobenzyl Bn 220 no. inh. >200 
11 96a Bn Bn 20 >200 >200 
12 96b Bn Bn >>200 no. inh. no. inh. 
no. inh.= no inhibition 
In conclusion, the feasibility of an organocatalytic, direct, asymmetric D-amination 
in combination with a Passerini reaction to provide diverse norstatines has been 
demonstrated. However, the introduction of a difluorophenylalanine moiety in 
compound 204 did not result in increased potency over the lead compound 96a. After 
a careful consideration of all spectroscopic data as well as physical data it was 
observed that compound 203 (Scheme 3.15) is identical to our pre-synthesized 
compound 96a from a different synthetic route (Scheme 3.7).   
3.1.3. Synthesis of a Solid Phase Supported Organocatalyst for the 
D-Amination Reaction
The 10 mol% of D-proline catalyst in D-amination reaction, which is necessary to 
attain sufficient enantioselectivity, will be incorporated into tripeptides by the Ugi 
reaction in competition with the Passerini reaction in following step. Any excess of 
catalyst is harmful and any trace amount leads to unnecessary side products resulting 
in reduction in the yield. Therefore, solid phase supported organocatalyst was 
designed and synthesized. 
The proline –NH proton is necessary for the catalytic process. The acidic proton can 
be converted to any amide or alcohol. Proline amide was found to be inactive while 
an amide of E-aminoalcohols with a terminal hydroxyl group exhibited increased 
catalytic activity and enantioselectivity.[165] Moreover, it is established that carbonyl 
activation by organic catalysts capable of double-hydrogen-bonding activation will 
exhibit high enantioselectivities.[166] Thus the immobilized proline derived catalyst 
(207) containing primary alcohol capable of extra hydrogen bonding was designed 
and synthesized. 
The attachment of such improved catalysts to a solid support will give rise to an easy 
removal of catalyst from reaction mixture and its reuse feasibility. L-Tyrosinol was 
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used to select the best support material and linker. The synthesis commenced by the 
coupling of L-proline with L-tyrosinol using EDAC and HOBt as coupling reagents 
to afford compound 205, which was purified by column chromatography and then 
immobilized by anchoring to Merrifield resin. Boc-deprotection of solid phase 
anchored catalyst 206 was achieved by treating it with 30% TFA in DCM, which led 
to immobilized catalyst (207). The resulting catalyst has been successfully applied to 
the direct D-amination reaction (Scheme 3.16).
OH
H2N
OH
N CO2H
Boc
+
OH
N
H
OH
O
N
O
OL-Tyrosinol 205
EDAC, HOBt,
TEA, DCM, RT, 
6 h, 94 %L-Proline
Merrifield Resin 
DCM, TEA, 
RT, 24 h
O
HN
HO
O
N
O
O
TFA, DCM
6 h, RT
O
HN
HO
O
N
H
206
207
Cl
Scheme 3.16: Synthesis of immobilized proline catalyst. 
3.1.4.1. Employment of immobilized catalyst and assignment of the absolute 
configuration of selected intermediates 
In order to use the catalyst for D-amination reaction, preliminary reactions of two 
aldehydes, i.e. phenylacetaldehyde and 3-phenyl propionaldehyde were performed 
with dibenzyl azodicarboxylate (DBAD) (Scheme 3.17). The D-aminated aldehydes 
were reduced in situ to their respective alcohols to avoid the recemization. The 
enantiomeric excess (ee) and assignment of the absolute stereochemistry of the D-
carbon (* in Scheme 3.17) for compound 210 and 211 was determined by their 
transformation to D-phenylglycinol 212 and D-phenylalaninol 213 and comparing 
their specific optical rotation [D]
20
D  to the commercial references. Synthesis of D-
phenylglycinol 212 and and D-phenylalaninol 213 involved, Cbz deprotection and 
NN bond cleavage in one-step (Scheme 3.17). The specific optical rotation [D]20D  of 
the products was measured on a Perkin-Elmer 241 instrument. The enantiomeric 
excess (ee) was determined to be between 9799% (Table 3.8).
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208 R1= Ph 
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210 R1= Ph 90%
211 R1= Bn 95%
BnO BnO+
108d R1= Ph
108e R1= Bn
107d
MeOH, RT, 
1_3 h,
H2N
R1
OH
Pd-C/H2, 500 Psi,
   
MeOH, 25 °C,
 18 h
*
212 R1 = Ph 89%
213 R1 = Bn 93%
*
*
Scheme 3.17: Solid phase supported proline derivative catalyzed D-amination reaction and 
the synthesis of D-phenylalaninol and D-phenylglycinol to measure specific optical rotation 
against optically pure references.* = D-carbon 1. 
Table 3.8: Enantioselective synthesis of D-phenylglycinol and D-phenylalaninol. 
Entry Substrate Product R1 Yield[a] [%] ee [%][b] Config.[c]
1 210 212 Ph 89 97 R
2 211 213 Bn 93 99 R
[a] Isolated yield. [b] Determined by comparison of the specific optical rotation [D]
20
D  of 212 and 213 
against optically pure samples of L-phenylglycinol and L-phenylalaninol obtained from Aldrich. [c] 
The absolute configurations were based on the specific rotations of 212 and 213.
The results show that the synthesized proline derived immobilized catalyst (207) is 
an efficient catalyst for direct asymmetric D-amination reaction. The catalyst capable 
of extra hydrogen-bonding activation of carbonyl group provided better performance. 
The product can be separated from the catalyst simply by filtration and the catalyst 
can be reused conveniently. The easy and complete removal of catalyst may avoid 
the undesirable side products during Passerini reaction and may thus improve the 
yield of the reaction. This immobilized catalyst can also be employed for other 
reactions.
3.1.4. In Situ Generation of HEA Containing Compounds by 
Modified Passerini Reaction 
SAR of compounds 9699 and 194204 (Scheme 3.7 and 3.15, Table 3.2 and 3.7)
for BACE-1 inhibitory activity revealed that induction of norstatine 
(hydroxymethylcarbonyl) motif did not enhance the activity. Based on known HEA 
containing BACE-1 inhibitors, it was presumed that conversion of 
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hydroxymethylcarbonyl moiety to hydroxyethylene might enhance the activity. A 
convenient and straightforward approach has already been developed to afford 
norstatine compounds, by sequential D-amination followed by Passerini reaction. 
Therefore, it was anticipated to apply the same synthetic methodology for the 
synthesis of HEA containing compounds by employing some modification in the 
method (Scheme 3.18).  
R1
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N
H
O
R2
R1
OH
N
H
R2
N
H
O
Pr2N
O R1
OH
N
H
R2
N
H
O
Pr2N
O R1
OH
N
H
R2
Passerini product
Modified Passerini
Product
O
Synthesized BACE-1 inhibitors
Proposed BACE-1 inhibitors
 by modified Passerini reaction
Scheme 3.18: Structure of Passerini and modified Passerini product. 
It was presumed that an in situ reduction of intermediate, formed during Passerini 
reaction may lead to such compounds. Consequently, a modification in the Passerini 
reactions was employed and a preliminary Passerini reaction was performed with 3-
phenylpropanal and benzylisonitrile in the presence of catalytic TFA in DCM. The 
reaction was monitored by HPLC. Once the benzylisonitrile was fully consumed, a 
reductive work up was performed by adding NaBH4 and MeOH carefully to the 
reaction mixture (Scheme 3.19). The intermediate was reduced in situ to 
hydroxyethylene containing compound i.e. 1-(benzylamino)-4-phenylbutan-2-ol
(214), which was characterized by spectroscopic as well as X-ray crystallographic 
analysis (Figure 3.4). Thus, a facile synthesis of HEA containing compounds by 
modified Passerini reaction has been established, which can be further employed for 
the synthesis of next generation of BACE-1 inhibitors (Scheme 3.18).
O
N
OH
H
N
TFA, DCM, 
Monitor by HPLC
3-phenylpropanal
Benzylisonitrile
1-(benzylamino)-4-phenylbutan-2-ol
OH
N
NaBH4
MeOH
Passerini Intermediate
214
Scheme 3.19: Synthesis of hydoxyethyleneamine (HEA) containing compounds by modified 
Passerini reaction. 
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Figure 3.4: X-ray crystal structure of compound 1-(benzylamino)-4-phenylbutan-2-ol (214)
showing the atom labelling and displacement ellipsoids drawn at the 50% probability level. 
3.1.5. Synthesis of Non Peptidic BACE-1 Inhibitors 
A series of isophthalamides 8, 9 and 10 (Figure 1.5, Scheme 1.6, Scheme 3.20) that 
are potent and selective BACE-1 inhibitors was reported by Merck and NeoGenesis 
researchers.[26, 28] These inhibitors displayed inhibition for BACE-1 (IC50= 25 PM for 
8, 1.4 PM for 9 and 11 nM for 10) in their enzymatic assay and presented a novel 
mode of binding to aspartyl proteases. The discovery of 8, 9 and 10 was the result of 
the combined efforts of high-throughput screening and following lead optimization. 
To date, the majority of the BACE-1 inhibitors in the literature are peptide-based 
analogues that replace the scissile amide bond with a noncleavable isostere. While 
these statine or hydroxyethylene (HE) based dipeptide isosteres resulted in potent 
enzymatic inhibition, their peptidic character precludes their use as therapeutic 
agents. The crystal structure of the inhibitor 9 (PDB: 1TQF) bound in the BACE-1 
active site exposed two important pieces of structural information that influenced 
potential compounds design. Compound 9 was bound in the S1-S4 region of the 
enzyme. Interestingly, there is no direct contact with Asp32 and Asp228, however a 
hydrogen bonding was observed between oxyacetamide NH to a water molecule 
situated between these aspartyl dyad. Most notably, this terminal aminopentyl chain 
coils back into S1 pocket, anchored to the backbone carbonyl oxygens of Gln73,
Lys107, and Phe108 by hydrogen bonding. Moreover, a weak hydrogen bonding was 
observed between sulfonate oxygens and Arg235. This unusual binding mode 
provided an opportunity for further modification to improve BACE-1 inhibitory 
potency. To study the SAR at the P2 and P3 positions, it was anticipated to introduce 
a variety of amides on one or both positions, whereas towards prime side S1, the 
motif was kept aminopentyl oxyacetamide or Boc-protected aminopentyl 
oxyacetamide to observe the effect of free and protected amine on BACE-1 
inhibitory potency. As a consequence, isophthalamides 221227 were designed and 
synthesized.
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Scheme 3.20: Non-peptidic BACE-1 inhibitors.[26, 28]   
The series of non-peptidic E-secretase inhibitors 221227 was synthesized as 
outlined in Scheme 3.21–3.22. The Phonolic –OH group in compound 70–71 was 
alkylated using anhydrous K2CO3 and tert.butylchloroacetate (ClCH2CO2tBu) in 
acetone at 60–70 °C to afford compound 215–216, in 82% and 60%, respectively
(Scheme 3.21). To circumvent the poor yield, NaH in DMF was employed as 
alkylating agent for alkylation of compound 71. The tert-butyl ester group in 215–
216 was deprotected to the corresponding free acids 217–218 by treatment with 20% 
trifluoroacetic acid in dichloromethane. These free acids 217–218 were coupled with 
tert-butyl 5-amino pentyl carbamate using EDAC and HOBt as coupling reagents to 
their corresponding amides 219–220 in 6894% yield. However, PyBrop promoted 
coupling reaction for compound 210 provided 80% yield. The methyl ester groups in 
219–220 were hydrolyzed using sodium carbonate in methanol–water (1:1) to obtain 
building blocks 221–222. Compound 221 was subjected to Boc-deprotection by 20% 
TFA in CH2Cl2 to obtain compound 223 (Scheme 3.21), which was synthesized to 
evaulate the structure activity relationship.  
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222 X = N 68%
Scheme 3.21: Synthesis of Compounds 221223.
Compound 221 was subjected to coupling with variety of amines (Scheme 3.22,
Table 3.9) and a mixture of two products was obtained in 1:1 ratio in all reactions. 
This mixture was separated via column chromatography using 40% ethylacetate in 
hexane as eluent. The spectroscopic data of the separated compounds revealed that 
compound 224 is di-amidation product and compound 225 is mono-amidation 
product. Inspite of the smaller polarity difference between di- and mono-amidation 
products, it was possible to obtain the pure compounds in an appreciable quantity (> 
50%) from the mixture. The unexpected formation of compound 225 as a side 
product minimized the efforts towards its designed and intended synthesis. The
justification of synthesis of compounds 225 is the use of two equivalents of EDAC 
and HOBt by considering two free acidic protons, which activated all acidic protons 
and enabled the production of mono as well as di-amidation product. The N-Boc of 
both separated di- and mono-amidation products was deprotected by 30% TFA in 
CH2Cl2 to afford the corresponding products 226–227 (Scheme 3.22, Table 3.9).
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Scheme 3.22: Synthesis of Compounds 226–227.
Table 3.9: Synthesis of Compounds 226–227. 
Entry Compound No. R 
1 223 OH
2 224a, 225a, 226a, 227a NH
3 224b, 225b, 226b, 227b NH
OCH3
4 224c, 226c 
N
H
CF3
5 224d, 225d, 226d, 227d
N
H
OCH3
O
HN
6 224e, 225e, N
H
O
O
7 224f, 225f, HN
O
O
O
O
8 224g, 225g, 226g, 227g 
N
H
NH
9 224h 
N
H
O
O
OH
10 224i, 225i, 226i, 227i 
NH
11 226e, 227e 
N
H
O
OH
12 226f, 227f 
HN
OH
O
O
OH
13 226h 
N
H
OH
O
OH
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3.1.5.1. Biological Evaluation 
Compounds 221, 223, 224, 225, 226 and 227 were profiled in the FRET based assay 
with full length BACE and results were shown in Table 3.10 and 3.11. This assay 
was carried out at Hoffmann-La Roche, Basel.[151]   
Table 3.10: SAR of compounds 221 and 223–227 for BACE-1 Inhibition.
R
O
R
O
O
N
H
N
H
O O
O
221 & 224
R
O
R
O
O
N
H
NH2O
223 & 226
R
O
OH
O
O
N
H
N
H
O O
O
225
R
O
OH
O
O
N
H
NH2O
227
FRET RLBA Tween RLBA BSA Entry Compound No. R IC50 (PM)
1 221 OH no inhibition no inhibition no inhibition 
2 223 OH >>200 no inhibition no inhibition 
3 224a NH no inhibition no inhibition no inhibition 
4 225a NH >200 no inhibition no inhibition 
5 226a NH activation no inhibition no inhibition 
6 227a NH >>200 no inhibition no inhibition 
7 224b NH
OCH3
no inhibition no inhibition no inhibition 
8 225b NH
OCH3
activation >>200 no inhibition 
9 226b NH
OCH3
activation no inhibition no inhibition 
10 227b NH
OCH3
>>200 no inhibition no inhibition 
11 224c 
N
H
CF3
no inhibition no inhibition no inhibition 
12 226c 
N
H
CF3
activation >>200 >>200 
13 224d 
N
H
OCH3
O
HN activation >>200 no inhibition 
14 225d 
N
H
OCH3
O
HN activation no inhibition no inhibition 
15 226d 
N
H
OCH3
O
HN activation >>200 251 
16 227d 
N
H
OCH3
O
HN activation no inhibition >>200 
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Table 3.11: SAR of compounds 221 and 223–227 for BACE-1 Inhibition.
R
O
R
O
O
N
H
N
H
O O
O
221 & 224
R
O
R
O
O
N
H
NH2O
223 & 226
R
O
OH
O
O
N
H
N
H
O O
O
225
R
O
OH
O
O
N
H
NH2O
227
FRET RLBA Tween RLBA BSA 
Entry Compound No. R IC50 (PM)
17 224e 
N
H
O
OtBu
>>200 no inhibition no inhibition 
18 225e 
N
H
O
OtBu
no inhibition no inhibition no inhibition 
19 226e 
N
H
O
OH
activation >>200 no inhibition 
20 227e 
N
H
O
OH
no inhibition no inhibition no inhibition 
21 224f 
HN
OtBu
O
O
OtBu
no inhibition no inhibition no inhibition 
22 225f 
HN
OtBu
O
O
OtBu
no inhibition no inhibition no inhibition 
23 226f 
HN
OH
O
O
OH
>>200 no inhibition no inhibition 
24 227f 
HN
OH
O
O
OH
>200 no inhibition no inhibition 
25 224g 
N
H
NH
activation 249 no inhibition 
26 225g 
N
H
NH
activation no inhibition no inhibition 
27 226g 
N
H
NH
activation >200 >>200 
28 227g 
N
H
NH
activation no inhibition no inhibition 
29 224h 
N
H
O
O
OH
activation no inhibition no inhibition 
30 226h 
N
H
O
O
OH
activation no inhibition no inhibition 
31 224i 
NH
no inhibition no inhibition no inhibition 
32 225i 
NH
no inhibition no inhibition no inhibition 
33 226i 
NH
no inhibition no inhibition no inhibition 
34 227i 
NH
>>200 no inhibition no inhibition 
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The SAR data revealed that in “a” series, where R is a benzyl amine motif, 224a
displayed no activity and 226a showed little activity for BACE-1 inhibition. 
However, 225a and 227a displayed BACE-1 inhibition with an IC50 values of >200 
PM and >>200 PM respectively. This concluded that a free acid in 225a and a free 
aminopentyl oxyacetamide ligand along with a free acid in case of 227a is
responsible for the inhibitory activity. In series “b” where R is p-methoxy benzyl 
amine motif, 224b exhibited no activity at all, while 225b and 226b displayed a little 
activation in BACE-1 assay, while an IC50 values of >>200 PM was observed in 
RLBA (Tween) assay for 225b. However, 227b displayed an IC50 values of >>200 
PM for BACE-1 assay. The activity displayed by 225b and 227b is supposed to be 
due to free pentylamine ligand. In series “c” where R is 3-
(triflouromethyl)benzylamine motif, 224c displayed no activity at all, 226c exhibited 
activation in BACE-1, while in RLBA (Tween & BSA) assay it showed inhibition 
with an IC50 values of >>200 PM, >>200 PM respectively. This again certify the 
importance of a free aminopentyl ligand for the activity. In series “d” where R is L-
tryptophan methyl ester motif in 224d and 225d showed a little activity for BACE-1 
whereas 224d displayed an activity with an IC50 values of >>200 PM in RLBA 
(Tween) assay. 226d was found to be the most active compound out of all series i.e. 
activation in BACE-1 assay, while in RLBA (Tween and BSA) showed an inhibition 
with an IC50 values of >>200 PM, 251 PM. This result showed that a free amine and 
L-tryptophan methyl ester motif on both sides of isophthalamide is responsible for 
the activity, which can be improved further by hydrolyzing the ester group in 226d to 
acid. 227d displayed little inhibitory activity in BACE-1 while no activation in 
RLBA (Tween) and displayed an inhibition with an IC50 values of >>200 PM in 
RLBA (BSA).
In “e” series where R is L-phenyl glycine ester, 224e displayed activity only in 
BACE-1 assay with an IC50 values of >>200 PM. 226e exhibited only activation in 
RLBA (Tween) with an IC50 values of >>200 PM. Compound 225e and 227e
exhibited no activity at all. This describes that the di-amidation by L-phenyl glycine 
ester in case of 224e and 226e provided such an orientation to the molecule to have 
some binding with the active site. In series “f” where R is L-aspartic acid E-tert-butyl
ester, 224f and 225f displayed no inhibition at all while 226f and 227f showed an 
inhibition in BACE-1 assay with an IC50 values of >>200 PM and >200 PM which 
certified that free amine is responsible for activity. In series “g” where R is a 
tryptamine, 224g, 225g, 226g and 227g showed little activation in BACE-1 while 
224g, 226g showed an activity with an IC50 values of 249 PM, >200 PM respectively 
in RLBA (Tween) where as 226g displayed an  activity with an IC50 values of >>200 
PM in RLBA (BSA) which illustrated that this motif with a free amine is responsible 
for activity. In “h” series where R is L-tyrosine tert-butyl ester, 224h and 226h
showed little activation in BACE-1 assay which displayed that this motif is impairing 
the activity. In “i” series where R is phenyl ethylamine, 224i, 225i, and 226i are not 
active at all however, 227i displayed little inhibition in BACE-1 (IC50 values of 
>>200 PM). The SAR data showed that potency was impaired when pentylamine 
ligand was protected. This verified that a free amine is crucial for BACE-1 inhibitory 
activity, while free acid in the molecule can enhance the activity. However, out of all 
amine motifs, L-tryptophan methyl ester and tryptamine were found to be the best in 
these “a-i” series. 
It is apparent from the SAR data that introduction of bulky amines containing indole 
functionality increased BACE-1 inhibitory activity. Moreover, free amine 
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functionality of aminopentyl oxyacetamide moiety affects the BACE-1 inhibitory 
activity. 
Recently Narlawar et al. reported that N-alkylated carprofen derivatives modulates J-
secretase.[167] BSc3040 and BSc3041 are acetic acid derivatives with a long 
lipophilic substituent branching out (Scheme 3.23). Compound 226e, 226f, 226h,
227e and 227f have similarity with BSc3040 and BSc3041 (Scheme 3.23).
Therefore, compound 221 and 223–227 were investigated on Ȗ-secretase for their 
modulatory activity and results are shown in Table 3.123.13 and Figure 3.53.10.
N
Cl
O
OH
nonyl
BSc3041
N
Cl
O
OH
decyl
BSc3040
Scheme 3.23: Structure of BSc3040 and BSc3041.[167] 
To evaluate the compounds for their potency in modulating and inhibiting Ȗ-secretase 
activity, the liquid phase electrochemiluminescence (LPECL) assay was used to 
measure AE isoforms. The assay was performed at Hoffman-La Roche, Basel, by 
Karlheinz Baumann. These compounds were investigated at 10 μM concentration 
and 40 μM concentrations. As anticipated, some of the compounds were turned out 
to be modulators of J-secretase but surprisingly they were found to be inverse 
modulators. However, most of them were found to be inhibitors. Out of investigated 
compounds of 224 series and 226 series, the most active compounds were found to 
be 224a, 224e and 224f which displayed inverse modulatory activity in low 
micromolar concentration. They affected the cleavage at the Ȗ38, Ȗ40 and Ȗ42 sites to 
a different extent and particularly reduced the formation of AE38, while increased the 
formation of more toxic AE42. Compound 221 and 223 with free acid functionality 
were found to be inhibitors of Ȗ-secretase. However, the conversion of the acid 
functionality of 221 to corresponding amides using various amines, transformed it 
into inverse modulators. Interestingly, Boc-deprotection of compound 224 abolished 
the Ȗ-secretase modulatory activity and transformed it into full blown inhibitor. This 
indicates the important contribution of protected amine for the inverse modulatory 
activity. Compound 226e, 226f and 226h were found to be inhibitors of Ȗ-secretase 
with free acid functionality. It can be speculated that the protection of aminopentyl 
oxyacetamide functionality by Boc, may transform 226e, 226f and 226h into 
classical modulators as carboxylic acid may interfere with uptake. 
Similar results were obtained with mono-amidation products 225 and 227.
Derivatization of one of the acid of 221 turned it into inverse modulator of Ȗ-
secretase. The most active compounds were 225e and 225i. They displayed potent 
inverse modulatory activity in low micromolar range. Surprisingly, the Boc-
deprotection of 225 reduced the modulatory activity but did not change the mode of 
action from modulation to inhibition. Thus, it cofirms the hypothesis that free acid is 
crucial for J-secretase modulatory activity.
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Table 3.12: SAR of compounds 221, 223, 224 and 226 for Ȗ-secretase inhibition.
R
O
R
O
O
N
H
N
H
O O
O
221 & 224
R
O
R
O
O
N
H
NH2O
223 & 226
IC50 [μM] Entry Compound R AE38 AE40 AE42
Viability 
1 221 OH inactive inactive inactive >40 
2 223 OH inactive inactive inactive >40 
3 224a NH 6.7 > 40 8.2c 40 
4 224ba NH
OCH3
> 10 > 10 n.d.d >10 
5 224cb
N
H
CF3
toxic toxic n.d.d >40 
6 224d 
N
H
OCH3
O
HN | 40 > 40 n.d.d >40 
7 224e 
N
H
O
OtBu
2.6 > 40 4.1c >40 
8 224f 
HN
OtBu
O
O
OtBu
1.2 > 40 1.3 c >40 
9 224g 
N
H
NH
| 40 > 40 n.d.d >40 
10 224h 
N
H
O
O
OH
| 40 > 40 n.d.d >40 
11 224ia
NH
< 10 > 10 n.d.d >40 
12 226a NH inactive inactive inactive >40 
13 226b NH
OCH3
inactive inactive inactive >40 
14 226c 
N
H
CF3
> 40 > 40 n.d.d >40 
15 226d 
N
H
OCH3
O
HN inactive inactive inactive >40 
16 226e 
N
H
O
OH
| 40 > 40 n.d.d >40 
17 226f 
HN
OH
O
O
OH
> 40 > 40 n.d.d >40 
18 226g 
N
H
NH
inactive inactive inactive >40 
19 226h 
N
H
O
O
OH
> 40 > 40 n.d.d >40 
20 226i 
NH
> 40 > 40 n.d.d >40 
a = cell toxicity observed at 40 μM, b = cell toxicity observed at 10 μM, c = EC50 value displayed for 
AE42, d = cannot be calculated or estimated, n.d. = not determined 
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Figure 3.5: Dose Response curve of 224a, 224e and 224f.
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Figure 3.6: Activity data for Ȗ-secretase at 10 μM conc. for compounds 221, 223, 224 and 
226.
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Figure 3.7: Activity data for Ȗ-secretase at 40 μM conc. for compounds 221, 223, 224 and 
226.
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Table 3.13: SAR of compounds 225 and 227 for Ȗ-secretase inhibition.
R
O
OH
O
O
N
H
N
H
O O
O
225
R
O
OH
O
O
N
H
NH2O
227
IC50 [μM] Entry Compound R Viability AE38 AE40 AE42
1 225a NH >40 | 40 > 40 n.d.a
2 225b NH
OCH3
>40 | 40 > 40 n.d.a
3 225d 
N
H
OCH3
O
HN >40 > 40 > 40 n.d.a
4 225e N
H
O
O
>40 5.1 > 40 5.4b
5 225f HN
O
O
O
O
>40 < 40 > 40 n.d.a
6 225g 
N
H
NH
>40 | 10 > 40 n.d.a
7 225i 
NH
>40 12.7 > 40 19.4 b
8 227a NH >40 | 40 > 40 n.d.a
9 227b NH
OCH3
>40 > 40 > 40 n.d.a
10 227d 
N
H
OCH3
O
HN >40 > 40 > 40 n.d.a
11 227e 
N
H
O
OH
>40 n.t. n.t. n.t.c
12 227f 
HN
OH
O
O
OH
>40 > 40 > 40 n.d.a
13 227g 
N
H
NH
>40 > 40 > 40 n.d.a
14 227i 
NH
>40 > 40 > 40 n.d.a
a = cannot be calculated or estimated, b = EC50 value displayed for AE42, c = not tested, n.d. = not 
determined 
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Figure 3.8: Activity data for Ȗ-secretase at 10 PM conc. for compounds 225 and 227.
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Figure 3.9: Activity data for Ȗ-secretase at 40 PM conc. for compounds 225 and 227.
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Figure 3.10: Dose response curves of 225e and 225i.
It is evident from SAR analysis, the conversion of acid 221 into its various mono and 
di-amide derivatives, transformed it into potent but inverse modulators of Ȗ-secretase
(Table 3.123.13, Figure 3.53.10). The di-amide products with protected amine 
(224a, 224b, 224e, 224f and 224i) particularly where it has a bulky and lipophilic 
substituents were found to be the potent modulators of Ȗ-secretase. Boc-deprotection 
of compounds of series 224 surprisingly changed the mode of action from 
modulation to inhibition. Compounds of series 227 having a free acid like 
compounds 221 and 223 were also found to be inhibitors. Compound 224f was found 
to be a good lead out of the series and can be optimized further to change its mode of 
action from inverse modulation to modulation as it displayed modulatory activity in 
the low micromolar concentration. The t-butyl ester hydrolysis of 224 compounds 
keeping its amine protected may transform it into a classical modulator of Ȗ-
secretase.
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3.2. Synthesis of Proteasome Inhibitors
“Serendipitous discoveries are of significant value in the advancement of science and 
often present the foundation for important intellectual leaps of understanding.". 
(M.K. Stoskopf)
A set of compounds 238249 were synthesized as peptide-based BACE-1 inhibitors 
which were analogues of compound 33 (MG132). Compound 33 (MG132) have a 
broad specificity and can inhibit cysteine, serine and aspartyl proteases. However, 
BACE-1 selectivity is important. To address this concern, all analogues were 
investigated for BACE-1 as well as proteasome inhibitory activity. It was observed 
that all compounds displayed moderate BACE-1 inhibitory activity however many of 
them were found to be highly potent proteasome inhibitors.  
"In the field of observation, chance favors only the prepared mind."
(Louis Pasteur) 
These serendipitous results encouraged further development, design and synthesis of 
proteasome inhibitors. 
3.2.1. Peptidomimetics Synthesized for 20S Proteasome Inhibition 
Proteasomes are multicatalytic proteinase complexes which play a key role in 
intracellular protein degradation. They are involved in protein degradation in 
eukaryotic cells, in cell cycle control, apoptosis, transcriptional regulation, and is the 
most likely route by which the majority of cytoplasmic and nuclear proteins are 
turned over. Thus, inhibition of proteasomes affects cell cycle processes and induces 
apoptosis.[49] Moreover, 20S proteasomal inhibitors are potential tools for the 
modulation of neoplastic growth. Compounds 238249 were synthesized as 
analogues of 33 (MG132) which is a potent yet nonspecific proteasome inhibitor. It 
was assumed that side chain modification of tripeptide might offer higher potency, 
selectivity and site specific inhibition of the 20S proteasome. This assumption was 
based on some known and potent peptidic inhibitors.[168-170]
The compounds 238249 were synthesized based on the established substrate 
preferences of E-secretase[171] as outlined in Scheme 3.24. Intermediate compounds 
231 and 232 were synthesized by the coupling of commercially available Z-
Asp(OtBu)-OH (228) and Boc-Asp(OBn)-OH (229) with L-Leucinol, respectively, 
using EDAC and HOBt as coupling reagents. The products were purified by column 
chromatography using 20% ethylacetate in hexane as solvent. L-Leucinol was 
synthesized in bulk amount by the reduction of commercially available L-Leucine
using LiAlH4 in THF. 
Z group of Z-Asp(OtBu)-Leucinol (231) was removed by hydrogenation using 20% 
Pd-C in ethanol to afford H-Asp(OtBu)-Leucinol (233) however, Boc-deprotection 
on the D-amine of Boc-Asp(OBn)-Leucinol (232) was carried out with 20% 
trifluoroacetic acid in CH2Cl2 to obtain H-Asp(OBn)-Leucinol (234). During scale up 
synthesis of 234, 18% HCl in Dioxane was used for Boc-deprotection of 232 as an 
alternative method as it provided a clean solid product as an acid salt of compound in 
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good yield. The resultant free amines 233 and 234 further underwent peptide 
coupling with Boc-Leu-OH (235), Z-Leu-OH (236) and Ac-Leu-OH (237) to afford 
corresponding tripeptide alcohols 238–243 (Scheme 3.24–3.25) followed by 
oxidation using IBX in DMSO. The tert-Butyl ester of 244 and 245 was cleaved by 
50% TFA in CH2Cl2 to obtain a free acid. It was presumed that free acid may 
enhance the activity.  
Sorg et al. synthesized analogous compounds by polymer supported IBX oxidation 
and scavenged by threonyl resin, where the last step involved the cleavage of the 
peptide compound from resin using a mixture of hexafluoroisopropanol (HFIP) and 
acetic acid in CH2Cl2, which will end up on free acid.[172] It is important to note that 
any compound prepared through this method will always ends up on a free acid like 
compound 248 (BSc2128) and 249 (BSc2129).  Compound with a protected ester 
moiety like 244 (BSc2115) and 245 (BSc2118) can never be synthesized by this 
method as cleavage step from solid phase will always results a free acid.
EDAC, HOBt, DCM,
231: Pd-C / H2, EtOH, 
RT, 6-12 h
EDAC, HOBt,
CH2Cl2, Et3N,
RT, 3-12 h
Et3N, L-Leucinol 230, 
RT, 6-12 h
IBX, DMSO
RT, 1-6 h
50 % TFA
DCM, RT, 
1-2 h
R1 Asp(OR2)OH R1 Asp(OR2)N
H
OH
H Asp(OR2)N
H
OH
Leu Asp(OR2)N
H
OH
R3
Leu Asp(OH) N
H
O
R3
238 BSc2114: R2 = tBu, R3 = Boc (97%)
239 BSc2117: R2 = tBu, R3 = Z (96%)
240 BSc2207: R2 = tBu, R3 = Ac (93%)
241 BSc2195: R2 = Bn, R3 = Ac (97%)
242 BSc2196: R2 = Bn, R3 = Z (97%)
243 BSc2194: R2 = Bn, R3 = Boc (90%)
244 BSc2115: R2 = tBu, R3 = Boc (98%)
245 BSc2118: R2 = tBu, R3 = Z (97%)
246 BSc2208: R2 = Bn, R3 = Ac (96%) 
247 BSc2197: R2 = Bn, R3 = Z (95%)
248 Bsc2128: R3 = Boc (97%)
249 BSc2129: R3 = Z (90%)
228 R1 = Z, R2 = tBu
229 R1 = Boc, R2 = Bn
232: TFA, CH2Cl2,
RT, 6-24 h
231 BSc2094: R1 = Z, R2 = tBu (83%)
232 BSc2192: R1 = Boc, R2 = Bn
233 BSc2113: R2 = tBu (100%)
234 BSc2193: R2 = Bn (100%)
Leu Asp(OR2)N
H
O
R3
R3-Leu-OH+
235 R3 = Boc
236 R3 = Z
237 R3 = Ac
Scheme 3.24: Synthesis of peptidomimetics designed for 20S proteasome inhibition.
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Scheme 3.25: Synthesized 20S proteasome inhibitors.
3.2.1.1. Biological Evaluation 
The intermediate alcohol derivatives 238–243 and the tripeptidic aldehydes 244–249
were investigated for enzyme inhibition. Inhibition of E-secretase was rather poor 
(IC50ҏҏ >>200 PM, Table 3.14), but several compounds turned out to be potent 
inhibitors of the 20S proteasome.  
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Table 3.14: Activity Report of the most active compounds on BACE-1 vs Proteasome 
inhibition
Entry Proteasome (IC50) BACE-1 (IC50) LogP Structure 
33 (MG132) 50 nM 100 nM 3.48 NH
O
H
N
O
N
H
O
O
O
238 (BSc2114) 100 nM 50 PM 2.05 
HN
O
H
N
O
N
H
OO O
O
OH
245 (BSc2118) 10 nM 10 PM 2.60 NH O
H
N
O
N
H
O
O
O
O
O
All peptide mimetics (238–249, Scheme 3.24–3.25) underwent many further 
experiments to investigate their ability to inhibit the 20S proteasome. Dr. Ulrike 
Kuckelkorn performed the biochemical characterization of the proteasome inhibitors 
(in vitro and in vivo), while co-crystallization of BSc2118 with yeast proteasomes 
was performed by Michael Groll, (both from Universitätsklinikum Charité Institut 
für Biochemie, Berlin). Izabela Mlynarczuk and colleagues (from 
Universitätsklinikum Charité Institut für Biochemie, Berlin) performed biological 
evaluation of compound BSc2118 for the combined effect of proteasome and calpain 
inhibition on cisplatin resistant human melanoma cells. 
3.2.2. Tripeptide Mimetics Inhibit the 20S Proteasome by Covalent 
Bonding to the Active Threonines
For detailed results and discussion (see Appendix Article I, Journal of Biological 
Chemistry, 2005, 280 (31), 28394-28411). 
All novel compounds were investigated for their inhibitory capacity in cell lysates. 
As a consequence, serine-, cysteine- and metallo-proteases were blocked during the 
assay with the synthesised mimetics by the protease inhibitor cocktail Complete
(Roche). Eleven of the investigated compounds in two assays diminished the 
proteolysis of the hydrophobic Suc-LLVY-AMC substrate. The specific inhibition of 
a single catalytic site is of special interest for drug development, therefore the 
inhibition of different proteasomal activities was analysed. The different cleavage 
preferences of proteasomes were determined by specific substrates for the 
hydrophobic (chymotrypsin-like), the trypsin-like and the postacidic (caspase-like) 
activities on isolated proteasomes. Four out of 12 derivatives inhibited proteasomal 
activities with IC50 values below 10 PM. The peptidic aldehydes 244 (BSc2115) and 
245 (BSc2118) inhibited all proteasomal hydrolytic activities, whereas compound 
247 (BSc2197) inhibited the chymotryptic and the caspase-like sites. However, the 
purpose of this investigation was the identification of fully selective inhibitors of 
proteasomal activity. The tripeptidic alcohol 238 (BSc2114) {and with lower potency 
239 (BSc2117)} specifically reduced the trypsin-like activity, and the compound 239
(BSc2117) resulted in an exclusive reduction of chymotryptic activity. Notably, the 
most potent of the new inhibitors featured IC50 values below 100 nM {238
(BSc2114), 245 (BSc2118)}. This is in the range of novel proteasomal inhibitors, 
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which are in clinical trials.[170] Remarkably, the tetrapeptide inhibitor PSI (Z-
IE(OtBu)AL-CHO), is structurally related to compound 245 (BSc2118, Z-
LD(OtBu)L-CHO),[173] which is among the strongest inhibitors (IC50 below 60 nM).
Moreover, it exhibited low toxicity and was found to be able to permeate cellular 
membranes. The comparison of the inhibitors indicated the major contributions of 
the ligand side chains to the specific tight interactions with the various 
proteolytically active sites. Similar observations were made for the alcohol 
derivatives, with compound 238 (BSc2114) being more effective than the other six.  
Tumor cells with their accelerated and neoplastic growth are often more sensitive to 
proteasomal inhibitors than normal cells. The clinically approved proteasomal 
inhibitor Bortezomib® causes growth arrest and apoptosis in the sensitive tumor 
cells, whereas “normal” cells tolerate higher inhibitor concentrations.[174] The 
restriction to myeloma tumors might overcome by more specific inhibitors, like PSI, 
which blocks angiogenesis and modulates the growth of solid tumors.[173] The 
differences in cellular features and the predictable resistance mechanisms require 
continuous development of new proteasomal inhibitors. Efficient cell permeation, 
stability in aquatic systems and potent induction of cellular events are all mandatory 
for clinical applications. Therefore, the permeation ability of these compounds and 
their in vivo impact on proteasomes was investigated and monitored the 
accumulation of polyubiquitinated proteins in cultured cells. More than 50% 
reduction of cellular proteasome activity was observed for one of the new inhibitors 
245 (BSc2118). The most potent inhibition was achieved by the compound 245
(BSc2118), which reduced the proteasome activity to 10% at a concentration of 1 
PM. Even 50 nM solutions of compound 245 (BSc2118) arrested 70% of the 
melanoma cells. These results indicated potency, membrane permeation and 
sufficient stability throughout the incubation period for the inhibitor 245 (BSc2118).
The cellular proteasomal activity was clearly reduced and accompanied by strong 
induction of apoptosis after 20 hours treatment with 1 PM of inhibitor (245)
(BSc2118). The prevalent enhanced sensitivity of tumor cells towards proteasomal 
inhibition was confirmed for inhibitor 245 (BSc2118). Compound 245 (BSc2118)
exerts its effects at considerably lower concentrations than MG132 (33) and exhibits 
an almost identical inhibitory profile as Bortezomib, which is characterized by a 
lower Ki-value. The low toxicity of our new compound and the effective proteasome 
inhibition encouraged to continue the evaluation of lead compound 245 (BSc2118).
3.2.3. Combined Effect of Proteasome and Calpain Inhibition on 
Cisplatin Resistant Human Melanoma Cells 
For detailed results and discussion (see Appendix Article II, Cancer Research, 2006, 66
(15), 7598-7605). 
Cisplatin resistance or, more generally, chemotherapy resistance is a major obstacle 
in the treatment of metastatic melanoma and other solid tumors. However, in most 
cases severe toxicity prohibits the administration of higher doses of 
chemotherapeutic agents. One of the practical ways to solve this problem in the 
clinic is to combine traditional chemotherapeutics with their synergistic modulators, 
thus improving therapeutic efficacy without increasing toxicity. Moreover, analysis 
of mechanisms leading to chemotherapy resistance might result in the identification 
of targets which will safely and effectively enhance therapeutic success. In this 
context, inhibition of the proteasome represents a new target for cancer therapy.[175]
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In this study the effects of the new proteasome inhibitor 245 (BSc2118) were 
analysed on both cisplatin-resistant and -sensitive melanoma cells. It was observed 
that 245 (BSc2118) induced reduction in cell viability in both MeWo and human 
melanoma cisplatin-resistant (MeWocis1) cell lines, diminished colony formation, 
promoted G2/M cell cycle arrest and apoptosis. However, the cisplatin-resistant cells 
required considerably higher inhibitor concentrations to exert the same biological 
effects as seen in the parental cisplatin-sensitive cells. Nevertheless, the extent of 
proteasome inhibition was identical in both cell lines, suggesting the existence of 
proteasome independent mechanisms for the relative proteasome inhibitor-resistance 
in MeWocis1 cells.
In WEHI-231, B cells, it has been shown that prolonged NF-NB activation is 
associated with continued degradation of INBD and that the NF-NB pathway may 
participate in proteasome inhibitor resistance.[176] On the other hand, Hideshima et al. 
verified that NF-NB blockade by proteasome inhibition cannot account for all of the 
anti-tumor activity observed in multiple myeloma.[177] Interestingly, it was observed 
that the analysis of the NF-NB pathway in MeWocis1 melanoma cells revealed a 
proteasome-independent but calpain inhibitor-mediated INBD stabilization and 
inhibition of NF-NB activation. In neuronal cells, it was shown previously that 
binding of glutamate to its receptor induces a shift from a proteasome-dependent to a 
calpain-dependent INBD degradation followed by NF-NB activation and that calpain-
dependent INBD degradation plays a role in inflammation, as well as in neuronal cell 
survival and cell death.[178] Interestingly, in MeWo cells both the proteasome and the 
calpain-sensitive INBD degradation seem to coexist, whereas in MeWocis1 cells the 
calpain-sensitive INBD degradation predominates. Furthermore, calpain activity in 
lysates of MeWocis1 cells was strongly increased, suggesting for the first time that 
calpain may play a role in chemotherapy resistance in melanoma cells. So far it has 
been acknowledged that calpain activity can lead tumor cells to apoptosis[179] and is 
involved in genistein-induced or cisplatin-mediated apoptosis.[180-181] In HCT 116 
human colon carcinoma cells it was shown that cisplatin induced increased cytosolic 
calcium level, calpain activation as well as endoplasmic reticulum stress.[180]
Interestingly, the cisplatin-resistant MeWocis1 cells studied here exhibit increased 
calpain activity even in the absence of cisplatin and already the inhibition of calpain 
activity is able to induce apoptosis. This latter finding may be explained in part by 
the recently described apoptotic defects in MeWocis1 cells[182] and by a shift in the 
NF-NB signalling pathway towards an ubiquitin-proteasome-system independent 
INBD degradation. Calpain and proteasome dependent NF-NB activation following 
TNF treatment has been observed also in human HepG2 cells.[183] When 
ubiquitinating enzymes were inactivated, INBD proteolysis occurred only in a strictly 
calpain-dependent manner.[183] However it is not yet defined which steps in the 
signalling cascade are affected in the MeWocis cells that result in an almost complete 
shift towards TNF induced calpain-sensitive INBD degradation. In this context it is 
important to note that it has recently been demonstrated that Bortezomib® and 
cisplatin induce apoptosis via ER-stress in pancreatic cancer cells. Therefore, 
selecting cisplatin resistant cells could have resulted in selection of ER-stress 
resistant cells and thus may in part account for the observed differences in growth 
arrest and apoptosis induction between MeWo and MeWocis cell lines.[184]
The experiments discussed above revealed that the combined inhibition of both the 
proteasome and calpain affects the viability of MeWocis1 cells considerably more 
than when each agent is applied alone, resulting in an almost complete cell death of 
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MeWocis1 cells. It is interesting to note that inhibition of calpain with non-toxic 
concentrations of PD150606 alone had no significant effect on cell viability of either 
MeWo or MeWocis1 cells and that only the application of PD150606 together with 
245 (BSc2118) significantly increased the anti-tumor activity of proteasome 
inhibition on cisplatin resistant cells. Thus, by combining proteasome and calpain 
inhibitors the data may display new therapeutic strategies for the treatment of 
chemotherapy resistant melanoma cells. 
3.2.4. Synthesis of Diazenecarboxylate Derivatives as Potential 
Proteasome Inhibitors 
The inversion of configuration of the D-carbon atoms of peptides to yield D-amino 
acids is generally a widespread manipulation.[78] The significance of this substitution 
in getting compounds with enhanced biological potencies, distorted conformational 
properties; improved resistance to enzymatic degradation has been widely 
acknowledged. The replacements of D-carbon atom isoelectronically by a trivalent 
nitrogen yield azapeptides or azatides.[79] Peptoids,[80] azapeptoids,[81]
ureapeptoids,[82] amino oxypeptoids,[83] retropeptoids,[84] and E-peptoids[85] belong to 
a new class of pseudopeptides in which the side chains are shifted on nitrogen atoms 
of the backbone (Scheme 1.17).
Hill et al. reported a number of bis-hydrazides (e.g., 250253, Scheme 3.26)
analogous as an inhibitors of cathepsin K (a cysteine proteinase) in nanomolar 
activity against HAV 3C and HRV 3C proteinases, but these compounds showed no 
significant inhibition of the viral enzymes.[189] However, oxidation of the bis-
hydrazides to the corresponding azodicarboxamides gave potent, irreversible 
inhibitors with IC50’s in the low micromolar concentration.[189]
Therefore, it was anticipated that such scaffold can be a potential 20S proteasome 
inhibitor. As a consequence, the analogues of the potent proteasome inhibitor 245
(BSc2118) were designed and synthesized by converting aldehyde functionality to 
hydrazides or azides motif to investigate their effect against 20S proteasome 
inhibitory activity. Furthermore, some side chain modifications were also employed.  
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Scheme 3.26: Azodicarboxamides as cysteine proteinase inhibitors.[189]
The synthesis of compounds 264–269 (Scheme 3.27) commenced by coupling of 
methyl carbazate (254) with Boc-L-Leucine (235) using EDAC and HOBt as 
coupling reagents in CH2Cl2 to afford compound 255. The resultant compound 255
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was purified as a colorless solid by column chromatography using 40% ethyl acetate 
in hexane as solvent followed by Boc-deprotection by treating with 20% TFA in 
CH2Cl2 to the corresponding amine 256. This amine 256 was coupled with various 
commercially available protected aspartic acids i.e. Z-Asp(OtBu)-OH (228), Boc-
Asp(OBn)-OH (229), and Boc-Asp(Ochexyl)-OH (257) simultaneously using EDAC 
and HOBt as coupling reagent to yield compounds 258–260. The coupled products 
258–260 were purified by column chromatography using 10% methanol in CH2Cl2 as 
eluent to afford colorless solid. The Z-group in compound 258 was removed by 
hydrogenation using 20% Pd-C in ethanol to attain H-Asp(OtBu)-Leu-NH2-NH2-
COCH3 (261) while Boc-deprotection of the D-amine group in compounds 259–260
were carried out by treating with 20% trifluoroacetic acid in CH2Cl2 to obtain amines 
262–263. The coupling of these free amines 262–263 was carried out by treating 
with Z-L-Leu-OH (236) using EDAC and HOBt as coupling reagents to yield 
hydrazide derivatives 264–266 (Scheme 3.27). The hydrazide derivatives 264–266
were oxidized to corresponding diazo compounds 267–269 using N-
bromosuccinimide and pyridine (Scheme 3.27). The tert-Butyl ester group in 
compound 264 was deprotected to corresponding free acid 270 by treating it with 
40% TFA in CH2Cl2 (Scheme 3.28).  
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Pyridine, RT, 
1-3 h
N
H
O
H
N
O
N
N
O
O
R2
O
O
O
HN
R3
254
+
228: R1= Z, R2= tBu
229: R1= Boc, R2= Bn
257: R1= Boc, R2= cHexyl
258: R1= Z, R2= tBu
259: R1= Boc, R2= Bn
260: R1= Boc, R2= cHexyl
261: R2 = tBu
262: R2= Bn
263: R2= cHexyl
264: R2= tBu, R3= Z
265: R2= Bn, R3= Z
266: R2= chexyl, R3= Z
R3
267: R2= tBu, R3= Z
268: R2= Bn, R3= Z
269: R2= chexyl, R3= Z
Scheme 3.27: Synthesis of compounds 267269.
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Scheme 3.28: Synthesis of compounds 270.
Compound 273 was synthesized by the coupling of commercially available Z-Leu-
Leu-OH (271) with amine 256, followed by oxidation of hydrazine moiety of 
resultant coupled product 272 to the corresponding diazo functionality using N-
bromosuccinimide and pyridine to afford compound 273 in 50% yield (Scheme
3.29).
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N
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EDAC, HOBt
TEA, DCM, RT,
6 h
NBS,
DCM, Pyridine
RT, 3 h
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Scheme 3.29: Synthesis of compounds 272273.
3.2.4.1. Biological Evaluation
The synthesized compounds 264268, 270 and 272273 were subjected for 
proteasome inhibition assay (Figure 3.11). Dr. Ulrike Kuckelkorn did the 
biochemical characterization of the proteasome inhibitors (in vitro and in vivo) from 
Universitätsklinikum Charité Institut für Biochemie, Berlin. All these compounds 
were compared for their ability to inhibit proteasomes in vitro in comparison with 
compound 245 (BSc2118). Isolated proteasomes were incubated with the compounds 
(264268, 270 and 272273) and the proteolytic activity of proteasomes was 
estimated with different substrates (hydrolysis of substrates); LLVY-AMC and GGL-
AMC for chymotrypsin-like, VGR-AMC for trypsin-like and LLE-AMC for caspase-
like acivity. It was investigated that compounds 264268, 270 and 272273
displayed marginal inhibitory effects on proteasome compared to 245 (BSc2118)
(Figure 3.11).
SAR analysis revealed that hydrazine/diazene derivatives did not display significant 
proteasome inhibitory activity as anticipated, in comparison with previously 
evaluated potent proteasome inhibitor 245 (BSc2118). Moreover, the activity data of 
compound 264 which is structurally related to inhibitor 245 (BSc2118), revealed that 
aldehyde functionality is crucial for proteasome inhibitory activity. Furthermore, side 
chain modification led to reduction in activity.
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Figure 3.11: Comparison of the compounds 264268, 270 and 272273 for their ability to 
inhibit proteasomes in vitro with compound 245 (BSc2118): isolated proteasomes was 
incubated with the compounds and the proteolytic activity of proteasomes were estimated 
with different substrates (hydrolysis of substrates); LLVY-AMC and GGL-AMC for 
chymotrypsin-like, VGR-AMC for trypsin-like and LLE-AMC for caspase-like acivity. 
Same set of compounds 264268, 270 and 272273 was profiled in the FRET based 
assay[151] with full length BACE-1 (Table 3.15). This assay was carried out at 
Hoffmann-La Roche, Basel. It can be noted that none of our compound displayed a 
significant BACE-1 inhibition. However, some compounds showed a certain degree 
of inhibition, i.e. with an IC50 of 200 μM or higher.
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Table 3.15: SAR of compounds 264268, 270 and 272273 for E-secretase inhibition.
FRET
Entry Compound  Structure 
IC50 (μM) 
1 264
H
N
O
N
H
H
N
N
H
O
OO
N
H
O
O
O
O
O
no inhibition 
2 265
H
N
O
N
H
H
N
N
H
O
OO
N
H
O
O
O
O
O
no inhibition 
3 266
H
N
O
N
H
H
N
N
H
O
OO
N
H
O
O
O
O
O
>>200
4 267
H
N
O
N
H
N
N
O
OO
N
H
O
O
O
O
O
>>200
5 268
H
N
O
N
H
N
N
O
OO
N
H
O
O
O
O
O
200
6 270
H
N
O
N
H
H
N
N
H
O
OO
N
H
O
O
O
O
O
>>200
7 272 NH
O
H
N
N
H
O
O
O
H
N
O
N
H
O
O
no inhibition 
8 273 NH
O
N
N
O
O
O
H
N
O
N
H
O
O
>>200
The first J-secretase inhibitors to be reported were the small peptidic aldehydes, such 
as 33 (MG132) (IC50 = 50 μM) and MDL-28170 (IC50 = >3 μmol/L). Surprisingly, 
they inhibit AE40 and NICD release, but have lesser effect on AE42. This may be 
because they also affect the proteasome that is implicated in the degradation of APP 
C-terminal fragments. Depends on the structural similarity of these compounds with
33 (MG132) all analogues were investigated for Ȗ-secretase inhibition. The 
compounds 264268, 270 and 272273 were subjected for Ȗ-secretase inhibition 
assay at 10 μM concentration and 40 μM concentrations. This assay was carried out 
by Dr. Karlheinz Baumann at Hoffmann-La Roche, Basel. Compound 266 and 270
displayed weak inhibitory activity while compounds 265 and 268 showed moderate 
Ȗ-secretase activity. Compounds 264, 267, 272 and 273 displayed potent Ȗ-secretase 
modulatory effect but interestingly they turned out to be inverse modulators. They 
reduced the formation of AE38 while while increased the formation of AE42 (see 
Table 3.16, Figure 3.12–3.14).
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Table 3.16: Activity data for Ȗ-secretase inhibition for compounds 264268, 270 and 
272273.
IC50 [μM]Entry Compound AE38 AE40 AE42b
1 264 > 10 > 40 n.d.a
2 265 > 40 > 40 > 40b
3 266 inactive Inactive inactive
4 267 | 10 > 40 n.d.a
5 268 > 10 > 10 > 10 
6 270 inactive Inactive inactive 
7 272 > 10 > 40 n.d.a
8 273 > 10 > 40 n.d.a
a cannot be calculated or estimated 
b EC50 value displayed for AE42
n.d. = not determined
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Figure 3.12: Activity data for Ȗ-secretase inhibition at 10 μM conc. for compounds 
264268, 270 and 272273.
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Figure 3.13: Activity data for Ȗ-secretase inhibition at 40 μM conc. for compounds 
264268, 270 and 272273.
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Figure 3.14: Activity data for Ȗ-secretase inhibition of compound 265. (Dose response 
curve).
Results and discussion 80
3.3. Synthesis of Active Metabolites of Losartan 
Prevention of dementia is a major public health challenge as it is a common 
neurological disorder in the elderly population. PPAR-Ȗ played an effective role in 
the amyloidogenic process causing AD.[135] Further reports indicated that PPAR-Ȗ
agonists down-regulate AE generation, although the mechanism of this phenomenon 
still remains controversial. Sastre and colleagues[136] illustrated that the AE down
regulation persuaded by PPAR-Ȗ is a consequence of E-secretase inhibition;
Camacho et al.[137] demonstrated that high levels of PPAR-Ȗ decrease AE without
altering either the E- or the Ȗ-secretase activity, suggesting the existence of a not-
well-identified extracellular clearance mechanism. It was clearly indicated that 
PPAR-Ȗ reduces the cellular content of APP without influencing its mRNA level, 
thus implying a post-transcriptional event, unlikely to be linked to the inhibition of 
the secretase pathways.[135] According to LIFE (The Losartan Intervention For End 
point reduction in hypertension) study 25% lower rate of new-onset diabetes was 
observed in hypertensive patients receiving the angiotensin type 1 receptor blocker 
(ARB) losartan than patients treated with the E-blocker atenolol[130] however the 
molecular mechanisms are still unknown. A subset of ARBs, including losartan, 
provokes the activity of a nuclear hormone receptor named PPAR-Ȗ by partial 
agonism.[131-132] The direct activation of the ligand-binding domain of PPAR-Ȗ by 
ARBs is an independent function than their angiotensin type 1 receptor (AT1R) 
blocking actions.[131] PPAR-Ȗ regulates multiple genes involved in lipid and glucose 
metabolism as a transcriptional regulator in adipose tissue.[133] PPAR-Ȗ activation by 
ARBs presents a promising molecular mechanism for metabolic actions of these 
compounds. Losartan induced PPAR-Ȗ activity only at high concentrations in
vitro.[131] In order to investigate these various biological aspects of Losartan active 
metabolites i.e. EXP3179 and EXP3174, their synthesis was carried out from 
losartan.
Different oxidizing agents were employed to synthesize EXP3179 from losartan. 
IBX in DMSO was found to be the best oxidizing agent for synthesizing EXP3179 in 
95% yield, with no further purification by column chromatography (Scheme 3.30). 
However, oxidation using PCC (pyridinium chloro chromate) and swern oxidation 
afforded 40% yield with a laborious separation of unreacted alcohol from aldehyde 
due to almost same polarity (Rf = aldehyde/alcohol; 0.75/0.73) by column 
chromatography using MeOH:CHCl3 (0.5:9.5) as solvent. 
EXP3174 (275) was synthesized by refluxing a mixture of 1 equiv. EXP3179 (274)
and 1.2 equiv. MnO2 in MeOH:H2O (4:6). The reaction was monitored by TLC. 
Excess of MnO2 was filtered after completion of reaction. The solvent was removed 
in vacuo and the product was obtained by acid base workup in 56% yield (Scheme
3.30).
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Scheme 3.30: Synthesis of EXP3179 and EXP3174. 
3.3.1. Regulation of PPAR-J Activity by Losartan Active Metabolites
For detailed results and discussion (see Appendix Article III, Hypertension, 2006, 47, 586-
589)
The present study identified the active losartan metabolite EXP3179 as a partial 
PPAR-Ȗ agonist. The regulation of PPAR-J activity by losartan metabolites was 
investigated by Michael Schupp and colleagues (from Center for Cardiovascular 
Research (CCR) Charité-Universitätsmedizin, Berlin). EXP3179 markedly promotes 
3T3-L1 adipocyte differentiation, induces PPAR-Ȗ-target gene expression and 
directly activates the PPAR-Ȗ-LBD. PPAR-Ȗ activation by EXP3179 may provide a 
mechanism for the beneficial anti-diabetic actions of losartan observed in clinical 
trials. Losartan is a prodrug which is actively metabolized by the cytochrome P450 
isoenzyme CYP2C9 upon first liver passage to its main anti-hypertensive metabolite 
EXP3174.[112] EXP3174 is 10-to 40-fold more potent compared to losartan and 
mediates most of losartan´s AT1R-blocking effects.[112] Recently, an important 
intermediate aldehyde metabolite of losartan, EXP3179, has been identified. In 
contrast to EXP3174, EXP3179 was found to has no AT1R-blocking activity and has 
been hypothesized to mediate pleiotropic actions of losartan observed in clinical and 
animal studies.[112] Krämer and colleagues demonstrated that EXP3179 potently 
inhibits the expression of endothelial cyclooxygenase-2 (COX-2) thereby exerting 
potent anti-inflammatory actions.[119] In addition, Watanabe and colleagues showed 
that EXP3179 stimulates endothelial nitric oxide synthase phosphorylation and 
suppresses tumor necrosis factor D-induced endothelial cells apoptosis independent 
of AT1R-mediated signalling.[190] The detailed underlying molecular mechanism of 
these pleiotropic EXP3179 actions are mostly unkown. Ligand-activated PPAR-Ȗ
exerts potent anti-inflammatory actions by inhibiting the action of pro-inflammatory 
transcription factors such as AP-1 and NF-ǉB.[191] Activation of PPAR-Ȗ has also 
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been shown to repress COX-2 promoter activity and mRNA expression by 
interacting with the c-jun component of the AP-1 complex. EXP3179-mediated 
activation of PPAR-Ȗ may, therefore, provide a new mechanism of the observed anti-
inflammatory actions of this compound.  
In clinical trials losartan has been shown to mediate prominent anti-diabetic actions 
such as a marked reduction of new-onset diabetes.[192-193] The molecular mechanism 
of these metabolic actions are still not fully understood. It is now well known that 
blockade of the AT1R results in multiple beneficial effects on insulin- and glucose 
metabolism mediated via an improvement of muscular and pancreatic blood flow, or 
an inhibition of the deleterious angiotensin II actions on insulin signalling.[192] It is 
recently demonstrated that certain ARBs act like activators of PPAR-Ȗ which might 
contribute to their anti-diabetic effects.[131-132] However, PPAR-Ȗ activation by 
losartan was only achieved at very high concentrations making it unlikely that 
PPAR-Ȗ is responsible for the anti-diabetic actions of this compound.[131] The 
losartan metabolite EXP3179 induced PPAR-Ȗ activation more potently compared to 
losartan identifying this metabolite as a possible mediator of losartan´s anti-diabetic 
properties.
Does EXP3179-mediated PPAR-Ȗ activation play a role for the anti-diabetic actions 
of losartan observed in clinical studies? Krämer and colleagues reported that after a 
single oral dose of losartan (100 mg) maximum serum concentrations of EXP3179
between 0.1 and 1 μmol/l were achieved.[119] In the present study PPAR-Ȗ-mediated 
adipocyte differentiation as well as activation of the PPAR-Ȗ-LBD by EXP3179
started between 1 and 10 μmol/l. In consideration of the high lipophilicity of 
EXP3179 rendering it receptive for tissue accumulation and in consideration of a 
further increase of serum levels under chronic losartan dosing, EXP3179
concentrations required for PPAR-Ȗ activation may be reached under losartan 
treatment. However, rapid hepatic metabolization of EXP3179 has to be taken into 
account, and additional studies are required to assess whether stable serum and tissue 
concentrations of EXP3179 are achieved to activate PPAR-Ȗ in patients treated with 
different doses of losartan. 
3.3.2. EXP3179 Inhibits Collagen-Dependent Platelet Activation Via 
Glycoprotein Receptor-VI Independent of AT1-Receptor
Antagonism: Potential Impact on Atherothrombosis 
For detailed results and discussion (see Appendix Article IV, ATVB, Arteriosclerosis, 
Thrombosis, and Vascular Biology, in press)
Recent studies have revealed the associations between cardiovascular disease, its risk 
factors and the prevalence of AD.[89] Heart disease and stroke are major crucial 
leading causes of death and detriment in the world. Many reviews have focus their 
studies on cardiovascular risk factors; hypertension, hyperlipidemia and diabetes 
mellitus as targets for prevention of cognitive decline, overall dementia and AD.[90]
Here EXP3179 an active metabolite of losartan, was identified as an individual and 
selective inhibitor of GPVI-receptor dependent platelet activation and aggregation in 
vitro and in vivo, independent of AT1-receptor antagonism which was investigated at
Abt. Kardiologie und Angiologie, Medizinische Hochschule Hannover by Christina 
Grothusen and colleagues.
Acute vessel injury by atherosclerotic plaque rupture exposes pro-coagulatory 
elements of the subendothelial ECM to circulating platelets, which are instantly 
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activated. Subsequently, occlusive arterial thrombosis may occur and result in ACS 
or stroke.[194] In this scenario, collagen-I is one of the major pro-coagulant ECM 
components in atherosclerotic vessels, which plays a critical role for stable platelet 
adhesion at the site of injury.[195] The major platelet collagen receptor is considered 
to be GPVI as suggested by recent experimental and clinical evidence showing the 
importance of GPVI-receptor activation in collagen-dependent platelet adhesion and 
thrombus formation, both in vitro and in vivo.[196-198] Interestingly, activation of 
GPVI may especially be critical for thrombotic events following atherosclerotic 
plaque rupture.[199] Thus, inhibition of GPVI-receptor activation may represent a 
novel pharmacological target in the search of more selective and specific anti-
thrombotic agents for the prevention and/or treatment of acute occlusive arterial 
thrombosis, e.g. myocardial infarction or stroke. 
Blockade of the renin-angiotensin system (RAS) by AT1-receptor antagonists such as 
LOS effectively reduce the incidence of cardiovascular events as demonstrated by 
large scale clinical trials.[130, 200] This impact seemingly involves the generation of 
active metabolites, i.e. EXP3179 or EXP3174.[112, 119] Rooted in recent observations 
which revealed various potentially vasoprotective effects of EXP3179, it was 
hypothesised, that EXP3179 might possess an individual pharmacological potency, 
which may not only contribute to the beneficial effects of LOS but qualify EXP3179
as an independent candidate for future treatment strategies to prevent acute 
atherothrombosis. Here, it is demonstrated that EXP3179 selectively reduces 
collagen-dependent human platelet activation, adhesion and aggregation independent 
of AT1-receptor antagonism. In this regard, Kalinowski et al. has already reported 
that application of LOS itself impairs collagen-induced platelet aggregation and 
adhesion, which was attributed to a release of NO.[201] Indeed, Watanabe et al. 
recently identified EXP3179 as a potent activator of the eNOS phosphorylation.[190]
In platelets, however, the role of eNOS remains controversially discussed. 
Furthermore, eNOS-associated signalling involves not only collagen-related but also 
alternative pathways, e.g. thrombin or ADP, both of which were not seen to be 
influenced by EXP3179 in the present study.[202-204] Instead, it was observed that 
EXP3179 markedly inhibited GPVI-receptor-mediated platelet aggregation and 
activation as determined by platelet PAC-1 expression. Furthermore, EXP3179 in 
contrast to the main LOS metabolite EXP3174 substantially reduced the adhesion of 
GPVI-receptor expressing CHO-cells on collagen-I under shear conditions 
confirming the specific impact of EXP3179 on GPVI-receptor function. Although 
the relevance of GPVI-receptor activation in experimental murine arterial thrombosis 
has lately been critically discussed,[205] recent observations by Penz et al. again 
emphasized the importance of collagen-dependent platelet activation via the GPVI-
receptor for acute thrombus formation at sites of human atherosclerotic lesions.[199]
Therefore, here it is investigated in addition to the in vitro experiments, the direct 
impact of EXP3179 on platelet aggregation induced by human atheromatous plaque 
material. It was demonstrated, that EXP3179 inhibits thrombus formation after 
stimulation with human plaque material. To evaluate the effect of EXP3179 on 
platelet adhesion and aggregation in vivo and an established mouse model of carotid 
injury was used. Moreover, it is reported that murine thrombus formation in this 
model crucially depends on GPVI-receptor activation.[196, 206] It is showed here, that 
EXP3179 substantially reduced platelet adhesion in response to vessel injury 
underlining the impact on GPVI-receptor-mediated platelet activation by EXP3179
also in vivo.
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3.3.3. Angiotensin Receptor Type 1 Blockade in Astrocytes 
Decreases Hypoxia-Induced Cell Damage and Inflammation 
For detailed results and discussion (see Appendix Article V, accepted in Neurochem
Research).
Little is known till now about the role of angiotensin receptor (AT-R) system in 
survival and inflammatory response of astrocytes upon various kinds of injury. This
study investigated the role AT1-R antagonist losartan and its main active metabolite, 
EXP3174, for the protection of astrocytes against hypoxia-induced cell damage and 
their prevention from initiating an inflammatory cascade. The biological studies were 
performed by Lusine Danielyan and colleague at Department of Clinical 
Pharmacology, University Hospital of Tubingen, Germany.  
The data obtained on cell death in terms of lactate dehydrogenase (LDH) release 
from astroglial cells showed that under both (normoxic conditions) NC and (hypoxic 
conditions) HC, losartan and EXP3174 possess a similar protective potency. It was 
previously shown that astrocytes express all known angiotensin receptor subtypes, 
namely AT1-R, AT2-R and AT (1-7)-R.[207-208] Increased survival of astrocytes 
provided by losartan and its metabolite may occur either due to their direct 
antagonistic effect on AT1-R or indirectly due to increased availability of 
endogenously produced (or exogenously applied) ATII for signal transduction via the 
remaining receptor subtypes. ATII is known to be produced by astrocytes and to be 
upregulated under ischemic injury of the brain.[209] The results of present work 
showed the increased survival of astrocytes under hypoxia after application of 
losartan or EXP3174 are reconcile able with data demonstrating AT1-R-mediated 
cell death in myocytes, endothelial cells and blood vessels, in vitro as well as in
vivo.[210-212] Apparently, AT1-R blockade exerts a direct protective effect on 
astrocytes during hypoxic injury. The reduction of LDH release from astroglial cells 
achieved by EXP3174 or losartan was concentration-dependent. Since application of 
ATII together with EXP3174 was not more efficient in protecting astrocytes from 
hypoxic cell death than EXP3174 alone, the blockade of AT1-R appears to be more 
important for survival than the stimulation of AT2-R or A(1-7)-R.
The possibility of astrocytes contribution to the local increase of inflammatory 
factors in response to hypoxia was performed by multiplex analysis of anti-
inflammatory IL-4, IL-5 and GM-CSF, as well as pro-inflammatory IFNȖ and TNFD.
All these factors have been shown to be upregulated after ischemic injury of the 
brain previously.[213-215] IL-4, IL-5, GM-CSF, IFNȖ were not detectable under NC or 
HC. It was previously shown that the exogenous application of IFNȖ induces the 
death of astrocytes via activation of the Jak2/Stat1 pathway in vitro.[216] The results 
presented here revealed that even under protracted HC (48 h), astrocytes did not 
respond with measurable changes in their production of IFNȖ. The fact that IL-4 
release from astrocytes was not influenced by hypoxia is in concordance with the 
data reported by Park et al.[217] presenting that after lipopolysaccharide-induced
inflammation of the brain, IL-4 was expressed exclusively in microglia, but not in 
astrocytes or neurons. Vitcovic et al.[218] revealed that the expression of GM-CSF in 
astrocytes was not substantially altered by IL-1, an important activator of reactive 
astrocytosis that is upregulated in astrocytes after hypoxic injury.[219] The level of IL-
5, an anti-inflammatory cytokine serving as a mitogenic factor for microglia[220] but 
not for astrocytes,[221] was not increased under HC either. The absence of anti-
inflammatory IL-4 and 5, as well as pro-inflammatory IFNȖ in cell culture 
supernatant after 48 h of hypoxia might hint at a marginal role of these cytokines in 
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the immediate inflammatory response of astrocytes to hypoxia. This suggestion is in 
agreement with data showing a slight transient increase of IL-4 and IL-5 in microglia 
and inflammatory leucocytes but not astrocytes during experimental allergic 
encephalomyelitis.[222]
The measured increase in the concentration of TNFD in the cell culture supernatants 
under HC suggested that the immediate inflammatory response of astrocytes to 
hypoxia might be reflected by release of this potent pro-inflammatory cytokine. The 
application of losartan and EXP3174 decreased the amount of released TNFD under 
NC and HC. This effect was pronounced by concomitant administration of ATII. 
This indicated the possible involvement of different AT receptors in the maintenance 
of the inflammatory response of astrocytes. Presumably, the production of TNFD can 
be diminished by antagonists at AT1-R and/or stimulation of the other AT receptor 
subtypes.
The present results are somewhat analogous to recently reported data showing that 
the peripheral anti-inflammatory action of the AT1-R antagonist candesartan during 
gastric ulceration[223] is in part reflected by a decreased expression of TNFD in 
stomach sections of rats under cold-restraint stress. The comparison of the anti-
inflammatory effects achieved by losartan and EXP3174 revealed nearly equal 
efficacy of both compounds under NC and HC. These data suggested that losartan 
delivered to the brain might reduce the susceptibility of astrocytes to hypoxic injury 
and provide an anti-inflammatory effect even without being converted to EXP3174
by the liver.
In summary, it can be concluded that AT1-R blockade could be of therapeutic benefit 
during neurodegenerative disorders accompanied by inflammation, such as AD, 
Parkinson’s disease, stroke and multiple sclerosis due to its anti-inflammatory and 
vulnerability-reducing effect on astrocytes. 
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4. SUMMARY 
4.1. Synthesis and Biological Evaluation of BACE-1 Inhibitors 
BACE-1 inhibition is currently perceived as a promising target for the treatment of 
AD, which stimulated the design and synthesis of BACE-1 inhibitors. The X-ray 
structure of E-secretase and the structure activity relationship (SAR) of transition 
state like inhibitors facilitate the design of hydroxyethylene and norstatine based 
scaffolds. Moreover, an introduction of the isophthalamide moiety was crucial for 
sufficient oral absorption and BBB penetration. As a consequence, a series of 
phenylnorstatine and isophthalamide based non-peptidic BACE-1 inhibitors were 
designed and synthesized (Scheme 3.7).  Furthermore, various groups were 
introduced towards S2´ pocket (Scheme 3.7, compounds 9699) and their effect on 
potency for BACE-1 inhibition was evaluated using FRET based assay. The SAR 
data (Table 3.2) revealed that benzyl group towards S2´ pocket is responsible for 
activity. Norstatine derivative 96a, one of two separated diastereoisomers in 1:1 ratio 
was identified as a lead structure for BACE-1 inhibition with an (IC50 = 20 PM,
Scheme 3.7 and 3.10). However, the compound assigned as 96b displayed much 
weaker inhibition (IC50 > 200 PM). This result stimulated the two-step synthesis of 
further norstatine intermediates (Scheme 3.11). Therefore, organocatalytic approach 
was applied for the lead optimization. The combination of the enantioselective, 
organocatalytic D-amination of aldehydes by diazodicarboxylates and the Passerini 
reaction provided rapid access to norstatine-based peptidomimetics. Moreover, it was 
suggested to introduce an electron deficient peptidomimetic like 3,5-
diflourophenylalanine moiety towards S1 pocket to enhance the BACE-1 inhibitory 
activity. This norstatine derivative containing 3,5-diflourophenyl moiety was 
synthesized via sequential D-amination and the Passerini reaction. The reaction was 
modified to ensure the complete consumption of aldehyde to avoid their laborious 
separation and was performed in a stechiometric ratio of 1 versus 1.5 (aldehyde: 
azodicarboxylate) and the excess azodicarboxylate was scavenged by PS-Trisamine. 
The high enantioselectivity in the D-amination in combination with the low 
diastereoselectivity of the Passerini reaction allowed simultaneous profiling of 
diastereomeric mixtures, which reduced the efforts towards the synthesis of inactive 
compounds. These intermediates were elaborated further by deprotection and 
cleavage of the N–N bond to provide useful building blocks for aspartic protease 
inhibitors. Coupling of the compounds 174–184 with the mono-isophthalamide 66
provided moderate inhibitors of human E-secretase (BACE-1) 194–204. Thus, the 
feasibility of an organocatalytic, direct, asymmetric D-amination in combination with 
a Passerini reaction to provide diverse norstatines has been demonstrated. The 
introduction of a difluorophenylalanine moiety in compound 204 did not result in 
increased potency over the lead compound 96a. The absolute stereochemistry of the 
D-carbon (* in Scheme 3.13) was assigned by comparing the specific optical rotation 
[D]
20
D  of two synthesized compounds 171172 with their commercial references, 
whereas the relative stereochemistry of 151b was determined by X-ray 
crystallographic analysis. It was observed that the presence of proline catalyst from 
D-amination reaction was harmful for subsequent Passerini reaction and any trace 
amount led to unnecessary side products. Therefore, an immobilized proline derived 
catalyst 207 was designed and synthesized which exhibited increased catalytic 
activity and enantioselectivity due to a terminal hydroxyl group and a possibility of 
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extra-hydrogen-bonding activation of aldehyde. Most importantly, this solid phase 
supported catalyst enabled the long-term use and provided a clean and 
straightforward separation of the product.
SAR studies of compounds 9699 and 194204 (Scheme 3.7 and 3.15, Table 3.2 
and 3.7) for BACE-1 inhibitory activity revealed that exchange of norstatine moiety 
with hydroxyethylene may enhance the activity. Consequently, a modification in the 
Passerini reaction was employed and hydroxyethyleneamine functionality was 
generated by in situ reduction of intermediate. This facile method can be successfully 
applied for the synthesis of HEA containing BACE-1 inhibitors. 
Based on the reported potent BACE-1 inhibitors isophthalamides 8, 9 by MSD 
researchers, a series of their analogues were designed and synthesized as non-
peptidic E-secretase inhibitors (Scheme 3.22). Varieties of amines were introduced 
towards S2 and S3 pocket to investigate their impact on the activity. The Boc 
protected and deprotected aminopentyl oxyacetamide motif was introduced to 
examine the impact of protected and free aminopentyl moiety on BACE-1 inhibitory 
potency. The synthesis provided an unexpected mixture of di- 224 and mono-
amidation product 225, which reduced the efforts towards the designed synthesis of 
mono-amidation product 225. This mixture was separated via tiresome column 
chromatography. Both series of compounds 224 and 225 were subjected to Boc-
deprotection. All synthesized compounds 221–227 were profiled in the FRET based 
assay with full length BACE-1. Out of all investigated compounds 226c, 227d, and 
226g displayed weak inhibition, however, 226d containing an indole moiety 
displayed reasonable inhibition with an  IC50 = 251 μM (Table 3.10 and 3.11). It is 
speculated that the hydrolysis of the methyl ester of compound 226d to its 
corresponding acid may improve the activity. Furthermore, a variety of substituents 
similar to this class can be introduced towards S2 and S3 pocket to improve the 
BACE-1 inhibitory activity.  
Based on similarity of the compounds 221 and 223–227 with some recently reported 
Ȗ-secretase modulators BSc3040 and BSc3041 (Scheme 3.23) by Narlawar et al.,[167]
they were subjected for Ȗ-secretase inhibition assay at 10 μM and 40 μM 
concentrations. Compounds 221, 223, 226a, 226b, 226d and 226g were found to be 
inactive, while N-Boc protected compounds 224 exhibited good Ȗ-secretase 
modulatory activity. Interestingly, compounds 224 were found to be inverse 
modulators. Compounds 225 and 227 displayed good Ȗ-secretase modulatory activity 
but again in an inverse mode (Table 3.123.13, Figure 3.53.10).
SAR data of compounds 224227 (Table 3.12 and 3.13) revealed that 226 and 227 
series are either inactive at all or have low inhibitory activity for J-secretase, while 
most of the compounds from 224 and 225 series resulted in the complete inverse 
modulation. The only difference between 224225 and 226227 series was Boc-
protection of aminopentyl oxyacetamide in 224 and 225. The most potent J-secretase 
inverse modulators were compounds 224a, 224e and 224f (Figure 3.5, 3.6 and Table
3.12). Out of these three compounds 224e and 224f have a protected acid. In order to 
investigate the impact of free acid on the modulation of J-secretase, they can be 
hydrolyzed to their corresponding acids. It is presumed that compounds containing 
Boc-protection of aminopentyl oxyacetamide with a free acid group may turn the 
compounds to modulator of Ȗ-secretase.
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4.2. Synthesis and Biological Evaluation of Proteasome Inhibitors 
Proteasomes play an important role in protein turnover in living cells. The inhibition 
of proteasomes affects cell cycle processes and induces apoptosis. Thus, 20S 
proteasomal inhibitors are potential tools for the modulation of neoplastic growth. 
The interest in potent and specific inhibitors that may be used as potential drugs 
against cancer or neoplastic growth was developed after getting some serendipitous 
results. This stimulated further synthesis of proteasome inhibitors with the side chain 
modification of the tripeptide to offer higher potency, selectivity, and sitespecificity.
A set of analogues of 33 (MG132), a non specific 20S proteasome inhibitor, was 
designed and synthesized as BACE-1 inhibitors and investigated for enzyme 
inhibition. All compounds displayed a weak inhibition in FRET based assay for 
BACE-1 while surprisingly they turned out to be potent inhibitors of 20S 
proteasome. Most of the synthesized compounds reduced the hydrolysis of LLVY-7-
aminomethylcoumarin peptide substrate in cell lysates, some of them drastically. 
Several compounds displayed inhibitory effects with lowest IC50 values of 58 nM 
(chymotrypsin-like activity), 53 nM (trypsin-like activity), and 100 nM (caspase-like 
activity) when tested in vitro on isolated 20S proteasomes. Compounds 249
(BSc2129) affected the chymotrypsin-like activity of the E5 subunit exclusively, 
whereas compounds 238 (2114) and 239 (2117) inhibited the E2 trypsin-like active 
site selectively. Compounds 244 (2115) and 245 (2118) inhibited all three proteolytic 
activities. Compound 245 (2118) was shown to interact with the active site by X-ray 
crystallography. The potential of these novel inhibitors was assessed by cellular 
tolerance and biological response. HeLa cells tolerated up to 1 μM concentrations of 
all substances. Intracellular reduction of proteasomal activity and accumulation of 
polyubiquitinated proteins were observed for compounds 238 (2114), 244 (2115) and 
245 (2118) on HeLa cells. Two of these compounds 238 (2114) and 245 (2118)
induced apoptosis in HeLa cells and thus are considered as promising leads for anti-
tumor drug development. The low toxicity of compound 245 (2118) and the effective 
proteasome inhibition encouraged further evaluation of the lead compound 
convincingly.
Resistance of tumor cells to cisplatin is a common feature frequently encountered 
during chemotherapy against melanoma caused by various known and unknown 
mechanisms. To overcome drug resistance toward cisplatin, a targeted treatment 
using alternative agents, such as proteasome inhibitors, has been investigated. This 
combination could offer a new therapeutic approach. The cytotoxic and cytostatic 
effects of proteasome inhibition on the parental cisplatin-sensitive MeWo human 
melanoma cell line and its cisplatin-resistant MeWocis1 variant was investigated. 
Experiments confirmed that proteasome inhibitor 245 (2118) treatment of both cell 
lines impairs cell viability at concentrations that are not toxic to primary human 
fibroblasts in vitro. However, significantly higher concentrations of proteasome 
inhibitor are required to reduce cell viability of MeWocis1 cells compared with the 
parental MeWo cell line. Moreover, proteasome activity was inhibited to the same 
extent in both cell lines. IțBD degradation and NF-țB activation in MeWocis1 cells 
was proteasome inhibitor independent but essentially sensitive to calpain inhibitor. 
Furthermore, combined exposure to proteasome and calpain-specific inhibitor 
PD150606 resulted in additive effects and a strongly reduced cell viability of 
MeWocis1 cells by a10%. The above results established that the combined treatment 
of MeWocis1 cells with 245 (BSc2118) and PD150606 affects two different 
proteolytic pathways and can enhance the proteasome inhibitor–mediated death of 
the tumor cells, especially of the cisplatin-resistant cells. 
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Analogues of 245 (BSc2118) were designed and synthesized by replacing aldehyde 
with hydrazide and diazene functionality along with side chain modification as 
potential inhibitors of 20S proteasome. All the synthesized compound 264–268, 270
and 272–273 were subjected for proteasome inhibition assay and it was observed that 
they displayed marginal inhibitory effects on proteasome as compared to 245 
(BSc2118) (Figure 3.11), which certified the crucial role of aldehyde functionality 
for 20S proteasome inhibitory activity. 
The same set of compounds was profiled in the FRET based assay with full length 
BACE-1 (Table 3.15) and observed that a few compounds also displayed weak 
BACE-1 inhibitory activity (Table 3.15).
4.3. Synthesis and Biological Evaluation of Losartan Active 
Metabolites
Dementia is a common neurological disorder in the elderly people and its prevention 
is a major public health challenge. PPAR-Ȗ played an effective role in the 
amyloidogenic process causing AD.[135-137] Losartan induce PPAR-J activity 
independent of its AT1R blocking action. It was hypothesized that EXP3179, an 
active metabolite of losartan, is responsible for this antidiabetic actions. Therefore, 
the active metabolites of losartan, i.e. EXP3174 and EXP3179 were synthesized and 
investigated for PPAR-J regulatory activity. Different methods were employed for 
the oxidation of losartan to EXP3179, however, IBX in DMSO was found to be the 
method of choice with 97% yield. EXP3174 was synthesized by the oxidation of 
EXP3179 using manganese dioxide (MnO2) in H2O:MeOH (6:4). The product was 
obtained in 56% yield and purification was carried out by acid base workup. 
PPAR-Ȗ activity of losartan, EXP3179 and EXP3174 was measured with a chimeric 
Gal4-DNA–binding domain–hPPARȖ-ligand–binding domain (LBD) fusion protein 
on a Gal4-dependent luciferase reporter system. EXP3179 prominently induced the 
activation of the PPAR-Ȗ–LBD reaching a maximum at 100 Pmol/L with a 7.1±1-
fold induction (P<0.05 versus vehicle-treated cells). Maximum PPAR-Ȗ–LBD 
activation by EXP3179 reached 51% of the maximum response induced by the full 
PPAR-Ȗ agonist pioglitazone, identifying EXP3179 as a partial PPAR-Ȗ agonist. 
EXP3174 did not induce PPAR-Ȗ–LBD activation. EC50 values were calculated for 
PPAR-Ȗ–LBD activity (pioglitazone EC50: 0.88 Pmol/L; EXP3179 EC50: 17.1 
Pmol/L; losartan EC50: >50 Pmol/L) in consistence with the activation of PPAR-Ȗ,
EXP3179 potently induced 3T3-L1 adipocyte differentiation, a typical PPAR-Ȗ–
dependent cell function, and markedly stimulated PPAR-Ȗ target gene expression. 
EXP3174 failed to regulate differentiation or PPAR-Ȗ target gene expression. 
Conclusively, the active losartan metabolite EXP3179 is characterized as a partial 
PPAR-Ȗ agonist. PPAR-Ȗ activation by EXP3179 may help to understand the 
beneficial metabolic effects of losartan observed in clinical trials. PPAR-Ȗ activation 
by EXP3179 may provide a new mechanism of anti-diabetic actions induced by 
losartan.
Recently, an association between cardiovascular disease, its risk factors and the 
prevalence of AD is demonstrated.[89] The impact of EXP3179 was investigated on 
collagen-induced platelet activation via the GPVI-receptor, which is critical for 
platelet adhesion to ruptured atherosclerotic lesions. EXP3179 selectively inhibited 
collagen-dependent platelet activation by blocking GPVI-receptor function, 
suggesting a novel role for EXP3179 as a platelet-inhibitory agent. Thrombus 
formation following atherosclerotic plaque rupture critically involves the platelet 
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collagen receptor glycoprotein (GP)VI. EXP3179 and losartan but not EXP3174
dose-dependently inhibited collagen-I and GPVI-dependent platelet aggregation 
analysed by optical aggregometry (p<0.01). Platelet activation was further 
determined by measuring the expression of platelet PAC-1, an epitope of the 
activated fibrinogen-receptor complex using flow cytometry. EXP3179 and losartan 
inhibited collagen-I and GPVI-dependent PAC-1 expression (p<0.01). EXP3174
reduced collagen-I (p<0.05) but not GPVI-dependent PAC-1 expression. EXP3179
and losartan but not EXP3174 decreased the adhesion of GPVI-receptor expressing 
chinese hamster ovarian (CHO)-cells on collagen-I under shear conditions as 
analysed by flow chamber (p<0.01). EXP3179 also reduced human atherosclerotic 
plaque material-induced platelet aggregation (p<0.01) in vitro and murine platelet 
adhesion after acute vessel injury in vivo as determined by intravital microscopy 
(p<0.01). Decisively, EXP3179 acts as a specific inhibitor of the platelet collagen 
receptor GPVI independent of AT1-receptor antagonism. Further investigations may 
clarify its individual potential as a novel pharmacological approach to specifically 
inhibit atherothrothrombotic events by GPVI-receptor blockade. 
Despite a multitude of data showing an involvement of the local angiotensin receptor 
(AT-R) system in the processes of development and survival of neurons, a very little 
information is available about its role in survival and inflammatory response of 
astrocytes upon different kinds of injury. The influence of losartan and its active 
metabolite EXP3174 on hypoxia-induced cell damage and release of inflammatory 
cytokines have been investigated in rat APCs. Losartan and EXP3174 reduced LDH 
release from astrocytes in a concentration-dependent manner under both, normoxic 
(NC) and hypoxic conditions (HC). It was found that simultaneous administration of 
100 nM ATII and 1 μM EXP3174 under NC and HC brought no additional decrease 
of LDH-release (63±14% decrease under NC) when compared with the effect of 1 
μM EXP3174 applied alone (52±16%). Exposure of astrocytes to hypoxia (48 h) 
resulted in a 3.5-fold increase in TNFD release, whereas IL-4,-5, INF-gamma and 
GM-CSF could not be detected under NC or HC even by a highly sensitive multiplex 
analysis. No significant effect on TNFD released by astroglial cells could be 
observed after application of EXP3174 under HC due to a high variability of data 
within the treated group. EXP3174 was effective only in the presence of ATII 
(56±20% decrease in TNFD-release). Losartan was capable of decreasing TNFD-
release under HC, alone and in combination with ATII. This data suggested that AT1-
R blockade may decrease the susceptibility of astrocytes to hypoxic injury and, in 
consequence, their propensity to release TNFD. Therefore, AT1-R antagonists may 
be of therapeutic value during hypoxia-associated neurodegeneration. 
In conclusion, AT1-R blockade could be of therapeutic benefit during 
neurodegenerative disorders accompanied by inflammation, such as AD, Parkinson’s 
disease, stroke and multiple sclerosis due to its anti-inflammatory and vulnerability-
reducing effect on astrocytes. 
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5. EXPERIMENTAL
5.1. Instrumentation and General Experimental Considerations 
5.1.1. Thin layer chromatography (TLC) 
Thin-layer chromatography (TLC) was carried out using aluminum sheets precoated 
with silica gel 60 F254 (0.2 mm; E. Merck). Chromatographic spots were visualized 
by UV and/or spraying with an acidic, ethanolic solution of p-anisaldehyde or an 
ethanolic solution of ninhydrin followed by heating. For preparative TLC plates 
precoated with silica gel 60 F254 (2.0 mm; E. Merck) were used.  
5.1.2. Column chromatography 
Flash column chromatography was carried out using Merck silica gel 60 (40-63 and 
15-40 μm) and 60G (5-40 μm). 
5.1.3. Melting points 
Measurements below 200 °C were determined on a Büchi 510 melting point 
apparatus and above 200 °C were carried out on a Kofler-Heiztischmikroskop 
apparatus and are uncorrected. 
5.1.4. NMR spectroscopy 
The 1H spectra were recorded on a Bruker AC 300 spectrometer at 300 MHz and 
Bruker AC 500 spectrometer at 500 MHz. The 13C spectra were recorded on a Bruker 
AC 300 spectrometer at 75 MHz and Bruker AC 500 spectrometer at 125 MHz. 
Chemical shifts are reported as % values (ppm) downfield from Me4Si.
5.1.5. IR spectroscopy 
IR spectra were recorded using a Nicolet 320 FT-IR and a Bruker Tensor 27 
spectrometer. Samples were prepared either as KBr pellets or as thin films. Band 
positions are reported in reciprocal centimetres. Band intensities are characterized by 
the following symbols; vs (very strong), s (strong), m (medium), w (weak).
5.1.6. Mass spectrometry 
Mass spectrometry was performed on Bruker-Franzen Esquire LC mass 
spectrometer. 
5.1.7. Specific optical rotation 
Specific optical rotations were determined with a Perkin-Elmer 241 polarimeter. 
5.1.8. X-ray analysis
X-ray data were obtained by single-crystal X-ray diffraction using the Xcalibur 
system from Oxford Diffraction, equipped with CCD detector and the Enhance X-ray 
source option. The software packages SHELXS[224] and SHELXL[225] were used for 
structure solution and refinement as included in X-STEP32.[226] Diffraction data were 
collected on a Xcalibur diffractometer using graphite-monochromated (Mo-KD)
radiation (O = 0.71073 Å). Unit cell parameters were determined by least-squares 
refinement of the optimized setting angles of 634 reflections in the range 1.32 d T d
Experimental 92
13.28°. A total of 9809 reflections, 3020 unique (Rint = 0.170), were collected up toT
= 23.89°.
5.1.9. Drying of solvents 
THF was dried and distilled from sodium and benzophenone under nitrogen prior to 
use. DMF was stored over 3 Å molecular sieves. All other commercial chemicals 
were used without further purification. CH2Cl2 and Et3N were distilled from CaH2
under nitrogen prior to use. Amino acid derivatives were bought from Fluka Chemie 
(Switzerland), NovaBiochem (Switzerland), or Bachem (Switzerland). All other 
chemicals were of reagent quality and used as obtained from the manufacturers. 
Reactions were carried out in dry N2 when necessary. 
5.2. General Experimental Procedures 
5.2.1. Synthesis of Chemical Reagents 
5.2.1.1. Preparation of IBX 
22.5 g (90.7 mmol) 2-iodobenzoic acid was added to a solution of potassium 
peroxymonosulphate (2KHSO5.KHSO4.K2SO4: oxone) (54.3 g, 88.3 mmol) and 300 
mL of water were stirred in a water bath at a temperature range of 70-75 °C for 3 h 
with a mechanical stirrer. The mixture was slowly cooled to 5 °C and again stirred 
for 1.5 h at the same temperature. As a result, there occurred the formation of 
colorless crystals, which were filtered. The solid product was washed with a water-
acetone mixture and dried in a vacuum oven to give 21.2 g (75.7 mmol) of o-iodoxy
benzoic acid (IBX) as colorless crystals 83% yield.
5.2.1.2. Synthesis of benzylisonitrile 
5.2.1.2.1. Method 1 
A one litre round bottomed flask was equipped with magnetic stirring bar, reflux 
condensor and charged with benzyl amine (1 mol) benzyltriethylammonium chloride 
(2.5 g) and CH2Cl2 (300 mL). 50% of aq. NaOH soln. (300 mL) was added in one 
portion after an induction period of about 10 min. The CH2Cl2 refluxed 
spontaneously. The reaction mixture was kept at 40 °C. After about 1 h the refluxing 
ceased and mixture was stirred for additional 1 h. Recation mixture was diluted with 
one litre water and isonitrile was extracted with CH2Cl2. Combined organic extract 
was washed with water, brine (NaCl soln.), buffer pH 4.5 NaH2PO4/Na2HPO4, dried 
over anhydrous sodium sulphate (Na2SO4) or potassium carbonate (K2CO3) and then 
distilled to yield the benzylisonitrile.
Yield: 46.8 g, 40%
Bp: 92-93 °C at 11 torr.
5.2.1.2.2. Method 2 
Step 1: Preparation of N-formyl benzyl amine 
In a 600 mL of dry CH2Cl2 was dissolved (1 mol, 109 g) benzylamine. A mixture of 
120 mL of formic acid and 120 mL of acetic anhydride was stirred for 1 h and then 
added to the reaction mixture at such a rate that the temperature was kept between 5 
and 10 °C. Subsequently, the reaction mixture was stirred for 16 h at room 
temperature and refluxed for 4 h. The solvent was evaporated under vacuum and the 
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residue was dissolved in CHCl3 and washed three times with a saturated aq. soln. of 
NaHCO3 and with water to remove acid and acetic anhydride. The organic layer was 
dried over anhydrous Na2SO4 and the CHCl3 was evaporated in vacuum. The product 
was recrystallized from diethylether.  
Yield: 132 g, 98% 
mp: 59.6 °C 
IR (KBr): 1645 (C=O) cm1.
1H NMR (300 MHz, CDCl3): G = 8.16 (s, 1H; CHO), 7.30 (s, 5H; C6H5), 4.42 (d, 
2H; CH2).
Step 2: Synthesis of benzylisonitrile 
A reflux condenser was inserted in the middle of a three neck flask while in the other 
two necks inserted thermometer and dropping funnel. Benzyl formamide (135 g, 1 
mol), pyridine (350 mL), CHCl3 (400 mL) were added and stirred during a course of 
15 min. 0.6 mol of phosphorous oxychloride (POCl3) was added in it under stirring 
and ice cooling at 0 °C. It was stirred for another 30 min at 20 °C. This solution was 
poured to one litre ice cold water. The organic layer was separated and washed three 
times with 500 mL of ice cooled 10% H3PO4 phosphoric acid, NaHCO3, and brine 
solution. It was dried over anhydrous Na2SO4 and distilled over fractional distillation 
column. 
Yield: 82 g, 70% 
Bp: 92-93 °C at 11 torr.
5.2.2. General Procedures 
5.2.2.1. General procedure of oxidation of alcohols with IBX
IBX (11 mmol) and (10 mmol) of alcohol were added to (27.5 mL) DMSO to form 
0.4 M of solution and this mixture was stirred at room temperature for 4 h. Water (20 
mL) was then added to the reaction mixture to precipitate 2-iodobenzoic acid 
crystals, and these crystals were filtered. The mother liquid was extracted with 
CH2Cl2 (3 u 25 mL), washed with NaHCO3 solution, and dried over anhydrous 
magnesium sulphate (MgSO4) to obtain aldehydes. 
5.2.2.2. General procedure for reduction of amino acids to amino alcohols 
The amino acid (1.0 equiv.) was added slowly in small portions, to an ice cooled 
solution of lithium aluminium hydride (2.0 equiv.) in dry THF (40 mL g1 LiAlH4).
The mixture was allowed to react at 0 °C for 1 h followed by reflux overnight. The 
solution was cooled to 0 °C and the excess of LiAlH4 quenched with aqueous sodium 
hydroxide (2 M). The precipitate was filtered off and extracted with boiling THF for 
1 h. The combined ethereal extract was concentrated under reduced pressure and the 
remaining mixture extracted with dichloromethane. The comined organic extract was 
washed with brine, dried over anhydrous Na2SO4 and the solvent evaporated under 
reduced pressure to give the known amino alcohols. 
5.2.2.2.1. Synthesis of (S)-phenylalaninol
(S)-Phenylalaninol was synthesized by following the general method 5.2.2.2.
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Reactants: 2.46 g of LiAlH4 in 125 mL of THF, (S)-phenylalanine (5.45 g, 33 
mmol)
Spectral data consistant with the literature.[227]
Yield: 4.0 g, 80% 
mp: 91.5 °C 
5.2.2.3. General procedure for peptide coupling by EDAC as coupling reagent 
1.0 equiv. Et3N was added to a solution of 1.0 equiv. of acid in CH2Cl2 which was 
followed by the addition of 1.0 equiv. ethyl-3-(3´-dimethylaminopropyl) 
carbodiimide hydrochloride (EDAC) and 1.2 equiv. HOBt (N-hydroxybenzotriazole
hydrate) during stirring in it. 1.2 equiv. Et3N and 1.2 equiv. amine was added to it 
simultaneously. The reaction mixture was kept on stirring at room temperature and 
monitored by TLC. The organic phase was washed with NaHCO3, (0.1 N) HCl, and 
brine simultaneously. The organic phase was dried over anhydrous Na2SO4 and the 
solvent was evaporated in vacuo.
5.2.2.4. General procedure for peptide coupling using ethyl chloro formate  
Et3N (0.468 mmol) and ethyl chloroformate (0.468 mmol) were added to a solution 
of acid (0.375 mmol) in THF or CH2Cl2 (4 mL) at 0 °C. The mixture was stirred at 
the same temperature for 1 h and at room temperature for an additional 1.5 h. The 
reaction mixture was partitioned between ethylacetate (EtOAc) and water. The 
aqueous phase was extracted with EtOAc, and combined organic extracts were 
washed with brine, dried over anhydrous Na2SO4, and concentrated in vacuo. The 
residue was purified by column chromatography. 
5.2.2.5. General procedure for peptide coupling by DCC as coupling reagent 
1.0 equiv. Et3N was added to a solution of 1.0 equiv. of acid in CH2Cl2. 1.0 equiv. 
N,N'-dicyclohexylcarbodiimide (DCC) and 1.2 equiv. HOBt were added successively 
in it while stirring. 1.2 equiv. Et3N and 1.2 equiv. amine was added to it 
simultaneously. Within 5 min, precipitate of N-N'-dicyclohexylurea appeared. The 
reaction mixture was kept on stirring at room temperature and monitored by TLC. 
The organic phase was washed with NaHCO3, (0.1 N) HCl, and brine 
simultaneously. The organic phase was dried over anhydrous Na2SO4 and the solvent 
was evaporated in vacuo.
5.2.2.6. General procedure for peptide coupling by PyBop as coupling reagent 
1.0 equiv. DIEA was added to a solution of 1.0 equiv. of acid in CH2Cl2 which 
followed by the addition of 1.0 equiv. of PyBop in it. 1.2 equiv. DIEA and 1.2 equiv. 
amine was added simultaneously to it. The reaction mixture was kept on stirring at 
room temperature and monitored by TLC. The organic phase was washed with 
NaHCO3, (0.1 N) HCl, and brine simultaneously. The organic phase was dried over 
anhydrous Na2SO4 and the solvent was evaporated in vacuo.
5.2.2.7. General procedure for peptide coupling by PyBrop as coupling reagent 
Same procedure was followed as mentioned in section 5.2.2.6. using PyBrop instead 
of PyBop.
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5.2.2.8. General procedure for peptide coupling by formation of acid chloride 
Monocarboxylic acid compound (23.3 mmol) and DMF (3 drops) was added to 
thionyl chloride (3.40 mL, 46.9 mmol) in toluene (20 mL). The mixture was heated 
to 92 °C with stirring for 50 min and then concentrated in vacuo to give oil. A 
solution of amine in Et2O or CH2Cl2 was added dropwise to the oil at 0 °C and 
stirred at room temperature for 3 h and then evaporated to dryness to give the amide 
compound. 
5.2.2.9. General procedure for esterification 
Thionyl chloride (1.7 mL, 24.09 mmol) was added dropwise to a stirred solution of 1 
equiv. acid (6.0 mmol) in anhydrous methanol (50 mL) at 0 °C under nitrogen. The 
reaction mixture was allowed to stirr at room temperature and monitored by TLC. 
Solvent was removed after completion of reaction to give ester as a colorless 
crystalline solid.
5.2.2.10. General procedure for O-alkylation of phenolic OH 
A cooled mixture of 60% NaH (0.164 mmol) in DMF (1.0 mL) was added to phenol 
(0.168 mmol) at 0 °C. The mixture was stirred for 30 min. compound RX (0.164
mmol) was added at 0 °C. After 30 min, it was partitioned between EtOAc and 
water. The aqueous phase was extracted with EtOAc, and the combined organic 
extracts were washed with water (4u) and brine, dried over anhydrous MgSO4 and 
concentrated.  
5.2.2.11. General procedure 1 for Passerini reaction 
Trifluoroacetic acid (2.0 equiv) was added dropwise to a cooled solution (10 to 0 
°C) of aldehyde (1.0 equiv), isonitrile (1.21.5 equiv), and pyridine (4.0 equiv) in 
CH2Cl2 [0.252.0 M] under nitrogen atmosphere while maintaining the temperature 
at  0 °C. After 0.52 h at 0 °C, the bath was removed and the reaction was stirred at 
ambient temperature for 12 to 72 h. In cases with sluggish reactants, the solution was 
slowly concentrated to afford viscous oil, which was further stirred until TLC or 
HPLC analysis revealed complete consumption of the aldehyde component. The 
resultant slurry was dissolved in ethyl acetate and washed with distilled water, and 
brine. The organic layer was dried over anhydrous Na2SO4, filtered, and 
concentrated. A diastereomeric mixture was obtained in each case. Separation of two 
diastereomers was done by flash column chromatography on silica gel using ethyl 
acetate/hexane or dichloromethane/methanol gradient systems. Pure products were 
obtained as either nearly colorless solids or as colorless to pale yellow viscous oils.
5.2.2.12. General procedure 2 for Passerini reaction 
Trifluoroacetic acid (2.0 equiv) was added dropwise to a cooled solution (10 to 0 
°C) of aldehyde (1.0 equiv), isonitrile (1.21.5 equiv), in dichloromethane under a 
nitrogen atmosphere while maintaining the temperature at  0 °C. After 0.52 h at 0 
°C, the bath was removed and the reaction was stirred at ambient temperature for 12 
to 72 h. In cases with sluggish reactants, the solution was slowly concentrated to 
afford viscous oil, which was further stirred until TLC or HPLC analysis revealed 
complete consumption of the aldehyde component. The resultant slurry was 
dissolved in ethyl acetate and washed with distilled water, and brine. The organic 
layer was dried over anhydrous Na2SO4, filtered, and concentrated. A diastereomeric 
mixture was obtained in each case. Separation of two diastereomers was done by 
Experimental 96
flash column chromatography on silica gel using ethyl acetate/hexane or 
dichloromethane/methanol gradient systems. Pure products were obtained either as 
nearly colorless solids or as colorless to pale yellow viscous oils. 
5.2.3. Synthesis of BACE-1 Inhibitors 
5.2.3.1. Dimethyl isophthalate (60)
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Thionyl chloride (1.7 mL, 24.09 mmol) was added dropwise to a stirred solution of 
isophthalic acid 58 (1.0 g, 6.0 mmol) in anhydrous methanol (50 mL) at 0 °C under 
nitrogen. The reaction mixture was allowed to stirr at room temperature and 
monitored by TLC. Solvent was removed after completion of reaction to give 
isophthalic dimethyl ester as a colorless crystalline solid 60 (Scheme 3.2).
Yield: 1.11 g, 95.7% 
Spectral data consistant with the literature.[228]
5.2.3.2. Dipicolinic acid dimethyl ester (61) 
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Dipicolinic acid, 59, (2 g, 12 mmol) was refluxed with methanol in the presence of 
concentrated H2SO4 as a catalyst for 8 h. The solvent was removed under vacuum 
and the residue was diluted with water (25 mL) and extracted into EtOAc (3 u 25 
mL). The combined EtOAc extracts were washed with water (3 u 25 mL), dried 
(anhydrous Na2SO4) and evaporated under reduced pressure to obtain 61 (Scheme
3.2).
Yield: 1.4 g, 60% 
Rf: 0.48 (benzene: ethylacetate = 3:2) 
Spectral data consistant with the literature.[229]
5.2.3.3. 3-(Methoxycarbonyl)benzoic acid (62) 
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Isophthalic diester 60, 1 equiv. (1.0 g, 5.15 mmol) and potassium hydroxide 1.2 
equiv. (0.347 g, 6.18 mmol) were stirred in ethanol (25 mL) for 15 h at room 
temperature. The ethanol was removed under vacuum, water (25 mL) was added, and 
the aqueous phase extracted with dichloromethane (3 u 25 mL). The aqueous phase 
was acidified with concentrated hydrochloric acid (37%) and the resulting precipitate 
was filtered, washed with water (5 mL), and dried to give 62 (Scheme 3.2) of 
isophthalic mono ester as a colorless solid.
Yield: 0.920 g, 99.2% 
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Mp: 200–202 °C
Spectral data consistant with the literature.[230]
5.2.3.4. Methyl 3-(dipropylcarbamoyl)benzoate (64) 
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EDAC (979 mg, 5.11 mmol) and HOBt (828 mg, 6.13 mmol) were added to a 
solution of 3-(methoxycarbonyl)benzoic acid 62 (920 mg, 5.11 mmol), dissolved in 
CH2Cl2 (10 mL). The resulting mixture was stirred at ambient temperature for 5 min, 
then treated with dipropylamine (0.84 mL, 6.13 mmol) and triethylamine (Et3N, 1.42 
mL, 10.22 mmol) for 8 h. CH2Cl2 (20 mL) was added and the solution was washed 
with HCl (0.1 N, 5 u 30 mL), NaOH (0.1 N, 3 u 30 mL), brine (1 u 30 mL), dried 
over anhydrous Na2SO4, and concentrated to obtain the product 64 as colorless oil 
(Scheme 3.2).
Yield: 1.23 g, 92%
Spectral data consistant with the literature.[231]
5.2.3.5. 3-(Dipropylcarbamoyl)benzoic acid (66)  
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Methyl 3-(dipropylcarbamoyl)benzoate 64 (1.0 g, 3.80 mmol) and sodium carbonate 
(2.0 g, 19.0 mmol) were stirred in methanol (15 mL) and water (1 mL) for 15 h. 
Methanol was removed under reduced pressure. The aqueous phase was acidified at 
0 °C with concentrated hydrochloric acid (37%) and the resulting precipitate was 
filtered, washed with water (5 mL), and dried to give 66 as a colorless solid (Scheme
3.2).
Yield: 0.920 g, 97% 
Spectral data consistant with the literature.[231]
5.2.3.6. 6-(Dipropylcarbamoyl)pyridine-2-carboxylic acid (67) 
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The title compound was synthesized by following same general procedure mentioned 
in 5.2.3.5.
Reactants: Methyl 6-(dipropylcarbamoyl)pyridine-2-carboxylate 65 (1.0 g, 3.80 
mmol), sodium carbonate (2.0 g, 19.0 mmol), methanol (15 mL) and water (1 mL) 
Yield: 0.920 g, 97% 
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1H NMR (DMSO, 300 MHz): G = 11.2 (s, 1H; H-13), 8.91 (dd, 3J = 7.7 Hz, 4J = 1.8
Hz, 1H; H-5), 8.76 (dd, 3J = 7.7 Hz, 4J = 1.8 Hz, 1H; H-3), 7.58 (t, 3J = 7.7 Hz, 1H; 
H-4), 3.38 (t, 3J = 7.7 Hz, 2H; H-7), 3.10 (t, 3J = 7.7 Hz, 2H; H-10), 1.67 (sext, 3J =
7.6 Hz, 2H; H-8), 1.45 (sext, 3J = 7.6 Hz, 2H; H-11), 1.00 (t, 3J = 7.7 Hz, 3H; H-9), 
0.91 (t, 3J = 7.7 Hz, 3H; H-12) ppm.  
13C NMR (DMSO, 75 MHz): G = 169.5 (C-13), 166.6 (C-6), 150.8 (C-1), 149.4 (C-
2), 129.8 (C-4), 129.0 (C-3), 128.8 (C-5), 49.9 (C-7), 45.6 (C-10), 21.3 (C-8), 20.2 
(C-11), 11.2 (C-9), 10.7 (C-12) ppm.  
MS (EI): m/z = 249 [M]+.
5.2.3.7. Dimethyl 4-hydroxypyridine-2,6-dicarboxylate (71) 
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The title compound was synthesized by following same general procedure mentioned 
in 5.2.3.2.
Reactants: Chelidamic acid (183 mg, 1 mmol), methanol (10 mL), H2SO4 (few 
drops).
Yield: 165 mg, 78% 
Spectral data consistant with the literature.[232]
5.2.3.8. 5-Hydroxy-1,3-benzenedicarboxylic acid dimethyl ester (72) 
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To a 250-mL, round-bottom flask equipped with a condenser were added 5-hydroxy-
1,3-benzenedicarboxylic acid dimethyl ester (3.75 g, 17.8 mmol), THF (30 mL), and 
H2O (300 mL), and the solution was cooled to 0 °C. To this solution was added 
NaOH (0.25 N, 240 mL) dropwise, and the reaction mixture was stirred for 1 h. After 
the completion of the reaction, HCl (1 N) was added until no further precipitation 
was observed. The precipitate was filtered to give a colorless solid, which was 
subjected to column chromatography with CHCl3/MeOH/NH4OH (6/3/1) as an 
eluent to isolate monomethylester as a colorless solid. 
Yield: 1.70 g, 49% 
Spectral data consistant with the literature.[233]
5.2.3.9. Methyl 3-(dipropylcarbamoyl)-5-hydroxybenzoate (74)
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The title compound was synthesized by following general procedure 5.2.2.3.
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Reactants: 5-hydroxy-1,3-benzenedicarboxylic acid dimethyl ester (196 mg, 1 
mmol), EDAC (191 mg, 1 mmol), HOBt (162 mg, 1.2 mmol), Et3N (278 PL, 2 
mmol), dipropylamine (165 PL, 1.2 mmol), CH2Cl2 (5 mL).
Yield: 223 mg, 80% 
Spectral data consistant with the literature.[234]
5.2.3.10. Methyl 6-(dipropylcarbamoyl)-4-hydroxypyridine-2-carboxylate (75) 
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The title compound was synthesized by following general procedure 5.2.2.3.
Reactants: 6-(Methoxycarbonyl)-4-hydroxypyridine-2-carboxylic acid (197 mg, 1 
mmol), EDAC (191 mg, 1 mmol), HOBt (162 mg, 1.2 mmol), Et3N (278 PL, 2 
mmol), dipropylamine (165 PL, 1.2 mmol), CH2Cl2 (5 mL).
Yield: 167 mg, 60% 
1H NMR (CD3OD, 300 MHz): G = 7.69 (s, 1H; H-3), 7.63 (s, 1H; H-5), 3.88 (s, 3H; 
H-14), 3.36 (t, 3J = 7.7 Hz, 2H; H-7), 3.15 (t, 3J = 7.7 Hz, 2H; H-10), 1.66 (sext, 3J =
7.6 Hz, 2H; H-8), 1.44 (sext, 3J = 7.6 Hz, 2H; H-11), 1.00 (t, 3J = 7.7 Hz, 3H; H-9), 
0.91 (t, 3J = 7.7 Hz, 3H; H-12) ppm. 
13C NMR (CDCl3, 75 MHz): G = 168.9 (C-6), 166.0 (C-13), 158.2 (C-4), 152.5 (C-
1), 143.4 (C-2), 116.3 (C-5), 115.7 (C-3), 49.9 (C-7), 45.6 (C-10), 21.3 (C-8), 20.2 
(C-11), 11.5 (C-9), 10.7 (C-12) ppm.  
MS (EI): m/z = 279 [M]+.
5.2.3.11. 3-(Dipropylcarbamoyl)-5-hydroxybenzoic acid (76)
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The title compound was synthesized by following same general procedure mentioned 
in 5.2.3.5.
Reactants: Methyl 3-(dipropylcarbamoyl)-5-hydroxybenzoate (279 mg, 1 mmol), 
sodium carbonate (631 mg, 6 mmol), methanol (5 mL), water (0.5 mL). 
Yield: 206 mg, 78% 
Spectral data consistant with the literature.[234]
5.2.3.12. 6-(Dipropylcarbamoyl)-4-hydroxypyridine-2-carboxylic acid (77) 
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The title compound was synthesized by following same procedure, which mentioned 
earliere in 5.2.3.8.
Reactants: Methyl 6-(dipropylcarbamoyl)-4-hydroxypyridine-2-carboxylate (75)
(280 mg, 1 mmol), THF (1.7 mL), H2O (1.7 mL), and NaOH (0.25 N, 1.4 mL). 
Yield: 127 mg, 48% 
1H NMR (CD3OD, 300 MHz): G = 10.0 (s, 1H; COOH), 7.75 (s, 1H; H-3), 7.64 (s, 
1H; H-5), 3.32 (t, 3J = 7.7 Hz, 2H; H-7), 3.21 (t, 3J = 7.7 Hz, 2H; H-10), 1.66 (sext, 
3J = 7.6 Hz, 2H; H-8), 1.52 (sext, 3J = 7.6 Hz, 2H; H-11), 1.00 (t, 3J = 7.7 Hz, 3H; H-
9), 0.91 (t, 3J = 7.7 Hz, 3H; H-12) ppm. 
13C NMR (CDCl3, 75 MHz): G = 168.9 (C-13), 166.0 (C-6), 158.2 (C-4), 152.5 (C-
1), 148.4 (C-2), 118.8 (C-5), 117.3 (C-3), 49.9 (C-7), 47.9 (C-10), 22.9 (C-8), 21.7 
(C-11), 11.5 (C-9), 11.3 (C-12) ppm.  
MS (EI): m/z = 266 [M]+.
5.2.3.13. Dimethyl 5-(benzyloxy)benzene-1,3-dioate (78) 
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K2CO3 (11.0 g, 79.6 mmol) was added to a stirred solution of dimethyl 5-
hydroxybenzene-1,3-dioate (8.00 g, 37.9 mmol) and benzyl bromide (13.5 g, 78.9 
mmol) in acetone (250 mL), and the solution was heated at 6070 °C for 18 h. After 
allowing the reaction mixture to cool down to room temperature, the unsoluble 
residue was removed by filtration and the solvent evaporated at reduced pressure. 
The crude product was dissolved in chloroform (300 mL), washed with water, dried 
over anhydrous Na2SO4 and the solvent removed under reduced pressure. Re-
crystalisation from ethyl acetate (30 mL) yielded the desired product. 
Yield: 10.5 g, 92% 
Spectral data consistant with the literature.[235]
1H NMR (CD3OD, 300 MHz): G = 8.20 (s, 1H; H-2), 7.74 (s, 2H; H-4/6), 7.377.17
(m, 5H; H-9-13), 5.04 (s, 2H; H-7), 3.83 (s, 6H; H-15/17) ppm
13C NMR (CDCl3, 75 MHz): G = 166.2 (C-14), 166.0 (C-16), 158.8 (C-5), 131.9 (C-
8), 129.1 (C-1), 128.7 (C-3), 128.6 (C-10), 128.5 (C-12), 128.0 (C-9), 127.6 (C-13), 
123.3 (C-11), 120.0 (C-2), 119.7 (C-6), 119.6 (C-4), 70.5 (C-7), 53.8 (C-15), 52.5 
(C-17) ppm.  
MS (EI): m/z = 300 [M]+.
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5.2.3.14. Dimethyl 4-(benzyloxy)pyridine-2,6-dicarboxylate (79) 
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The title compound was synthesized by following same general procedure mentioned 
in 5.2.3.13.
Reactants: 4-hydroxy-pyridine-2,6-dicarboxylic dimethyl ester (210 mg, 1 mmol), 
K2CO3 (276 mg, 2 mmol), benzyl bromide (342 mg, 2 mmol), acetone (20 mL). 
Yield: 231 mg, 77% 
M.p.: 102 ± 103 ° C 
Spectral data consistant with the literature.[236]
1H NMR (CD3OD, 300 MHz): G = 7.83 (s, 2H; H-2/4), 7.307.19 (m, 5H; H-8-12), 
5.16 (s, 2H; H-6), 3.87 (s, 6H; 14/16) ppm. 
13C NMR (CDCl3, 75 MHz): G = 166.8 (C-13), 165.2 (C-15), 162.0 (C-3), 148.6 (C-
1), 148.4 (C-5), 141.2 (C-7), 129.0 (C-9), 128.9 (C-11), 128.8 (C-10), 127.8 (C-8), 
127.6 (C-12), 114.9 (C-2), 114.8 (C-4), 70.9 (C-6), 53.3 (C-14), 53.0 (C-16) ppm.  
MS (EI): m/z = 301 [M]+.
5.2.3.15. 3-(Methoxycarbonyl)-5-(benzyloxy)benzoic acid (80) 
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The title compound was synthesized by following same procedure, which mentioned 
before in 5.2.3.8.
Reactants: Dimethyl 5-(benzyloxy)benzene-1,3-dioate (300 mg, 1 mmol), THF (1.7 
mL), H2O (1.7 mL), and NaOH (0.25 N, 1.4 mL). 
Yield: 275 mg, 96% 
Spectral data consistant with the literature.[237]
1H NMR (CD3OD, 300 MHz): G = 11.0 (s, 1H; COOH), 8.24 (s, 1H; H-2), 7.85 (s, 
1H; H-4), 7.82 (s, 1H; H-6), 7.28–7.11 (m, 5H; H-9-13), 5.11 (s, 2H; H-7), 3.87 (s, 
3H; H-15) ppm. 
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13C NMR (CDCl3, 75 MHz): G = 169.8 (C-16), 168.6 (C-14), 161.1 (C-5), 141.2 (C-
8), 131.1 (C-3), 131.0 (C-1), 129.3 (C-10), 129.0 (C-12), 127.7 (C-11), 127.2 (C-9), 
127.0 (C-13), 122.6 (C-2), 119.3 (C-6), 118.8 (C-4), 70.9 (C-7), 51.5 (C-15) ppm.  
MS (EI): m/z = 286 [M]+.
5.2.3.16. 6-(Methoxycarbonyl)-4-(benzyloxy)pyridine-2-carboxylic acid (81) 
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Reactants: Dimethyl 4-(benzyloxy)pyridine-2,6-dicarboxylate (301 mg, 1 mmol), 
THF (1.7 mL), H2O (1.7 mL), and NaOH (0.25 N, 1.4 mL). 
Yield: 187 mg, 65% 
Spectral data consistant with the literature.[238]
1H NMR (CD3OD, 300 MHz): G = 11.0 (s, 1H; COOH), 7.73–7.64 (m, 2H; H-2/4), 
7.25–7.15 (m, 5H; H-8-12), 5.11 (s, 2H; H-6), 3.87 (s, 3H; H-14) ppm. 
13C NMR (CDCl3, 75 MHz): G = 168.6 (C-13), 167.0 (C-15), 166.0 (C-3), 148.6 (C-
1), 148.4 (C-5), 141.2 (C-7), 129.4 (C-9), 129.0 (C-11), 127.7 (C-10), 127.2 ((C-8), 
127.0 (C-12), 112.9 (C-2), 112.0 (C-4), 70.9 (C-6), 51.5 (C-14) ppm.  
MS (EI): m/z = 287 [M]+.
5.2.3.17. 3-(Dipropylcarbamoyl)-5-(benzyloxy)benzoic acid (84) 
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The title compound was synthesized by following same general procedure mentioned 
in 5.2.3.5.
Reactants: Methyl 3-(dipropylcarbamoyl)-5-(benzyloxy)benzoate (369 mg, 1 
mmol), sodium carbonate (631 mg, 6 mmol), methanol (5 mL), water (0.5 mL). 
Yield: 312 mg, 90% 
1H NMR (CD3OD, 300 MHz): G = 10.9 (s, 1H; COOH), 8.16 (s, 1H; H-2), 7.68 (s, 
1H; H-4), 7.57 (s, 1H; H-6), 7.26–7.10 (m, 5H; H-9-13), 4.98 (s, 2H; H-7), 3.30 (t, 3J
= 7.7 Hz, 2H; H-15), 3.03 (t, 3J = 7.7 Hz, 2H; H-18), 1.69 (sext, 3J = 7.6 Hz, 2H; H-
16), 1.40 (sext, 3J = 7.6 Hz, 2H; H-19), 1.00 (t, 3J = 7.7 Hz, 3H; H-17), 0.91 (t, 3J = 
7.7 Hz, 3H; H-20) ppm. 
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13C NMR (CDCl3, 75 MHz): G = 169.8 (C-21), 168.6 (C-14), 160.4 (C-5), 141.2 (C-
8), 136.1 (C-1), 131.1 (C-3), 129.5 (C-10), 129.0 (C-12), 127.7 (C-11), 127.2 (C-9), 
127.0 (C-13), 119.0 (C-2), 116.8 (C-6), 115.5 (C-4), 70.9 (C-7), 49.9 (C-15), 49.5 
(C-18), 21.8 (C-16), 21.6 (C-19), 11.6 (C-17), 11.0 (C-20) ppm.  
MS (EI): m/z = 355 [M]+.
5.2.3.18. 6-(Dipropylcarbamoyl)-4-(benzyloxy)pyridine-2-carboxylic acid (85) 
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The title compound was synthesized by following same general procedure mentioned 
in 5.2.3.5.
Reactants: Methyl 6-(dipropylcarbamoyl)-4-(benzyloxy)pyridine-2-carboxylate
(370 mg, 1 mmol), sodium carbonate (631 mg, 6 mmol), methanol (5 mL), water (0.5 
mL).
Yield: 306 mg, 88% 
1H NMR (CD3OD, 300 MHz): G = 10.7 (s, 1H; COOH), 7.66 (s, 1H; H-3), 7.57 (s, 
1H; H-5), 7.27–7.10 (m, 5H; H-8-12), 4.98 (s, 2H; H-6), 3.30 (t, 3J = 7.7 Hz, 2H; H-
14), 3.03 (t, 3J = 7.7 Hz, 2H; H-17), 1.69 (sext, 3J = 7.6 Hz, 2H; H-15), 1.40 (sext, 3J
= 7.6 Hz, 2H; H-18), 1.00 (t, 3J = 7.7 Hz, 3H; H-16), 0.91 (t, 3J = 7.7 Hz, 3H; H-19) 
ppm. 
13C NMR (CDCl3, 75 MHz): G = 169.8 (C-20), 168.6 (C-13), 160.4 (C-4), 141.2 (C-
7), 156.1 (C-1), 148.1 (C-2), 129.5 (C-9), 129.0 (C-11), 127.7 (C-10), 127.2 (C-8), 
127.0 (C-12), 116.8 (C-5), 115.5 (C-3), 70.9 (C-6), 49.9 (C-14), 49.5 (C-17), 21.8 
(C-15), 21.6 (C-18), 11.6 (C-16), 11.0 (C-19) ppm.
MS (EI): m/z = 356 [M]+.
5.2.3.19. (S)-N1-(1-Hydroxy-3-phenylpropan-2-yl)-N3,N3-dipropyliso phthal 
amide (86) 
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EDAC (708 mg, 3.69 mmol) and HOBt (598 mg, 4.42 mmol) were added to a 
solution of 3-(dipropylcarbamoyl)benzoic acid 66 (920 mg, 3.69 mmol), dissolved in 
CH2Cl2 (10 mL). The resulting mixture was stirred at ambient temperature for 5 min, 
then treated with L-phenyl alaninol (667 mg, 4.42 mmol) and Et3N (1.03 mL, 7.38 
mmol) for 8 h. CH2Cl2 (20 mL) was added and the solution was washed with HCl 
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(0.1 N, 5 u 30 mL), NaHCO3 sat. soln. (3 u 30 mL), brine (1 u 30 mL), dried over 
anhydrous Na2SO4 and concentrated to obtain the product 86.
Yield: 1.30 g, 92% 
1H NMR (DMSO, 300 MHz): G = 8.52 (s, 1H; H-2)), 8.19 (dd, 3J = 7.7 Hz, 4J = 1.8
Hz, 1H; H-6), 8.01 (dd, 3J = 7.7 Hz, 4J = 1.8 Hz, 1H; H-4), 7.58 (t, 3J = 7.7 Hz, 1H; 
H-5), 7.25–7.15 (m, 4H; H-19/20/23/22), 6.77–6.73 (m, 1H; H-21), 4.39–4.33 (m, 
1H; H-15), 4.07 (dd, 3J = 7.0 Hz, 2J = 14 Hz, 1H; H-16), 3.66 (dd, 3J = 7.0 Hz, 2J = 
14 Hz, 1H; H-16), 3.38 (t, 3J = 7.7 Hz, 2H; H-8), 3.10 (t, 3J = 7.7 Hz, 2H; H-11), 
2.99-2.95 (m, 1H; H-17), 2.87–2.83 (m, 1H; H-17), 1.67 (sext, 3J = 7.6 Hz, 2H; H-9), 
1.45 (sext, 3J = 7.6 Hz, 2H; H-12), 1.00 (t, 3J = 7.7 Hz, 3H; H-10), 0.91 (t, 3J = 7.7 
Hz, 3H; H-13) ppm. 
13C NMR (DMSO, 75 MHz): G = 168.9 (C-7), 167.3 (C-14), 139.6 (C-18), 136.1 
(C-1), 134.4 (C-3), 130.8 (C-6), 130.4 (C-20), 129.8 (C-22), 129.0 (C-5), 128.8 (C-
4), 128.7 (C-19), 128.6 (C-23), 126.8 (C-21), 124.3 (C-2), 71.4 (C-16), 52.3 (C-15), 
49.9 (C-8), 49.7 (C-11), 48.3 (C-17), 22.6 (C-9), 21.7 (C-12), 11.7 (C-10), 11.4 (C-
13) ppm.  
MS (EI): m/z = 382 [M]+.
5.2.3.20. (S)-5-(Benzyloxy)-N1-(1-hydroxy-3-phenylpropan-2-yl)-N3,N3-dipropyl
isophthalamide (87)  
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The title compound was synthesized by following same general procedure mentioned 
in 5.2.3.19.
Reactants: 3-(dipropylcarbamoyl)-5-(benzyloxy)benzoic acid (84) (355 mg, 1 
mmol), EDAC (147 mg, 1 mmol), HOBt (162 mg, 1.2 mmol), Et3N (278 PL, 2 
mmol), L-phenyl alaninol (181 mg, 1.2 mmol), CH2Cl2 (5 mL). 
Yield: 425 mg, 87% 
1H NMR (DMSO, 300 MHz): G = 7.99 (s, 1H; H-2), 7.69 (s, 1H; H-4), 7.45 (s, 1H; 
H-6), 7.33–7.05 (m, 10H; H-9-13/26-30), 5.18 (s, 2H; H-7), 4.06–3.99 (m, 1H; H-
22), 3.91–3.88 (m, 1H; H-23), 3.66–3.54 (m, 1H; H-23), 3.35 (t, 3J = 7.7 Hz, 2H; H-
15), 3.05 (t, 3J = 7.7 Hz, 2H; H-18), 2.93–2.87 (m, 1H; H-24), 2.69–2.55 (m, 1H; H-
24), 1.67 (sext, 3J = 7.6 Hz, 2H; H-16), 1.45 (sext, 3J = 7.6 Hz, 2H, H-19), 1.00 (t, 3J
= 7.7 Hz, 3H; H-17), 0.91 (t, 3J = 7.7 Hz, 3H; H-20) ppm. 
13C NMR (DMSO, 75 MHz): G = 172.9 (C-14), 168.9 (C-21), 160.3 (C-5), 139.6 
(C-8), 138.1 (C-25), 136.3 (C-1), 135.0 (C-3), 129.4 (C-10), 129.2 (C-12), 128.8 (C-
27), 128.6 (C-29), 128.5 (C-26), 128.1 (C-30), 126.3 (C-11), 126.4 (C-9), 126.3 (C-
13), 126.0 (C-28), 117.1 (C-2), 114.8 (C-6), 112.0 (C-4), 70.9 (C-7), 65.8 (C-23), 
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54.9 (C-22), 49.6 (C-15), 49.4 (C-18), 22.6 (C-16), 21.7 (C-19), 11.7 (C-17), 11.4 
(C-20) ppm.  
MS (EI): m/z = 488 [M]+.
5.2.3.21. (S)-N1-(1-Oxo-3-phenylpropan-2-yl)-N3,N3-dipropylisophthalamide
(88)
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Dimethyl sulfoxide (20 PL, 0.29 mmol) in CH2Cl2 (1 mL) was slowly added to a 
cold (78 °C) solution of freshly distilled oxalyl chloride (12 PL, 0.14 mmol) in 
CH2Cl2 (1 mL). The resulting solution was then stirred for 15 min at 78 °C. The 
alcohol 86 (50 mg, 0.13 mmol) in CH2Cl2 (1 mL) was then added to the reaction 
mixture via a cannula and stirred at 78 °C for 1 hour. Et3N (90 PL, 0.65 mmol) in 
CH2Cl2 (1 mL) was then added to the reaction mixture, which was then slowly 
allowed to warm to room temperature over 30 min. The reaction was quenched by 
the addition of a few drops of 1 M HCl and diluted with CHCl3. The organic phase 
was then washed with distilled water, and brine, dried (anhydrous MgSO4), and 
concentrated. Chromatography (30% EtOAc in hexane) provided the aldehyde 88.
This compound was immediately used for next reaction after synthesis.
Yield: 0.47 g, 96% 
1H NMR (DMSO, 300 MHz): G = 9.63 (s, 1H; H-16)), 7.99 (s, 1H; H-2), 7.69 (dd, 
3J = 7.7 Hz, 4J = 1.8 Hz, 1H; H-6), 7.45 (dd, 3J = 7.7 Hz, 4J = 1.8 Hz, 1H; H-4), 7.48 
(t, 3J = 7.7 Hz, 1H; H-5), 7.25–7.15 (m, 4H; H-19/20/22/23), 6.77–6.73 (m, 1H; H-
21), 4.86–4.83 (m, 1H; H-15), 3.48–3.44 (m, 1H; H-17), 3.35 (t, 3J = 7.7 Hz, 2H; H-
8), 3.25–3.18 (m, 1H; H-17), 3.05 (t, 3J = 7.7 Hz, 2H; H-11), 1.67 (sext, 3J = 7.6 Hz, 
2H; H-9), 1.45 (sext, 3J = 7.6 Hz, 2H, H-12), 1.00 (t, 3J = 7.7 Hz, 3H; H-10), 0.91 (t, 
3J = 7.7 Hz, 3H; H-13).
13C NMR (DMSO, 75 MHz): G = 200.1 (C-16), 168.8 (C-7), 166.7 (C-14), 139.5 
(C-18), 138.1 (C-1), 134.4 (C-3), 130.6 (C-6), 129.4 (C-20), 129.2 (C-22), 128.8 (C-
5), 128.6 (C-4), 128.5 (C-19), 128.3 (C-23), 126.8 (C-21), 124.1 (C-2), 71.4 (C-15), 
49.6 (C-8), 49.4 (C-11), 38.1 (C-17), 22.6 (C-9), 21.7 (C-12), 11.7 (C-10), 11.4 (C-
13) ppm. 
MS (EI): m/z = 380 [M]+.
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5.2.3.22. (S)-5-(Benzyloxy)-N1-(1-oxo-3-phenylpropan-2-yl)-N3,N3-
dipropylisophthalamide (89)  
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The title compound was synthesized by following same general procedure mentioned 
in 5.2.3.21. and immediately used for next reaction after synthesis.
Reactants: (S)-5-(benzyloxy)-N1-(1-hydroxy-3-phenylpropan-2-yl)-N3,N3-dipropyli 
sophthalamide (87) (488 mg, 1 mmol), dimethyl sulfoxide (130 PL, 2.0 mmol) in 
CH2Cl2 (1 mL), oxalyl chloride (94 PL, 1.1 mmol) in CH2Cl2 (1 mL). Et3N (692 PL,
5 mmol) in CH2Cl2 (1 mL) 
Yield: 389 mg, 80% 
1H NMR (DMSO, 300 MHz): G = 9.57 (s, 1H; H-23), 7.98 (s, 1H; H-2), 7.70 (s, 1H; 
H-4), 7.55 (s, 1H; H-6), 7.31–7.15 (m, 10H; H-9-13/26-30), 5.20 (s, 2H; H-7), 4.09–
3.96 (m, 1H; H-22), 3.30 (t, 3J = 7.7 Hz, 2H; H-15), 3.05 (t, 3J = 7.7 Hz, 2H; H-18), 
2.95–2.87 (m, 1H; H-24), 2.69–2.55 (m, 1H; H-24), 1.66 (sext, 3J = 7.6 Hz, 2H; H-
16), 1.47 (sext, 3J = 7.6 Hz, 2H, H-19), 1.00 (t, 3J = 7.7 Hz, 3H; H-17), 0.91 (t, 3J = 
7.7 Hz, 3H; H-20) ppm. 
13C NMR (DMSO, 75 MHz): G = 199.4 (C-23), 168.9(C-14), 167.3 (C-21), 141.0 
(C-8), 138.3 (C-25), 136.2 (C-1), 135.0 (C-3), 129.3(C-10), 129.0 (C-12), 128.6(C-
27), 127.4 (C-29), 127.2(C-30), 127.1 (C-26), 127.0 (C-30), 126.9 (C-11), 126.4 (C-
28), 117.1 (C-2), 114.8 (C-6), 112.0 (C-4), 70.9 (C-7), 68.2 (C-22), 49.6 (C-15), 49.4 
(C-18), 34.1 (C-24), 22.6 (C-16), 21.7 (C-19), 11.7 (C-17), 11.4 (C-20) ppm.  
MS (EI): m/z = 486 [M]+.
5.2.3.23. (S)-N1-(1-Hydroxy-3-(4-hydroxyphenyl)propan-2-yl)-N3,N3-
dipropylisophthalamide (90)  
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The title compound was synthesized by following same general procedure mentioned 
in 5.2.3.19.
Reactants: 3-(Dipropylcarbamoyl)benzoic acid (66) (249 mg, 1 mmol), EDAC (147 
mg, 1 mmol), HOBt (162 mg, 1.2 mmol), Et3N (278 PL, 2 mmol), L-tyrosinol (200 
mg, 1.2 mmol), CH2Cl2 (5 mL).
Yield: 342 mg, 86% 
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1H NMR (DMSO, 300 MHz): G = 7.67 (s, 1H; H-2), 7.30 (d, 3J = 7.7 Hz, 1H; H-4), 
7.22 (t, 3J = 7.7 Hz, 1H; H-5), 7.10 (d, 3J = 7.7 Hz, 1H; H-6), 6.90 (d, 3J = 8.4 Hz, 
2H; H-19/23), 6.56 (d, 3J = 8.4 Hz, 2H; H-20/22), 4.16–4.03 (m, 1H; H-15), 3.81–
3.62 (m, 1H; H-16), 3.60–3.49 (m, 1H; H-16), 3.35 (t, 3J = 7.7 Hz, 2H; H-8), 3.05 (t, 
3J = 7.7 Hz, 2H; H-11), 2.93–2.70 (m, 2H; H-17), 1.62 (sext, 3J = 7.6 Hz, 2H; H-9), 
1.43 (sext, 3J = 7.6 Hz, 2H; H-12), 1.00 (t, 3J = 7.7 Hz, 3H; H-10), 0.91 (t, 3J = 7.7 
Hz, 3H; H-13) ppm. 
13C NMR (DMSO, 75 MHz): G = 171.4 (C-7), 167.5 (C-14), 155.3 (C-21), 136.9 
(C-1), 134.1 (C-3), 130.3 (C-6), 129.3 (C-18), 128.9 (C-19), 128.2 (C-23), 127.3 (C-
5), 127.0 (C-4), 124.6 (C-2), 116.0 (C-20), 115.7 (C-22), 63.5 (C-16), 53.9 (C-15), 
46.9 (C-8), 46.8 (C-11), 39.4 (C-17), 21.9 (C-9), 20.8 (C-12), 11.5 (C-10), 11.1(C-
13) ppm.  
MS (EI): m/z = 398 [M]+.
5.2.3.24. (S)-5-(Benzyloxy)-N1-(1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl)-N3,
N3-dipropylisophthalamide (91)  
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The title compound was synthesized by following same general procedure mentioned 
in 5.2.3.19.
Reactants: 3-(dipropylcarbamoyl)-5-(benzyloxy)benzoic acid (84) (355 mg, 1 
mmol), EDAC (147 mg, 1 mmol), HOBt (162 mg, 1.2 mmol), Et3N (278 PL, 2 
mmol), L-tyrosinol (200 mg, 1.2 mmol), CH2Cl2 (5 mL).
Yield: 449 mg, 89%
1H NMR (DMSO, 300 MHz): G = 7.71 (s, 1H; H-2), 7.58 (br s, 1H; NH), 7.25–7.10 
(m, 7H; H-4/6/9-13), 6.90 (d, 3J = 8.4 Hz, 2H; H-23/24), 6.56 (d, 3J = 8.4 Hz, 2H; H-
27/29), 4.97 (s, 2H; H-7), 4.10–4.07 (m, 1H; H-22), 3.54–3.46 (m, 2H; H-23), 3.28 
(t, 3J = 7.7 Hz, 2H; H-15), 2.95 (t, 3J = 7.7 Hz, 2H; H-18), 2.77–2.72 (m, 1H; H-24), 
2.59–2.55 (m, 1H; H-24), 2.54 (br s, 1H; OH), 1.48 (sext, 3J = 7.6 Hz, 2H; H-16), 
1.31 (sext, 3J = 7.6 Hz, 2H; H-19), 0.91 (t, 3J = 7.7 Hz, 3H; H-17), 0.77 (t, 3J = 7.7 
Hz, 3H; H-20) ppm. 
13C NMR (DMSO, 75 MHz): G = 173.9 (C-14), 170.1 (C-21), 161.3 (C-5), 158.0 
(C-28), 140.6 (C-8), 139.1 (C-1), 132.4 (C-3), 131.6 (C-25), 130.7 (C-26), 130.2(C-
30), 129.7(C-10), 129.5 (C-12), 128.7 (C-11), 127.7 (C-9), 127.6 (C-13), 119.6 (C-
2), 118.0 (C-27), 117.3 (C-29), 117.0 (C-6), 114.6 (C-4), 72.4 (C-7), 65.4 (C-23), 
56.4 (C-22), 49.8 (C-15), 49.5 (C-18), 38.1 (C-24), 23.9 (C-16), 22.8 (C-19), 12.8 
(C-17), 12.4 (C-20) ppm.
MS (EI): m/z = 504 [M]+.
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5.2.3.25. (S)-N1-(1-(4-(Benzyloxy)phenyl)-3-hydroxypropan-2-yl)-N3,N3-
dipropylisophthalamide (92) 
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K2CO3 (276 mg, 2 mmol) was added to a stirred solution of (S)-N1-(1-hydroxy-3-(4-
hydroxyphenyl)propan-2-yl)-N3,N3-dipropylisophthalamide (90) (398, 1 mmol) and 
benzyl bromide (342 mg, 2 mmol) in DMF (10 mL), and the solution was stirred at 
room temperature for 3 h. After completion of reaction, the unsoluble residue was 
removed by filtration. The crude product was dissolved in chloroform (300 mL), 
washed with water, dried over anhydrous Na2SO4 and the solvent removed under 
reduced pressure. Re-crystalisation from ethyl acetate (30 mL) yielded the desired 
product.
Yield: 449 mg, 92% 
1H NMR (DMSO, 300 MHz): G = 7.71 (s, 1H; H-2), 7.58 (br s, 1H; NH), 7.42–7.10 
(m, 12H; H-4-6/19/20/22/23/26-30), 4.95 (s, 2H; H-24), 4.22–4.19 (m, 1H; H-15), 
3.65–3.50 (m, 2H; H-16), 3.39 (t, 3J = 7.7 Hz, 2H; H-8), 3.08 (t, 3J = 7.7 Hz, 2H; H-
11), 2.85–2.82 (m, 2H; H-17), 2.54 (br s, 1H; OH), 1.67 (sext, 3J = 7.6 Hz, 2H; H-9), 
1.47 (sext, 3J = 7.6 Hz, 2H; H-12), 1.01 (t, 3J = 7.7 Hz, 3H; H-10), 0.91 (t, 3J = 7.7 
Hz, 3H; H-13) ppm. 
13C NMR (DMSO, 75 MHz): G = 171.5 (C-7), 167.6 (C-14), 157.5 (C-21), 137.0 
(C-25), 135.3 (C-1), 134.0 (C-3), 130.4 (C-6), 130.3 (C-18), 129.4 (C-19), 129.2 (C-
23), 129.0 (C-29), 128.8(C-27), 128.6 (C-5), 128.3 (C-4), 128.0 (C-27), 127.6(C-30), 
125.1 (C-26), 124.0 (C-2), 115.0 (C-20),114.9 (C-22), 70.1 (C-24), 63.3 (C-16), 53.6 
(C-15), 49.8 (C-8), 49.5 (C-11), 36.1 (C-17), 21.9 (C-9), 20.8 (C-12), 11.5 (C-10), 
11.1 (C-13) ppm.  
MS (EI): m/z = 488 [M]+.
5.2.3.26. (S)-5-(Benzyloxy)-N1-(1-(4-(benzyloxy)phenyl)-3-hydroxypropan-2-yl)-
N3,N3-dipropylisophthalamide (93)
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The title compound was synthesized by following same general procedure mentioned 
in 5.2.3.25.
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Reactants: (S)-5-(benzyloxy)-N1-(1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl)-
N3,N3-dipropylisophthalamide (91) (504, 1 mmol), K2CO3 (276 mg, 2 mmol), benzyl 
bromide (342 mg, 2 mmol), DMF (10 mL).
Yield: 564 mg, 95% 
1H NMR (DMSO, 300 MHz): G = 7.71 (s, 1H; H-2), 7.58 (br s, 1H; NH), 7.56 (s, 
2H; H-4/6), 7.25–7.07 (m, 10H; H-9-13/33-37), 6.99 (d, 3J = 8.4 Hz, 2H; H-26/30), 
6.55 (d, 3J = 8.4 Hz, 2H; H-27/29), 4.80 (s, 2H; H-7), 4.68 (s, 2H; H-31), 4.10–4.07 
(m, 1H; H-22), 3.54–3.46 (m, 2H; H-23), 3.28 (t, 3J = 7.7 Hz, 2H; H-15), 2.90 (t, 3J =
7.7 Hz, 2H; H-18), 2.77–2.72 (m, 1H; H-24), 2.59–2.55 (m, 1H; H-24), 2.54 (br s, 
1H; OH), 1.48 (sext, 3J = 7.6 Hz, 2H; H-16), 1.35 (sext, 3J = 7.6 Hz, 2H, H-19), 0.91 
(t, 3J = 7.7 Hz, 3H; H-17), 0.77 (t, 3J = 7.7 Hz, 3H; H-20) ppm. 
13C NMR (DMSO, 75 MHz): G = 171.1 (C-14), 168.1 (C-21), 160.3 (C-5), 158.0 
(C-28), 140.7 (C-8), 140.6 (C-32), 136.3(C-1), 135.4 (C-3), 130.6 (C-25), 130.1 (C-
10), 129.9 (C-12), 129.8 (C-34), 129.6 (C-36), 129.4 (C-26), 129.0 (C-30), 128.7 (C-
11), 128.5 (C-37), 127.7 (C-9), 127.5 (C-13), 127.4 (C-33), 127.3 (C-37), 117.6 (C-
3), 114.8 (C-6), 114.1 (C-27), 114.0 (C-29), 112.3 (C-4), 70.9 (C-7), 65.8 (C-23), 
54.9 (C-22), 49.8 (C-15), 49.5 (C-18), 39.2 (C-24), 21.9(C-16), 21.8 (C-19), 11.8(C-
17), 11.4 (C-20) ppm.  
MS (EI): m/z = 594 [M]+.
5.2.3.27. N1-((S)-2-(4-(Benzyloxy)phenyl)-1-formylethyl)-N3,N3-
dipropylisophthalamide (94) 
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The title compound was synthesized by following same general procedure mentioned 
in 5.2.3.21. and immediately used for next reaction after synthesis.
Reactants: (S)-N1-(1-(4-(benzyloxy)phenyl)-3-hydroxypropan-2-yl)-N3,N3-dipropyl
isophthalamide (92) (488 mg, 1 mmol), dimethyl sulfoxide (130 PL, 2.0 mmol), 
oxalyl chloride (94 PL, 1.1 mmol), Et3N (692 PL, 5 mmol), CH2Cl2 (4 mL) 
Yield: 389 mg, 80% 
1H NMR (DMSO, 300 MHz): G = 9.57 (s, 1H; H-16), 7.71 (s, 1H; H-2), 7.58 (br s, 
1H; NH), 7.42–7.10 (m, 12H; H-4-6/19/20/22/23/26-30), 4.95 (s, 2H; H-24), 4.22–
4.19 (m, 1H; H-15), 3.39 (t, 3J = 7.7 Hz, 2H; H-8), 3.08 (t, 3J = 7.7 Hz, 2H; H-11), 
2.85–2.82 (m, 2H; H-17), 2.54 (br s, 1H; OH), 1.67 (sext, 3J = 7.6 Hz, 2H; H-9), 1.47 
(sext, 3J = 7.6 Hz, 2H; H-12), 1.01 (t, 3J = 7.7 Hz, 3H; H-10), 0.91 (t, 3J = 7.7 Hz, 
3H; H-13) ppm. 
13C NMR (DMSO, 75 MHz): G = 199.4 (C-16), 171.5 (C-7), 167.6 (C-14), 157.5 
(C-21), 137.0 (C-25), 135.3 (C-1), 134.0 (C-3), 130.4 (C-6), 130.3 (C-18), 129.4 (C-
19), 129.2 (C-23), 129.0 (C-29), 128.8(C-27), 128.6 (C-5), 128.3 (C-4), 128.0 (C-
27), 127.6(C-30), 125.1 (C-26), 124.0 (C-2), 115.0 (C-20),114.9 (C-22), 70.1 (C-24), 
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68.2 (C-15), 49.8 (C-8), 49.5 (C-11), 34.1 (C-17), 21.9 (C-9), 20.8 (C-12), 11.5 (C-
10), 11.1 (C-13) ppm.  
MS (EI): m/z = 486 [M]+.
5.2.3.28. 5-(Benzyloxy)-N1-((S)-2-(4-(benzyloxy)phenyl)-1-formylethyl)-N3,N3-
dipropylbenzene-1,3-diamide (95) 
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The title compound was synthesized by following same general procedure mentioned 
in 5.2.3.21. and immediately used for next reaction after synthesis.
Reactants: (S)-5-(benzyloxy)-N1-(1-(4-(benzyloxy)phenyl)-3-hydroxypropan-2-yl)-
N3,N3-dipropylisophthalamide (93) (594 mg, 1 mmol), dimethyl sulfoxide (130 PL,
2.0 mmol), oxalyl chloride (94 PL, 1.1 mmol), Et3N (692 PL, 5 mmol), CH2Cl2 (4 
mL)
Yield: 47 mg, 78% 
1H NMR (DMSO, 300 MHz): G = 9.91 (s, 1H; H-23), 7.71 (s, 1H; H-2), 7.56 (br s, 
1H; NH), 7.54 (s, 2H; H-4/6), 7.25–7.08 (m, 10H; H9-13/33-37), 6.97 (d, 3J = 8.4 
Hz, 2H; H-26/30), 6.56 (d, 3J = 8.4 Hz, 2H; H-27/29), 5.04 (s, 2H; H-7), 4.94 (s, 2H; 
H-31), 4.07–3.99 (m, 1H; H-22), 3.28 (t, 3J = 7.7 Hz, 2H; H-15), 2.90 (t, 3J = 7.7 Hz, 
2H; H-18), 2.77–2.72 (m, 1H; H-24), 2.59–2.55 (m, 1H; H-24), 1.59 (sext, 3J = 7.6 
Hz, 2H; H-16), 1.37 (sext, 3J = 7.6 Hz, 2H, H-19), 1.01 (t, 3J = 7.7 Hz, 3H; H-17), 
0.91 (t, 3J = 7.7 Hz, 3H; H-20) ppm. 
13C NMR (DMSO, 75 MHz): G = 200.1 (C-23), 168.9 (C-14), 167.3(C-21), 158.0 
(C-28), 141.0 (C-8), 136.3 (C-1), 135.0 (C-3), 130.9 (C-10), 130.8 (C-12), 130.7 (C-
34), 130.6 (C-36), 129.9 (C-26), 129.6 (C-30), 129.4 (C-11), 129.0 (C-35), 128.7 (C-
9), 128.6 (C-13), 128.5 (C-33), 128.4 (C-37), 117.1 (C-2), 114.8 (C-6), 114.7 (C-27), 
114.6 (C-29), 112.7(C-4), 70.9 (C-7), 68.2 (C-22), 49.8 (C-15), 49.5 (C-18), 34.2 (C-
24), 21.8 (C-16), 21.7 (C-19), 11.7 (C-17), 11.0 (C-20) ppm.
MS (EI): m/z = 592 [M]+.
5.2.3.29. (S)-N1-(4-(Benzylamino)-3-hydroxy-4-oxo-1-phenylbutan-2-yl)-N3,N3-
dipropylisophthalamide (96)
The title compound was synthesized by following same general procedure mentioned 
in 5.2.2.12.
Reactants: Aldehyde (50 mg, 0.13 mmol), benzylisonitrile (23 μL, 0.195 mmol), 
TFA (20 μL, 0.29 mmol), CH2Cl2 (2 mL). 
Crude Yield: 0.064 g, 94.5% 
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dr[%]= 50:50 (determined by 1H NMR spectroscopic analysis of crude reaction 
mixture). 
Two diastereomers (96a) and (96b) were separated by flash column chromatography 
on silica gel using ethyl acetate/hexane (30:70) as gradient systems. 
5.2.3.29.1. Compound (96a) 
N
O
N
H
O
OH
N
H
O
1
6
5
4
3
210
9
8
7
13
12
11
17
16
1514
18 21
23
22
19 20
24
25
29
30
31
26 28
27
Yield: 32 mg, 50% 
Rf: 0.48 (ethylacetate:hexane = 1:2) 
Mp: 145–149 °C. 
1H NMR (CDCl3, 300 MHz): G = 8.14 (s, 1H; H-2), 7.58 (d, 3J = 7.7 Hz, 2H; H-
4/6), 7.47–7.46 (m, 1H; H-5), 7.33–7.13 (m, 10H; H-18-22/27-31), 4.75 (s, 2H; 
H25), 4.42 (d, 3J = 6.4 Hz, 1H; H23), 4.28–4.20 (m, 1H; H-15), 3.55 (t, 3J = 7.7 Hz, 
2H; H-8), 3.45–3.40 (m, 1H; H-16), 3.38–3.31 (m, 1H; H-16), 3.18 (t, 3J = 7.7 Hz, 
2H; H-11), 1.65–1.55 (m, 2H; H-9), 1.50–1.40 (m, 2H; H-12), 1.19 (t, 3J = 7.7 Hz, 
3H; H-10), 1.11 (t, 3J = 7.7 Hz, 3H; H-13).
13C NMR (CDCl3, 75 MHz): G = 172.9 (C-24), 168.6 (C-7), 167.3 (C-14), 138.1 (C-
26), 137.7 (C-17), 135.1 (C-1), 134.0 (C-3), 129.8 (C-6), 129.4 (C-19), 129.3 (C-21), 
129.2 (C-5), 128.8 (C-30), 128.6 (C-4), 128.1 (C-28), 127.9 (C-18), 127.6 (C-22), 
127.0 (C-27), 126.7 (C-31), 126.8 (C-29), 125.1(C-20), 124.4 (C-2), 68.6 (C-23), 
53.6 (C-15), 49.6 (C-8), 49.7 (C-11), 42.3 (C-25), 35.0 (C-16), 22.8 (C-9), 22.7 (C-
12), 11.6 (C-10), 11.1 (C-13) ppm.  
MS (EI): m/z = 515 [M]+.
5.2.3.29.2. Compound (96b) 
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Yield: 32 mg, 50% 
1H NMR (CDCl3, 300 MHz): G = 8.10 (s, 1H; H-2), 7.48 (d, 3J = 7.7 Hz, 2H; H-
4/6), 7.42–7.38 (m, 1H; H-5), 7.33–7.09 (m, 10H; H-18-22/27-31), 4.78 (s, 2H; H-
25), 4.44 (m, 1H; H-15), 4.25 (d, 3J = 6.4 Hz, 1H; H-23), 3.40–3.30 (m, 2H; H-8), 
3.38–3.31 (m, 1H; H-16), 3.25–3.18 (m, 1H; H-16), 3.15–3.05 (m, 2H; H-11), 1.65–
1.55 (m, 2H; H-9), 1.50–1.40 (m, 2H; H-12), 1.11 (t, 3J = 7.7 Hz, 3H; H-10), 0.65 (t, 
3J = 7.7 Hz, 3H; H-13).
Experimental 112
13C NMR (CDCl3, 75 MHz): G = 170.6 (C-24), 169.0 (C-7), 161.0 (C-14), 138.1 (C-
26), 137.7 (C-17), 135.1 (C-1), 134.0 (C-3), 130.1 (C-6), 129.3 (C-19), 128.9 (C-21), 
128.7 (C-5), 128.6 (C-30), 128.5 (C-4), 128.4 (C-28), 127.9 (C-18), 127.4 (C-22), 
127.0 (C-27), 126.9 (C-31), 125.5 (C-29), 125.0 (C-20), 124.4 (C-2), 56.9 (C-23), 
50.8 (C-15), 46.7 (C-8), 46.6 (C-11), 43.1 (C-25), 35.8 (C-16), 22.0 (C-9), 20.8 (C-
12), 11.6 (C-10), 11.2 (C-13) ppm.  
MS (EI): m/z = 515 [M]+.
5.2.3.30. (S)-N1-(4-(Cyclohexylamino)-3-hydroxy-4-oxo-1-phenylbutan-2-yl)-N3,
N3-dipropylisophthalamide (97) 
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The title compound was synthesized by following same general procedure mentioned 
in 5.2.2.12.
Reactants: Aldehyde (50 mg, 0.13 mmol), cyclohexylisonitrile (24 μL, 0.195 
mmol), TFA (20 μL, 0.29 mmol), CH2Cl2 (2 mL). 
dr[%]= 80:20 (determined by 1H NMR spectroscopic analysis of crude reaction 
mixture). 
Only one diastereoisomer 97 was separated by flash column chromatography on 
silica gel using ethyl acetate/hexane (30:70) as gradient systems. 
Yield: 0.06 g, 90% 
1H NMR (CDCl3, 300 MHz): G = 7.77 (s, 1H; H-2), 7.55–7.44 (m, 3H; H-4-6), 
7.25–7.15 (m, 2H; H-19/21), 7.05–6.89 (m, 3H; H-18/20/22), 4.36–3.33 (m, 1H; H-
15), 3.88–3.82 (d, 3J = 6.4 Hz, 1H; H-23), 3.54–3.52 (m, 1H; H-25), 3.42 (t, 3J = 7.7 
Hz, 2H; H-8), 3.20 (t, 3J = 7.7 Hz, 2H; H-11), 2.69–2.60 (m, 1H; H-16), 2.77–2.70 
(m, 1H; H-16), 1.65–1.55 (m, 2H; H-9), 1.50–1.40 (m, 2H; H-12), 1.35–1.20 (m, 4H; 
H-26/30), 1.20–0.95 (m, 6H; H-27-29), 0.75 (t, 3J = 7.7 Hz, 3H; H-10), 0.53 (t, 3J = 
7.7 Hz, 3H; H-13) ppm.  
13C NMR (CDCl3, 75 MHz): G = 171.8 (C-24), 168.9 (C-7), 167.3 (C-14), 138.1 (C-
17), 135.1 (C-1), 134.0 (C-3), 130.0 (C-6), 129.0 (C-19), 129.3 (C-21), 129.2 (C-5), 
128.8 (C-4), 128.6 (C-18), 128.1 (C-22), 126.2 (C-20), 124.9 (C-2), 68.1 (C-23), 50.8 
(C-15), 49.2 (C-8), 48.9 (C-11), 47.5 (C-25), 35.0 (C-16), 33.9 (C-26), 33.8 (C-30), 
32.4 (C-28), 25.1 (C-27), 24.5 (C-29), 21.6 (C-9), 20.4 (C-12), 10.9 (C-10), 10.5 (C-
13) ppm.  
MS (ESI): m/z = 530.4 [M+Na]+.
5.2.3.31. (S)-N1-(3-Hydroxy-4-oxo-1-phenyl-4-(pyridin-3-ylmethylamino)butan-
2-yl)-N3,N3-dipropylisophthalamide (98) 
The title compound was synthesized by following same general procedure mentioned 
in 5.2.2.12.
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Reactants: Aldehyde (50 mg, 0.13 mmol), 3-picolylisonitrile (24 μL, 0.195 mmol), 
TFA (20 μL, 0.29 mmol), CH2Cl2 (2 mL). 
Crude yield: 0.062 g, 92% 
dr[%]= 60:40 (determined by 1H NMR spectroscopic analysis of crude reaction 
mixture). 
Two diastereomers (98a) and (98b) were separated by flash column chromatography 
on silica gel using ethyl acetate/hexane (30:70) as gradient systems. 
5.2.3.31.1. Compound (98a)
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Yield: 37 mg, 60% 
1H NMR (CDCl3, 300 MHz): G = 8.44 (s, 1H; H-30), 8.38 (s, 1H; H-2), 8.30 (d, 3J =
7.0 Hz, 1H; H-29), 8.21 (d, 3J = 7.0 Hz, 2H; H-4/6), 7.88 (d, 3J = 7.0 Hz, 1H; H-27), 
7.55-7.44 (m, 2H; H-5/28), 7.18–7.08 (m, 4H; H-18,19/21,22), 6.92–6.88 (m, 1H; H-
20), 5.22 (s, 2H; H-25), 4.42 (d, 3J = 5.8 Hz, 1H; H-23), 4.28–4.20 (m, 1H; H-15), 
3.50 (t, 3J = 7.7 Hz, 2H; H-8), 3.42 (t, 3J = 7.7 Hz, 2H; H-11), 3.10–3.00 (m, 2H; H-
16), 1.60–1.50 (m, 2H; H-9), 1.44–1.39 (m, 2H; H-12), 0.92 (t, 3J = 7.7 Hz, 3H; H-
10), 0.65 (t, 3J = 7.7 Hz, 3H; H-13). 
13C NMR (CDCl3, 75 MHz): G = 172.3 (C-24), 168.7 (C-7), 167.3 (C-14), 150.2 (C-
30), 147.4 (C-29), 138.1 (C-17), 135.6 (C-26), 135.2 (C-1), 134.4 (C-27), 134.1 (C-
3), 130.0 (C-6), 128.6 (C-19), 128.5 (C-21), 128.4 (C-5), 128.3 (C-4), 128.2 (C-18), 
128.0 (C-22), 127.7 (C-20), 126.9 (C-2), 123.6, (C-28), 67.6 (C-23), 51.0 (C-15), 
46.4 (C-8), 46.3 (C-11), 44.4 (C-25), 35.0 (C-16), 21.9 (C-9), 20.8 (C-12), 11.6 (C-
10), 11.1 (C-13) ppm.  
MS (EI): m/z = 516 [M]+.
5.2.3.31.2. Compound (98b) 
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Yield: 25 mg, 40% 
1H NMR (CDCl3, 300 MHz): G = 8.44 (s, 1H; H-30), 8.38 (s, 1H; H-2), 8.30 (d, 3J =
7.0 Hz, 1H; H-29), 8.21 (d, 3J = 7.0 Hz, 2H; H-4/6), 7.88 (d, 3J = 7.0 Hz, 1H; H-27), 
7.55–7.44 (m, 2H; H-5/28), 7.18–7.08 (m, 4H; H-18,19/21,22), 6.92–6.88 (m, 1H; H-
20), 4.60–4.40 (m, 1H; H-15), 4.38 (d, 3J = 6.1 Hz, 1H; H-23), 4.15 (s, 2H; H-25), 
3.55 (t, 3J = 7.7 Hz, 2H; H-8), 3.37 (t, 3J = 7.7 Hz, 2H; H-11), 3.10–2.92 (m, 2H; H-
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16), 1.65–1.50 (m, 2H; H-9), 1.44–1.39 (m, 2H; H-12), 0.89 (t, 3J = 7.7 Hz, 3H; H-
10), 0.65 (t, 3J = 7.7 Hz, 3H; H-13) ppm. 
13C NMR (CDCl3, 75 MHz): G = 173.3 (C-24), 168.7 (C-7), 167.3 (C-14), 149.2 (C-
30), 148.4 (C-29), 137.6 (C-17), 135.2 (C-26), 134.4 (C-1), 134.1 (C-27), 129.7 (C-
3), 128.7 (C-6), 128.5 (C-19), 128.4 (C-21), 128.3 (C-5), 128.2 (C-4), 128.0 (C-18), 
127.7 (C-22), 126.6 (C-20), 125.6 (C-2), 123.4 (C-28), 67.6 (C-23), 51.0 (C-15), 46.4 
(C-8), 46.3 (C-11, 36.0 (C-25), 35.0 (C-16), 21.9 (C-9), 20.8 (C-12), 11.6 (C-10), 
11.1 (C-13) ppm.  
MS (EI): m/z = 516 [M]+.
5.2.3.32. (S)-N1-(3-Hydroxy-4-(2-morpholinoethylamino)-4-oxo-1-phenylbutan-
2-yl)-N3,N3-dipropylisophthalamide (99) 
The title compound was synthesized by following same general procedure mentioned 
in 5.2.2.12.
Reactants: Aldehyde (50 mg, 0.13 mmol), 2-morpholino ethyl isocyanide (27 μL, 
0.195 mmol), TFA (20 μL, 0.29 mmol) CH2Cl2 (2 mL). 
Crude yield: 0.060 g, 84.0% 
dr[%]= 50:50 (determined by 1H NMR spectroscopic analysis of crude reaction 
mixture). 
Two diastereomers (99a) and (99b) were separated by flash column chromatography 
on silica gel using ethyl acetate/hexane (30:70) as gradient systems. 
5.2.3.32.1. Compound (99a) 
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Yield: 30 mg, 50% 
1H NMR (CDCl3, 300 MHz): G = 7.77 (s, 1H; H-2), 7.58 (d, 3J = 7.7 Hz, 2H; H-
4/6), 7.47–7.46 (m, 1H; H-5), 7.25–7.15 (m, 2H; H-19/21), 7.05–6.89 (m, 3H; H-
18/20/22), 4.65 (d, 3J = 6.1 Hz, 1H; H-23), 4.36–3.33 (m, 1H; H-15), 3.99 (t, 3J = 5.5 
Hz, 4H; H-28/29), 3.56 (t, 3J = 7.7 Hz, 2H; H-8), 3.40 (t, 3J = 7.7 Hz, 2H; H-11), 
3.30 (t, 3J = 7.0 Hz, 2H; H-25), 2.77–2.70 (m, 1H; H-16), 2.69–2.63 (m, 1H; H-16), 
2.62 (t, 3J = 7.0 Hz, 2H; H-26), 2.26 (t, 3J = 5.5 Hz, 2H; H-27/30), 1.65–1.50 (m, 2H; 
H-9), 1.44–1.39 (m, 2H; H-12), 0.89 (t, 3J = 7.7 Hz, 3H; H-10), 0.65 (t, 3J = 7.7 Hz, 
3H; H-13) ppm. 
13C NMR (CDCl3, 75 MHz): G = 179.1 (C-24), 168.8 (C-7), 167.1 (C-14), 137.8 (C-
16), 135.1 (C-1), 134.0 (C-3), 130.0 (C-6), 129.0 (C-19), 128.9 (C-21), 128.8 (C-5), 
128.7 (C-18), 128.6 (C-22), 128.1 (C-4), 126.2 (C-20), 124.9 (C-2), 68.6 (C-23), 66.1 
(C-28), 65.9 (C-29), 53.6 (C-27), 53.5 (C-30), 53.4 (C-26), 50.8 (C-15), 49.2 (C-8), 
48.9 (C-11), 37.5 (C-25), 36.6 (C-16), 22.7 (C-9), 22.0 (C-12), 11.6 (C-10), 11.1 (C-
13) ppm.  
MS (EI): m/z = 538.4 [M]+.
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5.2.3.32.2. Compound (99b) 
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Yield: 30 mg, 50% 
1H NMR (CDCl3, 300 MHz): G = 8.21 (s, 1H; H-2), 8.00 (d, 3J = 7.7 Hz, 2H; H-
4/6), 7.69–7.63 (m, 1H; H-5), 7.40–7.33 (m, 2H; H-19/21), 7.25–7.14 (m, 3H; H-
18/20/22), 4.42 (d, 3J = 5.9 Hz, 1H; H-23), 4.36–3.33 (m, 1H; H-15), 4.00 (t, 3J = 6.8 
Hz, 4H; H-28/29), 3.56 (t, 3J = 7.7 Hz, 2H; H-8), 3.40 (t, 3J = 7.7 Hz, 2H; H-11), 
3.30 (t, 3J = 7.0 Hz, 2H; H-25), 2.75–2.70 (m, 1H; H-16), 2.69–2.63 (m, 1H; H-16), 
2.59 (t, 3J = 7.0 Hz, 2H; H-26), 2.26 (t, 3J = 5.5 Hz, 4H; H-27/30), 1.55–1.45 (m, 2H; 
H-9), 1.39–1.30 (m, 2H; H-12), 0.89 (t, 3J = 7.7 Hz, 3H; H-10), 0.65 (t, 3J = 7.7 Hz, 
3H; H-13) ppm.  
13C NMR (CDCl3, 75 MHz): G = 178.1 (C-24), 167.8 (C-7), 164.1 (C-14), 138.8 (C-
16), 136.1 (C-1), 134.1 (C-3), 130.5 (C-6), 129.2 (C-19), 128.9 (C-21), 128.8 (C-5), 
128.7 (C-18), 128.6 (C-22), 128.1 (C-4), 126.2 (C-20), 124.9 (C-2), 68.6 (C-23), 66.1 
(C-28), 66.0 (C-29), 53.5 (C-27), 53.4 (C-30), 52.9 (C-26), 51.0 (C-15), 49.2 (C-8), 
49.1 (C-11), 37.5 (C-25), 36.6 (C-16), 22.4 (C-9), 22.0 (C-12), 11.4 (C-10), 11.0 (C-
13) ppm.  
MS (EI): m/z = 538.4 [M]+.
5.2.3.33. (S)-3-Cyano-N-(1-hydroxy-3-phenylpropan-2-yl)benzamide (101) 
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The title compound was synthesized by following same general procedure mentioned 
in 5.2.3.19.
Reactants: 3-cyano benzoic acid (196 mg, 1 mmol), EDAC (147 mg, 1 mmol), 
HOBt (162 mg, 1.2 mmol), Et3N (278 PL, 2 mmol), L-phenyl alaninol (181 mg, 1.2 
mmol), CH2Cl2 (5 mL).
Yield: 247 mg, 88% 
1H NMR (CD3OD, 300 MHz): G = 8.23–8.05 (m, 2H; H-2/4), 8.04 (br s, 1H; NH), 
7.78–7.53 (m, 2H; H-5/6), 7.27–7.13 (m, 5H; H-14-18), 4.35–4.27 (m, 1H; H-10), 
3.68–3.57 (m, 2H; H-11), 3.01–2.94 (m, 1H; H-11), 2.90–2.83 (m, 2H; H-12) ppm  
13C NMR (CDCl3, 75 MHz): G = 167.3 (C-9), 139.6 (C-13), 137.3 (C-6), 135.9 (C-
3), 132.4 (C-4), 130.9 (C-2), 130.5 (C-5), 129.7 (C-15), 129.6 (C-17), 128.4 (C-14), 
128.2 (C-18), 126.0 (C-16), 119.4 (C-7), 113.8 (C-1), 64.2 (C-11), 55.1 (C-10), 38.2 
(C-12) ppm.  
MS (EI): m/z = 280 [M]+.
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5.2.3.34. (S)-3-Cyano-N-(1-oxo-3-phenylpropan-2-yl)benzamide (102) 
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The title compound was prepared by following general procedure 5.2.2.1. and 
immediately used for next reaction after synthesis.
Reactants: (S)-3-cyano-N-(1-hydroxy-3-phenylpropan-2-yl)benzamide (280 mg, 1 
mmol), IBX (342 mg, 1.2 mmol), DMSO (2 mL). 
Yield: 250 mg, 90% 
1H NMR (CD3OD, 300 MHz): G = 9.60 (s, 1H; H-11), 8.14–8.06 (m, 2H; H-2/4), 
8.04 (br s, 1H, NH), 7.78–7.53 (m, 2H; H-5/6), 7.26–7.03 (m, 5H; H-14-18), 4.32–
4.24 (m, 1H; H-10), 3.01–2.98 (m, 2H; H-12) ppm  
13C NMR (CDCl3, 75 MHz): G = 199.1 (C-11), 168.4 (C-9), 139.6 (C-13), 135.9 (C-
6), 132.0 (C-3), 130.8 (C-4), 129.7 (C-2), 129.5 (C-5), 128.7 (C-15), 128.5 (C-17), 
127.6 (C-14), 127.5 (C-18), 126.0 (C-16), 118.4 (C-7), 115.8 (C-1), 68.2 (C-10), 34.2 
(C-12) ppm.  
MS (EI): m/z = 278 [M]+.
5.2.3.35. (S)-4-(2-(3-Cyanobenzamido)-3-hydroxypropyl)phenyl 3-
cyanobenzoate (103) 
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The title compound was synthesized by following same general procedure mentioned 
in 5.2.3.19.
Reactants: 3-cyano benzoic acid (196 mg, 1 mmol), EDAC (147 mg, 1 mmol), 
HOBt (162 mg, 1.2 mmol), Et3N (278 PL, 2 mmol), L-tyrosinol (200 mg, 1.2 mmol), 
CH2Cl2 (5 mL).
Yield: 315 mg, 74% 
1H NMR (CD3OD, 300 MHz): G = 8.39–8.36 (m, 2H; H-21/25), 8.02–7.87 (m, 6H; 
H-2/4/5/6/22/23), 7.73–7.07 (m, 4H; H-14/15/17/18), 4.27–4.25 (m, 1H; H-10), 
3.65–3.55 (m, 2H; H-11), 3.01–2.99 (m, 1H; H-12), 2.96–2.82 (m, 1H; H-12) ppm  
13C NMR (CDCl3, 75 MHz): G = 167.8 (C-9), 165.1 (C-19), 150.5 (C-16), 138.1 (C-
23), 137.9 (C-6), 137.2 (C-21), 136.0 (C-3), 133.5 (C-13), 132.5 (C-25), 131.8 (C-4), 
131.0 (C-20), 130.9 (C-2), 129.0 (C-5), 128.0 (C-22), 128.6 (C-14), 128.4 (C-18), 
122.0 (C-17), 119.4 (C-26), 119.0 (C-7), 113.0 (C-1), 112.8 (C-24), 64.1 (C-11), 54.9 
(C-10), 37.5 (C-12) ppm.
MS (EI): m/z = 425 [M]+.
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5.2.4. Synthesis of Norstatine Derivatives by Sequential 
Organocatalytic D-Amination and Passerini Reaction 
5.2.4.1. General procedure for the synthesis of D-amino aldehydes 
11.5 mg L-proline (0.10 mmol) was suspended in 2.5 mL CH2Cl2 followed by the 
addition of of the aldehyde (1.50 mmol) and of azodicarboxylates (1.00 mmol). The 
reaction mixture was stirred at room temperature until the yellow color of 
azodicarboxylate disappeared. The reaction mixture was filtered through a Solid 
Phase Extraction (SPE) C18 Column. This column was washed with methanol and 
acetonitrile. The solvent and the excess aldehyde were removed in vacuo.
5.2.4.2. General procedure for the Passerini reactions
Trifluoroacetic acid (2.0 equiv.) was added dropwise to a cooled solution (10 to 0 
°C) of aldehyde (1.0 equiv.) 109138, isonitrile (1.21.5 equiv.) and pyridine (4.0 
equiv.) in CH2Cl2 under a nitrogen atmosphere while maintaining the temperature at 
 0 °C. After 0.52 h at 0 °C, the bath was removed and the reaction was stirred at 
ambient temperature for 12 to 72 h. In cases with sluggish reactions, the solution was 
concentrated slowly to afford viscous oil, which was further stirred until TLC or 
HPLC analysis revealed complete consumption of the D-N-protected-amino 
aldehyde. The resultant slurry was dissolved in ethyl acetate and washed with 
distilled water, and brine. The organic layer was dried over anhydrous Na2SO4,
filtered, and concentrated. The crude product was either recrystallized or purified by 
flash column chromatography on silica gel using ethyl acetate/hexane or 
dichloromethane/methanol gradient systems. Pure products 139168 (Scheme 3.11)
were obtained as either nearly colorless solids or as colorless to pale yellow viscous 
oils.
5.2.4.3. 3-(3,5-Difluorophenyl)propanal (108f) 
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1-bromo-3,5-difluoro benzene (1.15 mL, 10 mmol), allyl alcohol (1.02 mL, 15 
mmol), Na2CO3 (2.12 g, 20 mmol), TEBACl (2.28 g, 10 mmol), powdered 4 Å 
sieves (10 g), and Pd(OAc)2 (0.112 g, 0.5 mmol, 5 mol%) were added to dry, 
degassed DMF (60 mL) under a nitrogen atmosphere and heated to 60 °C for 6 h. 
The reaction mixture was cooled to room temperature, diluted with EtOAc (100 mL) 
and filtered through a pad of Celite. The solvents were removed under reduced 
pressure. The residue was taken up in Et2O (200 mL) and filtered again through 
Celite. The filtrate was washed with H2O (4 u 50 mL), dried (anhydrous MgSO4) and 
condensed to give a pale yellow liquid which after chromatography on silica gel (6% 
EtOAc in hexane) gave 3-(3,5-difluorophenyl)propanal 108f (Scheme 3.12) as a 
light yellow liquid. 
Yield: 1.54 g, 89% 
1H NMR (CDCl3, 300 MHz): G = 9.73 (s, 1H; H-9), 6.66 (d, 3J = 7.0 Hz, 2H; H-2/4), 
6.50 (t, 3J = 7.0 Hz, 1H; H-6), 2.85 (t, 3J = 7.0 Hz, 1H; H-7), 2.72 (t, 3J = 7.0 Hz, 2H; 
H-8) ppm. 
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13C NMR (CDCl3, 75 MHz): G = 200.5 (C-9), 164.8 (C-1), 164.7 (C-5), 144.4 (C-3), 
111.4 (C-2), 111.3 (C-4), 101.5 (C-6), 44.6 (C-8), 31.6 (C-7) ppm.  
MS (EI): m/z = 170 [M]+.
5.2.4.4. (R)-Di-tert-butyl 1-(4-(cyclohexylamino)-3-hydroxy-4-oxobutan-2-
yl)hydrazine-1,2-dicarboxylate (139a) 
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The title compound was synthesized by following general procedure 5.2.2.11.
Reactants: Aldehyde (288 mg, 1.0 mmol), cyclohexylisonitrile (184 μL, 1.5 mmol), 
pyridine (321 μL, 4 mmol), TFA (154 μL, 2.0 mmol), CH2Cl2 (5 mL). 
Yield: 332 mg, 80% 
1H NMR (CDCl3, 300 MHz): G = 7.22 (br s, 1H; NH), 6.74 (br s, 1H; NH), 4.23 (d, 
3J = 6.3 Hz, 1H; H-2), 4.104.03 (m, 1H; H-1), 3.683.50 (m, 1H; H-4), 1.851.73
(m, 2H; H-5/9), 1.681.56 (m, 2H; H-5´/9´), 1.551.35 (m, 6H; H-6-8), 1.40 (s, 18H; 
H-13-15/18-20), 1.30 (d, 3J = 6.3 Hz, 3H; H-10) ppm.  
13C NMR (CDCl3, 75 MHz): G = 171.6 (C-3), 156.4 (C-11), 156.1 (C-16), 79.9 (C-
12), 79.8 (C-17), 65.5 (C-2), 51.0 (C-1), 47.6 (C-4), 33.8 (C-5), 33.7 (C-9), 28.2 (C-
7), 22.9 (C-6), 22.8 (C-8), 8.9 (C-10) ppm. 
MS (EI): m/z = 415 [M]+.
5.2.4.5. (R)-Di-tert-butyl 1-(3-hydroxy-4-(2-morpholinoethylamino)-4-oxobutan-
2-yl)hydrazine-1,2-dicarboxylate (140a) 
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The title compound was synthesized by following general procedure 5.2.2.11.
Reactants: Aldehyde (288 mg, 1.0 mmol), 2-morpholinoethyl isocyanide (207 μL, 
1.5 mmol), pyridine (321 μL, 4 mmol), TFA (154 μL, 2.0 mmol), CH2Cl2 (5 mL).
Yield: 322 mg, 80% 
1H NMR (CDCl3, 300 MHz): G = 7.26 (br s, 1H; NH), 4.76 (d, 3J = 6.8 Hz, 1H; H-
2), 4.104.07 (m, 1H; H-1), 3.69 (t, 3J = 7.0 Hz, 4H; H-7/8), 3.34 (t, 3J = 7.0 Hz, 2H; 
H-4), 2.67 (t, 3J = 7.0 Hz, 2H; H-5), 2.33 (t, 3J = 7.0 Hz, 2H; H-6/9 ), 1.40 (s, 18H; 
H-13-15/18-20), 1.25 (d, 3J = 6.8 Hz, 3H; H-10) ppm.  
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13C NMR (CDCl3, 75 MHz): G = 172.1 (C-3), 156.6 (C-11), 156.4 (C-17), 79.5 (C-
12), 79.4 (C-17), 66.9 (C-2), 54.3 (C-5), 51.2 (C-1), 28.5 (C-13), 28.4 (C-14), 28.3 
(C-15), 28.2 (C-18), 28.1 (C-19), 28.0 (C-20), 8.9 (C-10) ppm.
MS (EI): m/z = 445 [M]+.
5.2.4.6. (R)-Diisopropyl 1-(4-(cyclohexylamino)-3-hydroxy-4-oxobutan-2-
yl)hydrazine-1,2-dicarboxylate (141) 
The title compound was synthesized by following general procedure 5.2.2.11.
Reactants: Aldehyde (260 mg, 1.0 mmol), cyclohexylisonitrile (184 μL, 1.5 mmol), 
pyridine (321 μL, 4 mmol), TFA (154 μL, 2.0 mmol), CH2Cl2 (5 mL). 
Two diastereomers 141a and 141b were separated by flash column chromatography 
on silica gel using ethyl acetate/hexane (30:70) as gradient. 
5.2.4.6.1. (R)-Diisopropyl 1-(4-(cyclohexylamino)-3-hydroxy-4-oxobutan-2-
yl)hydrazine-1,2-dicarboxylate (141a)  
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Yield: 108 mg, 40% 
1H NMR (CDCl3, 300 MHz): G = 8.02 (br s, 1H; NH), 6.80 (br s, 1H; NH), 
4.934.77 (m, 2H; H-12/16), 4.70 (d, 3J = 6.3 Hz, 1H; H-2), 4.154.00 (m, 1H; H-1), 
3.543.52 (m, 1H; H-4), 1.851.73 (m, 2H; H-5/9), 1.681.56 (m, 2H; H-5´/9´), 
1.551.35 (m, 6H; H-6-8), 1.24 (d, 3J = 6.3 Hz, 12H; H-13-14/17-18),1.20 (d, 3J = 
6.3 Hz, 3H; H-10) ppm.  
13C NMR (CDCl3, 75 MHz): G = 171.7 (C-3), 156.6 (C-11), 156.5 (C-15), 66.9 (C-
12), 66.8 (C-16), 51.0 (C-1), 47.6 (C-4), 33.8 (C-5), 33.7 (C-9), 28.2 (C-7), 23.6 (C-
13), 23.5 (C-14), 23.4 (C-17), 23.3 (C-18), 22.9 (C-6), 22.8 (C-8), 9.9 (C-10) ppm.  
MS (EI): m/z = 387 [M]+.
5.2.4.6.2. (R)-Diisopropyl 1-(4-(cyclohexylamino)-3-hydroxy-4-oxobutan-2-
yl)hydrazine-1,2-dicarboxylate (141b)  
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Yield: 162 mg, 60% 
1H NMR (CDCl3, 300 MHz): G = 8.00 (br s, 1H; NH), 6.78 (br s, 1H; NH), 4.85 (d, 
3J = 6.3 Hz, 1H; H-2), 4.594.30 (m, 2H; H-12/16), 4.053.93 (m, 1H; H-1), 
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3.713.56 (m, 1H; H-4), 1.901.64 (m, 4H; H-5/9), 1.601.56 (m, 6H; H-6-8), 1.27 
(d, 3J = 6.3 Hz, 12H; H-13-14/17-18), 1.20 (d, 3J = 6.3 Hz, 3H; H-10) ppm.
13C NMR (CDCl3, 75 MHz): G = 172.7 (C-3), 156.6 (C-11), 156.5 (C-15), 66.9 (C-
12), 66.5 (C-16), 51.4 (C-1), 47.7 (C-4), 33.8 (C-5), 33.7 (C-9), 28.2 (C-7), 23.6 (C-
13), 23.5 (C-14), 23.4 (C-17), 23.1 (C-18), 22.5 (C-6), 22.4 (C-8), 12.0 (C-10) ppm.  
MS (EI): m/z = 387 [M]+.
5.2.4.7. (R)-Diisopropyl 1-(3-hydroxy-4-(2-morpholinoethylamino)-4-oxobutan-
2-yl)hydrazine-1,2-dicarboxylate (142a)
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The title compound was synthesized by following general procedure 5.2.2.11.
Reactants: Aldehyde (260 mg, 1.0 mmol), 2-morpholinoethyl isocyanide (207 μL, 
1.5 mmol), pyridine (321 μL, 4 mmol), TFA (154 μL, 2.0 mmol), CH2Cl2 (5 mL). 
Yield: 167 mg, 80% 
1H NMR (CDCl3, 300 MHz): G = 7.26 (br s, 1H; NH), 6.55 (br s, 1H; NH), 4.78 (d, 
3J = 6.8 Hz, 1H; H-2), 4.34 (m, 2H; H-12/16), 4.154.07 (m, 1H; H-1), 3.63 (t, 3J = 
7.0 Hz, 4H; H-7/8), 3.34 (t, 3J = 7.0 Hz, 2H; H-4), 2.42 (t, 3J = 7.0 Hz, 2H; H-5), 
2.33 (t, 3J = 7.0 Hz, 4H; H-6/9), 1.35 (d, 3J = 6.8 Hz, 12H; H-13-14/17-18), 1.30 (d,
3J = 6.8 Hz, 12H; H-10) ppm.  
13C NMR (CDCl3, 75 MHz): G = 171.8 (C-3), 156.6 (C-15), 156.1 (C-11), 71.2 (C-
16), 71.0 (C-12), 66.9 (C-7), 66.8 (C-8), 54.3 (C-6), 54.2 (C-9), 53.1 (C-5), 51.2 (C-
1), 37.8 (C-4), 23.7 (C-13), 23.6 (C-14), 23.5 (C-17), 23.3 (C-18), 8.9 (C-10) ppm.  
MS (EI): m/z = 418 [M]+.
5.2.4.8. (R)-Di-tert-butyl 1-(1-(cyclohexylamino)-2-hydroxy-1-oxopentan-3-
yl)hydrazine-1,2-dicarboxylate (144a)  
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The title compound was synthesized by following general procedure 5.2.2.11.
Reactants: Aldehyde (302 mg, 1.0 mmol), cyclohexylisonitrile (184 μL, 1.5 mmol), 
pyridine (321 μL, 4 mmol), TFA (154 μL, 2.0 mmol), CH2Cl2 (5 mL).
Yield: 274 mg, 80% 
1H NMR (CDCl3, 300 MHz): G = 7.99 (br s, 1H; NH), 6.20 (br s, 1H; NH), 4.78 (d, 
3J = 6.3 Hz, 1H; H-2), 4.154.00 (m, 1H; 1), 3.723.60 (m, 1H; H-4), 1.701.53 (m, 
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4H; H-5/9), 1.551.52 (m, 2H; H-10), 1.461.43 (m, 6H; H-6-8), 1.40 (s, 18H; H-14-
16/19-21), 0.96 (t, 3J = 6.3 Hz, 3H; H-11) ppm.  
13C NMR (CDCl3, 75 MHz): G = 171.9 (C-3), 156.6 (C-17), 156.1 (C-12), 79.5 (C-
13), 79.2 (C-18), 63.0 (C-2), 56.7 (C-1), 47.6 (C-4), 33.8 (C-5), 33.6 (C-9), 28.6(C-
14), 28.5 (C-15), 28.4 (C-16), 28.3 (C-19), 28.2 (C-20), 28.1(C-21), 28.0 (C-7), 22.9 
(C-6), 22.6 (C-8), 15.7 (C-10), 9.9 (C-11) ppm.  
MS (EI): m/z = 429 [M]+.
5.2.4.9. (R)-Di-tert-butyl 1-(2-hydroxy-1-(2-morpholinoethylamino)-1-
oxopentan-3-yl)hydrazine-1,2-dicarboxylate (145a)
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The title compound was synthesized by following general procedure 5.2.2.11.
Reactants: Aldehyde (302 mg, 1.0 mmol), 2-morpholinoethyl isocyanide (207 μL, 
1.5 mmol), pyridine (321 μL, 4 mmol), TFA (154 μL, 2.0 mmol), CH2Cl2 (5 mL). 
Yield: 356 mg, 80% 
1H NMR (CDCl3, 300 MHz): G = 8.07 (br s, 1H; NH), 4.75 (d, 3J = 6.7 Hz, 1H; H-
2), 4.104.07 (m, 1H; H-1), 3.67 (t, 3J = 7.0 Hz, 4H; H-7/8), 3.33 (t, 3J = 7.0 Hz, 2H; 
H-4), 2.59 (t, 3J = 7.0 Hz, 2H; H-5), 2.31 (t, 3J = 7.0 Hz, 4H; H-6/9), 1.551.51 (m, 
2H; H-10), 1.40 (s, 18H; H-14-16/19-21), 0.96 (t, 3J = 6.8 Hz, 2H; H-11) ppm.  
13C NMR (CDCl3, 75 MHz): G = 172.4 (C-3), 156.4 (C-17), 156.1 (C-12), 79.5 (C-
13), 79.4 (C-18), 66.8 (C-7), 66.7 (C-8), 62.7 (C-2), 56.6 (C-1), 53.7 (C-6), 53.6 (C-
9), 53.3 (C-5), 28.6 (C-14), 28.5 (C-15), 28.4 (C-16), 28.3 (C-19), 28.2 (C-20), 28.1 
(C-21), 14.9 (C-10), 8.9 (C-11) ppm.  
MS (EI): m/z = 461 [M]+.
5.2.4.10. (R)-Diisopropyl 1-(2-hydroxy-1-(2-morpholinoethylamino)-1-
oxopentan-3-yl)hydrazine-1,2-dicarboxylate (146a) 
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The title compound was synthesized by following general procedure 5.2.2.11.
Reactants: Aldehyde (274 mg, 1.0 mmol), 2-morpholinoethyl isocyanide (207 μL, 
1.5 mmol), pyridine (321 μL, 4 mmol), TFA (154 μL, 2.0 mmol), CH2Cl2 (5 mL). 
Yield: 189 mg, 60% 
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1H NMR (CDCl3, 300 MHz): G = 7.58 (br s, 1H; NH), 7.43 (br s, 1H; NH), 4.92 (d, 
3J = 6.7 Hz, 1H; H-2), 4.314.29 (m, 2H; H-13/17), 4.084.01 (m, 1H; H-1), 3.65 (t,
3J = 7.0 Hz, 4H; H-7/8), 3.32 (t, 3J = 7.0 Hz, 2H; H-4), 2.45 (t, 3J = 7.0 Hz, 2H; H-5), 
2.31 (t, 3J = 7.0 Hz, 4H; H-5), 1.881.86 (m, 2H; H-10), 1.20 (d, 3J = 6.8 Hz, 12H; 
H-14-15/18-19), 0.89 (t, 3J = 6.8 Hz, 2H; H-11) ppm.  
13C NMR (CDCl3, 75 MHz): G = 172.3 (C-3), 156.6 (C-12), 156.3 (C-16), 77.5 (C-
7), 77.4 (C-8), 66.6 (C-13), 66.3 (C-17), 65.9 (C-2), 57.1 (C-1), 53.4 (C-6), 53.2 (C-
9), 51.2 (C-5), 35.6 (C-4), 23.9 (C-14), 23.8 (C-15), 23.4 (C-18), 23.1 (C-19), 14.2 
(C-10), 8.9 (C-11) ppm.  
MS (EI): m/z = 432 [M]+.
5.2.4.11. (R)-Diisopropyl 1-(1-(cyclohexylamino)-2-hydroxy-1-oxopentan-3-
yl)hydrazine-1,2-dicarboxylate (147a)
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The title compound was synthesized by following general procedure 5.2.2.11.
Reactants: Aldehyde (274 mg, 1.0 mmol), cyclohexylisonitrile (184 μL, 1.5 mmol), 
pyridine (321 μL, 4 mmol), TFA (154 μL, 2.0 mmol), CH2Cl2 (5 mL). 
Yield: 234 mg, 80%
1H NMR (CDCl3, 300 MHz): G = 8.01 (br s, 1H; NH), 6.80 (br s, 1H; NH), 4.90 (d, 
3J = 6.3 Hz, 1H; H-2), 4.154.00 (m, 2H; H-13/17), 3.723.60 (m, 1H; H-1), 
3.543.50 (m, 1H; H-4), 1.701.53 (m, 4H; H-5/9), 1.551.52 (m, 2H; H-10), 
1.501.43 (m, 6H; H-6-8), 1.35 (d, 3J = 6.3 Hz, 12H; H-14-15/18-19), 1.0 (t, 3J = 6.3 
Hz, 3H; H-11) ppm.  
13C NMR (CDCl3, 75 MHz): G = 171.8 (C-3), 156.6 (C-16), 156.1 (C-12), 70.1 (C-
13), 66.9 (C-17), 63.0 (C-2), 56.7 (C-1), 47.6 (C-4), 32.8 (C-5), 32.6 (C-9), 28.2 (C-
7), 23.6 (C-14), 23.5 (C-14), 23.4 (C-15), 23.3 (C-18), 23.1 (C-19), 22.9 (C-6), 22.8 
(C-8), 14.2 (C-10), 10.9 (C-11) ppm.  
MS (EI): m/z = 401 [M]+.
5.2.4.12. (R)-Di-tert-butyl 1-(1-(cyclohexylamino)-2-hydroxy-4-methyl-1-
oxopentan-3-yl)hydrazine-1,2-dicarboxylate (149a) 
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The title compound was synthesized by following general procedure 5.2.2.11.
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Reactants: Aldehyde (316 mg, 1.0 mmol), cyclohexylisonitrile (184 μL, 1.5 mmol), 
pyridine (321 μL, 4 mmol), TFA (154 μL, 2.0 mmol), CH2Cl2 (5 mL). 
Yield: 286 mg, 80% 
1H NMR (CDCl3, 300 MHz): G = 7.39 (br s, 1H; NH), 6.21 (br s, 1H; NH), 4.31 (d, 
3J = 6.3 Hz, 1H; H-2), 4.003.89 (m, 1H; H-1), 3.683.63 (m, 1H; H-4), 2.452.32
(m, 1H; H-10), 1.851.75 (m, 4H; 5/9), 1.681.56 (m, 6H; H-6-8), 1.40 (s, 18H; H-
15-17/19-21), 0.89 (d, 3J = 6.3 Hz, 6H; H-11-12) ppm.  
13C NMR (CDCl3, 75 MHz): G = 171.9 (C-3), 156.6 (C-18), 156.1 (C-13), 79.2 (C-
14), 79.1 (C-19), 61.5 (C-1), 60.5 (C-2), 47.7 (C-4), 33.7 (C-5), 33.6 (C-9), 28.6 (C-
15), 28.5 (C-16), 28.4 (C-17), 28.3 (C-20), 28.2 (C-21), 28.1 (C-22), 27.9 (C-7), 22.9 
(C-6), 22.8 (C-8), 21.6 (C-10), 17.3 (C-11), 17.2 (C-12) ppm.
MS (EI): m/z = 443 [M]+.
5.2.4.13. (R)-Di-tert-butyl 1-(2-hydroxy-4-methyl-1-(2-morpholinoethylamino)-1-
oxopentan-3-yl)hydrazine-1,2-dicarboxylate (150a) 
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The title compound was synthesized by following general procedure 5.2.2.11.
Reactants: Aldehyde (316 mg, 1.0 mmol), 2-morpholinoethyl isocyanide (207 μL, 
1.5 mmol), pyridine (321 μL, 4 mmol), TFA (154 μL, 2.0 mmol), CH2Cl2 (5 mL).
Yield: 259 mg, 70% 
1H NMR (CDCl3, 300 MHz): G = 7.91 (br s, 1H; NH), 4.75 (d, 3J = 6.7 Hz, 1H; H-
2), 4.904.05 (m, 1H; H-1), 3.66 (t, 3J = 7.0 Hz, 4H; H-7/8), 3.33 (t, 3J = 7.0 Hz, 2H; 
H-4), 2.59 (t, 3J = 7.0 Hz, 2H; H-5), 2.452.42 (m, 1H; H-10), 2.31 (t, 3J = 7.0 Hz, 
4H; H-6/9), 1.40 (s, 9H; H-15-17), 1.39 (s, 9H; H-20-22), 1.01 (d, 3J = 6.8 Hz, 6H; 
H-11-12) ppm.
13C NMR (CDCl3, 75 MHz): G = 172.4 (C-3), 156.4 (C-18), 156.1 (C-13), 79.5 (C-
14), 79.4 (C-19), 66.8 (C-7), 66.7 (C-8), 61.3 (C-1), 60.3 (C-2), 53.6 (C-6), 53.4 (C-
9), 51.2 (C-5), 37.9 (C-4), 28.7 (C-15), 28.6 (C-16), 28.5 (C-17), 28.4 (C-20), 28.3 
(C-21), 28.1 (C-22), 21.6 (C-10), 17.6 (C-11), 17.5 (C-12) ppm.  
MS (EI): m/z = 475 [M]+.
5.2.4.14. (R)-Diisopropyl 1-(1-(cyclohexylamino)-2-hydroxy-4-methyl-1-
oxopentan-3-yl)hydrazine-1,2-dicarboxylate (151) 
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The title compound was synthesized by following general procedure 5.2.2.11.
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Reactants: Aldehyde (288 mg, 1.0 mmol), cyclohexylisonitrile (184 μL, 1.5 mmol), 
pyridine (321 μL, 4 mmol), TFA (154 μL, 2.0 mmol), CH2Cl2 (5 mL). 
Two diastereomers 151a and 151b were separated by flash column chromatography 
on silica gel using ethyl acetate/hexane (30:70) as gradient systems. 
5.2.4.14.1. Diisopropyl 1-((2R,3R)-1-(cyclohexylamino)-2-hydroxy-4-methyl-1-
oxopentan-3-yl)hydrazine-1,2-dicarboxylate (151a)
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Yield: 116 mg, 40%
1H NMR (CDCl3, 300 MHz): G = 7.40 (br s, 1H; NH), 6.36 (br s, 1H; NH), 
4.984.80 (m, 2H; H-14/18), 4.35 (d, 3J = 6.3 Hz, 1H; H-2), 4.194.10 (m, 1H; H-1), 
3.753.60 (m, 1H; H-4), 2.322.22 (m, 1H; H-10), 1.851.75 (m, 4H; H-5/9), 
1.681.56 (m, 6H; H-6-8), 1.24 (d, 3J = 6.3 Hz, 12H; H-15-16/19-20), 0.89 (d, 3J = 
6.3 Hz, 6H; H-11-12) ppm.
13C NMR (CDCl3, 75 MHz): G = 170.9 (C-3), 156.5 (C-17), 156.1 (C-13), 65.7 (C-
14), 65.4 (C-18), 61.3 (C-1), 60.4 (C-2), 48.2 (C-4), 33.8 (C-5), 33.7 (C-9), 28.8 (C-
7), 23.6 (C-15), 23.5 (C-16), 23.4 (C-19), 23.3 (C-20), 22.9 (C-6), 22.8 (C-8), 22.0 
(C-10), 19.3 (C-11), 19.0 (C-12) ppm.
MS (EI): m/z = 415 [M]+.
5.2.4.14.2. Diisopropyl 1-((2S,3R)-1-(cyclohexylamino)-2-hydroxy-4-methyl-1-
oxopentan-3-yl)hydrazine-1,2-dicarboxylate (151b)
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Yield: 174 mg, 60% 
1H NMR (CDCl3, 300 MHz): G = 7.20 (br s, 1H; NH), 6.67 (br s, 1H; NH), 
4.954.75 (m, 2H; H-14/18), 4.25 (d, 3J = 6.3 Hz, 1H; H-2), 3.783.61 (m, 2H; H-
1/4), 2.402.29 (m, 1H; H-10), 1.881.72 (m, 4H; H-5/9), 1.681.52 (m, 6H; H-6-8), 
1.15 (d, 3J = 6.3 Hz, 12H; 15-16/19-20), 0.98 (d, 3J = 6.3 Hz, 6H; H-11-12) ppm.  
13C NMR (CDCl3, 75 MHz): G = 170.9 (C-3), 156.5 (C-17), 156.1 (C-13), 65.7 (C-
14), 65.4 (C-18), 61.3 (C-1), 60.4 (C-2), 48.2 (C-4), 33.8 (C-5), 33.7 (C-9), 28.8 (C-
7), 23.6 (C-15), 23.5 (C-16), 23.4 (C-19), 23.1 (C-20), 22.8 (C-6), 22.7 (C-8), 22.1 
(C-10), 17.9 (C-11), 17.3 (C-12) ppm.
MS (EI): m/z = 415 [M]+.
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X-ray Crystallographic data: The crystals used in the diffraction analysis were 
grown from a solution of 151b in DMF:MeOH (1:9). The crystal structure of 151b
was solved by single-crystal X-ray diffraction using the Xcalibur system from 
Oxford Diffraction, equipped with CCD detector and the Enhance X-ray source 
option. The software packages SHELXS[224] and SHELXL[225] were used for 
structure solution and refinement as included in X-STEP32.[226] Diffraction data were 
collected on a Xcalibur diffractometer using graphite-monochromated (Mo-K() 
radiation (( = 0.71073 Å). Unit cell parameters were determined by least-squares 
refinement of the optimized setting angles of 634 reflections in the range 1.32 ( ( ( 
13.28°. A total of 9809 reflections, 3020 unique (Rint = 0.170), were collected up to 
( = 23.89°.
Crystal data: C20H37N3O6, M = 415.52, colorless prismatic crystal (0.850 x 0.040 x 
0.025 mm), Orthorhombic, space group P 2 21 21, a = 5.590(2), b = 19.615(6) and c 
= 21.646(5) Å, (V = 2373.4(12) Å3, Z = 4, Dc = 1.163 g cm–3, F(000) = 904 , μ(Mo-
KD) = 0.085 mm–1). CCDC 610628 contains the supplementary crystallographic data 
for this paper. These data can be obtained free of charge from The Cambridge 
Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.
5.2.4.15. (R)-Diisopropyl 1-(2-hydroxy-4-methyl-1-(2-morpholinoethylamino)-1-
oxopentan-3-yl)hydrazine-1,2-dicarboxylate (152a)
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The title compound was synthesized by following general procedure 5.2.2.11.
Reactants: Aldehyde (288 mg, 1.0 mmol), 2-morpholinoethyl isocyanide (207 μL, 
1.5 mmol), pyridine (321 μL, 4 mmol), TFA (154 μL, 2.0 mmol), CH2Cl2 (5 mL). 
Yield: 192 mg, 60% 
1H NMR (CDCl3, 300 MHz): G = 8.11 (br s, 1H; NH), 4.954.70 (m, 3H; H-
2/14/18), 3.773.58 (m, 5H; H-1/7/8), 3.40 (d, 3J = 7.0 Hz, 2H; H-4), 2.682.55 (m, 
2H; H-5), 2.502.37 (m, 5H; H-6/9/10), 1.301.10 (m, 12H; H-15-16/19-20), 
0.900.77 (m, 6H; H-11-12) ppm.  
13C NMR (CDCl3, 75 MHz): G = 172.4 (C-3), 156.4 (C-17), 156.1 (C-13), 66.9 (C-
14), 66.8 (C-18), 61.3 (C-1), 60.3 (C-2), 53.6 (C-6), 53.4 (C-9), 51.2 (C-5), 37.9 (C-
4), 23.5 (C-15), 23.4 (C-16), 23.2 (C-19), 23.1 (C-20), 21.6 (C-10), 17.6 (C-11), 17.5 
(C-12) ppm.  
MS (EI): m/z = 446 [M]+.
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5.2.4.16. (R)-Di-tert-butyl 1-(3-(cyclohexylamino)-2-hydroxy-3-oxo-1-
phenylpropyl)hydrazine-1,2-dicarboxylate (154a) 
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The title compound was synthesized by following general procedure 5.2.2.11.
Reactants: Aldehyde (350 mg, 1.0 mmol), cyclohexylisonitrile (184 μL, 1.5 mmol), 
pyridine (321 μL, 4 mmol), TFA (154 μL, 2.0 mmol), CH2Cl2 (5 mL). 
Yield: 373 mg, 80% 
1H NMR (DMSO, 300 MHz): G = 8.60 (br s, 1H; NH), 7.66 (br s, 1H; NH), 
7.597.43 (m, 5H; H-11-15), 5.17 (d, 3J = 6.3 Hz; 2H, H-1-2) 3.543.40 (m, 1H; H-
4), 1.931.45 (m, 10H; H-5-9), 1.40 (s, 9H; H-18-20), 1.26 (s, 9H; H-23-25) ppm.  
13C NMR (CDCl3, 75 MHz): G = 170.3 (C-3), 156.6 (C-21), 156.4 (C-16), 141.6 (C-
10), 129.5 (C-12), 128.5 (C-14), 128.4 (C-11), 128.2 (C-15), 127.0 (C-13), 82.5 (C-
2), 77.6 (C-17), 77.1 (C-21), 48.6 (C-1), 47.6 (C-4), 32.8 (C-5), 32.6 (C-9), 28.6 (C-
18-20), 28.3 (C-23-25), 25.7 (C-7), 24.9 (C-6), 24.7 (C-8) ppm.  
MS (EI): m/z = 478 [M]+.
5.2.4.17. (R)-Di-tert-butyl 1-(2-hydroxy-3-(2-morpholinoethylamino)-3-oxo-1-
phenylpropyl)hydrazine-1,2-dicarboxylate (155a) 
N
N
O
O
O
O
H
OH
O
N
H
N
O
1
65
432
9
8
7
12
11
10
14
13
15
17 16
19
18
21
22
23
20
25
24
The title compound was synthesized by following general procedure 5.2.2.11.
Reactants: Aldehyde (351 1.0 mmol), 2-morpholinoethyl isocyanide (207 μL, 1.5 
mmol), pyridine (321 μL, 4 mmol), TFA (154 μL, 2.0 mmol), CH2Cl2 (5 mL). 
Yield: 292 mg, 80% 
1H NMR (CDCl3, 300 MHz): G = 8.05 (br s, 1H; NH), 7.457.12 (m, 5H; H-11-15), 
5.17 (d, 3J = 7.0 Hz, 2H; H-1-2), 3.653.50 (m, 4H; H-7/8), 3.333.28 (m, 2H; H-4), 
2.602.44 (m, 2H; H-5), 2.402.30 (m, 4H; H-6/9), 1.40 (s, 18H; H-18-20/23-25) 
ppm.  
13C NMR (CDCl3, 75 MHz): G = 172.4 (C-3), 156.4 (C-21), 156.2 (C-16), 143.5 (C-
10), 128.5 (C-12), 128.4 (C-14), 127.0 (C-11), 126.8 (C-15), 126.0 (C-13), 80.4 (C-
2), 79.5 (C-17), 79.4 (C-22), 66.8 (C-7), 66.7 (C-8), 57.7 (C-1), 53.6 (C-6), 53.2 (C-
9), 51.2 (C-5), 37.7 (C-4), 28.6 (C-18-20), 28.3 (C-23-25) ppm.  
Experimental 127
MS (EI): m/z = 508 [M]+.
5.2.4.18. (R)-Di-tert-butyl 1-(4-(cyclohexylamino)-3-hydroxy-4-oxo-1-
phenylbutan-2-yl)hydrazine-1,2-dicarboxylate (159a)  
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The title compound was synthesized by following general procedure 5.2.2.11.
Reactants: Aldehyde (364 mg, 1.0 mmol), cyclohexylisonitrile (184 μL, 1.5 mmol), 
pyridine (321 μL, 4 mmol), TFA (154 μL, 2.0 mmol), CH2Cl2 (5 mL). 
Yield: 239 mg, 80% 
1H NMR (CDCl3, 300 MHz): G = 7.99 (br s, 1H; NH), 7.237.12 (m, 5H; H-12-16), 
5.90 (br s, 1H; NH), 4.604.45 (m, 1H; H-1), 4.05 (d, 3J = 6.3 Hz, 1H; H-2), 
3.753.65 (m, 1H; H-4), 3.153.00 (m, 1H; H-10), 2.872.79 (m, 1H; H-10´), 
1.901.45 (m, 10H; H-5-9), 1.40 (s, 9H; H-19-21), 1.26 (s, 9H; H-24-26) ppm.  
13C NMR (CDCl3, 75 MHz): G = 170.4 (C-3), 155.6 (C-22), 156.2 (C-17), 138.5 (C-
11), 128.9 (C-13), 128.7 (C-15), 127.9 (C-12), 127.7 (C-16), 126.7 (C-14), 83.0 (C-
18), 82.6 (C-23), 62.7 (C-2), 56.6 (C-1), 48.6 (C-4), 33.2 (C-5), 32.8 (C-9, 32.6 (C-
10), 28.6 (C-19-21), 28.3 (C-22), 28.2 (C-24-26), 27.9 (C-7), 24.9 (C-6), 24.6 (C-8) 
ppm.  
MS (EI): m/z = 491 [M]+.
5.2.4.19. (S)-Di-tert-butyl 1-(4-(benzylamino)-3-hydroxy-4-oxobutan-2-
yl)hydrazine-1,2-dicarboxylate (162)  
The title compound was synthesized by following general procedure 5.2.2.11.
Reactants: Aldehyde (288 mg, 1.0 mmol), benzylisonitrile (181 μL, 1.5 mmol), 
pyridine (321 μL, 4 mmol), TFA (154 μL, 2.0 mmol), CH2Cl2 (5 mL). 
Two diastereomers 162a and 162b were separated by flash column chromatography 
on silica gel using ethyl acetate/hexane (30:70) as gradient systems.
5.2.4.19.1. (S)-Di-tert-butyl 1-(4-(benzylamino)-3-hydroxy-4-oxobutan-2-
yl)hydrazine-1,2-dicarboxylate (162a) 
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Yield: 182 mg, 50% 
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1H NMR (CDCl3, 300 MHz): G = 7.67 (br s, 1H; NH), 7.277.18 (m, 5H; H-6-10), 
6.39 (br s, 1H; NH), 4.75 (d, 3J = 6.8 Hz, 1H; H-2), 4.45 (s, 2H; H-4), 4.304.20 (m, 
1H; H-1), 1.40 (s, 18H; H-14-16/19-21), 1.25 (d, 3J = 6.8 Hz, 3H; H-11) ppm.  
13C NMR (CDCl3, 75 MHz): G = 171.4 (C-3), 156.6 (C-17), 156.1 (C-12), 141.6 (C-
5), 128.7 (C-7), 128.6 (C-9), 127.8 (C-6), 127.4 (C-10), 126.8 (C-8), 82.0 (C-13), 
81.9 (C-18), 58.0 (C-2), 51.2 (C-1), 42.2 (C-4), 27.8 (C-14-16), 27.5 (C-19-21), 11.6 
(C-11) ppm.  
MS (EI): m/z = 423.5 [M]+.
5.2.4.19.2. (S)-Di-tert-butyl 1-(4-(benzylamino)-3-hydroxy-4-oxobutan-2-
yl)hydrazine-1,2-dicarboxylate (162b) 
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Yield: 182 mg, 50% 
1H NMR (CDCl3, 300 MHz): G = 7.67 (br s, 1H; NH), 7.267.15 (m, 5H; H-6-10), 
6.41 (br s, 1H; NH), 5.20 (s, 2H; H-4), 4.504.42 (m, 1H; H-1), 4.22 (d, 3J = 6.2 Hz, 
1H; H-2), 1.39 (s, 18H; H-14-16/19-21), 1.25 (d, 3J = 6.8 Hz, 3H; H-11) ppm.  
13C NMR (CDCl3, 75 MHz): G = 171.4 (C-3), 156.6 (C-17), 156.1 (C-12), 141.6 (C-
5), 128.7 (C-7), 128.6 (C-9), 127.8 (C-6), 127.4 (C-10), 126.8 (C-8), 82.1 (C-13), 
81.9 (C-18), 58.0 (C-2), 53.5 (C-1), 43.2 (C-4), 28.2 (C-14-16), 27.7 (C-19-21), 11.6 
(C-11) ppm.  
MS (EI): m/z = 423.5 [M]+.
5.2.4.20. (S)-Di-tert-butyl 1-(1-(benzylamino)-2-hydroxy-1-oxopentan-3-
yl)hydrazine-1,2-dicarboxylate (163)  
The title compound was synthesized by following general procedure 5.2.2.11.
Reactants: Aldehyde (302 mg, 1.0 mmol), benzylisonitrile (181 μL, 1.5 mmol), 
pyridine (321 μL, 4 mmol), TFA (154 μL, 2.0 mmol), CH2Cl2 (5 mL). 
Two diastereomers 163a and 163b were separated by flash column chromatography 
on silica gel using ethyl acetate/hexane (30:70) as gradient systems. 
5.2.4.20.1. (S)-Di-tert-butyl 1-(1-(benzylamino)-2-hydroxy-1-oxopentan-3-
yl)hydrazine-1,2-dicarboxylate (163a) 
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Yield: 239 mg, 60% 
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1H NMR (CDCl3, 300 MHz): G = 8.23 (br s, 1H; NH), 7.207.06 (m, 5H; H-6-10), 
6.10 (br s, 1H; NH), 4.60 (d, 3J = 6.8 Hz, 1H; H-2), 4.45 (s, 2H; H-4), 4.154.00 (m, 
1H; H-1), 1.601.54 (m, 2H; H-11), 1.40 (s, 18H; H-15-17/20-22), 0.96 (t, 3J = 7.7 
Hz, 3H; H-12) ppm.  
13C NMR (CDCl3, 75 MHz): G = 172.4 (C-3), 156.6 (C-18), 156.1 (C-13), 141.6 (C-
5), 128.4 (C-7), 127.9 (C-9), 127.5 (C-6), 127.3 (C-10), 126.8 (C-8), 77.5 (C-14), 
77.3 (C-19), 62.7 (C-2), 56.7 (C-1), 44.6 (C-4), 28.6 (C-15-17), 28.3 (C-20-22), 19.3 
(C-11), 11.6 (C-12) ppm.
MS (EI): m/z = 437 [M]+.
5.2.4.20.2. (S)-Di-tert-butyl 1-(1-(benzylamino)-2-hydroxy-1-oxopentan-3-
yl)hydrazine-1,2-dicarboxylate (163b) 
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Yield: 159 mg, 40% 
1H NMR (CDCl3, 300 MHz): G = 8.05 (br s, 1H; NH), 7.247.19 (m, 5H; H-6-10), 
6.23 (br s, 1H; NH), 5.22 (s, 2H; H-4), 4.45 (d, 3J = 6.8 Hz, 1H; H-2), 4.204.05 (m, 
1H; H-1), 1.621.58 (m, 2H; H-11), 1.39 (s, 18H; H-15-17/20-22), 0.89 (t, 3J = 7.7 
Hz, 3H; 12) ppm.  
13C NMR (CDCl3, 75 MHz): G = 171.8 (C-3), 156.6 (C-18), 156.1 (C-13), 141.6 (C-
5), 128.7 (C-7), 128.6 (C-9), 127.8 (C-6), 127.5 (C-10), 127.4 (C-8), 77.5 (C-14), 
77.3 (C-19), 63.5 (C-2), 56.7 (C-1), 43.6 (C-4), 28.6 (C-15-17), 28.3 (C-20-22), 19.3 
(C-11), 11.2 (C-12) ppm.
MS (EI): m/z = 437 [M]+.
5.2.4.21. (S)-Di-tert-butyl 1-(1-(benzylamino)-2-hydroxy-4-methyl-1-oxopentan-
3-yl)hydrazine-1,2-dicarboxylate (164) 
The title compound was synthesized by following general procedure 5.2.2.11.
Reactants: Aldehyde (316 mg, 1.0 mmol), benzylisonitrile (181 μL, 1.5 mmol), 
pyridine (321 μL, 4 mmol), TFA (154 μL, 2.0 mmol), CH2Cl2 (5 mL). 
Two diastereomers 164a and 164b were separated by flash column chromatography 
on silica gel using ethyl acetate/hexane (30:70) as gradient systems. 
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5.2.4.21.1. (S)-Di-tert-butyl 1-(1-(benzylamino)-2-hydroxy-4-methyl-1-
oxopentan-3-yl)hydrazine-1,2-dicarboxylate (164a) 
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Yield: 219 mg, 50%
1H NMR (CDCl3, 300 MHz): G = 7.59 (br s, 1H; NH), 7.257.14 (m, 5H; H-6-10), 
6.01 (br s, 1H; NH), 4.69 (d, 3J = 5.7 Hz, 1H; H-2), 4.59 (s, 2H; H-4), 4.32 (dd, 3J = 
8.8 Hz, 3.9 Hz, 1H; H-1), 2.582.45 (m, 1H; H-11), 1.45 (s, 18H; H-16-18/21-23), 
1.08 (d, 3J = 6.6 Hz, 3H; H-12), 0.82 (d, 3J = 6.6 Hz, 3H; H-13) ppm.  
13C NMR (CDCl3, 75 MHz): G = 169.7 (C-3), 156.6 (C-19), 156.1 (C-14), 141.6 (C-
5), 128.6 (C-7), 128.4 (C-9), 128.3 (C-6), 127.9 (C-10), 127.5 (C-8), 77.6 (C-15), 
77.2 (C-20), 65.1 (C-1), 63.2 (C-2), 44.7 (C-4), 28.6 (C-16-18), 28.3 (C-21-23), 21.1 
(C-11), 14.3 (C-12), 14.0 (C-13) ppm.
MS (EI): m/z = 451 [M]+.
5.2.4.21.2. (S)-Di-tert-butyl 1-(1-(benzylamino)-2-hydroxy-4-methyl-1-
oxopentan-3-yl)hydrazine-1,2-dicarboxylate (164b) 
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Yield: 219 mg, 50%
1H NMR (CDCl3, 300 MHz): G = 7.67 (br s, 1H; NH), 7.267.17 (m, 5H; H-6-10), 
6.25 (br s, 1H; NH), 4.44 (s, 2H; H-4), 4.37 (d, 3J = 5.5 Hz, 1H; H-2), 4.1 (dd, 3J = 
8.8 Hz, 3.9 Hz, 1H; H-1), 2.262.19 (m, 1H; H-11), 1.44 (s, 18H; H-16-18/21-23), 
0.93 (d, 3J = 6.7 Hz, 6H; H-12-13) ppm.  
13C NMR (CDCl3, 75 MHz): G = 171.9 (C-3), 155.6 (C-19), 156.1 (C-14), 141.6 (C-
5), 128.9 (C-7), 128.7 (C-9), 127.9 (C-6), 127.4 (C-10), 127.0 (C-8), 82.9 (C-15), 
82.6 (C-20), 66.2 (C-1), 60.5 (C-2), 43.4 (C-4), 28.6 (C-16-18), 28.3 (C-21-23), 20.3 
(C-11), 19.4 (C-12), 19.3 (C-13) ppm.
MS (EI): m/z = 451 [M]+.
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5.2.4.22. (S)-Di-tert-butyl 1-(3-(cyclohexylamino)-2-hydroxy-3-oxo-1-phenyl 
propyl)hydrazine-1,2-dicarboxylate (165a) 
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The title compound was synthesized by following general procedure 5.2.2.11.
Reactants: Aldehyde (350 mg, 1.0 mmol), cyclohexylisonitrile (184 μL, 1.5 mmol), 
pyridine (321 μL, 4.0 mmol), TFA (154 μL, 2.0 mmol), CH2Cl2 (5 mL). 
Yield: 309 mg, 80% 
1H NMR (CDCl3, 300 MHz): G = 8.26 (br s, 1H; NH), 7.337.19 (m, 5H; H-11-15), 
6.06 (br s, 1H; NH), 5.22 (d, 3J = 6.3 Hz, 2H; H-1/2), 3.723.65 (m, 1H; H-4), 
1.901.45 (m, 10H; H-5-9), 1.40 (s, 9H; H-18-20), 1.26 (s, 9H; H-23-25) ppm.  
13C NMR (CDCl3, 75 MHz): G= 170.4 (C-3), 156.6 (C-21), 156.1 (C-16), 141.7 (C-
10), 129.7 (C-12), 128.7 (C-14), 128.4 (C-11), 128.2 (C-15), 127.0 (C-13), 82.5 (C-
2), 77.6 (C-17), 77.1 (C-22), 57.6 (C-1), 48.6 (C-4), 32.8 (C-5), 32.6 (C-9), 28.7 (C-
18-20), 28.4 (C-23-25), 28.0 (C-7), 25.7 (C-6), 24.9 (C-8) ppm.  
MS (EI): m/z = 478 [M]+.
5.2.4.23. (S)-Di-tert-butyl 1-(3-(benzylamino)-2-hydroxy-3-oxo-1-phenylpropyl)
hydrazine-1,2-dicarboxylate (166)  
The title compound was synthesized by following general procedure 5.2.2.11.
Reactants: Aldehyde (350 mg, 1.0 mmol), benzylisonitrile (181 μL, 1.5 mmol), 
pyridine (321 μL, 4 mmol), TFA (154 μL, 2.0 mmol), CH2Cl2 (5 mL). 
Two diastereomers 166a and 166b were separated by flash column chromatography 
on silica gel using ethyl acetate/hexane (30:70) as gradient systems. 
5.2.4.23.1. (S)-Di-tert-butyl 1-(3-(benzylamino)-2-hydroxy-3-oxo-1-phenyl 
propyl)hydrazine-1,2-dicarboxylate (166a)  
N
N
O
O
O
O
H
OH
O
N
H
1
6
5432
9
8
7
12
11
10
14
1315
17
1619
18
20
21
23
22
24
26
25
Yield: 226 mg, 50% 
1H NMR (CDCl3, 300 MHz): G = 8.01 (br s, 1H; NH), 7.597.00 (m, 10H; H-6-
10/12-16), 5.99 (br s, 1H; NH), 5.22 (d, 3J = 6.3 Hz, 2H; H-1/2), 4.46 (d, 3J = 6.3 Hz, 
2H; H-4), 1.40 (s, 18H; H-19-21/24-26) ppm.  
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13C NMR (CDCl3, 75 MHz): G = 170.4 (C-3), 156.6 (C-22), 156.1 (C-17), 143.7 (C-
11), 141.6 (C-5), 129.1 (C-7), 128.7 (C-9), 128.6 (C-13), 128.5 (C-15), 128.4 (C-6), 
128.2 (C-10), 127.0 (C-12), 126.9 (C-16), 126.7 (C-8), 126.3 (C-14), 81.7 (C-2), 78.6 
(C-18), 77.1 (C-23), 57.7 (C-1), 44.6 (C-4), 28.7 (C-19-21), 28.4 (C-24-26) ppm.  
MS (EI): m/z = 485 [M]+.
5.2.4.23.2. (S)-Di-tert-butyl 1-(3-(benzylamino)-2-hydroxy-3-oxo-1-
phenylpropyl)hydrazine-1,2-dicarboxylate (166b) 
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Yield: 226 mg, 50% 
1H NMR (CDCl3, 300 MHz): G = 8.01 (br s, 1H; NH), 7.506.99 (m, 10H; H-6-
10/12-16), 5.99 (br s, 1H; NH), 5.17 (d, 3J = 6.3 Hz, 2H; H-1/2), 4.47 (d, 3J = 6.3 Hz, 
2H; H-4), 1.40 (s, 18H; H-19-21/24-26) ppm.  
13C NMR (CDCl3, 75 MHz): G = 170.4 (C-3), 156.6 (C-22), 156.1 (C-17), 143.7 (C-
11), 141.6 (C-5), 129.1 (C-7), 128.7 (C-9), 128.4 (C-13), 128.2 (C-15), 127.9 (C-6), 
127.8 (C-10), 127.0 (C-12), 126.9 (C-16), 126.3 (C-8), 81.7 (C-2), 78.6 (C-18), 77.1 
(C-23), 57.7 (C-1), 44.6 (C-4), 28.7 (C-19-21), 28.4 (C-24-26) ppm.  
MS (EI): m/z = 485 [M]+.
5.2.4.24. (S)-Di-tert-butyl 1-(4-(benzylamino)-3-hydroxy-4-oxo-1-phenylbutan-2-
yl)hydrazine-1,2-dicarboxylate (167a)  
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The title compound was synthesized by following general procedure 5.2.2.11.
Reactants: Aldehyde (364 mg, 1.0 mmol), benzylisonitrile (181 μL, 1.5 mmol), 
pyridine (321 μL, 4 mmol), TFA (154 μL, 2.0 mmol), CH2Cl2 (5 mL). 
Two diastereomers 167a and 167b were separated by flash column chromatography 
on silica gel using ethyl acetate/hexane (30:70) as gradient systems. 
Yield: 343 mg, 80% 
1H NMR (CDCl3, 300 MHz): G = 8.28 (br s, 1H; NH), 7.537.08 (m, 10H; H-6-
10/13-17), 4.57 (d, 3J = 6.3 Hz, 1H; H-2) 4.32 (s, 2H; H-4), 3.973.90 (m, 1H; H-1), 
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2.952.88 (m, 1H; H-11), 2.872.79 (m, 1H; H-11´), 1.40 (s, 9H; H-20-22), 1.26 (s, 
9H; H-25-27) ppm.  
13C NMR (CDCl3, 75 MHz): G = 172.4 (C-3), 156.6 (C-23), 156.1 (C-18), 141.7 (C-
5), 138.1 (C-12), 129.3 (C-14), 129.0 (C-16), 128.8 (C-7), 128.7 (C-9), 128.6 (C-13), 
128.5 (C-17), 127.9 (C-6), 127.8 (C-10), 127.4 (C-8), 127.0 (C-15), 83.1 (C-19), 82.6 
(C-24), 62.3 (C-2), 56.6 (C-1), 43.8 (C-4), 35.6 (C-11), 28.5 (C-20-22), 28.2 (C-25-
27) ppm.  
MS (EI): m/z = 499 [M]+.
5.2.4.25. (S)-Dibenzyl 1-(4-(benzylamino)-1-(3,5-difluorophenyl)-3-hydroxy-4-
oxobutan-2-yl)hydrazine-1,2-dicarboxylate (168a) 
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The title compound was synthesized by following general procedure 5.2.2.11.
Reactants: Aldehyde (400 mg, 1.0 mmol), benzylisonitrile (181 μL, 1.5 mmol), 
pyridine (321 μL, 4 mmol), TFA (154 μL, 2.0 mmol), CH2Cl2 (5 mL). 
Yield: 415 mg, 80%
1H NMR (CDCl3, 300 MHz): G = 8.82 (br s, 1H; NH), 7.397.33 (m, 5H; H-6-10), 
6.61 (d, 3J = 5.6 Hz, 2H; H-13/17), 6.51 (t, 3J = 5.6 Hz, 1H; H-15), 4.78 (d, 3J = 3.0 
Hz, 1H; H-2), 4.46 (s, 2H; H-4), 4.284.12 (m, 1H; H-1), 2.892.87 (m, 1H; H-11), 
2.642.62 (m, 1H; H-11´) ppm.  
13C NMR (CDCl3, 75 MHz): G = 172.3 (C-3), 164.6 (C-14), 164.3 (C-16) 156.6 (C-
23), 156.2 (C-18), 141.3 (C-5), 141.2 (C-12), 129.5 (C-7), 128.8 (C-9), 128.6 (C-6), 
127.5 (C-10), 126.6 (C-8), 110.8 (C-13), 110.5 (C-17), 102.4 (C-15), 65.8 (C-19), 
65.5 (C-24), 62.6 (C-2), 56.5 (C-1), 44.5 (C-4), 30.8 (C-11), 28.5 (C-20-22) 28.2 (C-
25-27) ppm.  
MS (EI): m/z = 603 [M]+.
5.2.4.26. General procedure for synthesis of D-amino alcohol 
11.5 mg L-proline (0.10 mmol) was suspended in 2.5 mL CH2Cl2 followed by the 
addition of the aldehyde (1.50 mmol) and azodicarboxylate (1.00 mmol). The 
reaction mixture was stirred at room temperature until the yellow color of 
azodicarboxylate had disappeared. MeOH (2.5 mL) was added followed by careful 
addition of NaBH4 (50 mg). Reaction was monitored by TLC and the solvent was 
removed in vacuo after 20 min. The aqueous phase was diluted and extracted with 
EtOAc and washed three times with 50% soln of ammonium chloride (NH4Cl). The 
organic phase was dried over anhydrous Na2SO4 and concentrated in vacuo to give 
the product 169170 (Scheme 3.13). These underwent Boc-deprotection by 20% 
TFA in CH2Cl2, solvent evaporation and NN bond cleavage by following general 
procedure 6.2.4.29. resulted in compounds 171172 (Scheme 3.13).
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5.2.4.27. (S)-2-Amino-2-phenylethanol (171) 
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Reactants for D-amination and in situ reduction: 11.5 mg L-proline (11.5 mg, 
0.10 mmol), 2.5 mL CH2Cl2, phenylacetaldehyde (175 PL, 1.50 mmol), di-tert.butyl
azodicarboxylate (230 mg, 1.00 mmol), MeOH (2.5 mL), KBH4 (50 mg). 
Reactants for Boc-deprotection: Compound 169 (352 mg, 1.0 mmol), 20% TFA in 
CH2Cl2 (2 mL). 
Reactants for NN bond cleavage: Compound 169b (152 mg, 1.0 mmol), activated 
Raney nickel (182 mg, 1.2 equiv.), absolute ethanol (20 mL). 
Yield: 0.136 g, 99% 
[D]20D = +49.3 (c = 1.0, CHCl3).
1H NMR (CDCl3, 300 MHz): G = 7.257.21 (m, 2H; H-5/7), 7.137.7 (m, 3H; H-
4/6/8), 4.21 (m, 1H; H-2), 4.003.97 (m, 2H; H-2´/1), 2.1 (br s, 2H; NH or OH) ppm.  
13C NMR (CDCl3, 75 MHz): G = 144.1 (C-3), 128.7 (C-5), 128.6 (C-7), 127.0 (C-4), 
126.8 (C-8), 126.0 (C-6), 67.7 (C-2), 62.5 (C-1) ppm.  
MS (EI): m/z = 137 [M]+.
5.2.4.28. (S)-2-Amino-3-phenylpropan-1-ol (172) 
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Reactants for D-amination and in situ reduction: 11.5 mg L-proline (11.5 mg, 
0.10 mmol), 2.5 mL CH2Cl2, 3-phenyl propionaldehyde (198 PL, 1.50 mmol), di-
tert.butyl azodicarboxylate (230 mg, 1.00 mmol), MeOH (2.5 mL), KBH4 (50 mg). 
Reactants for Boc-deprotection: Compound 170 (366 mg, 1.0 mmol), 20% TFA in 
CH2Cl2 (2 mL). 
Reactants for NN bond cleavage: Compound 170b (166 mg, 1.0 mmol), activated 
Raney nickel (199 mg, 1.2 equiv.), absolute ethanol (20 mL). 
Yield: 0.148 g, 98% 
[D]20D  = 27.0 (c = 1.0, CHCl3).
1H NMR (CDCl3, 300 MHz): G = 7.217.19 (m, 2H; H-6/8), 7.127.7 (m, 3H; H-
5/7/9), 3.883.85 (m, 1H; H-2), 3.643.62 (m, 1H; H-2´), 3.103.08 (m, 1H; H-1), 
2.912.90 (m, 1H; H-3), 2.662.64 (m, 1H; H-3´), 2.0 (br s, 2H; NH or OH) ppm.  
13C NMR (CDCl3, 75 MHz): G = 138.3 (C-4), 128.9 (C-6), 128.8 (C-8), 128.2 (C-5), 
128.0 (C-9), 126.4 (C-7), 68.7 (C-2), 54.1 (C-1), 41.3 (C-3) ppm.  
MS (EI): m/z = 151 [M]+.
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5.2.4.29. General Procedure for Boc-deprotection
1 mL 18% HCl in dioxane was added to compound 162 in a flask and stirred it at 
room temperature for 30 min. Reaction was monitored by TLC. Solvent was 
removed, flushed three times with hexane and evaporated to dryness to yield 173
(Scheme 3.14). Same procedure was applied to compounds 163167 for the 
synthesis of compounds 174182.
5.2.4.30. General Procedure for NN bond Cleavage
To a 1.2 equiv. activated Raney nickel suspension in absolute ethanol was added 
compound 168 and mixture was kept for hydrogenation at 500 Psi in an autoclave for 
16 h at 25 °C. Reaction mixture was then filtered and evaporated to dryness. Crude 
product was purified by acid base work up to afford compound 193 (Scheme 3.14) as
a colorless solid. Same procedure was applied to compounds 173182 for the 
synthesis of compounds 183192.
5.2.4.31. (3S)-3-Amino-N-benzyl-2-hydroxybutanamide (183) 
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Reactants for Boc-deprotection: Compound 162a (423 mg, 1.0 mmol), 18% HCl in 
dioxane (5 mL). 
Reactants for NN bond cleavage: Compound 173 (223 mg, 1.0 mmol), activated 
Raney nickel (267 mg, 1.2 equiv.), absolute ethanol (20 mL). 
Yield: 179 mg, 86% 
1H NMR (CDCl3, 300 MHz): G = 7.197.06 (m, 5H; H-6-10), 4.45 (d, 3J = 5.7 Hz, 
1H; H-2), 4.43 (s, 2H; H-4), 3.643.56 (m, 1H; H-1), 1.18 (d, 3J = 5.7 Hz, 3H; H-11) 
ppm.  
13C NMR (CDCl3, 75 MHz): G = 172.0 (C-3), 141.6 (C-5), 128.8 (C-7), 128.6 (C-9), 
127.1 (C-6), 127.0 (C-10), 126.8 (C-8), 73.0 (C-2), 47.6 (C-1), 44.3 (C-4), 16.5 (C-
11) ppm.  
MS (EI): m/z = 208 [M]+.
5.2.4.32. (3S)-3-Amino-N-benzyl-2-hydroxybutanamide (184) 
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Reactants for Boc-deprotection: Compound 162b (423 mg, 1.0 mmol), 18% HCl in 
dioxane (5 mL). 
Reactants for NN bond cleavage: Compound 174 (223 mg, 1.0 mmol), activated 
Raney nickel (267 mg, 1.2 equiv.), absolute ethanol (20 mL). 
Yield: 179 mg, 86% 
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1H NMR (CDCl3, 300 MHz): G = 7.197.07 (m, 5H; H-6-10), 4.45 (d, 3J = 5.7 Hz, 
1H; H-2), 4.44 (s, 2H; H-4), 3.693.59 (m, 1H; H-1), 1.18 (d, 3J = 5.7 Hz, 3H; H-11) 
ppm.  
13C NMR (CDCl3, 75 MHz): G = 172.2 (C-3), 141.7 (C-5), 128.8 (C-7), 128.6 (C-9), 
127.1 (C-6), 127.0 (C-10), 126.8 (C-8), 73.0 (C-2), 47.6 (C-1), 44.3 (C-4), 16.1 (C-
11) ppm.  
MS (EI): m/z = 208 [M]+.
5.2.4.33. (3S)-3-Amino-N-benzyl-2-hydroxypentanamide (185) 
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Reactants for Boc-deprotection: Compound 163a (437 mg, 1.0 mmol), 18% HCl in 
dioxane (5 mL). 
Reactants for NN bond cleavage: Compound 175 (237 mg, 1.0 mmol), activated 
Raney nickel (285 mg, 1.2 equiv.), absolute ethanol (20 mL). 
Yield: 89 mg, 40% 
1H NMR (CDCl3, 300 MHz): G = 7.257.14 (m, 5H; H-6-10), 4.58 (s, 2H; H-4), 
4.45 (d, 3J = 5.7 Hz, 1H; H-2), 3.22 (pent, 3J = 1.68 Hz, 1.55 Hz, 1H; H-1), 
1.251.21 (m, 2H; H-11), 1.80 (br s, 2H; NH or OH), 0.88 (t, 3H, 3J = 7.7 Hz; H-12) 
ppm.  
13C NMR (CDCl3, 75 MHz): G = 172.4 (C-3), 139.9 (C-5), 128.8 (C-7), 128.6 (C-9), 
127.1 (C-6), 127.0 (C-10), 126.8 (C-8), 70.8 (C-2), 54.6 (C-1), 44.4 (C-4), 23.9 (C-
11), 8.7 (C-12) ppm. 
MS (EI): m/z = 222 [M]+.
5.2.4.34. (3S)-3-Amino-N-benzyl-2-hydroxypentanamide (186) 
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Reactants for Boc-deprotection: Compound 163b (437 mg, 1.0 mmol), 18% HCl in 
dioxane (5 mL). 
Reactants for NN bond cleavage: Compound 176 (237 mg, 1.0 mmol), activated 
Raney nickel (285 mg, 1.2 equiv.), absolute ethanol (20 mL). 
Yield: 133 mg, 60% 
1H NMR (CDCl3, 300 MHz): G = 7.197.09 (m, 5H; H-6-10), 4.55 (s, 2H; H-4), 
4.45 (d, 3J = 5.7 Hz, 1H; H-2), 3.22 (pent, 3J = 1.68 Hz, 1.55 Hz, 1H; H-1), 
1.251.21 (m, 2H; H-11), 1.80 (br s, 2H; NH or OH), 0.89 (t, 3J = 7.7 Hz, 3H; H-12) 
ppm.  
13C NMR (CDCl3, 75 MHz): G = 172.2 (C-3), 141.9 (C-5), 128.8 (C-7), 128.6 (C-9), 
127.2 (C-6), 127.1 (C-10), 126.8 (C-8), 70.6 (C-2), 54.5 (C-1), 44.4 (C-4), 23.9 (C-
11), 8.7 (C-12) ppm.  
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MS (EI): m/z = 222 [M]+.
5.2.4.35. (3S)-3-Amino-N-benzyl-2-hydroxy-4-methylpentanamide (187) 
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Reactants for Boc-deprotection: Compound 164a (451 mg, 1.0 mmol), 18% HCl in 
dioxane (5 mL). 
Reactants for NN bond cleavage: Compound 178 (251 mg, 1.0 mmol), activated 
Raney nickel (301 mg, 1.2 equiv.), absolute ethanol (20 mL). 
Yield: 130 mg, 55% 
1H NMR (CDCl3, 300 MHz): G = 7.297.12 (m, 5H; H-6-10), 4.38 (d, 3J = 5.7 Hz, 
1H; H-2), 4.35 (s, 2H; H-4), 2.89 (t, 3J = 6.2 Hz, 1H; H-1), 2.252.12 (m, 1H; H-11), 
0.95 (d, 3J = 6.7 Hz, 3H; H-12), 0.90 (d, 3J = 6.7 Hz, 3H; H-13) ppm.  
13C NMR (CDCl3, 75 MHz): G = 171.4 (C-3), 137.4 (C-5), 131.2 (C-7), 130.0 (C-9), 
128.9 (C-6), 127.8 (C-10), 127.8 (C-8), 61.6 (C-2), 55.3 (C-1), 43.4 (C-4), 28.8 (C-
11), 19.4 (C-12), 16.6 (C-13) ppm.  
MS (EI): m/z = 236 [M]+.
5.2.4.36. (3S)-3-Amino-N-benzyl-2-hydroxy-4-methylpentanamide (188) 
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Reactants for Boc-deprotection: Compound 164b (451 mg, 1.0 mmol), 18% HCl in 
dioxane (5 mL). 
Reactants for NN bond cleavage: Compound 178 (251 mg, 1.0 mmol), activated 
Raney nickel (301 mg, 1.2 equiv.), absolute ethanol (20 mL). 
Yield: 191 mg, 81% 
1H NMR (CDCl3, 300 MHz): G = 7.277.09 (m, 5H; H-6-10), 4.50 (d, 3J = 5.7 Hz, 
1H; H-2), 4.44 (s, 2H; H-4), 2.87 (t, 3J = 6.2 Hz, 1H; H-1), 2.242.10 (m, 1H; H-11), 
0.95 (d, 3J = 6.7 Hz, 3H; H-12), 0.90 (d, 3J = 6.7 Hz, 3H; H-13) ppm.  
13C NMR (CDCl3, 75 MHz): G = 172.0 (C-3), 141.4 (C-5), 131.3 (C-7), 130.5 (C-9), 
128.9 (C-6), 127.8 (C-10), 127.8 (C-8), 65.6 (C-2), 55.6 (C-1), 44.4 (C-4), 28.8 (C-
11), 17.4 (C-12), 16.6 (C-13) ppm.  
MS (EI): m/z = 236 [M]+.
5.2.4.37. General Procedure for the synthesis of analogues of 99
EDAC (708 mg, 3.69 mmol) and HOBt (598 mg, 4.42 mmol) were added to a 
solution of 3-(dipropylcarbamoyl)benzoic acid 66 (920 mg, 3.69 mmol), dissolved in 
CH2Cl2 (10 mL). The resulting mixture was stirred at ambient temperature for 5 min, 
then treated with compound 183, 1.2 equiv. and Et3N (1.03 mL, 7.38 mmol) for 8 h. 
CH2Cl2 (20 mL) was added and the solution was washed with HCl (0.1 N, 5 u 30 
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mL), NaHCO3 sat. soln. (3 u 30 mL), brine (1 u 30 mL), dried over anhydrous 
Na2SO4, and concentrated to obtain the product 194 (Scheme 3.15).
Same procedure was applied to the synthesis of compounds 195204.
5.2.4.38. N1-((2S)-4-(Benzylamino)-3-hydroxy-4-oxobutan-2-yl)- N3,N3-
dipropylisophthalamide (194)  
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Reactants: 3-(dipropylcarbamoyl)benzoic acid 66 (920 mg, 3.69 mmol), (EDAC,
708 mg, 3.69 mmol), HOBt (598 mg, 4.42 mmol), Et3N (1.03 mL, 7.38 mmol), 
compound 183 (989 mg, 4.75 mmol), CH2Cl2 (10 mL).
Yield: 1.39 g, 86%
1H NMR (CDCl3, 300 MHz): G = 8.05 (s, 1H; H-18), 7.98 (d, 3J = 7.7 Hz, 2H; H-
14/16), 7.707.69 (m, 1H; H-15), 7.317.11 (m, 5H; H-6-10), 4.49 (d, 3J = 5.7 Hz, 
1H; H-2), 4.43 (s, 2H; H-4), 4.304.23 (m, 1H; H-1), 3.31 (t, 3J = 7.7 Hz, 2H; H-20), 
3.02 (t, 3J = 7.7 Hz, 2H; H-23), 1.601.51 (m, 2H; H-21), 1.461.37 (m, 2H; H-24), 
1.09 (s, 3H; H-22), 0.89 (t, 3J = 7.7 Hz, 3H; H-25), 0.84 (t, 3J = 7.7 Hz, 3H; H-11) 
ppm.  
13C NMR (CDCl3, 75 MHz): G = 172.9 (C-3), 168.6 (C-19), 165.0 (C-12), 138.3 (C-
5), 137.8 (C-17), 134.9 (C-13), 134.6 (C-16), 134.0 (C-15), 129.8 (C-7), 129.4 (C-9), 
129.3 (C-14), 127.9 (C-6), 126.7 (C-10), 126.8 (C-8), 125.1 (C-18), 73.0 (C-2), 50.9 
(C-20), 50.8 (C-23), 46.6 (C-1), 44.1 (C-4), 22.0 (C-21), 20.8 (C-24), 13.9 (C-22), 
11.6 (C-25), 11.1 (C-11) ppm.  
MS (EI): m/z = 439.5 [M]+.
5.2.4.39. N1-((2S)-4-(Benzylamino)-3-hydroxy-4-oxobutan-2-yl)- N3,N3-
dipropylisophthalamide (195) 
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The title compound was synthesized by following general procedure 5.2.4.37.
Reactants: 3-(dipropylcarbamoyl)benzoic acid 66 (920 mg, 3.69 mmol), EDAC 
(708 mg, 3.69 mmol), HOBt (598 mg, 4.42 mmol), Et3N (1.03 mL, 7.38 mmol), 
compound 184 (989 mg, 4.75 mmol), CH2Cl2 (10 mL).
 Yield: 1.39 g, 86% 
1H NMR (CDCl3, 300 MHz): G = 8.03 (s, 1H; H-18), 7.97 (d, 3J = 7.7 Hz, 2H; H-
14/16), 7.747.69 (m, 1H; H-15), 7.397.11 (m, 5H; H-6-10), 4.50 (d, 3J = 5.7 Hz, 
1H; H-2), 4.42 (s, 2H; H-4), 4.304.22 (m, 1H; H-1), 3.33 (t, 3J = 7.7 Hz, 2H; H-20), 
3.05 (t, 3J = 7.7 Hz, 2H; H-23), 1.591.50 (m, 2H; H-21), 1.451.37 (m, 2H; H-24), 
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1.09 (s, 3H; H-22), 1.00 (t, 3J = 7.7 Hz, 3H; H-25), 0.94 (t, 3J = 7.7 Hz, 3H; H-11) 
ppm.  
13C NMR (CDCl3, 75 MHz): G = 171.9 (C-3), 167.9 (C-19), 165.0 (C-12), 138.1 (C-
5), 137.6 (C-17), 134.7 (C-13), 134.0 (C-16), 133.9 (C-15), 129.7 (C-7), 129.4 (C-9), 
129.3 (C-14), 127.9 (C-6), 126.7 (C-10), 126.8 (C-8), 125.1 (C-18), 71.0 (C-2), 50.8 
(C-20), 50.6 (C-23), 46.5 (C-1), 44.0 (C-4), 22.0 (C-21), 20.8 (C-24), 13.9 (C-22), 
11.6 (C-25), 11.1 (C-11) ppm.  
MS (EI): m/z = 439.5 [M]+.
5.2.4.40. N1-((3S)-1-(Benzylamino)-2-hydroxy-1-oxopentan-3-yl)-N3,N3-
dipropylisophthalamide (196) 
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The title compound was synthesized by following general procedure 5.2.4.37.
Reactants: 3-(dipropylcarbamoyl)benzoic acid 66 (920 mg, 3.69 mmol), EDAC 
(708 mg, 3.69 mmol), HOBt (598 mg, 4.42 mmol), Et3N (1.03 mL, 7.38 mmol), 
compound 185 (1054 mg, 4.75 mmol), CH2Cl2 (10 mL).
Yield: 1.52 g, 91% 
1H NMR (CDCl3, 300 MHz): G = 7.93 (s, 1H; H-19), 7.55 (d, 3J = 7.7 Hz, 2H; H-
15/17), 7.547.51 (m, 1H; H-16), 7.267.00 (m, 5H; H-6-10), 4.60 (d, 3J = 5.7 Hz, 
1H; H-2), 4.42 (s, 2H; H-4), 4.304.22 (m, 1H; H-1), 3.32 (t, 3J = 7.7 Hz, 2H; H-21), 
3.05 (t, 3J = 7.7 Hz, 2H; H-24), 1.671.60 (m, 2H; H-22), 1.591.50 (m, 2H; H-25), 
1.451.37 (m, 2H; H-11), 1.00 (t, 3J = 7.7 Hz, 3H; H-23), 0.96 (t, 3J = 7.7 Hz, 3H; H-
26), 0.94 (t, 3J = 7.7 Hz, 3H; H-12) ppm. 
13C NMR (CDCl3, 75 MHz): G = 172.0 (C-3), 168.8 (C-20), 165.6 (C-13), 139.1 
(C-5), 137.5 (C-18), 134.6 (C-14), 134.3 (C-17), 134.0 (C-16), 129.7 (C-7), 129.4 
(C-9), 128.3 (C-15), 127.9 (C-6), 126.5 (C-10), 126.3 (C-8), 125.9 (C-19), 67.0 (C-
2), 52.8 (C-1), 50.6 (C-21), 49.9 (C-24), 44.0 (C-4), 22.0 (C-22), 21.3 (C-25), 20.8 
(C-11), 11.6 (C-23), 11.1 (C-26), 8.6 (C-12) ppm.
MS (EI): m/z = 453 [M]+.
5.2.4.41. N1-((3S)-1-(Benzylamino)-2-hydroxy-1-oxopentan-3-yl)-N3,N3-
dipropylisophthalamide (197) 
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The title compound was synthesized by following general procedure 5.2.4.37.
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Reactants: 3-(dipropylcarbamoyl)benzoic acid 66 (920 mg, 3.69 mmol), EDAC 
(708 mg, 3.69 mmol), HOBt (598 mg, 4.42 mmol), Et3N (1.03 mL, 7.38 mmol), 
compound 186 (1054 mg, 4.75 mmol), CH2Cl2 (10 mL).
Yield: 1.52 g, 91% 
1H NMR (CDCl3, 300 MHz): G = 8.01 (s, 1H; H-19), 7.75 (d, 3J = 7.7 Hz, 2H; H-
15/17), 7.707.65 (m, 1H; H-16), 7.267.01 (m, 5H; H-6-10), 5.00 (d, 3J = 5.7 Hz, 
1H; H-2), 4.44 (s, 2H; H-4), 4.304.22 (m, 1H; H-1), 3.30 (t, 3J = 7.7 Hz, 2H; H-21), 
3.04 (t, 3J = 7.7 Hz, 2H; H-24), 1.661.59 (m, 2H; H-22), 1.581.48 (m, 2H; H-25), 
1.451.37 (m, 2H; H-11), 1.00 (t, 3J = 7.7 Hz, 3H; H-23), 0.97 (t, 3J = 7.7 Hz, 3H; H-
26), 0.96 (t, 3J = 7.7 Hz, 3H; H-12) ppm.  
13C NMR (CDCl3, 75 MHz): G = 171.9 (C-3), 168.5 (C-20), 165.0 (C-13), 139.0 (C-
5), 137.5 (C-18), 134.4 (C-14), 134.2 (C-17), 134.0 (C-16), 129.6 (C-7), 129.4 (C-9), 
128.1 (C-15), 127.8 (C-6), 126.5 (C-10), 126.0 (C-8), 124.9 (C-19), 67.9 (C-2), 52.0 
(C-1), 50.3 (C-21), 49.9 (C-24), 44.4 (C-4), 22.0 (C-22), 21.8 (C-25), 20.9 (C-11), 
11.7 (C-23), 11.5 (C-26), 8.8 (C-12) ppm.  
MS (EI): m/z = 453 [M]+.
5.2.4.42. N1-((3S)-1-(Benzylamino)-2-hydroxy-4-methyl-1-oxopentan-3-yl)-
N3,N3-dipropylisophthalamide (198) 
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The title compound was synthesized by following general procedure 5.2.4.37.
Reactants: 3-(dipropylcarbamoyl)benzoic acid 66 (920 mg, 3.69 mmol), EDAC 
(708 mg, 3.69 mmol), HOBt (598 mg, 4.42 mmol), Et3N (1.03 mL, 7.38 mmol), 
compound 187 (1121 mg, 4.75 mmol), CH2Cl2 (10 mL).
 Yield: 1.67 g, 97% 
1H NMR (CDCl3, 300 MHz): G = 8.01 (s, 1H; H-20), 7.97 (d, 3J = 7.7 Hz, 2H; H-
16/18), 7.657.60 (m, 1H; H-17), 7.387.30 (m, 5H; H-6-10), 5.00 (d, 3J = 5.7 Hz, 
1H; H-2), 4.46 (s, 2H; H-4), 4.304.22 (m, 1H; H-1), 3.30 (t, 3J = 7.7 Hz, 2H; H-22), 
3.04 (t, 3J = 7.7 Hz, 2H; H-25), 2.452.40 (m, 2H; H-11), 1.581.48 (m, 2H; H-23), 
1.451.37 (m, 2H; H-26), 1.03 (t, 3J = 7.7 Hz, 3H; H-24), 1.01 (d, 3J = 7.0 Hz, 6H; 
H-12-13), 0.96 (t, 3J = 7.7 Hz, 3H; H-27) ppm.  
13C NMR (CDCl3, 75 MHz): G = 172.3 (C-3), 168.9 (C-21), 167.0 (C-14), 141.6 (C-
5), 135.5 (C-19), 134.4 (C-15), 130.2 (C-18), 129.9 (C-17), 129.6 (C-7), 128.4 (C-9), 
128.1 (C-16), 127.8 (C-6), 127.5 (C-10), 126.0 (C-8), 124.8 (C-20), 65.0 (C-2), 57.0 
(C-1), 50.3 (C-22), 49.9 (C-25), 44.4 (C-4), 26.7 (C-11), 21.9 (C-23), 21.8 (C-26), 
17.8 (C-12), 17.9 (C-13), 11.7 (C-24), 11.5 (C-27) ppm.  
MS (EI): m/z = 468 [M]+.
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5.2.4.43. N1-((3S)-1-(Benzylamino)-2-hydroxy-4-methyl-1-oxopentan-3-yl)-
N3,N3-dipropylisophthalamide (199) 
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The title compound was synthesized by following general procedure 5.2.4.37.
Reactants: 3-(dipropylcarbamoyl)benzoic acid 66 (920 mg, 3.69 mmol), EDAC 
(708 mg, 3.69 mmol), HOBt (598 mg, 4.42 mmol), Et3N (1.03 mL, 7.38 mmol), 
compound 188 (1121 mg, 4.75 mmol), CH2Cl2 (10 mL). 
Yield: 1.40 g, 81% 
1H NMR (CDCl3, 300 MHz): G = 8.01 (s, 1H; H-20), 7.97 (d, 3J = 7.7 Hz, 2H; H-
16/18), 7.657.60 (m, 1H; H-17), 7.387.30 (m, 5H; H-6-10), 5.55 (d, 3J = 3.5 Hz, 
1H; H-2), 4.46 (s, 2H; H-4), 4.404.30 (m, 1H; H-1), 3.35 (t, 3J = 7.7 Hz, 2H; H-22), 
3.05 (t, 3J = 7.7 Hz, 2H; H-25), 2.101.90 (m, 2H; H-11), 1.651.55 (m, 2H; H-23), 
1.481.35 (m, 2H; H-26), 1.05 (t, 3J = 5.7 Hz, 3H; H-12), 0.93 (t, 3J = 5.7 Hz, 3H; H-
13), 0.84 (t, 3J = 7.7 Hz, 3H; H-24), 0.65 (t, 3J = 7.7 Hz, 3H; H-27) ppm.  
13C NMR (CDCl3, 75 MHz): G = 170.4 (C-3), 167.7 (C-21), 165.1 (C-14), 141.6 (C-
5), 137.6 (C-19), 134.4 (C-15), 130.5 (C-18), 130.0 (C-17), 129.6 (C-7), 128.9 (C-9), 
128.1 (C-16), 127.8 (C-6), 127.5 (C-10), 126.0 (C-8), 124.8 (C-20), 72.0 (C-2), 57.7 
(C-1), 50.3 (C-22), 49.9 (C-25), 43.6 (C-4), 30.0 (C-11), 21.9 (C-23), 20.8 (C-26), 
19.9 (C-12), 19.5 (C-13), 11.5 (C-24), 11.1 (C-27) ppm. 
MS (EI): m/z = 467 [M]+.
5.2.4.44. N1-((1S)-3-(Cyclohexylamino)-2-hydroxy-3-oxo-1-phenylpropyl)-
N3,N3-dipropylisophthalamide (200)
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The title compound was synthesized by following general procedure 5.2.4.37.
Reactants: 3-(dipropylcarbamoyl)benzoic acid 66 (920 mg, 3.69 mmol), EDAC 
(708 mg, 3.69 mmol), HOBt (598 mg, 4.42 mmol), Et3N (1.03 mL, 7.38 mmol), 
compound 189 (1245 mg, 4.75 mmol), CH2Cl2 (10 mL). 
Yield: 1.69 g, 93% 
1H NMR (CDCl3, 300 MHz): G = 8.01 (s, 1H; H-22), 7.52 (d, 3J = 7.7 Hz, 2H; H-
18/20), 7.517.49 (m, 1H; H-19), 7.307.15 (m, 5H; H-11-15), 5.01 (d, 3J = 5.5 Hz, 
1H; H-1), 5.00 (d, 3J = 5.5 Hz, 1H; H-2), 3.55 (t, 3J = 7.7 Hz, 2H; H-24), 3.453.40
(m, 1H; H-4), 3.18 (t, 3J = 7.7 Hz, 2H; H-27), 1.651.50 (m, 4H; H-5/9), 1.491.45
(m, 2H; H-25), 1.421.40 (m, 2H; H-28), 1.321.25 (m, 6H; H-6-8), 0.81 (t, 3J = 7.7 
Hz, 3H; H-26), 0.65 (t, 3J = 7.7 Hz, 3H; H-29) ppm.  
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13C NMR (CDCl3, 75 MHz): G= 172.0 (C-3), 168.1 (C-23), 167.5 (C-16), 142.9 (C-
10), 135.6 (C-21), 134.5 (C-17), 130.6 (C-20), 128.8 (C-19), 128.7 (C-12), 128.6 (C-
14), 128.5 (C-18), 127.6 (C-11), 127.0 (C-15), 126.7 (C-13), 124.8 (C-22), 84.5 (C-
2), 55.8 (C-1), 49.6 (C-24), 49.7 (C-27), 47.8 (C-4), 33.8 (C-5), 33.6 (C-9), 28.0 (C-
7), 22.6 (C-6), 22.4 (C-8), 21.9 (C-25), 20.9 (C-28), 11.5 (C-26), 11.1 (C-29) ppm.  
MS (EI): m/z = 493 [M]+.
5.2.4.45. N1-((2S)-4-(Benzylamino)-3-hydroxy-4-oxo-1-phenylbutan-2-yl)- N3,
N3-dipropylisophthalamide (203) 
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The title compound was synthesized by following general procedure 5.2.4.37.
Reactants: 3-(dipropylcarbamoyl)benzoic acid 66 (920 mg, 3.69 mmol), EDAC 
(708 mg, 3.69 mmol), HOBt (598 mg, 4.42 mmol), Et3N (1.03 mL, 7.38 mmol), 
compound 192 (1349 mg, 4.75 mmol), CH2Cl2 (10 mL).
Yield: 1.63 g, 86% 
Rf: 0.48 (ethylacetate: hexane = 1:2) 
Mp: 145–149 °C. 
1H NMR (CDCl3, 300 MHz): G = 8.14 (s, 1H; H-24), 7.58 (d, 3J = 7.7 Hz, 2H; H-
20/22), 7.477.46 (m, 1H; H-21), 7.337.13 (m, 10H; H-6-10/13-17), 4.75 (s, 2H; H-
4), 4.42 (d, 3J = 6.4 Hz, 1H; H-2), 4.284.20 (m, 1H; H-1), 3.55 (t, 3J = 7.7 Hz, 2H; 
H-26), 3.453.40 (m, 1H; H-11), 3.383.31 (m, 1H; H-11´), 3.18 (t, 3J = 7.7 Hz, 2H; 
H-29), 1.651.55 (m, 2H; H-27), 1.501.40 (m, 2H; H-30), 1.19 (t, 3J = 7.7 Hz, 3H; 
H-28), 1.11 (t, 3J = 7.7 Hz, 3H; H-31) ppm.  
13C NMR (CDCl3, 75 MHz): G = 172.8 (C-3), 168.5 (C-25), 167.1 (C-18), 138.1 (C-
5), 137.6 (C-12), 137.5 (C-23), 135.1 (C-19), 134.0 (C-22), 129.7 (C-16), 129.4 (C-
14), 129.3 (C-21), 129.2 (C-7), 128.8 (C-9), 128.6 (C-20), 128.1 (C-13), 127.8 (C-
17), 127.6 (C-6), 127.0 (C-10), 126.7 (C-8), 126.6 (C-15), 125.1 (C-24), 68.5 (C-2), 
53.0 (C-1), 49.6 (C-26), 49.7 (C-29), 42.3 (C-4), 35.0 (C-11), 22.8 (C-27), 22.7 (C-
30), 11.6 (C-28), 11.1 (C-31) ppm.  
MS (EI): m/z = 515 [M]+.
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5.2.4.46. N1-((2S)-4-(Benzylamino)-1-(3,5-difluorophenyl)-3-hydroxy-4-oxobutan
-2-yl)-N3,N3-dipropylisophthalamide (204)
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The title compound was synthesized by following general procedure 5.2.4.37.
Reactants: 3-(dipropylcarbamoyl)benzoic acid 66 (920 mg, 3.69 mmol), EDAC 
(708 mg, 3.69 mmol), HOBt (598 mg, 4.42 mmol), Et3N (1.03 mL, 7.38 mmol), 
compound 193 (1521 mg, 4.75 mmol), CH2Cl2 (10 mL).
Yield: 1.56 g, 77% 
1H NMR (CDCl3, 500 MHz): G = 7.45 (s, 1H; H-24), 7.61 (d, 3J = 7.7 Hz, 2H; H-
20/22), 7.397.24 (m, 1H; H-21), 7.207.09 (m, 5H; H-6-10), 6.74 (dd, 3J = 7.9 Hz,
2.1 Hz, 2H; H-13/17), 6.54 (tt, 3J = 7.9 Hz, 2.1 Hz, 1H; H-15), 4.504.42 (m, 1H; H-
1), 4.40 (s, 2H; H-4), 4.22 (d, 3J = 6.2 Hz, 1H; H-2), 3.80 (dd, 2J = 14.2 Hz, 3J = 10.2 
Hz, 1H; H-11), 2.20 (td, 2J = 14.2 Hz, 3J = 4.0 Hz, 1H; H-11´), 3.45 (t, 3J = 7.7 Hz, 
2H; H-26), 3.00 (t, 3J = 7.7 Hz, 2H; H-29), 1.651.49 (m, 2H; H-27), 1.591.39 (m, 
2H; H-30), 0.89 (t, 3J = 7.7 Hz, 3H; H-28), 0.63 (t, 3J = 7.7 Hz, 3H; H-31) ppm.  
13C NMR (CDCl3, 75 MHz): G = 172.3 (C-3), 168.7 (C-25), 167.4 (C-18), 164.6 (C-
16), 164.5 (C-14), 141.5 (C-5), 141.1 (C-12), 136.0 (C-23), 135.7 (C-19), 134.1 (C-
22), 128.9 (C-21), 128.7 (C-7), 128.3 (C-9), 128.2 (C-20), 127.8 (C-6), 127.6 (C-10), 
126.1 (C-8), 124.7 (C-24), 110.9 (C-13), 110.8 (C-17), 102.0 (C-15), 67.8 (C-2), 51.0 
(C-1), 49.7 (C-26), 49.6 (C-29), 44.3 (C-4), 35.0 (C-11), 21.8 (C-27), 21.7 (C-30), 
11.5 (C-28), 11.3 (C-31) ppm.  
MS (EI): m/z = 551 [M]+.
5.2.5. Synthesis of Immobilized Catalyst 
5.2.5.1. Synthesis of compound 205 
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The title compound was synthesized by following same general procedure mentioned 
in 5.2.2.3.
Yield: 342 mg, 94% 
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1H NMR (CDCl3, 300 MHz): G = 6.98 (d, 2H, 3J = 7.7 Hz; H-16/18), 6.65 (d, 2H, 3J
= 7.7 Hz; H-15/19), 4.30 (t, 1H, 3J = 6.2 Hz; H-4), 4.023.99 (m, 1H; H-2), 
3.883.62 (m, 2H; H-1), 3.453.30 (m, 2H; H-7), 2.892.66 (m, 2H; H-13), 
1.991.71 (m, 2H; H-5), 1.661.52 (m, 2H; H-6), 1.40 (s, 9H; H-10-12) ppm.  
13C NMR (CDCl3, 75 MHz): G = 170.4 (C-3), 159.9 (C-8), 155.8 (C-17), 129.9 (C-
14), 129.1 (C-15/19), 116.1 (C-16/18), 79.8 (C-9), 63.6 (C-4), 47.8 (C-7), 39.4 (C-
13), 29.5 (C-5), 22.1 (C-6), 28.7 (C-10-12) ppm. 
MS (EI): m/z = 364 [M]+.
5.2.5.2. Synthesis of immobilized catalyst 207 
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Pre-swell Merrifield resin {(Fluka, Cat. No.: 63871, polystyrene crosslinked with 1% 
divinylbenzene, 200–400 mesh, | 0.7 mmol Cl/g resin), 0.5 g of resin, 0.35 mmol} 
by shaking for 30 min in 5 mL of dry dichloromethane and washed with DMF. Then 
206 (360 mg, 0.99 mmol, 3 equiv.) and triethylamine (0.231 mL, 1.65 mmol) was 
added to a suspension of the Merrifield resin in a minimal volume of dry DCM and 
allowed to shake for 24 h. The mixture was poured into a fritted funnel (fine) and the 
resin was washed with dichloromethane (8 × 25 mL), ethanol (6 × 25 mL) and THF 
(6 × 25 mL) and dried in vacuo. Yield 95% to quantitative. The deprotection of Boc 
was performed by shaking the resin with 20% TFA in DCM for 6 h. Finally, the resin 
was filtered and then washed with the dichloromethane (8 × 25 mL), ethanol (6 × 25 
mL) and THF (6 × 25 mL) and dried in vacuo. Yield 95% to quantitative. 
5.2.5.3. (R)-2-Amino-2-phenylethanol (212) 
H2N
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Reactants for D-amination and in situ reduction: (catalyst loading 0.20 
mmol/0.341 g of resin), 2.5 mL CH2Cl2, phenylacetaldehyde (175 PL, 1.50 mmol), 
di-benzylazodicarboxylate (298 mg, 1.00 mmol), MeOH (2.5 mL), KBH4 (50 mg). 
Reactants for Cbz-deprotection and NN bond cleavage: Compound 210 (420 
mg, 1.0 mmol), activated Raney nickel (504 mg, 1.2 equiv.), absolute ethanol (20 
mL).
Yield: 0.136 g, 99% 
[D]20D = 30.3 (c = 1.0, CHCl3).
1H NMR (CDCl3, 300 MHz): G = 7.257.21 (m, 2H; H-5/7), 7.137.7 (m, 3H; H-
4/6/8), 4.21 (m, 1H; H-2), 4.003.97 (m, 2H; H-2´/1), 2.1 (br s, 2H; NH or OH) ppm.  
13C NMR (CDCl3, 75 MHz): G = 144.1 (C-3), 128.7 (C-5), 128.6 (C-7), 127.0 (C-4), 
126.8 (C-8), 126.0 (C-6), 67.7 (C-2), 62.5 (C-1) ppm.  
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MS (EI): m/z = 137 [M]+.
5.2.5.4. (R)-2-Amino-3-phenylpropan-1-ol (213) 
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Reactants for D-amination and in situ reduction: (catalyst loading 0.20 
mmol/0.341 g of resin), 3-phenyl propionaldehyde (198 PL, 1.50 mmol), di-
benzylazodicarboxylate (298 mg, 1.00 mmol), MeOH (2.5 mL), KBH4 (50 mg). 
Reactants for Cbz-deprotection and NN bond cleavage: Compound 211 (571 
mg, 1.0 mmol), activated Raney nickel (685 mg, 1.2 equiv.), absolute ethanol (20 
mL).
Yield: 0.148 g, 98% 
[D]20D  = +27.0 (c = 1.0, CHCl3).
1H NMR (CDCl3, 300 MHz): G = 7.217.19 (m, 2H; H-6/8), 7.127.7 (m, 3H; H-
5/7/9), 3.883.85 (m, 1H; H-2), 3.643.62 (m, 1H; H-2´), 3.103.08 (m, 1H; H-1), 
2.912.90 (m, 1H; H-3), 2.662.64 (m, 1H; H-3´), 2.0 (br s, 2H; NH or OH) ppm.  
13C NMR (CDCl3, 75 MHz): G = 138.3 (C-4), 128.9 (C-6), 128.8 (C-8), 128.2 (C-5), 
128.0 (C-9), 126.4 (C-7), 68.7 (C-2), 54.1 (C-1), 41.3 (C-3) ppm.  
MS (EI): m/z = 151 [M]+.
5.2.6. Synthesis of Hydroxyethylene Derivative by Modified 
Passerini Reaction 
5.2.6.1. Synthesis of compound 214 
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Benzylisonitrile (181 μL, 1.5 mmol) was added in 3-Phenylpropanal (134 mg, 1 
mmol) in the presence of catalytic TFA in DCM. Reaction was monitored by HPLC. 
MeOH (2.5 mL) was added followed by careful addition of NaBH4 (50 mg). 
Reaction was monitored by TLC and the solvent was removed in vacuo after 20 min. 
The aqueous phase was diluted and extracted with EtOAc and washed three times 
with 50% soln of ammonium chloride (NH4Cl). The organic phase was dried over 
anhydrous Na2SO4 and concentrated in vacuo to give the product 1-(benzylamino)-4-
phenylbutan-2-ol (214 ). 
Yield: 232 mg, 91% 
1H NMR (CDCl3, 300 MHz): G = 7.217.06 (m, 10H; H-2-6/13-17), 3.81 (s, 2H; H-
7), 3.47-3.41 (m, 1H; H-9), 2.832.80 (m, 1H; H-8), 2.602.56 (m, 3H; H-8´/H11), 
1.771.71 (m, 2H; H-10) ppm.  
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13C NMR (CDCl3, 75 MHz): G = 139.0 (C-12), 136.5 (C-1), 128.7 (C-3/5), 128.6 
(C-14/16), 128.2 (C-13/17), 128.1 (C-2/6), 127.0 (C-4), 126.1 (C-15), 71.3 (C-9), 
55.9 (C-8), 55.1 (C-7), 37.9 (C-10), 29.5 (C-11) ppm. 
MS (EI): m/z = 255 [M]+.
X-ray Crystallographic data: The crystals used in the diffraction analysis were 
grown from a solution of 214 in CHCl3:MeOH (8:2). The crystal structure of 214
was solved by single-crystal X-ray diffraction using the Xcalibur system from 
Oxford Diffraction, equipped with CCD detector and the Enhance X-ray source 
option. The software packages SHELXS[224] and SHELXL[225] were used for 
structure solution and refinement as included in X-STEP32.[226] Diffraction data were 
collected on a Xcalibur diffractometer using graphite-monochromated (Mo-KD
radiation, Ȝ=0.71073 Å). A total of 2658 reflections, 1262 unique (Rint = 0.171), 
were collected up to ș = 21.22°.
Crystal data: C17H21NO, M = 255.35, colorless prismatic crystal (0.20 x 0.14 x 0.04 
mm), Orthorhombic, space group Pbc21, a = 5.373(2), b = 8.562(3) and c = 
31.243(9) Å, (V = 1437.3(8) Å3, Z = 4, Dc = 1.180 g cm–3, F(000) = 552 , μ(Mo-KD)
= 0.073 mm–1).
5.2.7. Synthesis of Non-Peptidic BACE-1 Inhibitors
5.2.7.1. Dimethyl 5-((tert-butoxycarbonyl)methoxy)benzene-1,3-dioate (215) 
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The phenolic -OH functionality of dimethyl 5-hydroxybenzene-1,3-dioate (2.1 g, 10 
mmol) was alkylated by using anhydrous K2CO3 (4.14 g, 30 mmol) and 
ClCH2CO2tBu (1.43 mL, 10 mmol) in acetone under reflux for 18 h. The reaction 
mixture was filtered after completion of reaction and solvent was removed in vacuo
to yield dimethyl 5-((tert-butoxycarbonyl)methoxy)benzene-1,3-dioate 215.
Yield: 2.66 g, 82% 
1H NMR (CDCl3, 300 MHz): G = 8.29 (s, 1H; H-2), 7.73 (s, 2H; H-4/6), 4.58 (s, 2H; 
H-11), 3.94 (s, 6H; H-8/10), 1.47 (s, 9H; H-14-16) ppm. 
13C NMR (CDCl3, 75 MHz): G = 167.3 (C-12), 165.9 (C-7), 165.8 (C-9), 158.6 (C-
5), 131.3 (C-1), 131.0 (C-3), 123.0 (C-2), 118.4 (C-4), 118.3 (C-6), 82.9 (C-13), 66.6 
(C-11), 52.5 (C-8), 52.4 (C-10), 28.4 (C-14-16) ppm.  
MS (EI): m/z = 324 [M]+.
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5.2.7.2. Dimethyl 4-((tert-butoxycarbonyl)methoxy)pyridine-2,6-dicarboxylate 
(216)
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Dimethyl 4-hydroxypyridine-2,6-dicarboxylate (1.0 g, 4.75 mmol) was added in a 25 
mL flask. Flask was evacuated and flushed with nitrogen. DMF was added through 
septa in it. NaH was added in portions in it and nitrogen was flushed again in flask. 
(716 mg, 4.75 mmol) of ClCH2CO2tBu and catalytic amount of potassium iodide 
(KI) was added in it. The reaction was kept on stirring over night and monitored by 
TLC. Distilled water was added after completion of reaction in it and the reaction 
mixture was extracted with CH2Cl2. Combined organic extract was washed with 
water and evaporated in vacuo to afford crude compound. 
Yield: 2.67 g, 82% 
Spectral data consistant with the literature.[234]
1H NMR (CDCl3, 300 MHz): G = 7.80 (s, 2H; H-3/5), 4.56 (s, 2H; H-10), 3.94 (s, 
6H; H-7/9), 1.47 (s, 9H; H-13-15) ppm. 
13C NMR (CDCl3, 75 MHz): G = 167.7 (C-11), 165.9 (C-6), 165.8 (C-8), 158.6 (C-
4), 151.3 (C-1), 151.0 (C-2), 118.4 (C-3), 118.3 (C-5), 82.9 (C-12), 66.6 (C-10), 52.5 
(C-7), 52.4 (C-9), 28.4 (C-13-15) ppm. 
MS (EI): m/z = 325 [M]+.
5.2.7.3. 2-(3,5-Di(methoxycarbonyl)phenoxy)acetic acid (217) 
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To a 0 °C cooled solution containing 1.80 g (6.73 mmol) of the Dimethyl 5-((tert-
butoxycarbonyl)methoxy)benzene-1,3-dioate in 20 mL of CH2Cl2 was treated with 
10 mL of TFA. The resulting solution was stirred at room temperature for 2 h. 
Solvents was removed in vacuo to yield the desired carboxylic acid as a colorless 
solid.
Yield: 1.34 g, 90% 
Spectral data consistant with the literature.[239]
1H NMR (CDCl3, 300 MHz): G = 8.24 (s, 1H; H-2), 7.72 (s, 2H; H-4/6), 4.71 (s, 2H; 
H-11), 3.88 (s, 6H; H-8/10) ppm. 
13C NMR (CDCl3, 75 MHz): G = 171.9 (C-12), 167.6 (C-7), 167.5 (C-9), 159.6 (C-
5), 133.3 (C-1), 133.1 (C-3), 125.0 (C-2), 118.4 (C-4), 118.3 (C-6), 66.6 (C-11), 50.7 
(C-8), 50.5 (C-10) ppm.  
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MS (EI): m/z = 268 [M]+.
5.2.7.4. 2-(2,6-Di(methoxycarbonyl)pyridin-4-yloxy)acetic acid (218) 
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The title compound was synthesized by following same procedure as mentioned in 
5.2.7.3.
Reactants: Dimethyl 4-((tert-butoxycarbonyl)methoxy)pyridine-2,6-dicarboxylate 
(2.2 g, 6.73 mmol) 20 mL of CH2Cl2 and TFA 10 mL. 
Yield: 1.35 g, 90%
Spectral data consistant with the literature.[233]
5.2.7.5. Compound (219) 
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EDAC (979 mg, 5.11 mmol) and HOBt (828 mg, 6.13 mmol) were added to a 
solution of 217 (1.37 g, 5.11 mmol), dissolved in CH2Cl2 (10 mL). The resulting 
mixture was stirred at ambient temperature for 5 min, then treated with N-Boc-1,5-
diaminopentane (1.275 mL, 6.13 mmol) and Et3N (1.42 mL, 10.22 mmol) for 8 h. 
CH2Cl2 (20 mL) was added and the solution was washed with HCl (0.1 N, 5 u 30 
mL), NaOH (0.1 N, 3 u 30 mL), brine (1 u 30 mL), dried over anhydrous Na2SO4,
and concentrated to obtain the product 219 as colorless oil (Scheme 3.21).
Yield: 1.84 g, 80% 
1H NMR (CDCl3, 300 MHz): G = 8.28 (s, 1H; H-2), 7.71 (s, 2H; H-4/6), 7.20 (br s, 
1H, NH), 4.49 (s, 2H; H-11), 3.88 (s, 6H; H-8/10), 3.38–3.32 (m, 2H; H-13), 3.10–
3.09 (m, 2H; H-17), 1.59–1.54 (m, 4H; H-14/16), 1.42 (s, 9H; H-20-22), 1.32–1.28 
(m, 2H; H-15) ppm.
13C NMR (CDCl3, 75 MHz): G = 170.7 (C-12), 167.8 (C-7), 165.9 (C-9), 158.9 (C-
5), 157.4 (C-18), 132.1 (C-1), 131.0 (C-3), 122.8 (C-2), 118.9 (C-4), 118.7 (C-6), 
79.3 (C-19), 67.6 (C-11), 52.7 (C-8), 51.5 (C-10), 41.4 (C-17), 40.3 (C-13), 29.7 (C-
14), 29.2 (C-16), 28.3 (C-20-22), 21.2 (C-15) ppm.  
MS (EI): m/z = 452 [M]+.
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5.2.7.6. Compound (220) 
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The title compound was synthesized by following same procedure as mentioned in 
5.2.7.5.
Reactants: EDAC (979 mg, 5.11 mmol), HOBt (828 mg, 6.13 mmol), 218 (1.37 g, 
5.11 mmol), CH2Cl2 (10 mL). N-Boc-1,5-diaminopentane (1.275 mL, 6.13 mmol) 
and Et3N (1.42 mL, 10.22 mmol)  
Yield: 1.85 g, 80% 
1H NMR (CDCl3, 300 MHz): G = 8.54 (s, 1H; H-3/5), 7.20 (br s, 1H, NH), 4.80 (s, 
2H; H-10), 3.88 (s, 6H; H-7/9), 3.37–3.32 (m, 2H; H-12), 3.10–3.09 (m, 2H; H-16), 
1.59–1.54 (m, 4H; H-13/15), 1.42 (s, 9H; H-19-21), 1.32–1.28 (m, 2H; H-14) ppm.
13C NMR (CDCl3, 75 MHz): G = 170.1 (C-11), 167.9 (C-6), 165.8 (C-8), 162.9 (C-
4), 157.2 (C-17), 148.1 (C-1), 148.0 (C-2), 112.9 (C-3), 112.7 (C-5), 79.3 (C-18), 
67.5 (C-10), 52.7 (C-7), 51.5 (C-9), 41.4 (C-16), 40.3 (C-12), 29.7 (C-13), 29.2 (C-
15), 28.3 (C-19-21), 21.2 (C-14) ppm.
MS (EI): m/z = 453 [M]+.
5.2.7.7. 5-(2-(5-(tert-Butoxycarbonylamino)pentylamino)-2-
oxoethoxy)isophthalic acid (221) 
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To a 250-mL, round-bottom flask equipped with a condenser were added 219 (2.01
g, 4.45 mmol), THF (7.5 mL), and H2O (75 mL), and the solution was cooled to 0 
°C. To this solution was added NaOH (0.25 N, 60 mL) dropwise, and the reaction 
mixture was stirred for 1 h. After the completion of the reaction, HCl (1.0 N) was 
added until no further precipitation was observed. The precipitate was filtered to give 
a colorless solid. 
Yield: 1.69 g, 90% 
1H NMR (CDCl3, 300 MHz): G = 8.32 (s, 1H; H-2), 7.78 (s, 1H; H-4), 7.54 (s, 1H; 
H-6), 4.69 (s, 2H; H-9), 4.55 (br s, 1H, NH), 3.31–3.26 (m, 2H; H-11), 3.04–2.99 (m, 
2H; H-15), 1.57–1.54 (m, 4H; H-12/14), 1.44 (s, 9H; H-18-20), 1.30–1.25 (m, 2H; 
H-13) ppm. 
13C NMR (CDCl3, 75 MHz): G = 170.0 (C-7), 168.8 (C-8), 168.7 (C-10), 158.9 (C-
5), 158.4 (C-16), 134.1 (C-1), 134.0 (C-3), 125.8 (C-2), 119.8 (C-4), 119.7 (C-6), 
79.3 (C-17), 68.6 (C-9), 41.4 (C-15), 40.3 (C-11), 30.7 (C-14), 30.2 (C-12), 28.3 (C-
18-20), 25.2 (C-13) ppm.
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MS (ESI): m/z = 447.2 [M+Na]+, 423.1 [M+ņH].
5.2.7.8. Reaction of 5-(2-(5-(tert-butoxycarbonylamino)pentylamino)-2-
oxoethoxy)isophthalic acid with benzylamine: 
The title compound was synthesized by following general procedure 5.2.2.3.
Reactants: 5-(2-(5-(tert-butoxycarbonylamino)pentylamino)-2-oxoethoxy) 
isophthalic acid (100 mg, 0.236 mmol), EDAC (90 mg, 0.472 mmol), HOBt (77 mg, 
0.566 mmol), Et3N (145 PL, 1.04 mmol), benzylamine (62 PL , 0.566 mmol), 
CH2Cl2 (5 mL). 
Crude Yield: 0.127 g, 90% 
A mixture of di-amidation and mono-amidation product was separated by flash 
column chromatography using ethyl acetate and hexane (40: 60) as gradient. 
5.2.7.8.1. tert-Butyl 5-(2-(3,5-bis(benzylcarbamoyl)phenoxy)acetamido) 
pentylcarbamate (224a) 
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Yield: 71 mg, 50% 
1H NMR (CDCl3, 300 MHz): G = 7.86 (s, 1H; H-2), 7.77 (s, 2H; H-4/6), 7.67 (br s, 
1H, NH), 6.55 (br s, 2H, NH), 7.33–7.26 (m, 10H; H-11-15/18-22), 4.59 (d, 4H; H-
9/16), 4.51 (s, 2H; H-23), 3.31 (dd, 2H; H-25), 3.00 (dd, 2H; H-29), 1.52–1.50 (m, 
4H; H-26/28), 1.40 (s, 9H; H-32-34), 1.28–1.26 (m, 2H; H-27) ppm.  
13C NMR (CDCl3, 75 MHz): G = 167.3 (C-24), 165.9 (C-7), 165.8 (C-8), 160.9 (C-
5), 156.1 (C-30), 141.7 (C-10), 141.6 (C-17), 137.8 (C-1), 136.5 (C-3), 128.9 (C-12), 
128.8 (C-19), 128.6 (C-14), 128.0 (C-21), 127.9 (C-11), 127.7 (C-18), 127.6 (C-15), 
127.5 (C-22), 126.8 (C-13), 126.5 (C-20), 116.7 (C-4), 116.6 (C-6), 77.4 (C-31), 67.5 
(C-23), 44.3 (C-9), 44.2 (C-16), 40.3 (C-29), 29.7 (C-25), 29.3 (C-26), 29.0 (C-28), 
28.5 (C-32-34), 23.9 (C-27) ppm.  
MS (ESI): m/z = 625 [M+Na]+, 601 (M+-H).
5.2.7.8.2. 3-(Benzylcarbamoyl)-5-(2-(5-(tert-butoxycarbonylamino)pentylamino)-
2-oxoethoxy)benzoic acid (225a) 
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Yield: 48.4 mg, 40% 
1H NMR (CDCl3, 300 MHz): G = 7.85 (s, 1H; H-2), 7.77 (s, 1H; H-6), 7.66 (s, 1H; 
H-4), 7.53 (br s, 2H, NH), 7.33–7.26 (m, 5H; H-11-15), 4.57 (s, 2H; H-16), 4.53 (s, 
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2H; H-9), 3.33–3.00 (m, 2H; H-18), 2.99–2.95 (m, 2H; H-22), 1.52–1.50 (m, 4H; H-
19/21), 1.40 (s, 9H; H-25-27), 1.28–1.26 (m, 2H; H-20) ppm.  
13C NMR (CDCl3, 75 MHz): G = 168.3 (C-7), 167.9 (C-17), 167.0 (C-8), 160.9 (C-
5), 156.1 (C-23), 137.8 (C-10), 136.7 (C-3), 128.8 (C-1), 128.4 (C-12), 127.9 (C-14), 
127.4 (C-11), 127.0 (C-15), 126.7 (C-13), 116.7 (C-6), 116.0 (C-4), 77.4 (C-24), 67.5 
(C-16), 44.3 (C-9), 40.3 (C-22), 40.0 (C-18), 29.7 (C-19), 28.9 (C-21), 28.5 (C-25-
27), 23.9 (C-20) ppm.  
MS (EI): m/z = 513 [M]+.
5.2.7.9. Reaction of 5-(2-(5-(tert-butoxycarbonylamino)pentylamino)-2-
oxoethoxy)isophthalic acid with 4-methoxy benzylamine 
The title compound was synthesized by following general procedure 5.2.2.3.
Reactants: 5-(2-(5-(tert-butoxycarbonylamino)pentylamino)-2-oxoethoxy) 
isophthalic acid (100 mg, 0.236 mmol), EDAC (90 mg, 0.472 mmol), HOBt (77 mg, 
0.566 mmol), Et3N (145 PL, 1.04 mmol), 4-methoxy benzylamine (74 PL , 0.566 
mmol), CH2Cl2 (5 mL). 
Crude Yield: 0.146 g, 94% 
A mixture of di-amidation and mono-amidation product was separated by flash 
column chromatography using ethyl acetate and hexane (40: 60) as gradient. 
5.2.7.9.1. tert-Butyl 5-(2-(3,5-bis(4-methoxybenzylcarbamoyl)phenoxy) 
acetamido)pentylcarbamate (224b) 
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Yield: 73 mg, 47% 
1H NMR (CDCl3, 300 MHz): G = 7.83 (br s, 1H; NH), 7.50 (s, 1H; H-2), 7.29 (s, 2H; 
H-4/6), 7.22 (d, 3J = 8.7 Hz, 4H; H-11/15/19/23), 7.04 (br s, 1H; NH), 6.82 (d, 3J = 
8.7 Hz, 4H; H-12/14/20/22), 6.58 (br s, 1H; NH), 4.45 (s, 2H; H-25), 4.44 (s, 4H; H-
9/17), 3.76 (s, 6H; H-16/24), 3.33–3.20 (m, 2H; H-27), 3.00–2.98 (m, 2H; H-31), 
1.55–1.49 (m, 4H; H-28/30), 1.41 (s, 9H; H-34-36), 1.29–1.20 (m, 2H; H-29) ppm.  
13C NMR (CDCl3, 75 MHz): G = 167.4 (C-26), 166.1 (C-7), 166.0 (C-8), 159.9 (C-
5), 158.7 (C-13), 158.6 (C-21), 156.0 (C-32), 136.6 (C-1), 135.0 (C-3), 134.3 (C-10), 
134.1 (C-18), 130.0 (C-11), 129.9 (C-15), 129.7 (C-19), 129.6 (C-23), 118.7 (C-2), 
117.4 (C-4), 116.6 (C-6), 115.8 (C-12), 115.7 (C-20), 114.1 (C-14), 114.0 (C-22), 
79.4 (C-33), 67.4 (C-25), 55.9 (C-16), 55.8 (C-24), 43.7 (C-9), 43.6 (C-17), 40.4 (C-
31), 38.9 (C-27), 30.9 (C-28), 29.6 (C-30), 28.4 (C-34-36), 23.9 (C-29) ppm.  
MS (ESI): m/z = 685.4 [M+Na]+.
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5.2.7.9.2. 3-(2-(5-(tert-Butoxycarbonylamino)pentylamino)-2-oxoethoxy)-5-(4-
methoxybenzylcarbamoyl)benzoic acid (225b) 
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Yield: 60 mg, 47% 
1H NMR (CDCl3, 300 MHz): G = 7.92 (s, 1H; H-2), 7.63 (s, 2H; H-4/6), 7.22 (d, 3J
= 8.7 Hz, 2H; H-11/15 ), 6.82 (d, 3J = 8.7 Hz, 2H; H-12/14), 6.58 (br s, 1H; NH), 
5.23 (s, 2H; H-17), 4.44 (s, 2H; H-9), 3.74 (s, 3H; H-16), 3.29–3.27 (m, 2H; H-19), 
3.01–2.99 (m, 2H; H-23), 1.54–1.49 (m, 4H; H-20/22), 1.41 (s, 9H; H-27-28), 1.29–
1.20 (m, 2H; H-21) ppm.  
13C NMR (CDCl3, 75 MHz): G = 169.6 (C-7), 167.2 (C-18), 165.5 (C-8), 159.0 (C-
5), 157.5 (C-13), 156.2 (C-24), 136.6 (C-3), 135.0 (C-10), 134.0 (C-1), 130.0 (C-11), 
129.3 (C-15), 120.7 (C-2), 118.7 (C-6), 117.4 (C-4), 116.6 (C-12), 115.8 (C-14), 79.4 
(C-25), 67.4 (C-17), 43.7 (C-9), 40.4 (C-23), 40.0 (C-19), 29.7 (C-20), 29.2 (C-22), 
28.4 (C-26-28), 23.9 (C-21) ppm.  
MS (ESI): m/z = 543.6 [M]+.
5.2.7.10. Reaction of 5-(2-(5-(tert-butoxycarbonylamino)pentylamino)-2-
oxoethoxy)isophthalic acid with 3-(triflouromethyl)benzylamine 
The title compound was synthesized by following general procedure 5.2.2.3.
Reactants: 5-(2-(5-(tert-butoxycarbonylamino)pentylamino)-2-oxoethoxy) 
isophthalic acid (100 mg, 0.236 mmol), EDAC (90 mg, 0.472 mmol), HOBt (77 mg, 
0.566 mmol), Et3N (145 PL, 1.04 mmol), 3-(triflouromethyl)benzylamine (88 PL,
0.566 mmol), CH2Cl2 (5 mL). 
Crude yield: 160 mg, 92% 
A mixture of di-amidation and mono-amidation product was separated by flash 
column chromatography using ethyl acetate and hexane (40: 60) as gradient. 
5.2.7.10.1. tert-Butyl 5-(2-(3,5-bis(3-(trifluoromethyl)benzylcarbamoyl)phenoxy) 
acetamido)pentylcarbamate (224c) 
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1H NMR (CDCl3, 300 MHz): G = 7.80 (s, 1H; H-2), 7.71 (br s, 1H; NH), 7.47 (s, 2H; 
H-4/6), 7.45–7.36 (m, 8H; H-13-11/15/19-21/23), 6.80 (br s, 1H; NH), 5.22 (s, 2H; 
H-25), 4.47 (s, 4H; H-9/17), 3.30–3.19 (m, 2H; H-27), 2.87–2.77 (m, 2H; H-31), 
1.54–1.49 (m, 4H; H-28/30), 1.40 (s, 9H; H-34-36), 1.29–1.20 (m, 2H; H-29) ppm.  
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13C NMR (CDCl3, 75 MHz): G = 167.9 (C-26), 167.8 (C-87), 167.3 (C-8), 160.5 (C-
5), 156.3 (C-32), 142.0 (C-10), 141.9 (C-18), 135.9 (C-1), 135.0 (C-3), 132.3 (C-14), 
132.2 (C-22), 130.1 (C-11), 128.9 (C-19), 128.7 (C-12), 128.5 (C-20), 124.9 (C-15), 
124.2 (C-23), 124.1 (C-16), 124.0 (C-24), 123.2 (C-13), 123.0 (C-21), 118.4 (C-2), 
115.8 (C-6), 115.7 (C-4), 79.4 (C-33), 67.6 (C-25), 44.9 (C-9), 42.3 (C-17), 41.1 (C-
31), 40.3 (C-27), 29.6 (C-28), 29.3 (C-30), 28.9 (C-34-36), 23.9 (C-29) ppm.  
MS (ESI): m/z = 761.2 [M+Na]+.
5.2.7.11. Reaction of 5-(2-(5-(tert-butoxycarbonylamino)pentylamino)-2-
oxoethoxy)isophthalic acid with L-tryptophan methyl ester hydrochloride 
The title compound was synthesized by following general procedure 5.2.2.3.
Reactants: 5-(2-(5-(tert-butoxycarbonylamino)pentylamino)-2-oxoethoxy) 
isophthalic acid (100 mg, 0.236 mmol), EDAC (90 mg, 0.472 mmol), HOBt (77 mg, 
0.566 mmol), Et3N (145 PL, 1.04 mmol), L-tryptophan methyl ester hydrochloride 
(144 mg , 0.566 mmol), CH2Cl2 (5 mL). 
Crude Yield: 167 mg, 86% 
A mixture of di-amidation and mono-amidation product was separated by flash 
column chromatography using ethyl acetate and hexane (40: 60) as gradient.
5.2.7.11.1. Compound (224d) 
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Yield: 116 mg, 60% 
1H NMR (CDCl3, 300 MHz): G = 8.58 (br s, 2H; NH), 7.58 (d, 3J = 7.80 Hz, 1H; H-
2), 7.43 (s, 2H; H-4/6), 7.31 (br s, 2H; NH), 7.18–7.01 (m, 8H; H-13-16/25-28), 6.82 
(s, 2H; H-18/30), 4.99–4.97 (m, 4H; H-9/21/33), 3.69 (s, 6H; H-20/32), 3.24–3.20 
(m, 4H; H-10/22/35), 3.00–2.95 (m, 4H; H-10´/22´/39), 1.56–1.50 (m, 4H; H-36/38), 
1.41 (s, 9H; H-42-44), 1.28–1.20 (m, 2H; H-37) ppm.  
13C NMR (CDCl3, 75 MHz): G = 172.7 (C-19), 172.5 (C-31), 168.7 (C-34), 167.4 
(C-7), 167.0 (C-8), 166.2 (C-5), 157.4 (C-40), 136.3 (C-17), 136.0 (C-29), 135.4 (C-
1), 135.1 (C-3), 127.4 (C-12), 123.4 (C-24), 122.2 (C-14), 119.6 (C-26), 118.5 (C-
15), 118.3 (C-27), 117.8 (C-13), 117.2 (C-25), 117.0 (C-2), 115.2 (C-4), 115.1 (C-6), 
111.6 (C-16), 109.7 (C-28), 109.0 (C-11), 108.9 (C-23), 79.5 (C-41), 67.3 (C-33), 
60.4 (C-9), 59.0 (C-21), 53.3 (C-20), 52.6 (C-32), 40.4 (C-39), 39.0 (C-35), 30.7 (C-
10), 30.6 (C-22), 29.6 (C-36), 29.0 (C-38), 28.4 (C-42-44), 23.9 (C-37) ppm.  
MS (ESI): m/z = 824 [M]+, 847.4 [M+Na]+.
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5.2.7.11.2. (S)-3-(3-(1H-Indol-3-yl)-1-methoxy-1-oxopropan-2-ylcarbamoyl)-5-
(2-(5-(tert-butoxycarbonylamino)pentylamino)-2-oxoethoxy)benzoic acid (225d) 
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Yield: 58 mg, 40%
1H NMR (CDCl3, 300 MHz): G = 8.45 (br s, 2H; NH), 7.88 (d, 3J = 7.80 Hz, 1H; H-
2), 7.60 (s, 2H; H-4/6), 7.31 (br s, 2H; NH), 7.18–7.01 (m, 4H; H-13-16), 6.98 (s, 
1H; H-18), 5.08–5.05 (m, 3H; H-9/21), 3.72 (s, 3H; H-20), 3.31–3.26 (m, 3H; H-
10/23), 3.05–2.90 (m, 3H; H-10´/27), 1.60–1.40 (m, 4H; H-24/26), 1.40 (s, 9H; H-
30-32), 1.29–1.25 (m, 2H; H-25) ppm.  
13C NMR (CDCl3, 75 MHz): G = 172.3 (C-19), 171.1 (C-7), 167.2 (C-22), 165.7 (C-
8), 160.4 (C-5), 157.3 (C-28), 136.3 (C-17), 136.1 (C-3), 136.1 (C-1), 127.4 (C-12), 
123.0 (C-14), 122.9 (C-18), 122.3 (C-15), 119.8 (C-2), 118.5 (C-13), 116.0 (C-6), 
116.0 (C-4), 111.6 (C-16), 109.7 (C-11), 79.5 (C-29), 67.3 (C-21), 60.4 (C-9), 53.3 
(C-20), 42.6 (C-27), 40.4 (C-23), 38.9 (C-10), 29.6 (C-24), 29.0 (C-26), 28.5 (C-30-
32), 23.9 (C-25) ppm.  
MS (ESI): m/z = 647 [M+Na]+.
5.2.7.12. Reaction of 5-(2-(5-(tert-butoxycarbonylamino)pentylamino)-2-
oxoethoxy)isophthalic acid with L-phenyl glycine ester 
The title compound was synthesized by following general procedure 5.2.2.3.
Reactants: 5-(2-(5-(tert-butoxycarbonylamino)pentylamino)-2-oxoethoxy) 
isophthalic acid (100 mg, 0.236 mmol), EDAC (90 mg, 0.472 mmol), HOBt (77 mg, 
0.566 mmol), Et3N (145 PL, 1.04 mmol), L-phenyl glycine ester (H-Phg-OtBu) (138 
mg , 0.566 mmol), CH2Cl2 (5 mL). 
Crude Yield: 177 mg, 95% 
A mixture of di-amidation and mono-amidation product was separated by flash 
column chromatography using ethyl acetate and hexane (40: 60) as gradient. 
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5.2.7.12.1. Compound (224e) 
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Yield: 95 mg, 50% 
1H NMR (CDCl3, 300 MHz): G = 7.80 (s, 1H ; H-2), 7.71 (br s, 1H; NH), 7.47 (s, 
2H; Ar-H), 7.35 (br s, 1H; NH), 7.30–7.20 (m, 10H; H-15-19/28-32), 6.80 (br s, 1H; 
NH), 5.58–5.55 (m, 2H; H-8/21), 4.46 (s, 2H; H-33), 3.29–3.27 (m, 2H; H-35), 3.03–
3.01 (m, 2H; H-39), 1.54–1.49 (m, 4H; H-36/38), 1.41 (s, 27H; H-11-13/24-26/42-
44), 1.28–1.25 (m, 2H; H-37) ppm.  
13C NMR (CDCl3, 75 MHz): G = 171.1 (C-9), 170.9 (C-22), 168.9 (C-34), 167.3 (C-
7), 165.7 (C-20), 160.2 (C-5), 156.3 (C-40), 135.9 (C-27), 135.0 (C-14), 132.3 (C-1), 
132.2 (C-3), 130.5 (C-15), 130.4 (C-19), 130.3 (C-28), 129.8 (C-32), 127.0 (C-16), 
126.9 (C-18), 126.8 (C-29), 126.7 (C-31), 126.2 (C-17), 126.0 (C-30), 118.4 (C-2), 
117.9 (C-6), 116.8 (C-4), 82.1 (C-10), 79.4 (C-23), 79.3 (C-41), 67.6 (C-8), 59.4 (C-
21), 40.3 (C-39), 40.0 (C-35), 29.6 (C-36), 29.3 (C-38), 28.9 (C-11-13), 28.6 (C-24-
26), 28.3 (C-42-44), 23.0 (C-37) ppm.
MS (ESI): m/z = 825.4 [M+Na]+.
5.2.7.12.2. (S)-3-(2-tert-Butoxy-2-oxo-1-phenylethylcarbamoyl)-5-(2-(5-(tert-
butoxycarbonylamino)pentylamino)-2-oxoethoxy)benzoic acid (225e) 
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Yield: 65 mg, 45% 
1H NMR (CDCl3, 300 MHz): G = 8.20 (s, 1H; H-2), 7.72 (s, 1H; H-6), 7.66 (s, 1H; 
H-4), 7.60 (br s, 1H; NH), 7.56 (br s, 1H; NH), 7.38–7.20 (m, 5H; H-11-15), 6.80 (br 
s, 1H; NH), 5.59–5.57 (m, 2H; H-9), 4.49 (s, 2H; H-21), 3.29–3.27 (m, 2H; H-23), 
3.03–3.00 (m, 2H; H-27), 1.55–1.49 (m, 4H; H-24/26), 1.42 (s, 18H; H-18-20/30-
32), 1.29–1.25 (m, 2H; H-25) ppm.  
13C NMR (CDCl3, 75 MHz): G = 170.0 (C-16), 167.9 (C-7), 165.7 (C-22), 165.4 (C-
8), 160.3 (C-5), 157.4 (C-28), 136.9 (C-10), 135.9 (C-3), 132.3 (C-1), 128.8 (C-11), 
128.4 (C-15), 127.2 (C-12), 127.0 (C-14), 127.6 (C-13), 119.9 (C-2), 118.9 (C-6), 
116.8 (C-4), 83.1 (C-17), 79.4 (C-29), 67.6 (C-21), 60.0 (C-9), 57.4 (C-27), 52.5 (C-
23), 38.9 (C-26), 29.6 (C-24), 29.3 (C-18-20), 28.0 (C-30-32), 23.0 (C-25) ppm.  
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MS (ESI): m/z = 613.5 [M]+.
5.2.7.13. Reaction of 5-(2-(5-(tert-butoxycarbonylamino)pentylamino)-2-
oxoethoxy)isophthalic acid with L-aspartic acid E-tert-butyl ester (H-Asp(OtBu)-
OtBu.HCl)
The title compound was synthesized by following general procedure 5.2.2.3.
Reactants: 5-(2-(5-(tert-butoxycarbonylamino)pentylamino)-2-oxoethoxy) 
isophthalic acid (100 mg, 0.236 mmol), EDAC (90 mg, 0.472 mmol), HOBt (77 mg, 
0.566 mmol), Et3N (145 PL, 1.04 mmol), L-aspartic acid E-tert-butyl ester (H-
Asp(OtBu)-OtBu.HCl) (130 mg , 0.566 mmol), CH2Cl2 (5 mL). 
Crude Yield: 186 mg, 90% 
5.2.7.13.1. Compound (224f)
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Yield: 83 mg, 40% 
1H NMR (CDCl3, 300 MHz): G = 7.80 (br s, 1H; NH), 7.48 (s, 1H; H-2), 7.20 (s, 2H; 
H-4/6), 6.50 (br s, 1H; NH), 4.80 (t, 3J = 4.8 Hz, 2H; H-9/21), 4.48 (s, 2H; H-33), 
3.34–3.25 (m, 2H; H-35), 3.10–3.00 (m, 2H; H-39), 2.88 (dd, 2J = 14.0 Hz, 3J = 4.8 
Hz, 2H; H-15), 2.78 (dd, 2J = 14.0 Hz, 3J = 4.8 Hz, 2H; H-22), 1.54–1.50 (m, 4H; H-
36/38), 1.41 (s, 45H; H-12-14/18-20/25-27/30-32/42-44), 1.29–1.27 (m, 2H; H-37) 
ppm.  
13C NMR (CDCl3, 75 MHz): G = 173.4 (C-16), 173.2 (C-23), 170.1 (C-10), 170.0 
(C-28), 169.9 (C-34), 167.1 (C-7), 167.0 (C-8), 160.5 (C-5), 157.5 (C-40), 136.4 (C-
1), 136.3 (C-3), 118.9 (C-2), 117.8 (C-4), 116.8 (C-6), 82.7 (C-11), 82.6 (C-17), 82.5 
(C-24), 82.4 (C-29), 81.7 (C-41), 67.5 (C-33), 49.8 (C-9), 49.7 (C-21), 41.9 (C-39), 
40.8 (C-35), 38.9 (C-15), 37.4 (C-22), 30.9 (C-36), 29.7 (C-38), 29.2 (C-12-14), 28.9 
(C-18-20), 28.5 (C-25-27), 28.0 (C-30-32), 27.7 (C-42-44), 24.0 (C-37) ppm.  
MS (ESI): m/z = 901.5 [M+Na]+, 877.5 (M+H).
5.2.7.13.2. (S)-3-(2-(5-(tert-Butoxycarbonylamino)pentylamino)-2-oxoethoxy)-5-
(1,4-di-tert-butoxy-1,4-dioxobutan-2-ylcarbamoyl)benzoic acid (225f) 
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Yield: 77 mg, 50% 
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1H NMR (CDCl3, 300 MHz): G = 8.06 (br s, 1H; NH), 7.78 (s, 1H, H-2), 7.26 (s, 2H; 
H-4/6), 6.60 (br s, 1H; NH), 5.12 (br s, 1H; NH), 4.90–4.80 (t, 3J = 4.8 Hz, 1H; H-9), 
4.58 (s, 1H; H-21), 3.42–3.32 (m, 2H; H-23), 3.17–3.07 (m, 2H; H-27), 2.99 (dd, 2J
= 14.0 Hz, 3J = 4.8 Hz, 1H; H-15), 2.86 (dd, 2J = 14.0 Hz, 3J = 4.8 Hz, 1H; H-15´), 
1.59–1.56 (m, 4H; H-24/26), 1.44 (s, 27H; H-12-14/18-20/30-32), 1.29–1.27 (m, 2H; 
H-25) ppm.  
13C NMR (CDCl3, 75 MHz): G = 170.4 (C-16), 169.7 (C-10), 167.1 (C-22), 165.5 
(C-8), 160.7 (C-5), 157.4 (C-28), 136.2 (C-3), 132.3 (C-1), 121.1 (C-2), 118.8 (C-6), 
116.8 (C-4), 82.7 (C-17), 81.8 (C-29), 67.6 (C-21), 52.5 (C-9), 49.7 (C-15), 38.9 (C-
27), 37.4 (C-23), 29.7 (C-24), 29.2 (C-26), 28.7 (C-30-32), 28.4 (C-12-14/18-20), 
23.9 (C-25) ppm.  
MS (EI): m/z = 651.7 [M]+.
5.2.7.14. Reaction of 5-(2-(5-(tert-Butoxycarbonylamino)pentylamino)-2-
oxoethoxy)isophthalic acid with tryptamine 
The title compound was synthesized by following general procedure 5.2.2.3.
Reactants: 5-(2-(5-(tert-butoxycarbonylamino)pentylamino)-2-oxoethoxy) 
isophthalic acid (100 mg, 0.236 mmol), EDAC (90 mg, 0.472 mmol), HOBt (77 mg, 
0.566 mmol), Et3N (145 PL, 1.04 mmol), tryptamine (91 mg, 0.566 mmol), CH2Cl2
(5 mL). 
Crude Yield: 146 mg, 88% 
A mixture of di-amidation and mono-amidation product was separated by flash 
column chromatography using ethyl acetate and hexane (40: 60) as gradient. 
5.2.7.14.1. tert-Butyl 5-(2-(3-(2-(1H-indol-3-yl)ethylcarbamoyl)-5-(2-(3a,7a-
dihydro-1H-indol-3-yl)ethylcarbamoyl)phenoxy)acetamido)pentylcarbamate
(224g)
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Yield: 80 mg, 48% 
1H NMR (CDCl3, 300 MHz): G = 8.51 (br s, 2H; NH), 7.58 (d, 3J = 7.80 Hz, 1H; H-
2), 7.45 (br s, 2H; NH), 7.32 (d, 3J = 7.80 Hz, 2H; H-4/6), 7.16 (t, 4H, 3J = 6.90 Hz; 
H-13/16), 7.06 (t, 3J = 6.90 Hz, 4H; H-14/15), 6.87 (s, 2H; H-18/28), 4.35 (s, 2H; H-
29), 3.72–3.70 (m, 4H; H-9/19), 3.30–3.20 (m, 2H; H-31), 2.99–2.90 (m, 2H; H-35), 
2.73–2.72 (m, 4H; H-10/20), 1.56–1.55 (m, 4H; H-32/34), 1.43 (s, 9H; H-38-40), 
1.28–1.26 (m, 2H; H-33) ppm.  
13C NMR (CDCl3, 75 MHz): G = 167.5 (C-30), 166.5 (C-7), 166.2 (C-8), 160.9 (C-
5), 157.4 (C-36), 136.8 (C-27), 136.7 (C-17), 136.5 (C-1), 135.0 (C-3), 127.3 (C-12), 
127.0 (C-22), 122.4 (C-14), 122.0 (C-24), 119.4 (C-25), 119.0 (C-15), 118.6 (C-23), 
118.3 (C-13), 112.9 (C-26), 112.6 (C-16), 111.5 (C-11), 111.4 (C-21), 79.5 (C-37), 
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67.3 (C-29), 42.4 (C-19), 42.0 (C-9), 40.3 (C-35), 38.9 (C-31), 30.9 (C-32), 29.6 (C-
34), 29.0 (C-10), 28.9 (C-20), 28.8 (C-32), 28.7 (C-34), 28.6 (C-38-40), 23.9 (C-33) 
ppm.  
MS (ESI): m/z = 708 [M]+.
5.2.7.14.2. 3-(2-(5-(tert-Butoxycarbonylamino)pentylamino)-2-oxoethoxy)-5-(2-
(3a,7a-dihydro-1H-indol-3-yl)ethylcarbamoyl)benzoic acid (225g) 
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Yield: 53 mg, 40% 
1H NMR (CDCl3, 300 MHz): G = 8.38 (br s, 1H; NH), 7.58 (s, 1H; H-2), 7.58 (s, 1H; 
H-6), 7.50 (s, 1H; H-4), 7.40 (br s, 2H; NH), 7.14 (t, 3J = 6.90 Hz, 2H; H-14/15), 
7.05 (t, 3J = 6.90 Hz, 2H; H-13/16), 6.90 (s, 1H; H-18), 6.45 (br s, 1H; NH), 6.35 (br 
s, 1H; NH), 4.43 (s, 2H; H-19), 3.74–3.72 (m, 2H; H-9), 3.28–3.25 (m, 2H; H-21), 
3.06–2.99 (m, 2H; H-25), 2.73–2.72 (m, 2H; H-10), 1.48–1.43 (m, 4H; H-22/24), 
1.40 (s, 9H; H-28-30), 1.29–1.26 (m, 2H; H-23) ppm.  
13C NMR (CDCl3, 75 MHz): G = 167.2 (C-7), 166.5 (C-20), 165.2 (C-8), 157.3 (C-
5), 156.1 (C-26), 136.9 (C-3), 136.5 (C-17), 132.1 (C-1), 127.3 (C-12), 122.9 (C-18), 
122.2 (C-14), 120.2 (C-2), 120.0 (C-13), 117.9 (C-6), 116.6 (C-4), 111.7 (C-15), 
110.0 (C-11), 79.5 (C-27), 67.5 (C-19), 60.4 (C-17), 40.4 (C-12), 38.9 (C-25), 38.7 
(C-21), 38.6 (C-9), 29.9 (C-10), 29.7 (C-22), 29.6 (C-24), 29.1 (C-28-30), 23.9 (C-
23) ppm.  
MS (ESI): m/z = 579.2 [M+Na]+.
5.2.7.15. Reaction of 5-(2-(5-(tert-butoxycarbonylamino)pentylamino)-2-
oxoethoxy)isophthalic acid with L-tyrosine tert-butyl ester 
The title compound was synthesized by following general procedure 5.2.2.3.
Reactants: 5-(2-(5-(tert-butoxycarbonylamino)pentylamino)-2-oxoethoxy) 
isophthalic acid (100 mg, 0.236 mmol), EDAC (90 mg, 0.472 mmol), HOBt (77 mg, 
0.566 mmol), Et3N (145 PL, 1.04 mmol), L-tyrosine tert-butyl ester (125 mg , 0.566 
mmol), CH2Cl2 (5 mL). 
Crude Yield: 187 mg, 92% 
A mixture of di-amidation and mono-amidation product was separated by flash 
column chromatography using ethyl acetate and hexane (40: 60) as gradient. 
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5.2.7.15.1. Compound (224h) 
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1H NMR (CDCl3, 300 MHz): G = 8.00 (s, 1H; H-2), 7.51 (br s, 1H; NH), 7.35 (br s, 
1H; NH), 7.31 (s, 2H; H-4/6), 7.03–6.96 (m, 4H; H-16/20/30/34), 6.80–6.73 (m, 4H; 
H-17/19/31/33), 4.90–4.87 (m, 2H; H-8/22), 4.34 (s, 2H; H-35), 3.30–3.28 (m, 2H; 
H-41), 3.19–3.18 (m, 2H; H-37), 3.17–3.06 (m, 4H; ; H-14/41), 1.55–1.48 (m, 4H; ; 
H-38/40), 1.41 (s, 27H; ; H-11-13/25-27/44-46), 1.27–1.25 (m, 2H; ; H-39) ppm.  
13C NMR (CDCl3, 75 MHz): G = 171.1 (C-9), 170.9 (C-23), 167.7 (C-36), 167.3 (C-
7), 165.7 (C-21), 157.3 (C-5), 157.2 (C-18), 156.4 (C-32), 155.8 (C-42), 136.4 (C-1), 
132.3 (C-3), 132.2 (C-15), 130.5 (C-29), 127.9 (C-16), 127.6 (C-20), 127.5 (C-30), 
127.0 (C-34), 118.4 (C-19), 117.9 (C-17), 116.8 (C-31), 115.7 (C-33), 82.9 (C-10), 
79.4 (C-24), 67.6 (C-35), 54.0 (C-8), 53.4 (C-22), 40.3 (C-41), 39.0 (C-37), 36.8 (C-
14), 31.5 (C-28), 29.6 (C-38), 29.3 (C-40), 28.9 (C-11-13/25-27), 28.3 (C-44-46), 
23.9 (C-39) ppm.  
MS (ESI): m/z = 885.5 [M+Na]+
5.2.7.16. Reaction of 5-(2-(5-(tert-butoxycarbonylamino)pentylamino)-2-
oxoethoxy)isophthalic acid with phenyl ethylamine 
The title compound was synthesized by following general procedure 5.2.2.3.
Reactants: 5-(2-(5-(tert-butoxycarbonylamino)pentylamino)-2-oxoethoxy) 
isophthalic acid (100 mg, 0.236 mmol), EDAC (90 mg, 0.472 mmol), HOBt (77 mg, 
0.566 mmol), Et3N (145 PL, 1.04 mmol), phenyl ethylamine (68.6 mg , 0.566 mmol), 
CH2Cl2 (5 mL). 
Crude Yield: 133 mg, 90% 
A mixture of di-amidation and mono-amidation product was separated by flash 
column chromatography using ethyl acetate and hexane (40: 60) as gradient. 
5.2.7.16.1. tert-Butyl 5-(2-(3,5-bis(phenethylcarbamoyl)phenoxy)acetamido)
pentylcarbamate (224i) 
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Yield: 89 mg, 60% 
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1H NMR (CDCl3, 300 MHz): G = 7.80 (s, 1H; H-2), 7.61 (s, 1H; H-6), 7.54 (s, 1H; 
H-4), 7.27–7.16 (m, 10H; H-12-16/20-24), 6.41 (br s, 1H; NH), 5.22 (br s, 1H; NH), 
4.44 (s, 2H; H-25), 3.66–3.59 (m, 4H; H-9/17), 3.27–3.26 (m, 2H; H-27), 2.92–2.88 
(m, 2H; H-31), 2.86–2.84 (m, 4H; H-10/18), 1.56–1.50 (m, 4H; H-28/30), 1.42 (s, 
9H; H-34-36), 1.29–1.25 (m, 2H; H-29) ppm.  
13C NMR (CDCl3, 75 MHz): G = 167.7 (C-26), 166.3 (C-7), 166.1 (C-8), 160.9 (C-
5), 156.3 (C-32), 137.8 (C-11), 137.7 (C-19), 135.8 (C-3), 131.1 (C-1), 128.8 (C-15), 
128.7 (C-13), 128.6 (C-21), 128.3 (C-23), 127.7 (C-12), 127.5 (C-16), 127.3 (C-20), 
127.0 (C-24), 126.5 (C-14), 125.6 (C-22), 119.9 (C-2), 117.7 (C-6), 117.1 (C-4), 79.9 
(C-33), 66.8 (C-25), 41.7 (C-9), 41.4 (C-17), 41.2 (C-31), 40.4 (C-27), 37.9 (C-10), 
35.5 (C-18), 29.9 (C-28), 29.8 (C-30), 28.7 (C-34-36), 22.9 (C-29) ppm.  
MS (ESI): m/z = 653.4 [M+Na]+.
5.2.7.16.2. 3-(2-(5-(tert-Butoxycarbonylamino)pentylamino)-2-oxoethoxy)-5-
(phenethylcarbamoyl)benzoic acid (225i) 
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Yield: 50 mg, 40% 
1H NMR (CDCl3, 300 MHz): G = 7.84 (s, 1H; H-2), 7.61 (s, 1H; H-6), 7.55 (s, 1H; 
H-4), 7.26–7.16 (m, 5H; H-12-16), 5.22 (br s, 1H; NH), 4.48 (s, 2H; H-17), 3.66–
3.64 (m, 2H; H-9), 3.29–3.27 (m, 2H; H-19), 2.90–2.88 (m, 2H; H-23), 2.86–2.84 
(m, 2H; H-10), 1.55–1.50 (m, 4H; H-20/22), 1.27–1.25 (m, 2H; H-21) ppm.  
13C NMR (CDCl3, 75 MHz): G = 167.7 (C-7), 166.3 (C-18), 164.7 (C-8), 160.7 (C-
5), 156.3 (C-24), 137.7 (C-11), 135.8 (C-3), 131.1 (C-1), 127.8 (C-13), 127.7 (C-16), 
125.6 (C-12), 125.5 (C-16), 119.9 (C-2), 117.7 (C-6), 117.1 (C-4), 79.9 (C-25), 66.8 
(C-17), 51.7 (C-23), 41.2 (C-9), 40.4 (C-19), 37.9 (C-10), 30.6 (C-20), 29.8 (C-22), 
28.7 (C-26-28), 22.9 (C-21) ppm.  
MS (EI): m/z = 527.2 [M]+.
5.2.7.17. 5-(2-(5-Aminopentylamino)-2-oxoethoxy)isophthalic acid (223) 
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The title compound was synthesized by following same general procedure mentioned 
in 5.2.4.28.
Reactants: Compound 221 (43 mg, 0.1 mmol), 18% HCl in dioxane (2 mL). 
Yield: 33 mg, 99% 
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1H NMR (CDCl3, 300 MHz): G = 8.33 (s, 1H; H-2), 7.78 (s, 1H; H-6), 7.52 (s, 1H; 
H-4), 5.33 (s, 2H; H-9), 3.32–3.27 (m, 2H; H-11), 2.88–2.83 (m, 2H; H-15), 1.57–
1.55 (m, 4H; H-12/14), 1.28–1.25 (m, 2H; H-13) ppm.  
MS (ESI): m/z = 325.2 [MH]+.
5.2.7.18. 5-(2-(5-Aminopentylamino)-2-oxoethoxy)-N1,N3-
dibenzylisophthalamide (226a) 
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The title compound was synthesized by following same general procedure mentioned 
in 5.2.4.28.
Reactants: Compound 224a (60 mg, 0.1 mmol), 18% HCl in dioxane (2 mL). 
Yield: 50 mg, 99% 
1H NMR (CDCl3, 300 MHz): G = 7.95 (s, 1H; H-2), 7.61 (s, 1H; H-6), 7.59 (s, 1H; 
H-4), 7.32–7.23 (m, 10H; H-11-15/18-22), 4.81 (s, 2H; H-23), 4.58 (s, 4H; H-9/16), 
3.35–3.32 (m, 2H; H-25), 2.82–2.79 (m, 2H; H-29), 1.55–1.50 (m, 4H; H-26/28), 
1.28–1.26 (m, 2H; H-27 ) ppm.  
MS (ESI): m/z = 502.3 [M]+, 503.3 [MH]+.   
5.2.7.19. 3-(2-(5-Aminopentylamino)-2-oxoethoxy)-5-(benzylcarbamoyl)benzoic 
acid (227a) 
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The title compound was synthesized by following same general procedure mentioned 
in 5.2.4.28.
Reactants: Compound 225a (52 mg, 0.1 mmol), 18% HCl in dioxane (2 mL). 
Yield: 42 mg, 99% 
1H NMR (CDCl3, 300 MHz): G = 7.80 (s, 1H; H-2), 7.77 (s, 1H; H-6), 7.67 (s, 1H; 
H-4), 7.54 (br s, 2H;, NH), 7.33–7.26 (m, 5H; H-11-15, 4.59 (s, 2H; H-9), 4.53 (s, 
2H; H-16), 3.32–3.00 (m, 2H; H-18), 2.99–2.97 (m, 2H; H-22), 1.52–1.50 (m, 4H; 
H-19/21), 1.28–1.25 (m, 2H; H-20) ppm. 
13C NMR (CDCl3, 75 MHz): G = 168.1 (C-7), 167.9 (C-17), 167.4 (C-8), 160.9 (C-
5), 137.9 (C-10), 136.8 (C-3), 131.5 (C-1), 128.7 (C-12), 128.4 (C-14), 127.9 (C-11), 
127.7 (C-15), 126.6 (C-13), 120.2 (C-2), 117.9 (C-6), 116.3 (C-4), 67.7 (C-16), 44.1 
(C-9), 40.3 (C-22), 40.0 (C-18), 29.7 (C-19), 28.3 (C-21), 23.9 (C-20) ppm.
MS (EI): m/z = 413 [M]+.
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5.2.7.20. 5-(2-(5-Aminopentylamino)-2-oxoethoxy)-N1,N3-bis(4-methoxybenzyl) 
isophthalamide (226b) 
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The title compound was synthesized by following same general procedure mentioned 
in 5.2.4.28.
Reactants: Compound 224b (66 mg, 0.1 mmol), 18% HCl in dioxane (2 mL). 
Yield: 56 mg, 99% 
1H NMR (CDCl3, 300 MHz): G = 7.83 ( s, 1H; H-2), 7.50 (s, 1H; H-6), 7.46 (s, 1H; 
H-4), 7.20–7.17 (m, 4H; H-11/15/19/23), 6.80–6.77 (m, 4H; H-12/14/20/22), 4.61 (s, 
2H; H-25), 4.49 (s, 4H; H-9/17), 3.70 (s, 6H; H-16/24), 3.29–3.20 (m, 2H; H-27), 
2.78–2.74 (m, 2H; H-31), 1.55–1.46 (m, 4H; H-28/30), 1.28–1.20 (m, 2H; H-29) 
ppm.  
MS (ESI): m/z = 563.3 [MH]+.
5.2.7.21. 3-(2-(5-Aminopentylamino)-2-oxoethoxy)-5-(4-methoxybenzyl 
carbamoyl)benzoic acid (227b) 
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The title compound was synthesized by following same general procedure mentioned 
in 5.2.4.28.
Reactants: Compound 225b (54 mg, 0.1 mmol), 18% HCl in dioxane (2 mL). 
Yield: 44 mg, 99% 
1H NMR (CDCl3, 300 MHz): G = 8.05 ( s, 1H; H-2), 7.64 (s, 1H; H-6 ), 7.60 (s, 1H; 
H-4), 7.22–7.19 (m, 2H; H-11/15), 6.81–6.78 (m, 2H; H-12/14), 4.49 (s, 2H; H-17), 
4.45 (s, 2H; H-9), 3.71 (s, 3H; H-16), 3.27–3.21 (m, 2H; H-19), 2.81–2.76 (m, 2H; 
H-23), 1.57–1.48 (m, 4H; H-20/22), 1.32–1.29 (m, 2H; H-21) ppm.  
MS (ESI): m/z = 442.2 [M+ņH].
5.2.7.22. 5-(2-(5-Aminopentylamino)-2-oxoethoxy)-N1,N3-bis(3-(trifluoromethyl) 
benzyl)isophthalamide (226c) 
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The title compound was synthesized by following same general procedure mentioned 
in 5.2.4.28.
Reactants: Compound 224c (74 mg, 0.1 mmol), 18% HCl in dioxane (2 mL). 
Yield: 64 mg, 99%
1H NMR (CDCl3, 300 MHz): G = 7.89 (s, 1H; H-2), 7.54–7.39 (m, 10H; H-4/6/11-
13/15/19-21/23), 4.56 (s, 2H; H-25), 4.40 (s, 4H; H-9/17), 3.27–3.23 (m, 2H; H-27), 
2.87–2.77 (m, 2H; H-31), 1.57–1.49 (m, 4H; H-28/30), 1.29–1.20 (m, 2H; H-29) 
ppm.  
MS (ESI): m/z = 639.3 [MH]+, 637.3 [M+ņH].
5.2.7.23. Compound (226d) 
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The title compound was synthesized by following same general procedure mentioned 
in 5.2.4.28.
Reactants: Compound 224d (83 mg, 0.1 mmol), 18% HCl in dioxane (2 mL). 
Yield: 72 mg, 99% 
1H NMR (CDCl3, 300 MHz): G = 7.67 (s, 1H; H-2), 7.53 (s, 1H; H-6), 7.50 (s, 1H; 
H-4), 7.11–7.01 (m, 8H; H-13-16/25-28), 6.99 (s, 2H; H-18/30), 4.98–4.95 (m, 4H; 
H-9/21/33), 3.73 (s, 6H; H-20/32), 3.32–3.27 (m, 4H; H-10/22/35), 2.78–2.73 (m, 
4H; H-10´/22´/39), 1.53–1.51 (m, 4H; H-36/38), 1.24–1.21 (m, 2H; H-37) ppm.  
MS (ESI): m/z = 725.4 [MH]+, 723.4 [M+ņH].
5.2.7.24. (S)-3-(3-(1H-Indol-3-yl)-1-methoxy-1-oxopropan-2-ylcarbamoyl)-5-(2-
(5-aminopentylamino)-2-oxoethoxy)benzoic acid (227d) 
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The title compound was synthesized by following same general procedure mentioned 
in 5.2.4.28.
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Reactants: Compound 225d (63 mg, 0.1 mmol), 18% HCl in dioxane (2 mL). 
Yield: 53 mg, 99%
1H NMR (CDCl3, 300 MHz): G = 7.99 (s, 1H; H-2), 7.71 (s, 1H; H-6), 7.56 (s, 1H; 
H-4), 7.08–7.01 (m, 4H; H-13-16), 6.99 (s, 1H; H-18), 4.65–4.60 (m, 3H; H-9/21), 
3.72 (s, 3H; H-20), 3.32–3.29 (m, 3H; H-10/23), 2.78–2.73 (m, 3H; H-10´/27), 1.53–
1.51 (m, 4H; H-24/26), 1.24–1.21 (m, 2H; H-25) ppm.  
MS (ESI): m/z = 523.3 [M+ņH].
5.2.7.25. Compound (226e) 
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The title compound was synthesized by following same general procedure mentioned 
in 5.2.5.3.
Reactants: Compound 224e (80 mg, 0.1 mmol), 20% TFA in CH2Cl2 (2 mL).
Yield: 68 mg, 99% 
1H NMR (CDCl3, 300 MHz): G = 7.92 (s, 1H; H-2), 7.53 (s, 1H; H-6), 7.49 (s, 1H; 
H-4), 7.39–7.28 (m, 10H; H-11-15/20-24), 5.71 (s, 2H; H-8/17), 4.64 (s, 2H; H-25), 
3.29–3.24 (m, 2H; H-27), 2.76–2.65 (m, 2H; H-31), 1.55–1.47 (m, 4H; H-28/30), 
1.28–1.24 (m, 2H; H-29) ppm.  
MS (ESI): m/z = 591.3 [MH]+, 589.3 [M+ņH].
5.2.7.26. (S)-3-(2-(5-Aminopentylamino)-2-oxoethoxy)-5-(carboxy(phenyl)
methylcarbamoyl)benzoic acid (227e) 
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The title compound was synthesized by following same general procedure mentioned 
in 5.2.5.3.
Reactants: Compound 225e (62 mg, 0.1 mmol), 20% TFA in CH2Cl2 (2 mL).
Yield: 50 mg, 99%
1H NMR (CDCl3, 300 MHz): G = 8.21 (s, 1H; H-2), 7.51 (s, 1H; H-6), 7.49 (s, 1H; 
H-4), 7.37–7.25 (m, 5H; H-11-15), 5.29 (s, 1H; H-9), 4.60 (s, 2H; H-17), 3.28–3.23 
(m, 2H; H-19), 2.76–2.65 (m, 2H; H-23), 1.55–1.47 (m, 4H; H-20/22), 1.28–1.24 (m, 
2H; H-21) ppm.  
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MS (EI): m/z = 457.3 [M]+.
5.2.7.27. Compound (226f) 
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The title compound was synthesized by following same general procedure mentioned 
in 5.2.5.3.
Reactants: Compound 224f (88 mg, 0.1 mmol), 20% TFA in CH2Cl2 (2 mL).
Yield: 75 mg, 99%
1H NMR (CDCl3, 300 MHz): G = 7.84 (s, 1H; H-2), 7.52 (s, 1H; H-6), 7.51 (s, 1H; 
H-4), 4.59 (s, 4H; H-8/13/17), 3.28–3.24 (m, 2H; H-19), 2.93–2.91 (m, 2H; H-9/15), 
2.84–2.77 (m, 4H; H-9´/15´/23), 1.55–1.48 (m, 4H; H-20/22), 1.27–1.25 (m, 2H; H-
21) ppm.  
MS (ESI): m/z = 555.2 [MH]+, 553.2 [M+ņH].
5.2.7.28. (S)-2-(3-(2-(5-Aminopentylamino)-2-oxoethoxy)-5-carboxybenzamido) 
succinic acid (227f) 
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The title compound was synthesized by following same general procedure mentioned 
in 5.2.5.3.
Reactants for Boc-deprotection: Compound 225f (65 mg, 0.1 mmol), 20% TFA in 
CH2Cl2 (2 mL).
Yield: 52 mg, 99%
1H NMR (CDCl3, 300 MHz): G = 8.11 (s, 1H; H-2), 7.80 (s, 1H; H-6), 7.74 (s, 1H; 
H-4), 4.71 (s, 3H; H-9/13), 3.35–3.30 (m, 2H; H-15), 3.00–2.98 (m, 1H; H-11), 
2.84–2.77 (m, 3H; H-11´/19), 1.55–1.48 (m, 4H; H-16/18), 1.29–1.23 (m, 2H; H-17) 
ppm.  
MS (EI): m/z = 439.3 [M]+.
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5.2.7.29. N1-(2-(1H-Indol-3-yl)ethyl)-5-(2-(5-aminopentylamino)-2-oxoethoxy)-
N3-(2-(3a,7a-dihydro-1H-indol-3-yl)ethyl)isophthalamide (226g) 
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The title compound was synthesized by following same general procedure mentioned 
in 5.2.4.28.
Reactants: Compound 224g (88 mg, 0.1 mmol), 18% HCl in dioxane (2 mL). 
Yield: 76 mg, 99%
1H NMR (CDCl3, 300 MHz): G = 7.60 (s, 1H; H-2), 7.54 (s, 1H; H-6), 7.51 (s, 1H; 
H-4), 7.19–7.01 (m, 8H; H-13-16/23-26), 6.95 (s, 2H; H-18/28), 4.60 (s, 2H; H-29), 
3.63–3.60 (m, 4H; H-9/19), 3.29–3.23 (m, 2H; H-31), 3.00–2.90 (m, 2H; H-35), 
2.73–2.72 (m, 4H; H-10/20), 1.56–1.55 (m, 4H; H-32/34), 1.28–1.25 (m, 2H; H-33) 
ppm.  
MS (ESI): m/z = 609.3 [MH]+, 607.3 [M+ņH].
5.2.7.30. 3-(2-(5-Aminopentylamino)-2-oxoethoxy)-5-(2-(3a,7a-dihydro-1H-indol 
-3-yl)ethylcarbamoyl)benzoic acid (227g) 
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The title compound was synthesized by following same general procedure mentioned 
in 5.2.4.28.
Reactants: Compound 225g (57 mg, 0.1 mmol), 18% HCl in dioxane (2 mL). 
Yield: 40 mg, 99% 
1H NMR (CDCl3, 300 MHz): G = 7.96 (s, 1H; H-2), 7.74 (s, 1H; H-6), 7.41 (s, 1H; 
H-4), 7.19–7.01 (m, 4H; H-13-16), 6.95 (s, 1H; H-18), 4.63 (s, 2H; H-19), 3.64–3.60 
(m, 2H; H-9), 3.29–3.23 (m, 2H; H-21), 3.00–2.92 (m, 2H; H-25), 2.73–2.72 (m, 2H; 
H-10), 1.56–1.55 (m, 4H; H-22/24), 1.28–1.25 (m, 2H; H-23) ppm.  
MS (ESI): m/z = 467.3 [M+ņH].
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5.2.7.31. Compound (226h) 
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The title compound was synthesized by following same general procedure mentioned 
in 5.2.5.3.
Reactants: Compound 224h (86 mg, 0.1 mmol), 20% TFA in CH2Cl2 (2 mL).
Yield: 75 mg, 99% 
1H NMR (CDCl3, 300 MHz): G = 8.29 (s, 1H; H-2), 7.99 (s, 1H; H-6), 7.79 (s, 1H; 
H-4), 7.06–7.00 (m, 4H; H-11/15/21/25), 6.72–6.68 (m, 4H; H-12/14/22/24), 4.88–
4.82 (m, 4H; H-8/18/27), 3.34–3.32 (m, 4H; H-9/19/29), 3.09–3.01 (m, 2H; H-
9´/19´), 2.84–2.81 (m, 2H; H-33), 1.55–1.48 (m, 4H; H-30/32), 1.27–1.25 (m, 2H; H-
31) ppm. 
MS (ESI): m/z = 650.6 [M]+.
5.2.7.32. 5-(2-(5-Aminopentylamino)-2-oxoethoxy)-N1,N3-diphenethylisophthal
amide (226i) 
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The title compound was synthesized by following same general procedure mentioned 
in 5.2.4.28.
Reactants: Compound 224i (63 mg, 0.1 mmol), 18% HCl in dioxane (2 mL). 
Yield: 53 mg, 99% 
1H NMR (CDCl3, 300 MHz): G = 7.80 (s, 1H; H-2), 7.42 (s, 1H; H-6), 7.34 (s, 1H; 
H-4), 7.30–7.21 (m, 10H; H-12-16/20-24), 5.25 (s, 2H; H-25), 3.57–3.50 (m, 4H; H-
9/17), 3.31–3.28 (m, 2H; H-27), 2.85–2.80 (m, 4H; H-10/18), 2.65–2.60 (m, 2H; H-
31), 1.56–1.55 (m, 4H; H-28/30), 1.28–1.25 (m, 2H; H-29) ppm.  
MS (ESI): m/z = 531.4 [MH]+.
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5.2.7.33. 3-(2-(5-Aminopentylamino)-2-oxoethoxy)-5-(phenethylcarbamoyl)
benzoic acid (227i)
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The title compound was synthesized by following same general procedure mentioned 
in 5.2.4.28.
Reactants: Compound 225i (53 mg, 0.1 mmol), 18% HCl in dioxane (2 mL). 
Yield: 41 mg, 99% 
1H NMR (CDCl3, 300 MHz): G = 7.99 (s, 1H; H-2), 7.64 (s, 1H; H-6), 7.54 (s, 1H; 
H-4), 7.22–7.12 (m, 5H; H-12-16), 4.65 (s, 2H; H-17), 3.57–3.52 (m, 2H; H-9), 
3.28–3.24 (m, 2H; H-19), 2.87–2.80 (m, 2H; H-10), 2.79–2.65 (m, 2H; H-23), 1.56–
1.51 (m, 4H; H-20/22), 1.28–1.24 (m, 2H; H-21) ppm.  
MS (ESI): m/z = 427.3 [M]+, 428.3 [MH]+.
5.2.8. Synthesis of Proteasome Inhibitors
5.2.8.1. (S)-tert-Butyl 3-(benzyloxycarbonylamino)-4-((S)-1-hydroxy-4-methyl 
pentan-2-ylamino)-4-oxobutanoate (231)
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EDAC (191 mg, 1.0 mmol) and HOBt (183 mg, 1.2 mmol) were added to a solution 
of Z-Asp(OtBu)-OH (228, 323 mg, 1.0 mmol) dissolved in CH2Cl2 (10 mL). The 
resulting mixture was stirred at ambient temperature for 5 min, then treated with L-
leucinol (117 mg, 1.0 mmol) and Et3N (151 mg, 1.5 mmol) for 24 h. CH2Cl2 (20 mL) 
was added and the solution was washed with HCl (0.1 N, 5 u 30 mL), NaOH (0.1 N, 
3 u30 mL), brine (1 u 30 mL), dried over anhydrous Na2SO4, and concentrated to 
obtain the product 231 (BSc2094).
Yield: 350 mg, 83% 
1H NMR (CDCl3, 300 MHz): G = 7.24–7.21 (m, 5H; H-2-6), 6.45 (d, 1H; NH), 5.95 
(d, 1H; NH), 5.03 (s, 2H; H-7), 4.43–4.40 (m, 1H; H-9), 3.57 (dd, 2J = 11.0 Hz, 3J = 
3.3 Hz, 1H; H-12), 3.40 (dd, 2J = 11.0 Hz, 3J = 3.3 Hz, 1H; H-12´), 2.79 (d, 1H, 3J = 
4.3 Hz; H-17), 2.59 (d, 1H, 3J = 4.3 Hz; H-17´), 1.87 (m, 1H; H-14), 1.54–1.50 (m, 
2H; H-13), 1.34 (s, 9H; H-20-22), 0.90–0.87 (m, 6H; H-15/16) ppm.  
13C NMR (CDCl3, 75 MHz): G = 171.3 (C-18), 171.0 (C-10), 156.2 (C-8), 136.1 (C-
1), 128.6 (C-3), 128.4 (C-5), 128.2 (C-4), 127.8 (C-2), 127.7 (C-6), 82.0 (C-19), 67.3 
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(C-12), 65.5 (C-7), 52.2 (C-9), 51.5 (C-11), 40.0 (C-13), 37.5 (C-17), 28.8 (C-20-22), 
24.7 (C-15), 23.2 (C-16), 22.1 (C-14) ppm. 
MS (ESI): m/z (%) [M]+ 422 (40). 
5.2.8.2. (S)-tert-Butyl 3-amino-4-((S)-1-hydroxy-4-methylpentan-2-ylamino)-4-
oxobutanoate (233) 
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A solution of Z-Asp(OtBu)-Leucinol 231 (422 mg, 0.8 mmol) in absolute ethanol (10 
mL) was treated with palladium on activated carbon (100 mg) under hydrogen 
atmosphere at room temperature. The suspension was filtered after 3 h and the 
solvent was removed in vacuo to yield 233 (BSc2113).
Yield: 228 mg, 100% 
5.2.8.3 (S)-tert-Butyl 3-((S)-2-(tert-butoxycarbonylamino)-4-methylpentanamido)
-4-((S)-1-hydroxy-4-methylpentan-2-ylamino)-4-oxobutanoate (238) 
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EDAC (157 mg, 0.82 mmol) and HOBt (132 mg, 0.98 mmol) were added to the 
solution of Boc-Leu-OH (235, 189 mg, 0.82 mmol) in CH2Cl2 (10 mL). The resulting 
mixture was stirred at ambient temperature for 5 min, then treated with 233 (228 mg, 
0.82 mmol) and Et3N (124 mg, 1.23 mmol) for 24 h. CH2Cl2 (20 mL) was added and 
the solution was washed with HCl (0.1 N, 5 u 30 mL), NaOH (0.1 N, 3 u 30 mL), 
and brine (1 u 30 mL). The solvent was removed after drying (Na2SO4) in vacuo to 
yield 238 (BSc2114).
Yield: 400 mg, 97%
1H NMR (CDCl3, 300 MHz): G = 7.65 (d, 3J = 8.3 Hz, 1H; NH), 6.8 (d, 3J = 8.3 Hz, 
1H; NH), 5.03 (d, 3J = 8.3 Hz, 1H; H-3), 4.55–4.45 (m, 1H; H-1), 3.99–3.89 (m, 1H; 
H-5), 3.57 (dd, 2J = 11.0 Hz, 3J = 3.3 Hz, 1H; H-6), 3.47 (dd, 2J = 11.0 Hz, 3J = 3.3 
Hz, 1H; H-6´), 2.99 (d, 3J = 4.3 Hz, 1H; H-20), 2.58 (d, 3J = 4.3 Hz, 1H; H-20´), 
2.15–2.14 (m, 2H; H-8/12), 1.86–1.76 (m, 2H; H-11), 1.51–1.47 (m, 2H; H-7), 1.44 ( 
s, 9H; H-17-19), 1.34 (s, 9H; H-23-25), 0.90–0.87 (m, 6H; H-9-10), 0.80–0.75 (m, 
6H; H-13-14) ppm.  
13C NMR (CDCl3, 75 MHz): G = 173.0 (C-21), 171.5 (C-2), 170.5 (C-4), 156.3 (C-
15), 81.9 (C-22), 81.0 (C-16), 65.6 (C-6), 54.3 (C-1), 50.6 (C-3), 50.5 (C-5), 40.8 (C-
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11), 39.7 (C-7), 35.9 (C-20), 28.9 (C-17-19), 28.7 (C-23-25), 23.2 (C-8), 22.2 (C-12), 
21.6 (C-9), 21.5 (C-10), 21.1 (C-13), 21.0 (C-14) ppm. 
MS (EI): m/z = 501 [M]+.
5.2.8.4. (S)-tert-Butyl 3-((S)-2-(benzyloxycarbonylamino)-4-methylpentanamido)
-4-((S)-1-hydroxy-4-methylpentan-2-ylamino)-4-oxobutanoate (239) 
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The title compound 239 (BSc2117) was prepared from 233 according to the same 
procedure as mentioned in 5.2.8.3.
Reactants: EDAC (157.1 mg, 0.82 mmol) and HOBt (132.9 mg, 0.98 mmol), Z-Leu-
OH (236, 210.8 mg, 0.82 mmol), CH2Cl2 (10 mL), H-Asp(tBoc)-Leucinol (228 mg, 
0.82 mmol), Et3N ( 124.4 mg, 1.23 mmol). 
Yield: 420 mg, 96% 
1H NMR (CDCl3, 300 MHz): G = 7.51 (d, 3J = 8.3 Hz, 1H; NH), 7.29–7.19 (m, 5H; 
H-2-6), 6.70 (d, 3J = 8.3 Hz, 1H; NH), 5.35 (d, 3J = 8.3 Hz, 1H; NH), 5.50 (s, 2H; H-
7), 4.60–4.58 (m, 1H; H-11), 4.10–4.75 (m, 1H; H-9), 3.95–3.87 (m, 1H; H-13), 3.58 
(dd, 2J = 11.0 Hz, 3J = 3.3 Hz, 1H; H-14), 3.45 (dd, 2J = 11.0 Hz, 3J = 3.3 Hz, 1H; H-
14´), 2.89 (dd, 2J = 16.0 Hz, 3J = 4.1 Hz, 1H; H-23), 2.80 (d, 2J = 16.0 Hz, 3J = 4.1 
Hz, 1H; H-23´), 2.15–2.05 (m, 2H; H-20), 2.00–1.96 (m, 2H; H-16), 1.90–1.78 (m, 
2H; H-19), 1.61–1.50 (m, 2H; H-15), 1.34 (s, 9H; H-26-28), 0.89 (dd, 3J = 7.0 Hz, 4J
= 4.3 Hz, 6H; H-17-18), 0.80 (dd, 3J = 7.0 Hz, 4J = 4.3 Hz, 6H; H-21-22) ppm.  
13C NMR (CDCl3, 75 MHz): G = 167.0 (C-24), 166.2 (C-10), 165.1 (C-12), 151.4 
(C-8), 130.4 (C-1), 129.3 (C-3), 129.1 (C-5), 127.1 (C-4), 127.0 (C-2), 126.9 (C-6), 
77.1 (C-25), 76.6 (C-14), 62.2 (C-7), 60.2 (C-9), 49.0 (C-11), 45.8 (C-13), 41.2 (C-
19), 40.0 (C-15), 35.6 (C-23), 28.8 (C-26-28), 22.7 (C-17), 22.7 (C-18), 22.7 (C-21), 
22.3 (C-22), 19.5 (C-16), 17.8 (C-20) ppm. 
MS (EI): m/z = 535 [M]+.
5.2.8.5. (S)-tert-Butyl 3-((S)-2-acetamido-4-methylpentanamido)-4-((S)-1-
hydroxy-4-methylpentan-2-ylamino)-4-oxobutanoate (240)  
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The title compound 240 (BSc2207) was prepared from 233 according to the same 
procedure as mentioned in 5.2.8.3.
Experimental 171
Reactants: EDAC (147 mg, 1 mmol), HOBt (162 mg, 1.2 mmol), Et3N (278 PL, 2 
mmol), (S)-tert-Butyl 3-amino-4-((S)-1-hydroxy-4-methylpentan-2-ylamino)-4-
oxobutanoate (233) (288 mg, 1.0 mmol), Ac-Leu-OH (207 mg, 1.2 mmol), CH2Cl2 (5
mL).
Yield: 411 mg, 93%
1H NMR (CDCl3, 300 MHz): G = 7.67 (d, 3J = 8.3 Hz, 1H; NH), 7.40 (d, 3J = 9.2 
Hz, 1H; NH), 7.26 (d, 3J = 8.4 Hz, 1H; NH), 4.70–4.63 (m, 1H; H-3), 4.43–4.33 (m, 
1H; H-1), 4.04–3.94 (m, 1H; H-5), 3.30 (dd, 2J = 17.0 Hz, 3J = 4.8 Hz, 1H; H-6), 2.8 
(dd, 2J = 17.0 Hz, 3J = 4.8 Hz, 1H; H-6´), 2.65–2.55 (m, 1H; H-17), 2.54–2.45 (m, 
1H; H-17´), 2.15–2.05 (m, 2H; H-8/12), 2.00 (d, 3J = 15.0 Hz, 3H; H-16), 1.97–1.87 
(m, 2H; H-7), 1.75–1.69 (m, 2H; H-11), 1.44 (s, 9H; H-20-22), 0.90–0.87 (m, 6H; H-
9-10), 0.80–0.78 (m, 6H; H-13-14) ppm.  
13C NMR (CDCl3, 75 MHz): G = 172.5 (C-18), 172.3 (C-4), 171.6 (C-2), 169.9 (C-
15), 82.0 (C-19), 66.6 (C-6), 53.4 (C-3), 50.4 (C-1), 49.5 (C-5), 40.8 (C-17), 28.9 (C-
20-22), 25.0 (C-9), 24.7 (C-10), 22.9 (C-8), 23.2 (C-13), 23.1 (C-14), 22.1 (C-12) 
ppm.
MS (EI): m/z = 443 [M]+.
5.2.8.6. (S)-Benzyl 3-((S)-2-acetamido-4-methylpentanamido)-4-((S)-1-hydroxy-
4-methylpentan-2-ylamino)-4-oxobutanoate (241)
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The title compound 241 (BSc2195) was prepared from 234 (BSc2193) according to 
the same procedure as mentioned in 5.2.8.3.
Reactants: EDAC (147 mg, 1 mmol), HOBt (162 mg, 1.2 mmol), Et3N (278 PL, 2 
mmol), (S)-benzyl 3-((S)-1-hydroxy-4-methylpentan-2-ylcarbamoyl)-3-
aminopropanoate (234) (322 mg, 1.0 mmol), Ac-Leu-OH (207 mg, 1.2 mmol), 
CH2Cl2 (5 mL).
Yield: 419 mg, 88%. 
1H NMR (CDCl3, 300 MHz): G = 8.26 (d, 3J = 7.2 Hz, 1H; NH), 7.59 (m, 5H; H-21-
25), 6.70 (d, 3J = 7.3 Hz, 1H; NH), 6.35 (d, 3J = 7.0 Hz, 1H; NH), 5.20 (s, 2H; H-19), 
4.62–4.48 (m, 1H; H-3), 4.44–4.42 (m, 1H; H-1), 4.01–4.00 (m, 1H; H-5), 3.98–3.97 
(m, 1H; H-6), 3.91–3.90 (m, 1H; H-6´), 2.89–2.88 (m, 1H; H-17), 2.80–2.78 (m, 1H; 
H-17´), 2.59–2.58 (m, 1H; H-8), 2.50–2.49 (m, 1H; H-12), 2.00–1.99 (m, 2H; H-11), 
1.55–1.54 (m, 2H; H-7), 1.34 (s, 3H; H-16), 0.89 (dd, 3J = 3.8 Hz, 6.7 Hz, 6H; H-9-
10), 0.80 (dd, 3J = 3.8 Hz, 6.7 Hz, 6H; H-13-14) ppm. 
13C NMR (CDCl3, 75 MHz): G = 175.5 (C-18), 173.7 (C-4), 173.0 (C-2), 169.7 (C-
15), 140.1 (C-20), 128.8 (C-22), 128.3 (C-24), 127.7 (C-23), 127.4 (C-21), 127.1 (C-
25), 68.5 (C-19), 66.5 (C-6), 50.7 (C-1), 50.1 (C-3), 48.4 (C-5), 41.4 (C-11), 40.8 (C-
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7), 40.2 (C-17), 23.9 (C-9), 23.8 (C-10), 23.7 (C-13), 23.6 (C-14), 22.9 (C-12), 22.7 
(C-8), 22.6 (C-16) ppm. 
MS (EI): m/z = 477 [M]+.
5.2.8.7. (S)-Benzyl 3-((S)-2-(benzyloxycarbonylamino)-4-methylpentanamido)-4-
((S)-1-hydroxy-4-methylpentan-2-ylamino)-4-oxobutanoate (242)
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The title compound 242 (BSc2196) was prepared from 234 (BSc2193) according to 
the same procedure as mentioned in 5.2.8.3.
Reactants: EDAC (147 mg, 1 mmol), HOBt (162 mg, 1.2 mmol), Et3N (278 PL, 2 
mmol), (S)-benzyl 3-((S)-1-hydroxy-4-methylpentan-2-ylcarbamoyl)-3-
aminopropanoate (234) (322 mg, 1.0 mmol), Z-Leu-OH (318 mg, 1.2 mmol), CH2Cl2
(5 mL).
Yield: 438 mg, 77%.
1H NMR (CDCl3, 300 MHz): G = 7.29–7.19 (m, 10H; H-18-22/28-32), 6.65 (d, 3J = 
7.0 Hz, 1H; NH), 6.33 (d, 3J = 7.0 Hz, 1H; NH), 5.35 (s, 4H; H-16/26), 5.28–5.17 
(m, 1H; H-3), 4.22–4.21 (m, 1H; H-1), 4.00–3.99 (m, 1H; H-5), 3.74–3.73 (m, 1H; 
H-6), 3.66–3.65 (m, 1H; H-6´), 3.223.21 (m, 1H; H-26), 2.99–2.98 (m, 1H; H-26´), 
2.92–2.91 (m, 1H; H-8), 2.62–2.60 (m, 1H; H-12), 2.50–2.51 (m, 2H; H-11), 1.57–
1.56 (m, 2H; H-7), 0.87 (dd, 3J = 6.4 Hz, 4J = 3.8 Hz, 6H; H-9/10), 0.80 (dd, 3J = 6.4 
Hz, 4J =3.8 Hz, 6H; H-13/14) ppm. 
13C NMR (CDCl3, 75 MHz): G = 172.4 (C-24), 172.0 (C-4), 170.2 (C-1), 156.8 (C-
15), 142.8 (C-17), 135.8 (C-27), 128.7 (C-19), 128.6 (C-21), 128.5 (C-31), 128.4 (C-
29), 128.3 (C-20), 128.1 (C-30), 127.9 (C-18), 127.7 (C-22), 127.6 (C-28), 127.5 (C-
32), 68.5 (C-26), 67.2 (C-6), 62.2 (C-16), 52.0 (C-1), 49.8 (C-3), 49.2 (C-5), 41.6 (C-
11), 40.4 (C-7), 33.1 (C-23), 23.4 (C-9), 23.1 (C-10), 22.6 (C-8), 22.4 (C-13), 22.3 
(C-14), 22.1 (C-12) ppm. 
MS (EI): m/z = 569 [M]+.
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5.2.8.8. (S)-Benzyl 3-((S)-2-(tert-butoxycarbonylamino)-4-methylpentanamido)-
4-((S)-1-hydroxy-4-methylpentan-2-ylamino)-4-oxobutanoate (243)
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The title compound 243 (BSc2194) was prepared from 234 (BSc2193) according to 
the same procedure as mentioned in 5.2.8.3.
Reactants: EDAC (147 mg, 1 mmol), HOBt (162 mg, 1.2 mmol), Et3N (278 PL, 2 
mmol), (S)-benzyl 3-((S)-1-hydroxy-4-methylpentan-2-ylcarbamoyl)-3-aminopropan 
oate (234) (322 mg, 1.0 mmol), Boc-Leu-OH (277 mg, 1.2 mmol), CH2Cl2 (5 mL). 
Yield: 481 mg, 90%.
1H NMR (CDCl3, 300 MHz): G = 7.32–7.28 (m, 5H; H-24-28), 7.01 (d, 3J = 7.0 Hz, 
1H; H-NH), 6.33 (d, 3J = 7.0 Hz, 1H; NH), 5.32 (s, 2H; H-22), 4.91 (d, 3J = 7.0 Hz, 
1H; H-1), 4.25–4.22 (m, 1H; H-3), 4.08–4.06 (m, 1H; H-5), 3.98–3.97 (m, 1H; H-6), 
3.68–3.65 (m, 2H; H-6´), 2.99–2.97 (m, 1H; H-20), 2.92–2.86 (m, 1H; H-20´), 1.97–
1.87 (m, 2H; H-8/12), 1.55–1.54 (m, 1H; H-11), 1.50–1.47 (m, 2H; H-7), 1.34 (s, 9H; 
H-17-19), 0.89 (dd, 3J = 3.8 Hz, 6.4 Hz, 6H; H-9-10), 0.80 (dd, 3J = 3.8 Hz, 6.4 Hz, 
6H; H-13-14) ppm.  
13C NMR (CDCl3, 75 MHz): G = 172.8 (C-21), 172.4 (C-4), 170.1 (C-2), 155.8 (C-
15), 135.4 (C-23), 128.6 (C-25), 128.5 (C-27), 128.4 (C-26), 128.3 (C-24), 128.1(C-
28), 77.1 (C-16), 67.2 (C-22), 62.2 (C-6), 52.5 (C-1), 50.7 (C-3), 49.0 (C-5), 45.8 (C-
11), 41.2 (C-7), 35.6 (C-20), 28.7 (C-17-19), 24.4 (C-9), 23.1 (C-10), 22.7 (C-13), 
22.4 (C-14), 22.1 (C-8), 21.6 (C-12) ppm.  
MS (EI): m/z = 535 [M]+.
5.2.8.9. (S)-tert-Butyl 3-((S)-2-(tert-butoxycarbonylamino)-4-
methylpentanamido)-4-((S)-4-methyl-1-oxopentan-2-ylamino)-4-oxobutanoate
(244)
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Compound 238 (BSc2114) (400 mg, 0.8 mmol) was oxidized with IBX (2-
iodoxybenzoic acid, 268 mg, 0.95 mmol) in DMSO (5 mL) at room temperature for 6 
h. CH2Cl2 (30 mL) was added and the solution was washed with water (3 u 30 mL), 
NaHCO3 solution (3 u 30 mL, sat.), and brine (1 u 30 mL). The solvent was removed 
after drying (Na2SO4) under vacuum to yield 244 (BSc2115).
Experimental 174
Yield: 390 mg, 98%
1H NMR (CDCl3, 300 MHz): G = 9.4 (s, 1H; H-6), 7.54 (d, 3J = 8.3 Hz, 1H; NH), 
7.27 (d, 3J = 8.3 Hz, 1H; NH), 4.89 (d, 3J = 8.3 Hz, 1H; H-3), 4.66–4.56 (m, 2H; H-
1/5), 2.99 (dd, 2J = 11.0 Hz, 3J = 3.3 Hz, 1H; H-20), 2.69 (dd, 2J = 11.0 Hz, 3J = 3.3 
Hz, 1H; H-20´), 2.00–1.95 (m, 2H; H-11), 1.88–1.80 (m, 2H; H-7), 1.66–1.55 (m, 
1H; H-8), 1.47–1.45 (m, 1H; H-12), 1.44 (s, 9H; H-17-19), 1.34 (s, 9H; H-23-25), 
0.90–0.86 (m, 6H; H-9-10), 0.80–0.76 (m, 6H; H-13-14) ppm.
13C NMR (CDCl3, 75 MHz): G = 200.1 (C-6), 172.6 (C-21), 171.6 (C-4), 170.9 (C-
2), 156.2 (C-15), 82.0 (C-22), 80.8 (C-16), 54.3 (C-1), 50.6 (C-3), 50.5 (C-5), 40.8 
(C-11), 39.7 (C-20), 35.9 (C-7), 28.9 (C-17-19), 28.6 (C-23-25), 23.2 (C-8), 22.2 (C-
12), 21.6 (C-9), 21.5 (C10), 21.4 (C-13), 21.0 (C-14) ppm.  
MS (EI): m/z = 499 [M]+.
5.2.8.10. (S)-tert-Butyl 3-((S)-2-(benzyloxycarbonylamino)-4-methylpentan 
amido)-4-((S)-4-methyl-1-oxopentan-2-ylamino)-4-oxobutanoate (245) 
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The title compound 245 (BSc2118) was prepared from 239 (BSc2117) by following 
general procedure 5.2.2.1.
Reactants: IBX (268.2 mg, 0.94 mmol), Z-Leu-Asp(tBoc)-Leucinol (420 mg, 0.78 
mmol), DMSO (5 mL).
Yield: 400 mg, 96% 
1H NMR (CDCl3, 300 MHz): G = 9.49 (s, 1H; H-14), 7.48 (d, 3J = 8.3 Hz, 1H; NH), 
7.35–7.33 (m, 5H; H-2-6), 7.25 (d, 3J = 7.3 Hz, 1H; NH), 5.23–5.22 (m, 1H; H-11), 
5.12 (s, 2H; H-7), 4.80–4.79 (m, 1H; H-9), 4.38–4.37 (m, 1H; H-13), 3.00 (d, 3J = 
3.3 Hz, 1H; H-23), 2.98 (d, 3J = 3.3 Hz, 1H; H-23´), 2.30–2.28 (m, 2H; H-15), 2.23–
2.22 (m, 2H; H-19), 1.77–1.76 (m, 1H; H-16), 1.70–1.67 (m, 1H; H-20), 1.44 (s, 9H; 
26-28), 0.89–0.86 (m, 6H; H-17-18), 0.80–0.78 (m, 6H; H-21-22) ppm. 
13C NMR (CDCl3, 75 MHz): G = 200 (C-14), 172.1 (C-24), 171.6 (C-12), 170.8 (C-
10), 156.0 (C-8), 135.9 (C-1), 128.7 (C-3), 128.4 (C-5), 128.1 (C-2), 128.0 (C-6), 
82.1 (C-25), 67.4 (C-7), 57.5 (C-9), 54.5 (C-11), 49.8 (C-13), 41.1 (C-19), 37.4 (C-
15), 36.5 (C-23), 28.8 (C-26-28), 24.5(C-17), 23.3 (C-18), 23.0 (C-21), 21.7 (C-22), 
21.6 (C-16), 21.0 (C-20) ppm.  
MS (ESI): m/z = 533 [M]+.
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5.2.8.11. (S)-Benzyl 3-((S)-2-acetamido-4-methylpentanamido)-4-((S)-4-methyl-
1-oxopentan-2-ylamino)-4-oxobutanoate (246) 
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The title compound 246 (BSc2208) was prepared from 241 (BSc2195) by following 
general procedure 5.2.2.1.
Reactants: IBX (268.2 mg, 0.94 mmol), Ac-Leu-Asp(OBn)-Leucinol (294 mg, 0.78 
mmol), DMSO (5 mL).
Yield: 216 mg, 74%. 
1H NMR (CDCl3, 300 MHz): G = 9.40 (s, 1H; H-6), 8.26 (d, 3J = 7.0 Hz, 1H; NH), 
7.28–7.19 (m, 5H; H-21-25), 6.70 (d, 3J = 7.0 Hz, 1H; NH), 5.65 (d, 3J = 7.0 Hz, 1H; 
NH), 5.30 (s, 2H; H-19), 4.82–4.81 (m, 1H; H-3), 4.35–4.33 (m, 1H; H-1), 3.96–3.95 
(m, 1H; H-5), 2.80–2.79 (m, 1H; H-17), 2.75–2.74 (m, 1H; H-17´), 2.49–2.48 (m, 
1H; H-8), 2.45–2.44 (m, 1H; H-12), 2.0–1.98 (m, 2H; H-7), 1.51–1.50 (m, 1H; H-
11), 1.30 (s, 3H; H-16), 0.89 (dd, 3J = 3.8 Hz, 6.4 Hz, 6H; H-9-10), 0.80 (dd, 3J = 3.8 
Hz, 6.4 Hz, 6H; H-13-14) ppm.  
13C NMR (CDCl3, 75 MHz): G = 200 (C-6), 174.5 (C-18), 173.5 (C-4), 173.0 (C-2), 
170.0 (C-15), 141.7 (C-20), 128.6 (C-22), 128.3 (C-24), 127.7 (C-23), 127.6 (C-21), 
127.5 (C-25), 68.5 (C-19), 50.7 (C-1), 50.4 (C-3), 49.9 (C-5), 41.4 (C-11), 40.8 (C-
7), 23.6 (C-9), 23.5 (C-10), 23.4 (C-8), 23.1 (C-13), 23.0 (C-14), 22.9 (C-12), 22.4 
(C-16) ppm. 
MS (EI): m/z = 475 [M]+.
5.2.8.12. (S)-Benzyl 3-((S)-2-(benzyloxycarbonylamino)-4-methylpentanamido)-
4-((S)-4-methyl-1-oxopentan-2-ylamino)-4-oxobutanoate (247)
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The title compound 247 (BSc2197) was prepared from 242 (BSc2196) by following 
general procedure 5.2.2.1.
Reactants: IBX (268.2 mg, 0.94 mmol), Z-Leu-Asp(OBn)-Leucinol (443 mg, 0.78 
mmol), DMSO (5 mL).
Yield: 327 mg, 74%.
Experimental 176
1H NMR (CDCl3, 300 MHz): G = 9.33 (s, 1H; H-6), 7.26–7.19 (m, 10H; H-18-
22/27-31), 7.03 (d, 3J = 7.0 Hz, 1H; H-NH), 6.41 (d, 3J = 7.0 Hz, 1H; NH), 5.66 (d, 
3J = 7.0 Hz, 1H; NH), 5.23–4.95 (s, 4H; H-16/25), 4.26–4.13 (m, 1H; H-3), 4.12–
4.03 (m, 1H; H-1), 3.57–3.54 (m, 1H; H-5), 2.94 (d, 3J = 7.3 Hz, 1H; H-23), 2.72 (d, 
3J = 7.3 Hz , 1H; H-23´), 1.93–1.86 (m, 1H; H-8), 1.83–1.81 (m, 1H; H-12), 1.57–
1.44 (m, 2H; H-11), 1.45–1.42 (m, 1H; H-7), 0.87 (dd, 3J = 3.8 Hz, 6.4 Hz, 6H; H-9-
10), 0.80 (dd, 3J = 3.8 Hz, 6.4 Hz, 6H; H-13-14) ppm. 
13C NMR (CDCl3, 75 MHz): G = 200 (C-6), 173.4 (C-24), 172.6 (C-4), 171.2 (C-2), 
156.8 (C-15), 142.8 (C-17), 142.1 (C-26), 129.0 (C-19), 128.9 (C-21), 128.7 (C-30), 
128.7 (C-28), 128.6 (C-20), 128.5 (C-29), 127.9 (C-18), 127.8 (C-22), 127.7 (C-27), 
127.3 (C-31), 66.5 (C-25), 65.2 (C-16), 52.0 (C-1), 49.7 (C-3), 48.2 (C-5), 41.7 (C-
11), 40.6 (C-7), 33.5 (C-23), 22.6 (C-9), 22.3 (C-10), 21.9 (C-8), 21.5 (C-13), 21.4 
(C-14), 21.0 (C-12) ppm.
MS (ESI): m/z = 567 [M]+.
5.2.8.13. (S)-3-((S)-2-Amino-4-methylpentanamido)-4-((S)-4-methyl-1-oxopentan
-2-ylamino)-4-oxobutanoic acid (248) 
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TFA (1.0 mL) was added to the stirred solution of 238 (BSc2114, 390 mg, 0.78 
mmol) in CH2Cl2 (4.0 mL). The solvent was evaporated after 3 h to obtain 248
(BSc2128).
Yield: 260 mg, 97%
1H NMR (DMSO, 300 MHz): G = 9.37 (s, 1H; H-6), 8.85 (d, 3J = 8.3 Hz, 1H; NH), 
8.19 (d, 3J = 8.3 Hz, 1H; NH), 4.67–4.56 (m, 1H; H-3), 4.05–3.89 (m, 2H; H-1/5), 
3.77–3.65 (m, 2H; H-15), 1.90–1.87 (m, 1H; H-7), 1.79–1.69 (m, 1H, H-11), 1.60–
1.58 (m, 1H; H-8), 1.46–1.44 (m, 1H; H-12), 0.80–0.76 (m, 6H; H-9/10), 0.70–0.66 
(m, 6H; H-13/14) ppm. 
13C NMR (DMSO, 75 MHz): G = 200.1 (C-6), 171.1 (C-16), 171.0 (C-4), 169.9 (C-
2), 55.2 (C-1), 53.8 (C-3), 50.4 (C-5), 40.8 (C-11), 39.7 (C-15), 35.9 (C-7), 23.2 (C-
8), 22.2 (C-12), 21.6 (C-9), 21.1 (C-10), 21.0 (-13), 20.9 (C-14) ppm .  
MS (ESI): m/z = 343.4 [M]+.
5.2.8.14. (S)-3-((S)-2-(Benzyloxycarbonylamino)-4-methylpentanamido)-4-((S)-
4-methyl-1-oxopentan-2-ylamino)-4-oxobutanoic acid (249) 
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The title compound 249 (BSc2129) was prepared from 245 (BSc2118) according to 
the same procedure as mentioned in 5.2.8.13.
Experimental 177
Reactants: TFA (1 mL), Z-Leu-Asp(OtBu)-Leucinal (400 mg, 0.74 mmol) 245
(BSc2118).
Yield: 320 mg, 90% 
1H NMR (DMSO, 300 MHz): G = 9.80 (s, 1H; COOH), 9.37 (s, 1H; H-14), 8.30 (d, 
3J = 8.3 Hz, 1H; NH), 8.24 (d, 3J = 7.3 Hz, 1H; NH), 7.36–7.34 (m, 5H; H-2-6), 
5.22–5.21 (m, 1H; H-11), 5.12 (s, 2H; H-7), 4.80–4.79 (m, 1H; H-9), 4.50–4.45 (m, 
1H; 13), 3.30–3.29 (m, 1H; H-23), 2.98–2.97 (m, 1H; H-23´), 2.60–2.59 (m, 2H; H-
16), 1.77–1.76 (m, 1H; H-20), 0.89–0.88 (m, 6H; H-17-18), 0.80–0.79 (m, 6H; 21-
22) ppm. 
13C NMR (DMSO, 75 MHz): G = 200 (C-14), 177.1 (C-24), 171.6 (C-12), 170.8 (C-
9), 156.6 (C-8), 135.9 (C-1), 128.7 (C-3), 128.4 (C-5), 128.1 (C-4), 127.8 (C-2), 
127.1 (C-6), 67.4 (C-7), 57.5 (C-9), 54.5 (C-11), 49.8 (C-13), 41.2 (C-19), 40.1 (C-
23), 37.4 (C-15), 24.5(C-17), 24.3 (C-18), 24.2 (C-21), 24.1 (C-22), 23.5 (C-16), 
23.1 (C-20) ppm.  
MS (ESI): m/z = 476 [M]+.
5.2.9. Synthesis of Diazenecarboxylate Derivatives as Potential 
Proteasome Inhibitors 
5.2.9.1. (S)-Methyl 2-(2-(tert-butoxycarbonylamino)-4-methylpentanoyl) 
hydrazinecarboxylate (255) 
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The title compound 255 was prepared according to the same procedure as mentioned 
in 5.2.8.3.
Reactants: EDAC (147 mg, 1 mmol), HOBt (162 mg, 1.2 mmol), Et3N (278 PL, 2 
mmol), methyl carbazate (108 mg, 1.2 mmol), Boc-Leu-OH (231 mg, 1.0 mmol), 
CH2Cl2 (5 mL).
Yield: 282 mg, 93%
1H NMR (CDCl3, 300 MHz): G = 8.66 (br s, 1H; NH), 7.01 (br s, 1H; NH), 5.10 (br 
s, 1H; NH), 4.25–4.18 (m, 1H; H-4), 3.76 (s, 3H; H-1), 1.87–1.79 (m, 1H; H-6), 
1.77–1.72 (m, 2H; H-5), 1.42 (s, 9H; H-11-13), 1.01 (d, 3J = 6.8 Hz, 6H; H-7-8) 
ppm.  
13C NMR (CDCl3, 75 MHz): G = 170.4 (C-3), 156.0 (C-2), 155.4 (C-9), 79.5 (C-10), 
54.6 (C-4), 49.0 (C-1), 28.5 (C-11-13), 23.0 (C-6), 22.9 (C-7), 22.7 (C-8) ppm.  
MS (EI): m/z = 303.3 [M]+.
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5.2.9.2. (S)-Methyl 2-(2-amino-4-methylpentanoyl)hydrazinecarboxylate (256) 
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The title compound was prepared according to the same procedure as mentioned in 
5.2.8.13.
Reactants: TFA (1 mL), compound 255 (303 mg, 1.0 mmol), CH2Cl2 (5 mL). 
Yield: 181 mg, 89% 
5.2.9.3. Compound (258) 
N
H
O
H
N
N
H
O
O
O
H
N
O
O
O
O
1
6 5 4
3 2
8
79
12
11
10
21
16
15
14
13
22
17
20
19
18
23
24
The title compound was prepared according to the same procedure as mentioned in 
5.2.8.3.
Reactants: EDAC (147 mg, 1 mmol), HOBt (162 mg, 1.2 mmol), Et3N (278 PL, 2 
mmol), compound 256 (243 mg, 1.2 mmol), Z-Asp(OtBu)-OH (323 mg, 1.0 mmol), 
CH2Cl2 (5 mL).
Yield: 442 mg, 87% 
5.2.9.4. Compound (259) 
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The title compound was prepared according to the same procedure as mentioned in 
5.2.8.3.
Reactants: EDAC (147 mg, 1 mmol), HOBt (162 mg, 1.2 mmol), Et3N (278 PL, 2 
mmol), compound 256 (243 mg, 1.2 mmol), Boc-Asp(OBn)-OH (323 mg, 1.0 
mmol), CH2Cl2 (5 mL).
Yield: 472 mg, 93% 
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5.2.9.5. Compound (260) 
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The title compound was prepared according to the same procedure as mentioned in 
5.2.8.3.
Reactants: EDAC (147 mg, 1 mmol), HOBt (162 mg, 1.2 mmol), Et3N (278 PL, 2 
mmol), compound 256 (243 mg, 1.2 mmol), Boc-Asp(Ochexyl)-OH (315 mg, 1.0 
mmol), CH2Cl2 (5 mL).
Yield: 390 mg, 78% 
5.2.9.6. Methyl 2-((S)-2-((S)-2-amino-4-tert-butoxy-4-oxobutanamido)-4-
methylpentanoyl)hydrazinecarboxylate (261) 
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The title compound was prepared according to the same procedure as mentioned in 
5.2.8.2.
Reactants: compound 258 (508 mg, 1.0 mmol) in absolute ethanol (10 mL) 20% Pd-
C (100 mg) under hydrogen atmosphere at room temperature. 
Yield: 293 mg, 82% 
5.2.9.7. Methyl 2-((S)-2-((S)-2-amino-4-(benzyloxy)-4-oxobutanamido)-4-
methylpentanoyl)hydrazinecarboxylate (262) 
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The title compound was synthesized by following same general procedure mentioned 
in 5.2.8.13.
Reactants: Compound 259 (508 mg, 1.0 mmol), 20% TFA in CH2Cl2 (10 mL).
Yield: 382 mg, 97% 
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5.2.9.8. Methyl 2-((S)-2-((S)-2-amino-4-(cyclohexyloxy)-4-oxobutanamido)-4-
methylpentanoyl) hydrazinecarboxylate (263) 
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The title compound was synthesized by following same general procedure mentioned 
in 5.2.8.13.
Reactants: Compound 259 (500 mg, 1.0 mmol), 20% TFA in CH2Cl2 (10 mL).
Yield: 360 mg, 90% 
5.2.9.9. Compound (264) 
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The title compound was prepared according to the same procedure as mentioned in 
5.2.8.3.
Reactants: EDAC (147 mg, 1 mmol), HOBt (162 mg, 1.2 mmol), Et3N (278 PL, 2 
mmol), Methyl 2-((S)-2-((S)-2-amino-4-tert-butoxy-4-oxobutanamido)-4-
methylpentanoyl)hydrazinecarboxylate (261) (448 mg, 1.2 mmol), Z-Leu-OH (265 
mg, 1.0 mmol), CH2Cl2 (5 mL). 
Yield: 584 mg, 94%
1H NMR (CDCl3, 300 MHz): G = 8.57 (br s, 1H; NH), 7.61 (br s, 1H; NH), 7.28–
7.19 (m, 5H; H-12-16), 5.30–5.26 (m, 1H; H-6), 4.99 (s, 2H; H-10), 4.65–4.55 (m, 
1H; H-4), 4.50–4.44 (m, 1H; H-8), 3.64 (s, 3H; H-1), 2.90–2.80 (m, 1H; H-25), 2.64–
2.55 (m, 1H; H-25´), 1.74–1.70 (m, 6H; H-17-18/21-22), 1.42 (s, 9H; H-28-30), 1.01 
(d, 3J = 6.8 Hz, 12H; H-19-20/23-24) ppm.  
13C NMR (CDCl3, 75 MHz): G̓= 171.8 (C-26), 171.6 (C-5), 170.8 (C-7), 156.8 (C-
2), 156.1 (C-9), 141.0 (C-11), 129.0 (C-13), 128.7 (C-15), 128.5 (C-14), 127.3 (C-
12), 127.1 (C-16), 79.9 (C-27), 67.6 (C-10), 54.5 (C-4), 53.0 (C-8), 50.9 (C-6), 50.1 
(C-1), 42.2 (C-17), 40.9 (C-21), 39.6 (C-25), 28.9 (C-28-30), 24.9 (C-23), 24.5 (C-
24), 23.2 (C-22), 23.0 (C-19), 21.7 (C-20), 21.3 (C-18) ppm.
MS (EI): m/z = 621.3 [M]+.
Experimental 181
5.2.9.10. Compound (265) 
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The title compound was prepared according to the same procedure as mentioned in 
5.2.8.3.
Reactants: EDAC (147 mg, 1 mmol), HOBt (162 mg, 1.2 mmol), Et3N (278 PL, 2 
mmol), Methyl 2-((S)-2-((S)-2-amino-4-(benzyloxy)-4-oxobutanamido)-4-
methylpentanoyl)hydrazinecarboxylate (262) (489 mg, 1.2 mmol), Z-Leu-OH (265 
mg, 1.0 mmol), CH2Cl2 (5 mL).
Yield: 596 mg, 91% 
1H NMR (CDCl3, 300 MHz): G = 8.91 (br s, 1H; NH), 8.00 (br s, 2H; NH), 7.36–
7.26 (m, 10H; H-12-16/21-25), 5.19–5.09 (m, 3H; H-6/17), 4.99 (s, 2H; H-10), 4.44–
4.20 (m, 2H; H-4/8), 3.64 (s, 3H; H-1), 2.90–2.80 (m, 1H; H-17), 2.64–2.55 (m, 1H; 
H-17´), 1.74–1.70 (m, 6H; H-26-27/30-31), 1.01 (d, 3J = 6.8 Hz, 12H; H-28-29/32-
33) ppm.  
13C NMR (CDCl3, 75 MHz): G = 173.0 (C-18), 171.8 (C-5), 171.5 (C-7), 170.8 (C-
3), 156.8 (C-2), 155.8 (C-9), 141.2 (C-11), 141.1 (C-20), 129.0 (C-13), 128.9 (C-15), 
128.8 (C-22), 128.7 (C-24), 128.6 (C-14), 127.7 (C-23), 127.6 (C-12), 127.5 (C-16), 
127.4 (C-21), 127.3 (C-25), 67.3 (C-17), 65.9 (C-10), 53.2 (C-4), 52.6 (C-8), 50.9 
(C-6), 50.1 (C-1), 42.2 (C-30), 40.9 (C-26), 39.5 (C-17), 24.9 (C-31), 24.9 (C-32), 
24.5 (C-33), 23.2 (C-28), 23.0 (C-29), 21.7 (C-27) ppm.  
MS (EI): m/z = 655 [M]+.
5.2.9.11. Compound (266) 
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The title compound was prepared according to the same procedure as mentioned in 
5.2.8.3.
Reactants: EDAC (147 mg, 1 mmol), HOBt (162 mg, 1.2 mmol), Et3N (278 PL, 2 
mmol), Methyl 2-((S)-2-((S)-2-amino-4-(cyclohexyloxy)-4-oxobutanamido)-4-
methylpentanoyl) hydrazinecarboxylate (263) (480 mg, 1.2 mmol), Z-Leu-OH (265 
mg, 1.0 mmol), CH2Cl2 (5 mL). 
Yield: 550 mg, 85% 
1H NMR (CDCl3, 300 MHz): G = 8.89 (br s, 1H; NH), 7.99 (br s, 2H; NH), 7.36–
7.25 (m, 5H; H-12-16), 5.19–5.09 (m, 1H; H-6), 4.99 (s, 2H; H-10), 4.46–4.45 (m, 
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1H; H-8), 4.44–4.20 (m, 1H; H-4), 4.00–3.91 (m, 1H; H-19), 3.64 (s, 3H; H-1), 2.88–
2.80 (m, 1H; H-17), 2.66–2.55 (m, 1H; H-17´), 1.79–1.76 (m, 6H; H-25-26/29-30), 
1.60–1.12 (m, 10H; H-20-24), 1.01 (d, 3J = 6.8 Hz, 12H; H-27-28/31-32) ppm.  
13C NMR (CDCl3, 75 MHz): G = 173.1, 171.6, 171.5, 170.9, 156.8, 155.7, 141.1, 
129.0, 128.8, 128.6, 127.1, 65.8, 53.2, 52.6, 50.8, 50.0, 49.0, 40.8, 38.2, 33.2, 26.9, 
24.5, 23.2, 23.0, 22.2, 21.7, 21.3 ppm.
MS (EI): m/z = 647 [M]+.
5.2.9.12. Compound (267) 
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Compound 264 (68 mg, 0.11mmol) in CH2Cl2 (5 mL) was treated with pyridine (9.4 
PL, 0.12 mmol) and N-bromosuccinimide (19.5 mg, 0.12 mmol) under an argon 
atmosphere for 2 h. Removal of the solvent in vacuo followed by purification by 
coulmn chromatography on silica gel, eluting with EtOAc, yielded compound 267 as
a yellow solid. 
Yield: 30 mg, 45% 
1H NMR (CDCl3, 300 MHz): G = 8.56 (br s, 1H; NH), 7.28–7.19 (m, 5H; H-12-16), 
5.30–5.25 (m, 1H; H-6), 5.02 (s, 2H; H-10), 4.64–4.56 (m, 1H; H-4), 4.50–4.44 (m, 
1H; H-8), 3.65 (s, 3H; H-1), 2.89–2.80 (m, 1H; H-25), 2.65–2.54 (m, 1H; H-25´), 
1.75–1.70 (m, 6H; H-17-18/21-22), 1.41 (s, 9H; H-28-30), 1.01 (d, 3J = 6.8 Hz, 12H; 
H-19-20/23-24) ppm.  
13C NMR (CDCl3, 75 MHz): G = 200.0 (C-3), 173.0 (C-26), 171.6 (C-5), 170.8 (C-
7), 161.0 (C-2), 156.8 (C-9), 141.2 (C-11), 129.0 (C-13), 128.7 (C-15), 128.5 (C-14), 
127.2 (C-12), 127.1 (C-16), 82.1 (C-27), 67.6 (C-8), 65.1 (C-4), 52.5 (C-6), 52.0 (C-
1), 42.3 (C-17), 42.1 (C-21), 39.6 (C-25), 28.9 (C-28-30), 24.2 (C-19), 24.1 (C-20), 
23.2 (C-23), 23.0 (C-24), 21.7 (C-18), 21.3 (C-22) ppm.  
MS (EI): m/z = 619.7 [M]+.
5.2.9.13. Compound (268) 
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The title compound was prepared according to the same procedure as mentioned in 
5.2.9.12.
Reactants: Compound 265 (655 mg, 1.0 mmol) in CH2Cl2 (50 mL) was treated with 
pyridine (94.8 PL, 1.2 mmol) and N-bromosuccinimide (213 mg, 1.2 mmol). 
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Yield: 261 mg, 40% 
1H NMR (CDCl3, 300 MHz): G = 8.21 (br s, 1H; NH), 7.37–7.25 (m, 10H; H-12-
16/21-25), 5.17–5.08 (m, 3H; H-6/19), 4.98 (s, 2H; H-10), 4.45–4.20 (m, 2H; H-4/8), 
3.65 (s, 3H; H-1), 2.89–2.80 (m, 1H; H-17), 2.66–2.58 (m, 1H; H-17´), 1.78–1.73 
(m, 6H; H-26-27/30-31), 1.01 (d, 3J = 6.8 Hz, 12H; H-28-29/32-33) ppm.  
13C NMR (CDCl3, 75 MHz): G = 201.0 (C-3), 173.1 (C-18), 171.7 (C-5), 171.0 (C-
7), 161.3 (C-2), 156.7 (C-9), 141.2 (C-11), 141.1 (C-20), 129.0 (C-13), 128.9 (C-15), 
128.8 (C-22), 128.7 (C-24), 128.6 (C-14), 128.5 (C-23), 127.7 (C-12), 127.6 (C-16), 
127.4 (C-21), 127.1 (C-25), 68.5 (C-19), 65.3 (C-10), 52.2 (C-8), 50.9 (C-4), 50.1 
(C-6), 49.0 (C-1), 41.1 (C-26), 40.9 (C-30), 37.9 (C-17), 24.9 (C-32), 24.5 (C-33), 
23.6 (C-28), 23.5 (C-29), 23.2 (C-31), 23.0 (C-27) ppm.  
MS (EI): m/z = 653 [M]+.
5.2.9.14. (S)-3-((S)-2-(Benzyloxycarbonylamino)-4-methylpentanamido)-4-((S)-
1-(2-(methoxycarbonyl)hydrazinyl)-4-methyl-1-oxopentan-2-ylamino)-4-oxo
butanoic acid (270) 
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The title compound was synthesized by following same general procedure mentioned 
in 5.2.8.13.
Reactants: Compound 259 (621 mg, 1.0 mmol), 20% TFA in CH2Cl2 (10 mL).
Yield: 452 mg, 80% 
1H NMR (CDCl3, 300 MHz): G = 8.21 (br s, 1H; NH), 7.30–7.19 (m, 5H; H-12-16), 
5.02 (s, 2H; H-10), 4.86–4.77 (m, 1H; H-6), 4.64–4.55 (m, 1H; H-4), 4.50–4.44 (m, 
1H; H-8), 3.65 (s, 3H; H-1), 2.89–2.80 (m, 1H; H-25), 2.65–2.55 (m, 1H; H-25´), 
1.75–1.70 (m, 6H; H-17-18/21-22), 1.01 (d, 3J = 6.8 Hz, 12H; H-19-20/23-24) ppm.  
13C NMR (CDCl3, 75 MHz): G = 177.3 (C-26), 171.7 (C-5), 171.4 (C-7), 170.8 (C-
3), 156.5 (C-2), 155.9 (C-9), 141.2 (C-11), 129.0 (C-13), 128.9 (C-15), 128.7 (C-14), 
128.5 (C-12), 127.2 (C-16), 65.8 (C-10), 53.0 (C-4), 52.5 (C-8), 50.3 (C-6), 50.0 (C-
1), 42.1 (C-17), 40.1 (C-21), 40.0 (C-25), 24.2 (C-22), 24.1 (C-23), 23.2 (C-24), 23.0 
(C-19), 21.7 (C-20), 21.3 (C-18) ppm.
MS (EI): m/z = 565.3 [M]+.
5.2.9.15. Compound (272) 
N
H
O
H
N
N
H
O
O
O
H
N
O
N
H
O
O
1
6 5 4
3
28
79
12
11
10
2116
15
14
13
22
17 20
19
18
23
24
26
28
27
25
The title compound was prepared according to the same procedure as mentioned in 
5.2.8.3.
Experimental 184
Reactants: EDAC (147 mg, 1 mmol), HOBt (162 mg, 1.2 mmol), Et3N (278 PL, 2 
mmol), compound 256 (243 mg, 1.2 mmol), Z-Leu-Leu-OH (377 mg, 1.0 mmol), 
CH2Cl2 (5 mL). 
Yield: 535 mg, 95% 
1H NMR (CDCl3, 300 MHz): G = 7.28–7.18 (m, 5H; H-12-16), 4.99 (s, 2H; H-10), 
4.34–4.27 (m, 1H; H-6), 4.24–4.11 (m, 1H; H-4), 4.09–4.06 (m, 1H; H-8), 3.65 (s, 
3H; H-1), 1.59–1.45 (m, 9H; H-17-18/21-22/25-26), 1.01 (d, 3J = 6.8 Hz, 18H; H-19-
20/23-24/27-28) ppm.  
13C NMR (CDCl3, 75 MHz): G = 173.6 (C-5), 172.6 (C-8), 172.3 (C-3), 157.2 (C-2), 
156.8 (C-9), 136.1 (C-11), 128.5 (C-13), 128.2 (C-15), 127.8 (C-14), 127.5 (C-12), 
127.0 (C-16), 67.0 (C-10), 53.4 (C-4), 52.8 (C-8), 52.1 (C-6), 50.1 (C-1), 41.2 (C-
21), 41.0 (C-17), 40.9 (C-25), 24.8 (C-26), 24.6 (C-27), 24.5 (C-28), 23.8 (C-19), 
23.7 (C-20), 23.6 (C-23), 23.1 (C-24), 22.7 (C-18), 21.6 (C-22) ppm.  
MS (EI): m/z = 563.6 [M]+.
5.2.9.16. Compound (273) 
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The title compound was prepared according to the same procedure as mentioned in 
5.2.9.12.
Reactants: Compound 271 (563 mg, 1.0 mmol) in CH2Cl2 (50 mL) was treated with 
pyridine (94.8 PL, 1.2 mmol) and N-bromosuccinimide (213 mg, 1.2 mmol). 
Yield: 280 mg, 50% 
1H NMR (CDCl3, 300 MHz): G = 7.29–7.19 (m, 5H; H-12-16), 4.98 (s, 2H; H-10), 
4.35–4.27 (m, 1H; H-6), 4.24–4.14 (m, 1H; H-8), 4.09–4.06 (m, 1H; H-4), 3.67 (s, 
3H; H-1), 1.58–1.44 (m, 9H; H-17-18/21-22/25-26), 1.01 (d, 3J = 6.8 Hz, 18H; H-19-
20/23-24/27-28) ppm.  
13C NMR (CDCl3, 75 MHz): G = 199.1 (C-3), 171.6 (C-5), 171.3 (C-7), 161.1 (C-2), 
155.2 (C-9), 141.2 (C-11), 129.0 (C-13), 128.9 (C-15), 128.2 (C-14), 127.1 (C-12), 
127.0 (C-16), 65.8 (C-10), 52.4 (C-8), 50.9 (C-6), 50.1 (C-4), 49.0 (C-1), 41.2 (C-
21), 41.0 (C-17), 40.9 (C-25), 24.2 (C-19), 24.1 (C-20), 22.3 (C-23), 22.2 (C-24), 
22.1 (C-27), 22.0 (C-28), 21.6 (C-26), 21.5 (C-18), 21.3 (C-22) ppm.  
MS (EI): m/z = 561.6 [M]+.
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5.2.10. Synthesis of Active Metabolites of Losartan 
EXP3174/EXP3179
5.2.10.1. 1-((2'-(2H-Tetrazol-5-yl)biphenyl-4-yl)methyl)-2-butyl-4-chloro-1H-
imidazole-5-carbaldehyde (274) EXP3179 
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Losartan (49, 0.422 g, 1 mmol) and IBX (2-iodoxybenzoic acid, 321 mg, 1.2 mmol) 
were added in DMSO (5 mL) and stirred at room temperature for 6 h. CH2Cl2 (30 
mL) was added and the solution was washed with water (3 u 30 mL), NaHCO3
solution (3 u 30 mL, sat.), and brine (1 u 30 mL). The solvent was removed after 
drying (Na2SO4) in vacuo to yield the product (274) EXP3179.
Yield: 410 mg, 98%. 
1H NMR (CDCl3, 400 MHz): G = 9.65 (s, 1H; H-8), 7.86 (dd, 1H, 3J = 7.7 Hz; H-
17), 7.58 (ddd, 3J = 7.7 Hz, 3J = 7.5 Hz, 4J = 1.3 Hz, 1H; H-18), 7.49 (dt, 3J = 7.5 Hz,
4J = 1.3 Hz, 1H; H-19), 7.41 (dd, 3J = 7.7 Hz, 4J = 1.1 Hz, 1H; H-20), 7.09 (d, 3J = 
8.2 Hz, 2H; H-12/14), 6.95 (d, 3J = 8.2 Hz, 2H; H-11/15), 5.50 (s, 2H; H-9), 2.60 (t, 
3J = 7.8 Hz, 2H; H-4), 1.71–1.51 (m, 2H; H-3), 1.42–1.31 (m, 2H; H-2), 0.87 (t, 3J = 
7.4 Hz, 3H; H-1) ppm.  
13C NMR (CDCl3, 75 MHz): G = 188.1 (C-8), 165.1 (C-22), 154.9 (C-5), 143.2 (C-
7), 140.7 (C-6), 139.1 (C-10), 135.3 (C-16), 131.3 (C-13), 130.7 (C-16), 129.6 (C-
11), 128.9 (C-15), 128.6 (C-18), 128.5 (C-17), 128.4 (C-19), 126.6 (C-20), 124.2 (C-
12), 122.6 (C-14), 48.0 (C-9), 33.2 (C-3), 26.3 (C-4), 22.3 (C-2), 13.6 (C-1) ppm.  
IR (CHCI3): Ȟ 3412 (m), 3000 (m), 2962 (m), 1744 (w), 1708 (m), 1668 (s, C=O),
1516 (m), 1460 (m), 1384 (m), 1232 (m) cm-1.
MS (EI): m/z = 420 [M]+.
5.2.10.2. Synthesis of 1-((2'-(2H-Tetrazol-5-yl)biphenyl-4-yl)methyl)-2-butyl-4-
chloro-1H-imidazole-5-carboxylic acid (275, EXP3174) via EXP3179 
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EXP3179 was synthesized by previously described method. A mixture of (147 mg, 
0.35 mmol) of EXP3179 and (287 mg, 3.3 mmol) of activated manganese dioxide in 
10 mL of H2O:MeOH (6:4) was refluxed for 78 h. The reaction was monitored by 
TLC (CHCl3/MeOH/CH3COOH 95/5/0.5). Excess of MnO2 was filtered, the solvent 
was removed under reduced pressure and the residue was purified by acid base 
workup to get EXP3174. 
Experimental 186
Yield: 200 mg, 56%. 
Mp: 176–178 °C. 
1H NMR (DMSO, 300 MHz): G = 7.69 (d, 3J = 8.0 Hz, 1H; H-17), 7.66 (t, 3J = 8.0 
Hz, 1H; H-18), 7.59 (t, 3J = 8.0 Hz, 1H; H-19)), 7.53 (d, 3J = 8.0 Hz, 1H; H-20), 7.08 
(d, 3J = 8.5 Hz, 2H; H-12/14), ̓6.97 (d, 3J = 8.5 Hz, 2H; H-11/15), 5.60 (s, 2H; H-9), 
2.58 (t, 3J = 7.0 Hz, 2H; H-4), 1.53 (quint, 3J = 7.0 Hz, 2H; H-3), 1.24 (sext, 3J = 7.0 
Hz, 2H; H-2), 0.82 (t, 3J = 7.0 Hz, 3H; H-1) ppm.
13C NMR (CDCl3, 75 MHz): G = 167.5 (C-8), 163.0 (C-22), 154.9 (C-5), 143.2 (C-
21), 140.7 (C-10), 139.2 (C-16), 135.5 (C-13), 135.2 (C-7), 133.5 (C-6), 129.6 (C-
11), 129.4 (C-15), 129.3 (C-18), 128.3 (C-17), 128.2 (C-19), 128.0 (C-20), 127.9 (C-
12), 127.8 (C-14), 39.7 (C-9), 33.1 (C-3), 25.3 (C-4), 22.4 (C-2), 14.1 (C-1) ppm.
MS (ESI): 435 (MH)+.
References 187
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Proteasomes play an important role in protein turnover
in living cells. The inhibition of proteasomes affects cell
cycle processes and induces apoptosis. Thus, 20 S protea-
somal inhibitors are potential tools for the modulation of
neoplastic growth. Based on MG132, a potent but nonspe-
cific 20 S proteasome inhibitor, we designed and synthe-
sized 22 compounds and evaluated them for the inhibition
of proteasomes. The majority of the synthesized com-
pounds reduced the hydrolysis of LLVY-7-aminomethyl-
coumarin peptide substrate in cell lysates, some of them
drastically. Several compounds displayed inhibitory ef-
fects when tested in vitro on isolated 20 S proteasomes,
with lowest IC50 values of 58 nM (chymotrypsin-like activ-
ity), 53 nM (trypsin-like activity), and 100 nM (caspase-like
activity). Compounds 16, 21, 22, and 28 affected the chy-
motrypsin-like activity of the 5 subunit exclusively,
whereas compounds 7 and 8 inhibited the 2 trypsin-like
active site selectively. Compounds 13 and 15 inhibited all
three proteolytic activities. Compound 15 was shown to
interact with the active site by x-ray crystallography. The
potential of these novel inhibitors was assessed by cellu-
lar tolerance and biological response. HeLa cells tolerated
up to 1 M concentrations of all substances. Intracellular
reduction of proteasomal activity and accumulation of
polyubiquitinated proteins were observed for compounds
7, 13, 15, 22, 25, 26, 27, and 28 on HeLa cells. Four of these
compounds (7, 15, 26, and 28) induced apoptosis in HeLa
cells and thus are considered as promising leads for anti-
tumor drug development.
The balance of protein synthesis and degradation processes
is essential to maintain cellular homeostasis. Cells possess two
major pathways to fulfill protein degradation: proteins are
digested either by proteolytic enzymes within the lysosomes or
via the ubiquitin-proteasome system. The imbalance of the
protein synthesis and degradation processes causes many
pathological processes (1).
26 S proteasomes, multi-subunit protease complexes, per-
form ATP-dependent degradation of polyubiquitinated proteins
and are responsible for most of the non-lysosomal proteolysis in
eukaryotic cells. They consist of the proteolytic 20 S protea-
some core particle and are capped at one or both ends by 19 S
regulatory particles (2, 3). The 20 S core particle is a cylindrical
assembly of 28 subunits arranged in four stacked heptameric
rings; two rings are formed by 7 -type subunits, and two rings
are build of 7 -type subunits (4, 5). The two inner -rings form
the central cavity of the cylinder and harbor the proteolytic
sites. In contrast to prokaryotic 20 S proteasomes, which con-
tain 14 identical proteolytically active -type subunits, eukary-
otic 20 S proteasomes belong to the family of N-terminal nu-
cleophilic hydrolases (6, 7). They possess only three subunits
with N-terminal active site threonines in the -ring. In addi-
tion, the stimulation of mammalian cells by -interferon causes
the replacement of the three active -subunits 1, 2, and 5
by their immunohomologues 1i, 2i, and 5i, resulting in the
formation of immunoproteasomes, which display modified
cleavage patterns of substrate peptides. The functional integ-
rity of proteasomes is indispensable for a variety of cellular
functions, such as metabolic adaptation, cell differentiation,
cell cycle control, stress response, degradation of abnormal
proteins, and generation of epitopes presented by major histo-
compatibility complex class I receptors (for reviews, see Refs. 8
and 9). However, proteasomes are an important supplier (but
not the exclusive supplier) of antigenic peptides (10, 11).
The deregulation of the ubiquitin-proteasome protein degra-
dation pathway in humans causes several diseases, such as
cancer and neurodegenerative, autoimmune, and metabolic
disorders. Inhibition of proteasomes influences the stability of
many proteins, especially those that are involved in the cell
cycle regulation. In fact, most of the cells treated with protea-
somal inhibitors become sensitive to apoptosis (12, 13). Thus,
selective inhibitors of catalytic proteasome subunits are attrac-
tive targets for drug development (14). Interestingly, tumor
cells are usually more sensitive to proteasomal inhibition than
normal cells. Healthy cells display cell cycle arrest when
treated with proteasomal inhibitors but, in contrast to tumor
cells, are not as susceptible to apoptosis (15, 16). So far, several
proteasomal inhibitors have been characterized, both selective
(4, lactacystin; 5, TMC-95A; and 6, epoxomicin) and nonspecific
(1, dichlorovinyl ester; 3, MG132) (Fig. 1A) (17).
The most prominent proteasomal inhibitor 2 (Bortezomib®,
VELCADETM) is approved by the United States Food and Drug
Administration as a prescription drug for the treatment of
multiple myeloma (18–20). Similar applications of proteasomal
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inhibitors in oncology and neurodegenerative diseases are at
the focus of our interest (21). We intend to develop selective
inhibitors for the three different proteolytic activities of the
20 S proteasome. Our goals may be achieved by creating com-
pounds or reactive moieties, which bind covalently to the
N-terminal threonine.
The proteasomal amide hydrolysis differs from all other
classes of proteases and is performed by N-terminal threonines,
as depicted in Fig. 1B. The crystal structure analysis of the 20 S
proteasome revealed that the Thr-1O functions as the nucleo-
phile and that the N-terminal amino group serves as an acyl
carrier (6). Covalent inhibitors can bind to the active site
through the Thr-1O hydroxyl group or both the free N termi-
nus and Thr-1O (for review, see Ref. 17).
Effective in vivo inhibitors of the 20 S proteasome require
high selectivity and good penetration of the cellular mem-
branes. We decided to address the selectivity problems of 3
(MG132) first. A focused set of peptide analogue aldehydes
13–18 aimed at the proteolytic activity of 5 subunit was syn-
thesized and tested for inhibition of the 20 S proteasome and
-secretase (22, 23). These results encouraged us to address the
design of irreversible and selective proteasome inhibitors. We
concentrated on the nonspecific serine protease inhibitor 1 and
introduced modifications to improve its selective inhibition of
the chymotrypsin-like activity of the 20 S proteasome.
MATERIALS AND METHODS
Isolation of 20 S Proteasomes—20 S proteasomes were isolated from
red blood cells. Cells were lysed with dithiothreitol (1 mM), and the
stroma-free supernatant was applied to DEAE-Sepharose (Toyopearls).
20 S proteasome was eluted with a NaCl gradient in TEAD (20 mM
Tris-HCl, pH 7.4, 1 mM EDTA, 1 mM azide, and 1 mM dithiothreitol)
from 100 to 350 mM NaCl. 20 S proteasome was concentrated by am-
monium sulfate precipitation (between 40 and 70% of saturation) and
separated in a 10–40% sucrose gradient by centrifugation at 40,000
rpm for 16 h (SW40; L7; Beckman & Coulter). Finally, 20 S proteasome
was purified on MonoQ column and eluted with a NaCl gradient at 280
mM NaCl. The fractions containing purified 20 S proteasome were
dialyzed against 50 mM NaCl in TEAD and stored on ice. The purity was
determined by SDS-PAGE.
Protease Assays—Suc-LLVY-AMC,1 Z-VGR-AMC, and LLE-AMC
(Bachem, Calbiochem) were used to estimate chymotrypsin-like, tryp-
sin-like, and caspase-like (post-acidic) activities of the 20 S proteasome,
respectively. Substrates were incubated with 20 S proteasome at 37 °C
in assay buffer (20 mM Tris-HCl, pH 7.2, 1 mM EDTA, and 1 mM
dithiothreitol) for 1 h. 100 ng of 20 S proteasome was preincubated with
0.01–10 M of the inhibitors for 15 min. The reaction was started by
addition of substrate (50 M). The released AMC was detected by
fluorescence emission at 460 nm (excitation at 390 nm) using a TECAN
fluorometer. Activity was estimated in fluorescence units, and the in-
hibition is represented by IC50 values.
Cell Culture—HeLa cells and MeWo cells (human melanoma) were
cultured in RPMI 1640 supplemented with 10% heat-inactivated fetal
calf serum and penicillin/streptomycin at 5% CO2. Inhibitors were
applied from 100 stocks (in Me2SO) at the indicated final concentra-
tions and incubated for variable times.
Sensitivity of Cells against Added Compounds—The viability of
HeLa cells was tested by crystal violet staining after incubation with
inhibitors. The cells were washed once with PBS, fixed with 1% of
glutardialdehyde for 30 min, and washed again. Finally, the fixed cells
were stained with 0.1% crystal violet in PBS for 30 min and subse-
quently washed carefully with water to remove unbound dye. The
remaining dye was eluted by 0.1% Triton X-100 in PBS and determined
at 550 nm.
Inhibition of 20 S Proteasomes within Cells—Cells were harvested
and lysed with 0.1% Nonidet P-40 in TEAD in the presence of the
commercial protease inhibitor mixture Complete (Roche Applied Sci-
ence). The proteasomal activity was measured in 10 l of lysates by
using Suc-LLVY-AMC as a substrate. The protein content was quanti-
fied by Bradford (Protein assay; Bio-Rad).
Detection of Accumulated Polyubiquitinated Proteins—50 g of total
cell lysate was separated by SDS-PAGE and blotted onto polyvinylidene
difluoride membrane (Millipore). Blots were blocked by 5% of milk
suspension. The polyubiquitinated proteins were detected by anti-ubiq-
1 The abbreviations used are: AMC, 7-aminomethylcoumarin; Z, ben-
zyloxycarbonyl; PBS, phosphate-buffered saline.
FIG. 1. A, serine and threonine protease inhibitors. B, hydrolysis by threonine proteases.
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uitin antibody (DAKO) and anti-rabbit peroxidase-labeled as secondary
antibody (DIANOVA) and then visualized by ECL.
Analysis of Cell Cycle—MeWo cells were treated with inhibitor 15
and MG132 for 24 h. Cells were trypsinized, washed with cold PBS,
suspended in 70% ethanol, and fixed at 20 °C for 2 h. Fixed cells were
washed twice with PBS, incubated with RNase A (Sigma) at room
temperature for 20 min, and placed on ice. Propidium iodide was added
to a final concentration of 5 g/ml, and cells were stained at least for 2 h
at 4 °C. The cells were analyzed after staining by flow cytometry (FAC-
SCalibur flow cytometer; BD Biosciences) using CellQuest software.
Statistical significance was determined by the 2 test.
Apoptosis Assay—HeLa cells (10,000 cells/well) were disseminated in
a 96-well plate and treated with 1 M of inhibitors for 20 h. The ongoing
apoptosis was estimated by the Apo-One® assay (Promega).
Co-crystallization—Crystals of 20 S proteasome from Saccharomyces
cerevisiae were grown in hanging drops at 24 °C as described previously
(6) and incubated for 60minwith compound 15. The protein concentration
used for crystallization was 40 mg/ml in Tris-HCl (10 mM, pH 7.5) and
EDTA (1mM). The drops contained 3 l of protein and 2 l of the reservoir
solution, which contained 30 mM magnesium acetate, 100 mM morpholi-
noethanesulfonic acid, pH 7.2, and 10% 2-methylpentane-2,4-diol.
The space group belongs to P21 with cell dimensions of a  135.8 Å,
b  300.1 Å, c  144.4 Å, and   113.1°. Data to 2.8 Å were collected
using synchrotron radiation with   1.05 Å on the BW6-beamline at
DESY (Hamburg, Germany). Crystals were soaked in a cryoprotecting
buffer (30% 2-methylpentane-2,4-diol, 20 mM magnesium acetate, 100
mM morpholinoethanesulfonic acid, pH 6.9) and frozen in a stream of
liquid nitrogen gas at 90 K (Oxford Cryo Systems). X-ray intensities
were evaluated by using the MOSFILM program package (version 6.1),
and data reduction was performed with CCP4 (24). The anisotropy of
diffraction was corrected by an overall anisotropic temperature factor
by comparing observed and calculated structure amplitudes using the
program X-PLOR (25). A total of 2,383,416 reflections yielding
248,616 unique reflections (96.9% completeness) was collected. The
corresponding Rmerge was 8.7% at 2.8 Å resolution (41.9% for the last
resolution shell). Electron density was improved by averaging and
back-transforming the reflections 10 times over the 2-fold noncrys-
tallographic symmetry axis using the program package MAIN (26).
Conventional crystallographic rigid body, positional, and tempera-
ture factor refinements were carried out with X-PLOR using the yeast
20 S proteasome structure as starting model (6). For model building,
the program MAIN was used. The structure was refined to a R-factor
of 21.7% (free R-factor, 24.9%) with root mean square deviations from
target values of 0.007 Å for bonds and 1.30° for angles (27). Modeling
experiments were performed using the coordinates of yeast 20 S
proteasome with the program MAIN (26).
Synthesis—Compounds 7–18 were synthesized as analogues of 3
(MG132) based on the established substrate preferences of -secretase
(23) by standard methodology or as published previously (28). The
condensation of commercial protected dipeptides and amino acids with
FIG. 2. Peptidomimetics designed for 20 S proteasome inhibition.
FIG. 3. Estimation of proteolysis in cell lysates by addition of
MG132 and 7–28. Compounds (10 M) were added to clarified lysates
and preincubated for 30 min on ice prior to the proteolysis assay (black
bars). In parallel, lysate was preincubated with the commercial prote-
ase inhibitor mixture Complete for 30 min, which inhibited most of the
cytosolic serine/aspartate proteases, but not proteasomes (white bars).
This partial inactivation was followed by incubation with the indicated
compounds. The proteolytic activity was determined in 10 l of the
lysates by addition of LLVY-AMC (100 l, 50 M) in TEAD. The AMC
released by non-inhibited lysate was set to 100%. MG132 was used as
inhibition control.
Tripeptide Mimetics Inhibit the 20 S Proteasome28396
commercial amino alcohols was followed by oxidation to the aldehydes
by 2-iodooxybenzoic acid in Me2SO.
RESULTS
The intermediate alcohol derivatives 7–12 and the tripep-
tidic aldehydes 13–18 were investigated for enzyme inhibition.
Inhibition of -secretase was rather poor (IC50 200 M),
2 but
several compounds turned out to be potent inhibitors of the 20
S proteasome. Peptide aldehydes generally lack selectivity in
enzyme inhibition. Therefore, other moieties were tested for
their ability to inhibit threonine proteases. The nonselective
dichlorovinyl ester 1, which reacts readily with all sorts of
nucleophiles such as cysteine, serine, and, eventually, threo-
nine, served as our lead, but we intended to reduce the inherent
overactivation. The removal of the acyl group may reduce the
nonspecific hydrolysis by ubiquitous nucleophiles and results
in reasonably stable dichlorovinyl ethers (28). Such ethers (19
and 20) tolerate acidic environment but hydrolyze readily at
pH 11 to be converted into -chloroacetates, which in turn may
react with nucleophiles. This dual reactivity, which is delivered
in a cascade reaction, meets the specific requirements of an
N-terminal threonine protease inhibitor. An analogue dual re-
activity may be observed for propargylic ketones. A similar
compound was synthesized, but unfortunately, the alcohol 21
resisted oxidation to the desired ketone. Therefore, we focused
on transition state mimetics as inhibitors. Lead structures,
such as statines (34), -ketoamides, and chloromethyl ketones,
are well established in protease inhibition. Combination of
these structures with a 5 selective tripeptide furnished the
compounds 22–28 (Fig. 2). Compound 22 was prepared from
commercial Z-LL and chloromethyl leucine. Compounds 23–25
were obtained by a Passerini reaction of MG132 with three
isonitriles. The subsequent oxidation by 2-iodooxybenzoic acid
in Me2SO furnished the -ketoamides 26–28.
All peptide mimetics (7–28) were tested for their ability to
inhibit the 20 S proteasome. Initially, we investigated the
inhibition of cellular soluble proteases. 10 M solutions of com-
pounds 7–28 were added to the cytosolic fraction of HeLa cells
and incubated for 30 min on ice. Subsequently, the proteolytic
process was monitored by addition of the peptidic substrate
Suc-LLVY-AMC. In parallel, the cytosolic fraction was treated
with the broad specific protease inhibitor mixture Complete
(Roche Applied Science) prior to the addition of substrate. This
inhibitor mixture did not affect 20 S proteasomes. 11 of 22
investigated compounds diminished proteolysis in the cytosolic
fraction as well as in the Complete-pretreated lysate (Fig. 3).
The inhibition rates differed drastically. Some of the com-
pounds displayed no inhibition, whereas five of the analyzed
compounds decreased the hydrolysis of Suc-LLVY-AMC
by 75%.
To ensure that the inhibitory effect observed in the cytosolic
fraction was indeed caused by inhibition of 20 S proteasomes,
the inhibitors were added at different concentrations to iso-
lated 20 S proteasomes. The effect of the inhibitors was com-
pared with that of the frequently employed 20 S proteasome
inhibitor 3 (MG132). The chymotryptic-like (Suc-LLVY-AMC),
tryptic-like (Bz-VGR-AMC), and caspase-like (Z-LLE-AMC) ac-
tivities of 20 S proteasomes were determined after incubation
at 37 °C for 1 h. The strongest inhibitory effects were observed
for chymotryptic-like activity. Six of the tested inhibitors (13,
15, 25, 26, 27, and 28) displayed IC50 values of 1 M. The
inhibition of tryptic-like activity was1 M for the inhibitors 7,
13, and 15. Only compounds 7 and 8 showed exclusive inhibi-
tion of tryptic-like activity. The inhibition of caspase-like ac-
tivity was even weaker (Table I). 20 S proteasomes isolated
from HeLa cells contain more constitutive proteasomes than
immunoproteasomes. Therefore, we repeated the inhibition ex-
periments with immunoproteasomes isolated from stably
transfected T2.27 cells. These experiments revealed that im-
munoproteasomes and constitutive proteasomes display simi-
lar sensitivities to the inhibitors (data not shown). 26 S protea-
somes are responsible for ATP-dependent degradation of2 M. Willem, S. Umbreen, and B. Schmidt, unpublished results.
TABLE I
Calculated IC50 values for compounds 7–28.
IC50 values were calculated from inhibition of proteasomes at increasing amounts of inhibitors. Samples were preincubated for 15 min in ice. The
assay was started by addition of 50 M fluorogenic peptide substrate. LLVY-AMC and GLL-AMC for chymotryptic-like, VGR-AMC for tryptic-like,
and LLE-AMC for caspase-like activity. The release of AMC was determined at 460 nm emission (excitation, 390 nm). Calculated IC50 values for
MG132 served as controls.
Inhibitor Access no.
IC50
5 Chymotrypsin-like (Y) 5 Ch-I (L) 2 Trypsin-like (R) 1 Caspase-like (E)
M M M M
7 BSc2114 10 a 0.053 10
8 BSc2117 10  5.481 10
9 BSc2207 10   
10 BSc2195 10   
11 BSc2196 10   
12 BSc2194 10   
13 BSc2115 0.382 0.102 0.495 0.098
14 BSc2128 10 10 10 10
15 BSc2118 0.058 0.031 0.155 1.791
16 BSc2129 7.26  10 10
17 BSc2208    
18 BSc2197 1.731   3.122
19 BSc2158    
20 BSc2166 10 10 10
21 BSc2167 1.303 10  
22 BSc2160 2.196   
23 BSc2159    
24 BSc2185    
25 BSc2186 0.981  4.04
26 BSc2187 0.441  1.72
27 BSc2188 0.350  7.966
28 BSc2189 0.072  10
3 MG132 0.0242 2.240 9.215 2.288
a , no inhibition.
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polyubiquitin-tagged proteins within living cells. They exhib-
ited a similar susceptibility to the most potent inhibitor (15)
in vitro (data not shown).
Protease inhibitors are often very toxic for organisms or
single cells (1). Therefore, selected inhibitors were tested on
cell cultures for cell lysis or cell death. The viability of HeLa
cells in the presence of different compounds was tested in 24-h
cultures. HeLa cells tolerated 1 M concentrations of inhibitory
and non-inhibitory substances (Fig. 4A). The relative survival
rate of the cells was clearly diminished at concentrations of 10
M. This effect was pronounced for the most potent inhibitors
from the in vitro experiments (15, 28, and 27) (Fig. 4B).
The impact of inhibitors on living cells and organisms cru-
cially depends on adequate cell permeability. Therefore, we
analyzed the proteasome function within cells at different in-
hibitor concentrations. The application to cell cultures or ani-
mals required the concentrations of the inhibitors to be as low
as possible. The specific proteasome activity was reduced below
50% (Fig. 5A) in cells treated with 1 M solutions of 15, 22, 25,
26, and 28. Compounds 7, 13, and 27 exhibited weaker effects
on the specific activity, whereas compounds 18 and 21 hardly
inhibited the cellular proteasome at all. Remarkably, inhibitors
15, 22, and 28 reduced the proteolytic activity already at a
concentration of 100 nM (Fig. 5A). Specific inhibition of protea-
somes results in the accumulation of polyubiquitinated pro-
teins. Indeed, the amounts of polyubiquitinated proteins in-
creased during incubation with the inhibitors. First effects
were observed after 2 h for the potent compound 15 (Fig. 5B)
and for compounds 20, 22, 25, and 28 (data not shown). The
accumulation of polyubiquitinated proteins via proteasome in-
hibition depended strongly on the applied concentrations (Fig.
5C). Thus, several of these new inhibitors are able to permeate
cells and affect the activity of proteasomes. The consequences
of proteasome inhibition for distinct cellular functions are sub-
ject to ongoing investigations.
The particular sensitivity of tumor cells to proteasome inhib-
itors (1) was evaluated in the melanoma cell line MeWo at
different concentrations of compound 15 for 72 h. The viability
was compared with MeWo cells treated with MG132 under the
same conditions (Fig. 6A). 50% of the MeWo cells treated with
35 nM MG132 were still alive after 72 h. Very few cells survived
the treatment with inhibitor 15, which demonstrated its po-
tency. Proteasome inhibitors can induce a cell cycle arrest in
the G1/S or G2 phase, therefore the cell cycle progress was
analyzed after 24-h inhibitor treatment of MeWo cells (Fig. 6, B
and C). Compound 15 led to a cell cycle arrest in the G2 phase,
like MG132, albeit at considerably lower concentrations.
Proteasomes determine the delicate balance of life and death
of the cells by controlling transcription factors and proteins
involved in apoptosis. The reduction of proteasomal capacity
FIG. 5. Inhibition of proteasomes within cells. The proteasome
activity and intracellular accumulation of polyubiquitinated proteins in
cells co-cultured with inhibitors were tested in lysed cells. A, HeLa cells
were cultured in the presence of inhibitors for 24 h. After lysis of cells,
the protein concentration was measured according to Bradford to nor-
malize the different cell amounts. Thereafter, Complete (Roche Applied
Science) was added to all lysates, and the proteasomal activity was
determined by hydrolysis of Suc-LLVY-AMC. Lysates of HeLa cells
cultured without inhibitors served as control (black bars) and were
compared with cell lysates cultivated at 100 nM (gray bars) and 1 M
(white bars). B, HeLa cells were cultured with 1 M compound 15 for 2,
4, 6, and 24 h. Cells were lysed, and proteins were separated by
SDS-PAGE in a 10% gel, blotted onto a polyvinylidene difluoride mem-
brane, and detected in Western blot by an anti-ubiquitin antibody
(DAKO). C, HeLa cells were treated with increasing concentrations of
the inhibitors 15, 25, 26, 27, and 28 for 24 h (c, inhibitor concentration).
Cells were lysed, proteins were separated in 15% gels, and the accumu-
lation of polyubiquitinated proteins was controlled by Western blots.
FIG. 4. A, viability of HeLa cells after
incubation with MG132 and 7–28. The
viability of HeLa cells incubated with in-
hibitors (1 M) was determined by crystal
violet staining after 20 h. B, the viability
of HeLa cells is dependent on inhibitor
concentrations. HeLa cells were cultured
in the presence of increasing concentra-
tions (100 nM, gray bars; 1 M, white dot-
ted bars; 10 M, white bars) of inhibitors
for 20 h. Control cells are indicated by
black bars. Cell survival was determined
by crystal violet staining.
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may result in the initiation of apoptosis, as reported for the
proteasome inhibitor MG132 (29). Therefore, HeLa cells co-
cultured with 1 M solutions of the inhibitors 7, 8, 11, 13–16,
18, 20–23, and 25–28 for 24 h were monitored for the induction
of apoptosis by measuring caspase 3/7 activity. Most of the
tested inhibitors did not affect cell viability. In contrast, appli-
cation of the inhibitors 7, 15, 26, and 28 caused an activation of
caspase 3/7, signaling apoptotic events (Fig. 7).
We determined the crystal structure of the yeast 20 S pro-
teasome in complex with inhibitor 15 to reveal the inhibition
mechanism of the most potent inhibitor, 15. This compound
binds in a similar orientation to the active site threonine as
observed for calpain inhibitor I (6). Defined electron density
was found in all active sites, indicating that compound 15 lacks
subunit specificity at the high concentrations employed (10
mM). The functional aldehyde of the inhibitor forms a covalent
hemiacetal bond to the Thr-1O. The peptide backbone of 15
adopts a -conformation and fills the gap between -strands
and generates an anti-parallel -sheet structure (Fig. 8). The
leucine side chain projects into the S1 pocket, whereas the P2
side chain at P2 is not in contact with the protein. The leucine
side chain at P3 closely interacts with the amino acids of the
adjacent -subunit. In general, both S1 and S3 specificity pock-
ets play a prominent role in inhibitor binding as observed in the
crystal structures of the 20 S proteasome in complex with
lactacystin (6) and vinylsulfone (30). The neutral character of
Met-45 in subunit 5 has a dominant role for the specificity of
this subunit. The crystallographic data (Fig. 8) reveal that the
P1-Leu side chain of 15 causes a structural rearrangement of
Met-45. In contrast to the crystal structure of the 20 S pro-
teasome in complex with lactacystin, Met-45 is rearranged by
3 Å, avoiding a clash with the leucine side chain in P1 of 15,
thereby making the S1 pocket more spacious. Remarkably,
the hydrophobic interactions between the Leu residue of the
inhibitor and Met-45 are only weak, thus reducing the mean
residence time of the compound at the active center. The
specificity defining pockets of subunits 1 and 2 have posi-
tive and negative charges, respectively, which destabilize the
protein-ligand interactions. However, the inherent reactivity
of the aldehyde in compound 15 causes binding to all proteo-
lytically active sites. These observations indicate that the
functional group of this inhibitor plays the dominant role in
binding.
DISCUSSION
Proteasomes are involved in a number of different cellular
processes. They are important for control of the cell cycle and
protect cells from apoptosis by maintaining the balance of
anti-apoptotic and pro-apoptotic proteins (9, 31, 32). The inter-
est in potent and specific inhibitors that may be used as poten-
tial drugs against cancer or neoplastic growth is very high.
Here we report the synthesis of inhibitors based on the protea-
somal peptide inhibitor MG132, which is a potent yet nonspe-
cific inhibitor. We assumed that side chain modifications of the
tripeptide might offer higher potency, selectivity, and site-
specific inhibition of the 20 S proteasome. This assumption is
based on a couple of known and potent peptidic inhibitors (16,
17, 33, 35).
All novel compounds were tested for their inhibitory capacity
in cell lysates. Therefore, serine proteases, cysteine proteases,
and metalloproteases were blocked by the protease inhibitor
mixture Complete (Roche Applied Science) during the assay
with the synthesized mimetics. The proteolysis of the hydro-
phobic Suc-LLVY-AMC substrate was diminished by 11 of the
investigated compounds in two assays. The specific inhibition
of a single catalytic site is of special interest for drug develop-
ment; therefore, we analyzed the inhibition of the different
proteasomal activities. The different cleavage preferences of
proteasomes were determined by specific substrates for the
hydrophobic (chymotrypsin-like), trypsin-like, and post-acidic
(caspase-like) activities on isolated proteasomes. 12 of 22 de-
rivatives inhibited proteasomal activities with IC50 values be-
low 10 M. The peptidic aldehydes 13 and 15 inhibited all
proteasomal hydrolytic activities, whereas four compounds (18,
24, 25, and 26) inhibited the chymotryptic and caspase-like
sites. However, the purpose of this investigation was the iden-
tification of fully selective inhibitors of proteasomal activity.
The tripeptidic alcohol 7 (and with lower potency, 8) specifi-
cally reduced the trypsin-like activity, and compounds 16, 21,
22, and 28 resulted in an exclusive reduction of chymotryptic
FIG. 6. Higher susceptibility of hu-
man melanoma cells to inhibitor 15.
A, human melanoma cells (MeWo) were
treated with increasing concentrations of
inhibitor 15 or 3 (MG132) for 72 h. The
viability of the cells after treatment with
15 (gray diamonds) or MG132 (white
squares) was estimated by crystal violet
staining. Statistical significance (aster-
isks) was calculated by Student’s t test.
B and C, investigation of cell cycle arrest.
MeWo Cells were cultured with inhibitors
15 and 3 (MG132) for 24 h. The harvested
cells were washed and fixed in 70% etha-
nol. Subsequently, the cells were incu-
bated with RNase A. DNA was stained by
addition of propidium iodide to a final
concentration of 5 g/ml. DNA was ana-
lyzed by fluorescence-activated cell sort-
ing (FACSCalibur flow cytometer; BD
Biosciences). Statistical significance was
calculated by the 2 test. The relative dis-
tribution of cells that resided in G1 (black
bar), S (white bar), or G2 phase (checkered
bar) is shown for inhibitor 15 in B and for
MG132 in C.
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FIG. 8. Stereoview of a 30 Å sector of
the crystal structures of the (top
panel) 1, (middle panel) 2, and (bot-
tom panel) 5 active sites of the yeast
20 S proteasome in complex with the
aldehyde 15. 15 is depicted in yellow and
shown for each subunit with its unbiased
electron density. The active site Thr-1 is
highlighted in black, and the covalent
bond between 15 and Thr-1O is high-
lighted in pink. Residues that are partic-
ularly responsible for the character of the
S1 subsite are drawn in green.
FIG. 7. Proteasomal inhibition by 7,
15, 26, and 28 resulted in induction of
apoptosis. HeLa cells treated with 1 M
of the indicated inhibitors for 20 h were
incubated with caspase substrates (Apo-
One®; Promega) for 2 h. The activation of
caspase 3/7 was measured at 538 nm (ex-
citation, 485 nm). Treatment of cells with
tumor necrosis factor  (TNF) or MG132
(M) served as positive controls; controls
without treatment are indicated as co.
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activity. Notably, the most potent of the new inhibitors feature
IC50 values below 100 nM (7, 15, and 28). This is in the range of
novel proteasomal inhibitors, which are in clinical trials (33).
Remarkably, the tetrapeptide inhibitor PSI (Z-IE(OtBu)AL-
CHO) is structurally related to our component 15 (Z-LD(Ot-
Bu)L-CHO) (36), which is among the strongest inhibitors (IC50,
60 nM). Moreover, it exhibited low toxicity and was able to
permeate cellular membranes. The comparison of our inhibi-
tors indicates the major contributions of the ligand side chains
to the specific tight interactions with the various proteolyti-
cally active sites (Fig. 8). Similar observations were made for
the alcohol derivates, with compound 7 being more effective
than the other six compounds. Furthermore, very potent inhib-
itors were identified in the chloromethyl ketone (22) and in
compounds 25–28.
Tumor cells with their accelerated and neoplastic growth are
often more sensitive to proteasomal inhibitors than normal
cells. The clinically approved proteasomal inhibitor Bort-
ezomib® causes growth arrest and apoptosis in the sensitive
tumor cells, whereas “normal” cells tolerate higher inhibitor
concentrations (37). The restriction to myeloma tumors may be
overcome by more specific inhibitors, such as PSI, which blocks
angiogenesis and modulates the growth of solid tumors (36).
The differences in cellular features and the predictable resist-
ance mechanisms require continuous development of new pro-
teasomal inhibitors. Efficient cell permeation, stability in
aquatic systems, and potent induction of cellular events are all
mandatory for clinical applications. Therefore, we tested the
permeation ability of our compounds and their in vivo impact
on proteasomes, and we monitored the accumulation of polyu-
biquitinated proteins in cultured cells. A 50% reduction of
cellular proteasome activity was observed for five of the new
inhibitors (15, 22, 25, 26, and 28). The most potent inhibitions
were achieved by compounds 15, 26, and 28, which reduced the
proteasome activity to 10% at a concentration of 1 M. Even 50
nM solutions of compound 15 arrested 70% of the melanoma
cells. Our results indicate potency, membrane permeation, and
sufficient stability throughout the incubation period for the
inhibitors 15, 22, 25, 26, and 28. The cellular proteasomal
activity was clearly reduced and accompanied by strong induc-
tion of apoptosis after 20 h treatment with 1 M of inhibitors
(15, 26, and 28). The prevalent enhanced sensitivity of tumor
cells toward proteasomal inhibition was confirmed for inhibitor
15. Compound 15 exerts its effects at considerably lower con-
centrations than MG132 and exhibits an almost identical in-
hibitory profile as Bortezomib®, which is characterized by a
lower Ki value. The low toxicity of our new compounds and the
effective proteasome inhibition encourage us to continue our
evaluation of the lead compounds, 15, 26, and 28.
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